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ABSTRACT
In 2011 the Netherlands Heart Foundation initiated consortium funding (CVON,
Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and basic
(preclinical) researchers on specific areas of research. One of those areas involves genetic
heart diseases, which are frequently caused by pathogenic variants in genes that encode
sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited
cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing
their research on secondary disease hits involved in the initiation and progression of
cardiomyopathies. This thesis describes several main findings of the work performed in the
DOSIS consortium. This chapter introduces the clinical genetic phenotypes and provides
an introduction to the work described in this thesis.
1
INTRODUCTION
Inherited cardiomyopathies, caused by pathogenic variants in genes encoding proteins
that regulate cardiomyocyte contractility, are a major cause of morbidity and mortality.
In 50–60% of familial hypertrophic cardiomyopathy (HCM) and 30–40% of dilated
cardiomyopathy (DCM), a pathogenic gene variant can be identified. The most common
genes that are affected in HCM are MYH7, MYBPC3 and TNNT2, which encode the
thick filament proteins myosin heavy chain, cardiac myosin-binding protein C (cMyBP-C),
and the thin filament protein troponin T. Tropomyosin (TPM1) variants are observed
in DCM, HCM and restrictive cardiomyopathy (RCM) patients (Chapter 2). In DCM
the titin (TTN) gene, which encodes the giant myofilament protein titin, is the most
frequently affected gene (˜15–20% of all gene variants);
1 in particular gene variants
that lead to TTN truncation have been shown to be pathogenic.2 In addition, in the
Netherlands, a founder mutation in the PLN gene, which encodes the calcium-handling
protein phospholamban, was identified in 2012 as a now well-known cause of DCM and
arrhythmogenic cardiomyopathy.3,4 Figure 1.1 depicts a cardiomyocyte to illustrate the
affected proteins involved in cardiomyopathies. Upon activation of a cardiomyocyte,
calcium enters the cell via the L-type calcium channel, which subsequently releases calcium
from the intracellular calcium store, the sarcoplasmic reticulum. Calcium binds to the
troponin complex, which induces a conformational change of troponin-tropomyosin, and
thereby releases binding sites for myosin heads on the thin actin filament. Binding of
myosin to actin (so-called cross-bridge) results in force development. The kinetics of
cross-bridge cycling is regulated by cMyBP C, and the giant protein titin, encoded by TTN
and linked with DCM, underlies passive stiffness of sarcomeres.5
In past years the number of genes in genetic diagnostic panels has increased with the hope
to identify a disease-causing variant in a larger group of patients and their family members.
However, recent studies conclude that the additional benefit of screening large numbers of
genes is disappointingly low and of marginal clinical utility7,8 Numerous new TTN gene
variants have been identified, mainly because of its large size. A study in three European
cardiogenic centres showed that missense and non-frameshifting insertions/deletions
variants are most likely benign, as reference populations showed comparable frequencies of
these rare TTN variants.9 The current panels thus rather increase the number of variants
with unknown significance, which are likely benign, though they may have a modifier role
in disease. Cardiomyopathy patients with a suspected genetic aetiology should be referred
for genetic screening. For HCM this includes patients with asymmetric left ventricular
hypertrophy, not explained by abnormal loading conditions, with or without a clear family
history. For DCM this includes patients with non-ischemic DCM, not fully explained
by other aetiological factors. Young age of onset and familial occurrence are important
parameters that hint towards a genetic aetiology. However, late onset in seemingly sporadic
cases does not exclude a genetic origin due to the reduced penetrance and variable disease
expression. All HCM and DCM patients in whom genetic screening was performed can be
added to the biobanks, including their relatives (asymptomatic mutation carriers).
STRENGTH OF PATIENT COHORTS AND BIOBANKS FOR CM RESEARCH 15
Figure 1.1: Activation of a cardiomyocyte triggers calcium entry and release of calcium from
the sarcomplasmic reticulum (SR), which results in contraction of the cardiac myofibrils. To
relax the cardiomyocyte, calcium is pumped back into the SR, and out of the cell via the
sodium-calcium exchanger (NCX). Myofibrils consist of sarcomeres composed of the thin actin and
thick myosin filament, and the third filament titin. Sarcomeres consist of sub-regions (depicted by
the different bands), which underlie the striated pattern of cardiac muscle. Gene variants that cause
cardiomyopathies are frequently found in myosin heavy chain, troponin T, cardiac myosin-binding
protein C (located in the Z zone) and titin. (Figure is adapted from Sequeira et al.6).
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Since cardiomyopathies continue to constitute one of the most common causes
of sudden cardiac death in the young and still represent major causes for cardiac
transplantation, adequate identification of additional disease triggers and understanding
the pathomechanisms is of utmost importance. The clinical approach is furthermore
complicated since inherited cardiomyopathies are clinically heterogeneous: age-dependent
penetrance and disease-severity differ greatly between patients with the identical genetic
variant. The mechanisms that underlie the variation in disease expression are still largely
unknown. By combining cellular, genetic and clinical data from well-phenotyped national
patient cohorts, DOSIS strived to define disease factors (i.e. secondary hits) that in addition
to the pathogenic gene variant cause and aggravate cardiac disease in cardiomyopathy
patients (Figure 1.2; Table 1.1). Several recent observations are highlighted below.
Figure 1.2: Disease modifiers in inherited cardiomyopathies (PQC, protein quality control).
Table 1.1: Cohorts of DOSIS
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Table 1.1: Continued
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INDEXATION FOR BODY SIZE TO SET THE DIAGNOSTIC THRESHOLD FOR
LEFT VENTRICULAR THICKENING
Using a large collection of myectomy samples from patients with obstructive HCM, we have
shown that there is a sex-specific difference in diastolic function at the time of myectomy in
HCM patients carrying pathogenic variants in MYH7 and MYBPC3.10 Women showed more
diastolic dysfunction evident from significantly higher E/e’ ratios, impaired left ventricular
filling patterns, and higher tricuspid regurgitation velocities. Of the female patients, 50%
showed grade III diastolic dysfunction, while the majority of male patients (56%) had only
mild (grade I) diastolic dysfunction. Correction of maximal septal thickness and left atrial
diameter for body surface area (BSA) resulted in significantly higher values in female
compared with male patients. Histological and protein analyses revealed more advanced
remodelling of the heart in female compared with male HCM patients evident from higher
levels of fibrosis and activation of the cardiac foetal gene program, which is characteristic
of heart failure. In chapter 8 we performed a proteomics analysis in age-matched female
and male HCM patients to define sex-specific changes in cardiac tissue at the time of
myectomy. In addition to genetic screening, the current diagnostic criterion of hypertrophy
is a maximal left ventricular wall thickness of ≥15 mm, or ≥13 mm in first-degree relatives
of HCM patients. As the hearts of women, and in general relatively small persons, are
smaller than the hearts of men, this threshold for the diagnosis of HCM should probably
be corrected for body size.11 The current diagnostic threshold, which does not take into
account body size, may likely explain the male predominance in HCM patient cohorts,
simply because males in general have larger hearts. A recent study in a Dutch cohort of
199 genotype-positive subjects, family members of HCM patients who were referred for
cardiac screening between 1995 and 2018, indexation of wall thickness by BSA decreased
the number of HCM diagnoses.12 Moreover, predictive accuracy for HCM-related events
18 CHAPTER 1
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(mortality, cardiac transplantation, implantable cardioverter-defibrillator implantation and
septal reduction therapy) improved significantly after indexation by BSA. These studies
indicate that correcting left ventricular thickness for body size should be considered for
the diagnosis of HCM and longitudinal follow-up studies in larger cohorts of preclinical
genotype-positive individuals are needed to confirm this.
ALTERED PROTEIN QUALITY CONTROL AS DISEASE MODIFIER IN
CARDIOMYOPATHY
An age-related decline in protein quality control (PQC) has been proposed as a contributor
to disease progression in cardiomyopathy. As sarcomere proteins are the most abundant
proteins in the heart, maintenance of sarcomere structure and function depends on PQC
mechanisms. Pathogenic gene variants result in poison polypeptides or reduced protein levels
(haploinsufficiency) and may trigger PQC and/or stress cellular protein homeostasis. DCM
patients with truncating TTN variants show a relatively mild disease course, though with
significant excess mortality in elderly patients. The latter may be explained by an age-related
deterioration of the PQC mechanisms. As life expectancy increases, TTN-associated
morbidity and mortality will likely become more prevalent.13 Also in PLN-associated
cardiomyopathy, protein aggregation and activation of PQC pathways has been observed in
end-stage disease.14
Terminally misfolded and aggregation-prone proteins are cleared by the two degradation
systems, the ubiquitin-proteasome system and autophagy.15 Furthermore, pathways of PQC
are strongly linked to cell architecture, such as the microtubules network. The role of the
PQC in inherited cardiomyopathies is reviewed in chapter 3. Mutations in heat shock
proteins, which are components of the PQC system, cause DCM (chapter 4), and oral
geranylgeranylacetone (GGA), a HSP protein inducer, may activate specific HSPs to prevent
cardiac dysfunction (chapter 5). As such, HSPs represent a key cellular component which
may underlie development of cardiac disease, but also a target for drug therapy. Subsequent,
DOSIS studies in a large set of cardiac tissues from a well-characterised HCM patient
group showed altered PQC with several specific changes in gene-variant positive patients
(genotype-positive) compared with genotype-negative patients and non-failing controls
(chapters 6, 7 and 8).
ALTERED METABOLISM AS KEY DRIVER OF DISEASE IN
CARDIOMYOPATHIES
Several studies suggest an important role for secondary disease modifiers such as additional
epigenetic and genetic variations and environmental disease triggers. Compelling data
have accumulated that obesity is an overarching risk factor, also for age-of-onset and
severity of cardiomyopathies. Proof that obesity contributes to disease onset and severity
comes from cohort studies. The international HCM SHaRe registry showed that patients
with a high body mass index have a significantly increased risk of heart failure, more
advanced left ventricular outflow tract obstruction and more arrhythmias (i.e. HCM-related
outcomes).16 Moreover, a prospective study in adolescent men demonstrated that even
mildly elevated body weight in late adolescence significantly increased the risk to develop
dilated cardiomyopathy in adulthood.17 At the heart level, a recent proteomics study
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in human HCM tissue samples showed reduced levels of energy metabolism proteins.18
We performed the largest proteomic study in HCM patient material and also observed
this reduction in proteins involved in a wide array of metabolic processes (chapter 6).
These observations are in line with studies in human HCM showing energy deficiency
of the heart.19,20 Energy deficiency has been proposed as the primary variant-induced
pathomechanism of HCM,21 which is supported by studies showing reduced cardiac
efficiency in preclinical asymptomatic carriers of sarcomere gene variants in the absence
of cardiac hypertrophy.20,22 Accordingly, DCM caused by TTN gene variants has been
linked with mitochondrial dysfunction and metabolic perturbations as cause of disease
progression.23 Overall, these studies indicate that timely disease stage-specific treatment of
metabolic perturbations may slow down disease progression in cardiomyopathy patients.24
An observational cohort to determine the predictive value of metabolic biomarkers (BIO
FOr CARe: identification of biomarkers for development and progression of HCM in carriers
of the Dutch MYBPC3 founder carriers) and a clinical trial using metabolic drug therapy
aimed to improve energetics of the heart at preclinical stage in HCM gene variant carriers
are currently being performed by several DOSIS principal investigators (ENERGY trial).25
CELL-TO-CELL mRNA/PROTEIN VARIABILITY AS PATHOMECHANISM IN
CARDIOMYOPATHY
As familial cardiomyopathies represent an autosomal dominant genetic disorder, most
patients are heterozygous for the mutation and carry one variant and one normal wild-type
allele. In cardiomyopathy patients, the heart of a genotype-positive individual produces
the variant protein in addition to the normal protein. As indicated above, the homeostasis
of cellular proteins is tightly regulated by the PQC system, but it is also regulated at the
mRNA level by non-sense mediated mRNA decay. Both systems are needed to suppress
the accumulation of variant protein while keeping the normal protein at sufficient levels
in cardiac muscle cells. It was recently shown that transcription of both alleles occurs
independently and in a stochastic manner, where one cell favours one allele and the next cell
favours the other allele.26 This burst-like, stochastic on/off switching of allele transcription
does not affect mRNA and protein levels in case of homozygous wild-type alleles. However,
heterozygosity of alleles as present in genotype-positive individuals may introduce cell-to-cell
variation with one cardiomyocyte expressing high levels of variant protein, while variant levels
may be low in another cardiomyocyte.27 Indeed, it has been shown that MYH7 gene variants
cause a variable variant to wild-type ratio of mRNA expression in cardiomyocytes from the
same heart.26,28
The DOSIS consortium showed intercellular variation of cMyBP-C myofilament protein
expression due to truncating MYBPC3 variants in the myocardium of HCM patients.29
The functional consequences of the variable protein expression, which results in a mosaic
pattern of cardiomyocytes with low and high variant/wild-type expression, remain to be
determined. Loss of cMyBP-C causes severe dysfunction in mouse studies and engineered
heart tissue.30,31 We propose that the intercellular variation of cMyBP-C protein levels
causes inhomogeneous contraction and relaxation and underlies the formation of myofibrillar
disarray, a currently unexplained disease characteristic of HCM. As ageing reduces the quality
of PQC, an age-dependent progression of the degree of allelic imbalance and cell-to-cell
variation may contribute to cardiomyopathy development.
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In conclusion, monogenetic cardiomyopathies have been intensely studied in the last three
decades, and this has resulted in major progress in understanding what genes are involved.
On the other hand, the striking heterogeneity, the highly variable age of onset, and the
presence of gene variant carriers that never develop disease is as of yet largely unexplained.
Given the profound repercussion for carriers, patients and family members we must improve
our understanding of the individual’s response to the presence of a pathogenic gene variant.
DOSIS aims to study unexplored mechanisms that will probably modify the pathogenic gene
variant (Figure 1.3).
Figure 1.3: By combining cellular, genetic and clinical data from well-phenotyped national patient
cohorts, DOSIS strives to define disease factors that in addition to the pathogenic gene variant
cause and aggravate cardiac disease in cardiomyopathy patients.
We have set up important initiatives and collaborations and have generated preliminary
results showing that environmental and genetic modifiers are indeed important in our
understanding. In the future we will step up our initiatives and projects and have identified
an agenda, which contains - what we feel - important additional factors that when fully
understood will guide clinicians in proper diagnosis, risk prediction, prognostication and,
ultimately, cause-specific novel treatments.
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AIM AND OUTLINE OF THIS THESIS
I. DIVERSE CLINICAL PHENOTYPES
Variants in the exact same gene may cause diverse forms of cardiomyopathy. In Chapter 2
we investigated three different TPM1 variants observed in DCM and RCM. In addition to a
comprehensive clinical evaluation showing the heterogeneous cardiomyopathy phenotype, we
describe, for the first time, the compound heterozygote TPM1E62Q/M281T gene variants in
a child with RCM. Since in thin filament cardiomyopathies, altered intracellular calcium
homeostasis may contribute to contractile dysfunction and ultimately perturb cardiac
structure,32,33 we overexpressed the identified TPM1 variants in HL-1 cardiomyocytes to
measure the effect on the resulting calcium transients.
II. PROTEIN QUALITY CONTROL AND MICROTUBLE SIGNATURE IN
CARDIOMYOPATHIES
The PQC is crucial for cardiac health and requires the collaboration of all its components
to be functional. In chapter 3, we present recent mechanistic findings on the role of
proteostasis derailment in inherited cardiomyopathies with a special focus on the presence
of sarcomeric gene mutations. We were interested in whether key modulators of the PQC,
such as heat shock proteins (HSPs), Ubiquitin-proteasome system and autophagy, are
disease- and mutation-specifically altered and derailed in cardiomyopathies. Inter-individual
differences in the capacity of the PQC and/or the specific effect of the sarcomeric gene
mutation on the PQC may explain part of the disease heterogeneity. Since all three PQC
components are pharmacologically targetable, we provide therapeutic strategy suggestions
to improve the clinical outcome of cardiomyopathy patients.
In chapter 4 the focus is shifted towards two gene variants in the small heat shock
protein HSPB5 (alpha-B crystallin) that cause dominantly inherited DCM.34,35 HSPB5
function relies on oligomerization of HSPB5 proteins and oligomeric dynamics are important
for HSPB5 to bind to destabilized client proteins.36 In a first step, we overexpressed the two
HSPB5 variants in various cell systems to measure loss of function of HSPB complexes,
formation of aggregates, insolubilization and the effect on calcium transients. In a second
step, we studied whether introduction of two different secondary gene variants alleviates
protein aggregation and leads to regain of chaperone and contractile function.
The development of atrial fibrillation (AF) is an often complication of inherited
cardiomyopathies either as a direct consequence of disease-specific defects, secondary
to the primary illness, or a combination thereof.37 In chapter 5, left and right atrial
appendages of patients undergoing coronary artery bypass grafting were collected. Prior
to surgery, oral geranylgeranylacetone (GGA), a HSP protein inducer, or placebo was
administered for three days to determine HSPB1, HSPA1, HSPA5, HSPD1, heat shock
factor-1 (HSF1) and phosphorylation HSF1 levels in the appendages and the occurrence of
postoperative atrial fibrillation. The myofilament fraction was investigated for HSPB1 and




In more than half of HCM patients a causative mutation is identified in genes encoding
sarcomere proteins. With more than 1500 identified HCM-causing mutations, the
heterogeneity in genetic background of HCM is enormous.38 We performed an unbiased
proteomics approach in cardiac tissue from a clinically well-phenotyped HCM patient group
to define if genotype-specific changes at the protein level may explain the heterogeneity
in disease development (chapter 6). Furthermore, a novel MYBPC32373insG mouse model
was used to confirm functional relevance of our proteomic findings.
Sarcomere proteins are highly abundant proteins in cardiomyocytes and mutant forms of
these likely stress the PQC system. As mentioned before, the PQC system relies on a
functional microtubule network to maintain proteostasis. Therefore, in the same clinically
well-phenotyped HCM patient group, we quantified microtubule network markers (for
example acetylation of α-tubulin) and key PQC players, such as stabilizing and refolding
HSPs and degradation markers (ubiquitinated proteins, p62, LC3BII) (chapter 7). We
aimed to understand if the presence of a sarcomere mutation differentially affects PQC and
assessed mutation-specific PQC changes by comparing HCM with missense mutations and
haploinsufficiency-causing MYBPC3 (cardiac myosin-binding protein-C) mutations.
Besides the different genotypes, sex-differences in clinical presentation contribute to
the phenotypic heterogeneity of HCM patients. The observations so far point to a higher
disease prevalence in men and a higher age of women at the time of diagnosis as well as at
the time of myectomy.10,39 Since the disease severity in female patients with HCM may be
underestimated due to the smaller cardiac anatomy than men and setting the diagnostic
criterion of ≥15 mm wall thickness without taking correction by body surface area into
account,11 it is important to study cellular differences which are caused by sex differences.
In chapter 8, we analysed sex-differences at the protein level in proteomics data of HCM
patient tissue to define sex-specific protein expression which may explain the differences in
clinical presentation such as diastolic dysfunction.
Triggered by our findings of increased levels of α-tubulin and posttranslational modifications
(acetylation and detyrosination) in genotype-positive HCM patients at the time of septal
myectomy (chapter 6 and 7), we were interested whether we observe the same changes of
the microtubule network in various model systems for hypertrophy and/or heart failure in
mouse and swine (chapter 9). Furthermore, we investigated whether the observed changes
are HCM-specific remodelling of the microtubule network or also apply to other inherited
or acquired cardiac diseases, such as DCM and ischemic heart disease.
III. DROSOPHILA MELANOGASTER – A MODEL SYSTEM TO STUDY
INHERITED CARDIOMYOPATHIES
In the third part of this thesis, we aimed to generate clustered regularly interspaced, short
palindromic repeats (CRISPR)/CRISPR-associated (Cas)9-edited Drosophila melanogaster
strains as a model system to study inherited cardiomyopathies and test drug interventions.
In chapter 10, we intended to study two distinct TNNI3 variants (wupA in Drosophila
melanogaster), whereby one variant is causing DCM and the other one HCM in humans.
In chapter 11, we introduced two distinct Mhc variants to investigate the effects of
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HCM-causing variants in humans located in either the head or the tail region of the protein.
All four variants represent orthologues of clinically relevant variants in humans.
Our attempt using scarless CRISPR/Cas9-mediated genome editing to make the
wupA-mutant strains in chapter 10 was not successful and therefore we provide various
explanations for the observed dominant lethal phenotype of both CRISPR edited strains.
In chapter 11, we thoroughly describe the phenotype of the two Mhc-mutant Drosophila
melanogaster strains.
In chapter 12, we summarize and discuss the data obtained in our experimental
chapters and provide future perspectives related to PQC derailment and microtubule
remodelling in inherited cardiomyopathies.
Sources of funding: CVON-DOSIS consortium 2014-40 Netherlands Heart Foundation
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ABSTRACT
BACKGROUND
Variants within the alpha-tropomyosin gene (TPM1) cause dominantly inherited
cardiomyopathies, including dilated (DCM), hypertrophic (HCM) and restrictive (RCM)
cardiomyopathy. Here we investigated whether TPM1 variants observed in DCM and HCM
patients affect cardiomyocyte physiology differently.
METHODS
We identified a large family with DCM carrying a recently identified TPM1 gene variant
(T201M) and a child with RCM with compound heterozygote TPM1 variants (E62Q and
M281T) whose family members carrying single variants show diastolic dysfunction and HCM.
The effects of TPM1 variants (T201M, E62Q or M281T) and of a plasmid containing both
the E62Q and M281T variants on single-cell Ca2+ transients (CaT) in HL-1 cardiomyocytes
were studied. To define toxic threshold levels, we performed dose-dependent transfection of
TPM1 variants. In addition, cardiomyocyte structure was studied in human cardiac biopsies
with TPM1 variants.
RESULTS
Overexpression of TPM1 variants led to time-dependent progressive deterioration of CaT,
with the smallest effect seen for E62Q and larger and similar effects seen for the T201M and
M281T variants. Overexpression of E62Q/M281T did not exacerbate the effects seen with
overexpression of a single TPM1 variant. T201M (DCM) replaced endogenous tropomyosin
dose-dependently, while M281T (HCM) did not. Human cardiac biopsies with TPM1
variants revealed loss of sarcomeric structures.
CONCLUSION
All TPM1 variants result in reduced cardiomyocyte CaT amplitudes and loss of sarcomeric




Cardiomyopathies are a heterogeneous group of diseases of the myocardium that are
associated with mechanical and/or electrical dysfunction and frequently caused by a genetic
defect.1 The working group on Myocardial and Pericardial Diseases of the European Society
of Cardiology proposed a clinically oriented classification system in which heart muscle
disorders are grouped into the following subtypes according to ventricular morphology and
function: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive
cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC) and
unclassified cardiomyopathies.1,2
Pathogenic variants in sarcomere genes are a frequent cause of cardiomyopathies
and may lead to different cardiomyopathy subtypes.3 One of these sarcomere genes is
TPM1 , which encodes alpha-tropomyosin and causes HCM (10 TPM1 gene variants),
DCM (11 TPM1 variants), cardiomyopathy (2 TPM1 variants) and left-ventricular
non-compaction (3 TPM1 variants) according to ClinVar database (January 2020).4
All reported TPM1 variants are missense variants that result in a single amino acid
substitution, and they account for 1.5% of all likely pathogenic and pathogenic gene
variants in HCM and 1.9% in DCM.5
Since distinct variants in the same sarcomere gene have been observed to cause
either HCM or DCM, it has been proposed that these gene variants have to trigger two
different series of events to culminate in the distinct cardiomyopathy subtypes.6 Several
studies have been published on the functional consequences of TPM1 variants, adding to
our understanding of the different pathophysiological processes that lead to distinct forms
of cardiomyopathy.7-9
Here we describe a large family with DCM carrying a TPM1 variant that was previously
reported in a large Dutch cohort study.10 We also identified compound heterozygote TPM1
variants in a child with RCM, with family members carrying one of the two variants and
showing HCM(-like) phenotypes. As changes in calcium-handling have been suggested to
be central in determining the type of remodelling that occurs in genetic cardiomyopathies,11
we expressed the three TPM1 variants in HL-1 cardiomyocytes and measured the resulting
Ca2+ transients (CaT).
METHODS
The comprehensive method section is available in the Data Supplement.
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RESULTS
CLINICAL CHARACTERISTICS OF DCM FAMILY MEMBERS
Two probands (III:20 and IV:5) were investigated separately at the outpatient clinic and
diagnosed with DCM. Clinical data of members of this DCM family (Figure 2.1A) are listed
in Table 2.1. Individual III:20 complained of progressive dyspnoea, had a dilated LV and a
LV ejection fraction (LVEF) of 15%, leading to a diagnosis of DCM at age 31. She received
an implantable cardioverter defibrillator (ICD) at age 40. Ten years later, her LVEF was
18%. Genetic testing revealed that she carried the c.602C>T (p.(Thr201Met)) variant in
exon 6 of TPM1 (referred to as T201M), which had been previously identified in a large
Dutch cohort study of DCM patients.10 We classified T201M as likely pathogenic because
it fulfills one strong and two moderate criteria (Table SI). This variant has not been further
investigated so far.
Figure 2.1: Pedigree of TPM1 variant carrier and echocardiographic images of a DCM
patient. (A) Pedigree of the DCM family. Presence (+) or absence (-) of the TPM1 variant
c.602C>T p.(Thr201Met) is indicated for the analysed subjects. (B) Parasternal long axis view and
(C) apical 4-chamber view of patient IV:5 (DCM family) at presentation. The left ventricle is dilated
(normal value <58 mm) and fractional shortening (FS) is reduced (normal value >25%). The left
atrium is also enlarged (normal value <40 mm). (D) Pedigree of the family with the RCM patient.
Presence (E62Q and/or M281T/-) or absence (-) of the TPM1 variants c.184G>C p.(Glu62Gln)
and c.842T>C p.(Met281Thr) is indicated for the analysed subjects. Squares represent males and
circles represent females. Filled symbols indicate those with a diagnosis of (A) DCM and (D)
RCM or HCM. Vertical lines indicate those who are asymptomatic or with mild signs or features of
cardiomyopathies. Slashed symbols indicate deceased subjects. Arrowhead mark the index cases.
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Table 2.1: Clinical data of members of DCM family.
Pedi- TPM1 1st presentation Echocardiogram Phenotypes
gree genotype Age Reason LVEDd LVESd FS LVEF
(years) (mm) (mm) (%) (%)
II:1 p.(Thr201Met)* NA D/83yr
II:4 p.(Thr201Met) 84 Screening 62 44 29 NA DCM, atrial fibrillation
II:10 p.(Thr201Met)* NA D/63yr, “enlarged
heart”
II:11 p.(Thr201Met) 62 Dyspnoea 59 40 32 35 DCM, ICD at 66yr,
replaced at 84yr, nsVTs
II:13 p.(Thr201Met) 70 Screening 61 50 18 35 DCM, atrial fibrillation
at 75yr, no ICD
III:3 p.(Thr201Met) 53 CVA 60 45 25 NA DCM, no follow-up
available
III:5 p.(Thr201Met)* NA D/44yr, traffic accident
III:7 p.(Thr201Met) 53 Screening 56 40 29 44 DCM, no follow-up
available
III:11 p.(Thr201Met) 43 Dyspnoea 62 54 13 36 At 46yr discharged from
follow-up after
normalization echo
III:13 p.(Thr201Met) 53 Screening 52 37 29 50 No follow-up available
III:16 p.(Thr201Met) 48 Screening 42 29 31 55 At 57yr mild diastolic
dysfunction, no DCM
III:20 p.(Thr201Met) 31 Dyspnoea 67 60 10 15 ICD at 40yr, LVEF 18%
at 50yr
III:22 p.(Thr201Met) 38 Screening 58 47 19 28 DCM, no follow-up
available
III:24 p.(Thr201Met) 47 Screening 48 30 38 60 Asymptomatic, no signs
of DCM at 56yr
III:25 p.(Thr201Met) 45 Screening 51 34 33 55 Asymptomatic, no signs
of DCM at 53yr
IV:1 p.(Thr201Met) 33 Screening 59 45 24 NA No follow-up available
IV:5 p.(Thr201Met) 21 Dyspnoea 82 74 10 12 ICD at 21yr, at 34yr no
ICD shocks, LVEF 40%
IV:7 p.(Thr201Met) 24 Screening No signs of DCM, no
follow-up available
IV:10 p.(Thr201Met) 18 Screening 52 37 29 60 Asymptomatic, LVEF
54% at 25yr
IV:13 p.(Thr201Met) 14 Screening 51 32 37 68 Asymptomatic, no signs
of DCM at 22yr
IV:14 p.(Thr201Met) 12 Screening 51 33 35 62 Asymptomatic, no signs
of DCM at 19yr
IV:15 p.(Thr201Met) 21 Screening 41 Mild DCM, no
follow-up available
IV:17 p.(Thr201Met) 13 Screening 48 32 33 62 Died of heart failure at
24yr
IV:22 p.(Thr201Met) 7 Screening 41 29 29 55 Asymptomatic, LVEF
50% at 19yr
IV:23 p.(Thr201Met) 19 Screening 58 37 36 60 Asymptomatic, no signs
of DCM at 27yr
V:1 p.(Thr201Met) 6 Screening 41 28 32 62 Asymptomatic, LVEF
41% at 17yr
V:3 p.(Thr201Met) 6 Screening 39 26 33 NA No signs of DCM at 6yr
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Table 2.1: Continued
Pedi- TPM1 1st presentation Echocardiogram Phenotypes
gree genotype Age Reason LVEDd LVESd FS LVEF
(years) (mm) (mm) (%) (%)
V:4 p.(Thr201Met) 3 Screening 36 23 36 NA No signs of DCM at 3yr
V:5 p.(Thr201Met) 3 Screening 37 22 41 NA No signs of DCM at 3yr
* obligate carrier; CVA, cerebrovascular accident; D/, death; DCM, dilated cardiomyopathy; echo,
echocardiogram; FS, fractional shortening; ICD, implantable cardioverter-defibrillator; LVEDd, left
ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESd, left ventricular
end-systolic diameter; NA, not available; nsVT, non-sustained ventricular tachycardia; yr, years.
This proband’s son (IV:17) died at age 24 from heart failure that had worsened after a high
energy trauma (car accident) two months before his death. Her sister (III:22) was diagnosed
with DCM at age 38 following family screening, but no follow-up is available. Two other
siblings tested negative for the familial TPM1 variant. The father of the proband (II:11)
was diagnosed with DCM at age 62. At age 66, he received an ICD, which was replaced at
age 84. No ICD shocks were recorded.
The other proband in this family (IV:5) was diagnosed with DCM (Figures 2.1B-C) and
received an ICD at age 21. After 13 years of follow-up, he had not experienced any ICD
shocks and his LVEF was 40%. His mother (III:5) died at age 44 in a traffic accident. His
maternal aunt (III:7) was diagnosed with DCM at age 53 following family screening. His
maternal grandfather (II:4), who had not undergone prior cardiac evaluations, was diagnosed
with DCM and atrial fibrillation at age 84 following family screening.
Both probands were linked to the same ancestral couple (I:1 and I:2). After cascade family
screening, 29 family members were identified as carriers of the familial TPM1 variant. The
phenotypic variability and age-related penetrance is further illustrated by III:24 and III:25,
who were asymptomatic and without signs of DCM at ages 56 and 53, respectively. The
penetrance, as indicated by age at DCM diagnosis, is shown in Figure SI. The youngest age
at diagnosis was 17 (V:1), though this individual was asymptomatic at that time. At age
60, a diagnosis of DCM was made in 55% of the family members who carried the T201M
variant.
CLINICAL CHARACTERISTICS OF RCM FAMILY MEMBERS
We describe, for the first time, compound heterozygote TPM1 variants in a child with
RCM, with family members carrying one of the two variants and showing HCM(-like)
phenotypes (Figure 2.1D).
An asymptomatic 6-year-old girl (V:1) was referred to the paediatrician after the sudden
death of her brother (V:2) at 22 months of age. No autopsy was performed, and no
DNA was available for genetic testing. At age six, the proband’s cardiac evaluation was
normal. At age nine, she was referred to a paediatric cardiologist because she reported
chest pain during exercise. Cardiac evaluation showed bi-atrial dilatation with near-normal
LV volume and raised ventricular end-diastolic pressures at cardiac catheterization. There
was no evidence of LV hypertrophy or constrictive pericarditis. Based on these findings,
a diagnosis of RCM was made in this patient. At age 12, she received an orthotopic
cardiac transplantation, and she reached adult age in good clinical condition. Genetic
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screening identified two missense variants in TPM1 : c.184G>C (p.(Glu62Gln)) (referred
to as E62Q) and c.842T>C (p.(Met281Thr)) (referred to as M281T). Both variants
had previously been identified in HCM patients.12,13 We classified both variants as likely
pathogenic, with E62Q fulfilling one strong and two moderate criteria and M281T fulfilling
two moderate and ≥2 supporting criteria (Table SI).
The proband’s sister (V:3) had a normal cardiac evaluation at age seven and has so
far not undergone genetic testing. The proband’s father (IV:11), a carrier of the E62Q
variant, had minor abnormalities suggestive for RCM, with mild LV diastolic dysfunction
on echo. Her mother (IV:12), a carrier of the M281T variant, was asymptomatic but
had a mildly enlarged left atrium at age 40. The maternal uncle (IV:13), also a carrier
of the M281T variant, was asymptomatic, but echocardiography at age 40 showed mild
LV hypertrophy (13 mm). The paternal grandmother (III:12) and other carriers in her
generation (III) who were positive for the E62Q variant showed stable diastolic dysfunction
and atrial dilatation in an age range of 51-69 years. Notably, a cousin of the father (IV:8),
a carrier of the E62Q variant, was diagnosed with HCM at age 17 with an LV wall thickness
of 18 mm.
TIME-DEPENDENT REDUCTION OF CALCIUM TRANSIENT AMPLITUDE BY
TPM1 VARIANTS
Variants in TPM1 may lead to disturbed intracellular calcium handling that contributes
to contractile dysfunction,14 and different changes in calcium handling have been linked
to the development of either DCM or HCM.11 We therefore overexpressed the three
identified TPM1 variants (untagged, 0.75 µg/µL) in HL-1 cardiomyocytes and determined
the effect on CaT. All three TPM1 variants significantly reduced CaT amplitude 48 h
post-transfection when compared to HL-1 cardiomyocytes overexpressing untagged
wild-type TPM1 (Figures 2.2A,G and SII).
The reduction in CaT amplitude was significantly larger for TPM1T201M and TPM1M281T
compared to TPM1WT, with means ± SEM of 34.90% ± 0.05 and 35.78% ± 0.04,
respectively, while the reduction for the TPM1E62Q variant was smaller (19.33% ± 0.07). As
the RCM patient carried both the E62Q and M281T variants (TPM1E62Q/M281T), we studied
if expression of both variants exacerbated the phenotype and found that TPM1E62Q/M281T
expression did not significantly decrease CaT (24.64% ± 0.06) in comparison to the
reductions we saw for the individual variants. Longer overexpression (72 h) of all TPM1
variants further reduced the CaT amplitude, but did not change the variant-specific effects
that we had observed 48 h post-transfection (Figures 2.2B,E). With the exception of
TPM1E62Q/M281T 48 h post-transfection, no significant differences in calcium re-uptake
kinetics were observed between the wild-type and variant TPM1 forms 48 h and 72 h
post-transfection (Figure 2.2C-D,F-G).
DOSE-DEPENDENT EFFECT OF TPM1 VARIANTS EXPRESSION
Since overexpression of TPM1T201M and TPM1M281T 48 h post-transfection resulted in a
strong reduction in CaT amplitudes, we wanted to see if this effect is dose-dependent. Using
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Figure 2.2: Time- (B-I) and dose-dependent (J-N) transfection of TPM1 variants.
(A) Schematic representation of the ratio of double transfected DNA. 0.25 µg/mL DNA encoding
RFP (red circle) was co-transfected with 0.75 (used in B-I), 0.50 or 0.25 µg/mL DNA encoding
TPM1 (green circle). Green circles: TPM1 plasmids. Red circle: RFP plasmid. Thick green line:
exogenous TPM1 encoded by TPM1 plasmid. Thick black line: endogenous TPM1. Grey circles:
actin. Complex of yellow circles: troponin complex. (B) Quantified CaT amplitude data of single
HL-1 cardiomyocytes 48 h post-transfection. N = number of transfections; n = number of measured
HL-1 cardiomyocytes that were RFP-positive transfected. Exponential curve fitting was applied to
obtain (C) the mean time constant of CaT decay (tau) and (D) the time to 70% decay. (E)
Quantified CaT amplitude data of single HL-1 cardiomyocytes 72 h post-transfection, (F) tau and
(G) time to 70% decay. Representative CaT traces detected (H) 48 h and (I) 72 h post-transfection.
(J) Due to the amino-terminal V5-tag, exogenous TPM1 (green line) was larger and therefore
displayed migration on Western blot that was distinguishable from endogenous TPM1 (black line).
(K) Representative blot images for endogenous (TPM1-antibody) and exogenous (V5-antibody)
TPM1 expression level after dose-dependent double transfection of TPM1 and RFP. Ctrl: Control
cell lysate to compare different membranes. (L) Dose-dependent expression of exogenous V5-tagged
TPM1WT, TPM1T201M and TPM1M281T. Each dot represents one transfection and each value was
normalized to the mean of TPM1WT_0.75µg/mL. (M) Endogenous TPM1 levels after dose-dependent
transfection. (N) Quantified CaT amplitude data of single HL-1 cardiomyocytes 48 h after
dose-dependent double transfection (N = 2) of untagged wild-type/variant TPM1 and RFP. Per
transfection, each CaT value was normalized to the mean value of overexpressed (B-I) TPM1WT




different ratios of RFP (0.25 µg/mL) and V5-tagged TPM1 (0.25, 0.50 and 0.75 µg/mL
(used in previous experiment)), we were able to express TPM1 in a dose-dependent
manner (Figures 2.2J-L and SIII). Transfection of TPM1WT and TPM1T201M resulted in
partial replacement of endogenous TPM1 (Figure 2.2M). Notably, endogenous TPM1 levels
increased with higher doses of transfected TPM1M281T. Dose-dependent transfection of
untagged TPM1 variants and CaT assessment 48 h post-transfection showed that calcium
handling dysfunction was influenced by the dose of TPM1T201M (Figure 2.2N), showing
significant effects at 0.5 µg/mL and a trend toward significance at 0.75 µg/mL TPM1T201M
levels. Transfection of 0.25 µg/mL TPM1T201M, however, had no detrimental effect on CaT
amplitude, while transfection of 0.25 µg/mL TPM1M281T already significantly decreased CaT
amplitude. A lower transfection dose of TPM1M281T reduced CaT amplitude more than a
higher one.
TPM1 VARIANTS HAVE NO EFFECT ON AUTOPHAGY AND F-ACTIN
Based on the increase in endogenous TPM1 after high-dose transfection of TPM1M281T,
we defined the effect of TPM1 variants on components of cellular protein quality control.
Immunofluorescent staining of V5-tagged TPM1 revealed no difference in localization of
TPM1 variants 48 h post-transfection, nor the formation of aggregates (Figure SIVA).
We also observed unaltered levels of markers for cardiac-specific proteins (α-actinin and
myosing heavy chain 7 (MYH7)), autophagy (LC3B and p62), endoplasmic reticulum stress
(phosphorylation of translation-initiation factor eIF2α) and stress fibers (F-actin) in HL-1
cardiomyocytes transfected with TPM1 variants as compared to wild-type TPM1-transfected
cardiomyocytes (Figures SIV-V).
LOSS OF SARCOMERIC STRUCTURES IN HUMAN TISSUE BIOPSIES WITH
TPM1 VARIANTS
As HL-1 cardiomyocytes do not show the highly organized myofilament structure of adult
cardiomyocytes,15,16 we determined the localization of TPM1 in the myocardium of patients
carrying either the TPM1T201M variant or the TPM1E62Q/M281T variants. We stained patient
samples (small endomyocardial biopsies) with antibodies against TPM1 and α-actinin. Both
biopsies showed a loss of cardiomyocyte-typical architecture indicated by a loss of sarcomere
striations and a loss of intact cardiac muscle fibers (Figure 2.3). TPM1 epitopes appeared
disrupted and were not organized in the characteristic contractile filaments, and this was
accompanied by an almost complete loss of α-actinin. Biopsies from end-stage ischemic
heart failure and non-failing subjects were used as controls, and these show the expected
sarcomere striation and distribution of TPM1 and α-actinin.
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Figure 2.3: Representative images of immunohistochemical staining for TPM1 (left column)
and α-actinin (right column) of endomyocardial biopsies.(A) Subject (III:11) with TPM1 T201M
variants, (B) proband (V:1) with TPM1 E62Q/M281T variants, (C) remote area biopsies from the
left ventricle of one of three patients with end-stage ischemic heart failure (HF) and (D) septal
tissue from one of four subjects that died due to a non-cardiac cause of death (non-failing Ctrl).




Gene variants in thin filament components, including alpha-tropomyosin, are known to
cause a complex heterogeneous pattern of progressive ventricular remodelling and clinical
phenotypes.17 Our study confirms this clinical heterogeneity in two families with TPM1
variants and different cardiomyopathy subtypes, namely TPM1T201M (DCM) and TPM1E62Q
and TPM1M281T (HCM; and in combination RCM). We also describe, for the first time,
compound heterozygote TPM1E62Q/M281T variants in a child with RCM. Overall, the
genotypes and diverse clinical characteristics of the family members of the DCM and RCM
probands suggest that additional causal factors are necessary for the development of cardiac
abnormalities in carriers of a heterozygous TPM1 variant, whereas compound heterozygosity
for TPM1 variants causes severe cardiomyopathy in childhood.
IMPAIRED CARDIAC PERFORMANCE DUE TO REDUCED CALCIUM
TRANSIENT AMPLITUDES
In thin filament cardiomyopathies, altered myocellular Ca2+ homeostasis may trigger events
that remodel the cardiomyocyte and ultimately perturb cardiac structure.17,18 Data from
experiments in which adenovirus was used to express human HCM-causing variants in
isolated guinea pig left ventricular cardiomyocytes showed that altered CaT were one of
the primary effects of HCM-causing variants expression.14 We therefore measured CaT
amplitudes in HL-1 cardiomyocytes. Cardiac muscle cell properties have been measured
in this model system before.19,20 In our experimental model system, production of all
TPM1 variants resulted in reduced CaT amplitudes that were independent of the clinical
cardiomyopathy phenotype. Previous studies on HCM- and DCM-related thin filament
gene variants have shown opposing changes in myofilament Ca2+-sensitivity, specifically
an increase for HCM variants and a decrease for DCM variants (reviewed in 21). Tardiff
and colleagues suggested that the observed primary alterations in Ca2+-sensitivity at the
myofilament level indicate a disruption of the Ca2+-dependent sarcomeric activation by
thin filament gene variants.17 These Ca2+-sensitivity changes were associated with similar
opposite effects in the Ca2+ affinity of myofilaments, i.e. an increase for HCM variants and
a decrease for DCM variants.14 These opposing changes may alter cytosolic Ca2+ buffering
in different ways, and thereby alter cellular CaT. Davis and colleagues provided evidence for
diverse changes in developed tension and CaT when comparing HCM- and DCM-related
cardiac troponin C variants, a finding they related to diverse activation of signaling
pathways leading to either concentric or eccentric remodelling.11 While previous studies
on TPM1 variants have also reported a similar opposite effect on the Ca2+-sensitivity of
myofilaments for HCM- and DCM-associated variants,8 two DCM-related TPM1 variants
have shown opposite effects: the Glu40Lys variant decreased Ca2+ affinity, while the
Glu54Lys variant increased Ca2+ affinity (but at 100% variant level).14 Importantly, no
effect on Ca2+ affinity was observed when a mixture of 50% variant:50% wild-type TPM1
was studied.14
In contrast, we observed a decrease in CaT for both HCM- and DCM-related TPM1
variants. The previous study and our current data indicate that TPM1 variant-related
changes in Ca2+ affinity and CaT are independent of the type of cardiac remodelling, which
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suggests that the diverse clinical cardiac phenotypes seen in affected subjects may rather
involve modifier genes and/or environmental factors.17
Reduced CaT amplitudes may affect tension development of cardiomyocytes. Comparing
the CaT amplitudes at 48 h and 72 h post-transfection revealed that longer overexpression
of all TPM1 variants further reduced CaT amplitude, suggesting a progressive pathogenic
process. This is in line with a series of longitudinal studies of patients with thin filament
variants in whom the ventricle, in particular, was progressively remodeled.22,23 Reduced CaT
amplitudes have been associated with impaired cell-shortening of HL-1 myocytes, indicating
contractile dysfunction.19 Taken together, reduced CaT amplitudes may contribute to the
poor cardiac contraction seen in affected individuals.
DOSE-DEPENDENT TRANSFECTION: MAINTENANCE TPM1
STOICHIOMETRY
Previous studies in several transgenic mouse models revealed that increasing the expression
of Tpm1 variants causes a concomitant decrease in wild-type TPM1 levels, histopathological
changes and severe impairment of both contractility and relaxation.24,25 Given the large
decrease in CaT amplitude 48 h post-transfection induced by production of TPM1T201M
(DCM) and TPM1M281 (HCM) (Figure 2.2B), and the previously reported dose-effects of
TPM1 variants, we studied the effect of dose-dependent transfection of these particular
variants. A dose-dependent decrease in endogenous TPM1 was observed upon transfection
with TPM1T201M, and this coincided with a reduction in CaT. These data illustrate that a
heterozygous gene variant, which results in a mixture of the variant and wild-type TPM1,
is sufficient to suppress CaT. We therefore propose for TPM1T201M that total TPM1 levels
seem to be kept constant to preserve stoichiometry of sarcomere proteins. Furthermore,
“threshold” levels of TPM1T201M seem to have been reached when TPM1T201M was
transfected between 0.25 and 0.50 µg/mL since functional compensation by wild-type
TPM1 became insufficient. This is in line with Tpm1 transgenic mouse experiments
indicating that there may be “threshold” levels of TPM1 expression that lead to defined
phenotypes rather than a gradient of physiological or pathological conditions.24,25 While
the total amount of TPM1 protein remained unchanged in these Tpm1 transgenic mice,
wild-type TPM1 levels were reduced by 35 to 65%.24,25
In contrast to the TPM1T201M-induced reduction of endogenous wild-type TPM1,
higher transfection doses of the TPM1M281T variant did not lower endogenous TPM1,
instead resulting in higher levels of wild-type TPM1. This indicates that synthesis of
TPM1 is increased and/or its degradation decreased in the presence of an increasing dose
of the TPM1M281T variant. The largest drop in CaT was observed at the lowest dose of
TPM1M281T transfection, which coincided with the lowest level of wild-type TPM1.
Overall, we observed that the dose-dependent effect on CaT may be determined by
the mixture of variant and wild-type TPM1. DCM- and HCM-associated TPM1 variants




DESTRUCTION OF HUMAN CARDIOMYOCYTES IN TISSUE BIOPSIES WITH
LONG-TERM EXPRESSION OF TPM1 VARIANTS
In contrast to our observations in short-term TPM1 overexpression experiments and
previous findings suggesting that Tpm1 variants expressed in isolated rat cardiomyocytes
or 12-month-old transgenic mice were normally incorporated into the sarcomeres without
altering sarcomeric structures,26,27 cardiomyocytes in the respective human tissue biopsies
displayed obvious structural changes. To our knowledge this is the first time that
cardiac biopsies with these TPM1 variants have been immunohistochemically analysed
for intracellular localization of TPM1 and α-actinin. We used α-actinin as a Z-disc
marker to assess normal myofilament structure. The combination of chronic expression of
TPM1 variants and cardiomyopathy-associated pathological remodelling may have been
responsible for the loss of cardiomyocyte-typical architecture. Cardiac histopathologic
findings of myocyte disarray and interstitial fibrosis have also been reported in an affected
subject with the TPM1D175N variant,28 and myofibril loss has been observed in subjects
with HCM, DCM and RCM.29-31 Reduced myofibril density may subsequently impair
contractility and enhance the respective cardiomyopathy-associated pathomechanisms.
Since the TPM1 epitopes appeared disrupted and not organized in the characteristic
contractile filaments and α-actinin was almost completely lost, we hypothesize that
these TPM1 variants affect the sarcomeric organization, especially assembly of α-actinin.
TPM1 -deficient cardiomyocytes have been shown to assemble aberrant F-actin fibrils
with α-actinin puncta dispersed irregularly along their lengths.32 Moreover, disrupting
the tropomodulin–TPM1 interaction in chicken cardiac myocytes led to thin filament
depolymerization and disassembly that was accompanied by perturbation of Z-lines,
thick filaments and titin filaments.33 Likewise, the TPM1 variants we studied may
disrupt interactions of TPM1, leading to its depolymerization and, as a consequence, to
disassembly of α-actinin.
LIMITATIONS OF HL-1 CARDIOMYOCYTES
As sarcomeric structures are immature,15,16 HL-1 cardiomyocytes present with limited
contractility.16 We therefore focused on the effect on Ca2+ transients since disturbed Ca2+
handling will impair contractility. CaT data in HL-1 cardiomyocytes has been shown to
be similar to that of isolated rat and dog atrial cardiomyocytes, indicating that HL-1
cardiomyocytes represent a cardiac cell model to trace changes in Ca2+ transients in
relation to cardiac diseases.19,34
HL-1 cardiomyocytes are immortalized cells of mouse atrial origin and therefore do
not precisely recapitulate a cellular milieu that reflects the ventricular cardiac myocytes
in human or of acutely isolated ventricular cardiomyocytes.35 In future, it is important
to test these TPM1 variants in a human cell-based model such as human iPSC-derived
cardiomyocytes.
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CONCLUSION
In conclusion, various TPM1 variants lead to heterogeneous clinical manifestations of
different cardiomyopathy subtypes. Overexpression of TPM1 variants led to time-dependent
progressive deterioration of cardiomyocyte CaT amplitudes. The dose-dependent effect
on CaT was opposite for DCM- and HCM-associated TPM1 variants. Overall, our data
indicate that reduced cardiomyocyte CaT amplitudes and loss of sarcomeric structures are
independent of the TPM1 variant and of the clinical cardiomyopathy phenotype.
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ABSTRACT
Mutations in genes encoding sarcomeric proteins are the most important cause of
inherited cardiomyopathies, which are a major cause of mortality and morbidity worldwide.
Although genetic screening procedures for early disease detection have been improved
significantly, treatment to prevent or delay mutation-induced cardiac disease onset is lacking.
Recent findings indicate that loss of protein quality control (PQC) is a central factor
in the disease pathology leading to derailment of cellular protein homeostasis. Loss of
PQC includes impairment of heat shock proteins, the ubiquitin-proteasome system and
autophagy. This may result in accumulation of misfolded and aggregation-prone mutant
proteins, loss of sarcomeric and cytoskeletal proteins, and, ultimately, loss of cardiac
function. PQC derailment can be a direct effect of the mutation-induced activation, a
compensatory mechanism due to mutation-induced cellular dysfunction or a consequence
of the simultaneous occurrence of the mutation and a secondary hit. In this review,
we discuss recent mechanistic findings on the role of proteostasis derailment in inherited




Cardiomyopathies (CM) constitute one of the most common causes of sudden cardiac death
in young adults and represent major causes for cardiac transplantation.1 Disease onset
generally ranges between 20-50 years of age. CMs are defined by abnormal myocardial
structure and function in the absence of any other diseases sufficient to cause these
abnormalities.2 These can be sub-classified based on their functional phenotype and
their specific morphological changes. The most common types are hypertrophic CM
(HCM), characterized by increased left ventricular (LV) wall thickness often occurring
asymmetrically, and dilated CM (DCM), in which the presence of LV dilatation is
accompanied by contractile dysfunction.2 Besides HCM and DCM, there are less frequent
forms such as restrictive CM (RCM) and desmin-related cardiomyopathy.2 All these
cardiomyopathies can be familial and are typically inherited in an autosomal dominant
manner. Mutations in genes encoding sarcomeric proteins are the most common cause of
these types of CMs.3 However, the genotype-phenotype relationship is far from clear. The
variations in age of CM onset and disease phenotype suggest that additional factors play a
role in CM pathogenesis.
Accumulating evidence indicates the presence of derailed proteostasis in CMs as well
as its contribution to CM onset and progression. This derailment could either be caused
directly by the mutation or indirectly due to a compensatory mechanism. In the former
case, the mutant protein might be instable or improperly folded leading to direct activation
of the protein quality control (PQC). In the latter case, the mutation does not interfere
with protein folding or stability but causes functional impairment which in turn leads
to cellular stress and indirect activation of the PQC. Furthermore, the “secondary-hit”
model may apply in CMs, in which a primary sarcomere mutation enhances vulnerability
to secondary stressors which increases cellular burden resulting in PQC derailment. This
review summarizes the current knowledge about perturbations in the different components
of the PQC in CMs that are caused by mutations in sarcomeric proteins.
PROTEOSTASIS NETWORK ENSURES CARDIAC HEALTH
The heart has a very limited regenerative capacity and therefore requires surveillance
by a system that maintains protein homeostasis to ensure cardiac health.4 The PQC
system sustains proteostasis by refolding misfolded proteins or removing them if refolding
is impossible. It is composed of heat shock proteins (HSPs), the ubiquitin-proteasome
system (UPS) and autophagy. PQC is only then functional when all three components are
operative and interact with each other. This means that derailment of one of the parts
might impair the function of the others in a direct or indirect manner. In a physiological
state, protein folding and refolding is ensured by HSPs and their regulators. Terminally
misfolded and aggregation-prone proteins are cleared by the two degradation systems, i.e.
the UPS and autophagy, that work in collaboration with the HSPs (Figure 3.1). First, the
different parts of the PQC in normal physiology are described, before addressing their role
in CMs.
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Figure 3.1: Collaboration of the protein quality control components.
Stress leads to misfolding of proteins which may result in abnormal interaction and subsequent
aggregation. Small HSPs (white/grey rectangle) and HSPs with ATPase activity (blue moon shape
with black rectangle) prevent aggregation formation by binding to the hydrophobic surfaces of
misfolded protein. They either refold the misfolded protein to its native structure or initiate its
polyubiquitination (Ub, orange hexagon). Misfolded proteins with polyubiquitin chains linked to
lysine 48 (K48) are mainly degraded by the proteasome. Misfolded proteins carrying K63-linked




HSPs, originally identified as heat responsive proteins, are constitutively expressed in the
cell to serve as molecular chaperones to ensure correct folding and assembly of proteins.
HSPs are classified in two categories: the small HSPs with a low molecular weight
(15-30 kDa) and the chaperones with a high molecular weight (>30 kDa).
One functional group of HSPs are chaperonin complexes, which are ATP-dependent
chaperones with a barrel-like structure, that provide correct folding of nascent proteins
after translation. Besides their folding function during protein translation, HSPs are also
induced in response to cellular and environmental stressors to maintain a healthy cellular
proteostasis by clearance of misfolded proteins.5,6
As reviewed by Garrido et al, small HSPs show an ATP-independent holdase activity. This
means that they bind to misfolded proteins, keep them in a state competent for either
refolding or degradation, and thereby prevent or attenuate their aggregation. Due to the
association of small HSPs with the HSPs that have an ATP-dependent folding activity,
the misfolded proteins can be refolded into their native and functional conformation.7
The binding affinity of HSPs to the misfolded protein is dependent on the chaperone
cofactors bound to the HSPs. Furthermore, this binding of chaperone cofactors determines
the processing of the misfolded protein for either refolding or degradation. Chaperone
cofactors involved in degradation pathways can switch off the refolding activity of HSPs
by inhibiting their ATPase activity and assist the HSPs and the UPS or autophagy in the
breakdown of misfolded proteins (Figure 3.2).8,9 The degradation of the thick filament
protein myosin-binding protein-C (MyBP-C), for instance, is mediated via the chaperone
cofactor HSC70 playing a major role in regulating MyBP-C protein turnover.10 These
degradation pathways are addressed in the following sections.
To maintain the structure and function of the highly dynamic cardiac sarcomeres, HSPs
play an important role. The molecular chaperones GimC (Prefoldin), chaperonin TCP-1
Ring Complex (TRiC), αB-crystallin and HSP27 ensure correct folding and assembly of
proteins, maturation of actin and prevent aggregate formation.11-14 HSP27 is mostly found
as high–molecular weight oligomers in the cytosol of unstressed cells.15 Upon stress, HSP27
deoligomerizes and translocates to F-actin and thereby stabilizes the F-actin network.16
To assemble the myosin thick filament, the chaperones UNC-45, HSP90 and HSP70 are
required, whereas the actin filament is self-assembled.17-19 Several members of the small
HSPs family are expressed in the heart and associate with cytoskeletal proteins.20,21 These
HSPBs stabilize cytoskeletal structures and improve coping with stress situations.21-23
UBIQUITIN-PROTEASOME SYSTEM
In case of terminally misfolded proteins, that failed be refolded, HSPs and their chaperone
cofactors recruit enzymes to mediate polyubiquitination of the target substrate and thereby
mark them for the appropriate degradation pathway. Short-lived proteins are typically
degraded by the UPS, whereas autophagy is mainly used for degrading long-lived proteins
and entire organelles.24,25
The polyubiquitination of the target substrate requires the sequential action of three
enzymes. The ubiquitin-activating enzyme (E1) activates ubiquitin which is then
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Figure 3.2: Chaperone cofactor binding determines the heat shock protein (HSP) function.
Small HSPs (white/grey rectangle) and HSPs with ATPase activity (blue moon shape with black
rectangle) bind to the misfolded protein to stabilize it. Dependent on the chaperone cofactors
(green circles or turquoise squares), the misfolded protein gets either refolded or ubiquitinated for
subsequent degradation. If refolding is impossible, the chaperone cofactors can be exchanged to
promote degradation. In case of ubiquitination, the chaperone cofactors can switch off the HSP
refolding activity by blocking the ATPase activity and, together with HSPs, assist in clearance of
the misfolded protein via the degradation pathways.
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transferred to a ubiquitin-conjugating enzyme (E2). In the last step, a ubiquitin ligase (E3)
links ubiquitin from the E2 enzyme to a lysine residue of the target protein. There are only
two E1 enzymes, several E2 enzymes and many E3 ligases, each of which recognizes one
or several specific protein motifs. Therefore, the substrate specificity is achieved by the
selectivity of the different E3 ligases.26,27 Dependent on the combination of E2 enzyme
and E3 ligase, polyubiquitin chains are linked to the preceding ubiquitin molecule either via
lysine 48 (K48) or via lysine 63 (K63) which marks the protein for degradation. Therefore,
the polyubiquitination process determines the degradation pathways: Proteins carrying
K48-linked polyubiquitin chains are predominantly targeted to proteasomal degradation,
and proteins carrying K63-linked polyubiquitin chains enter the autophagic pathways as
discussed in the following paragraph.28
K48-linked polyubiquitinated proteins are transferred to the proteasome, which is
almost exclusively the 26S proteasome in eukaryotic cells. This protein complex consist
of one 20S core- and two 19S regulatory subunits forming a barrel-like structure. The
regulatory subunits have ubiquitin-binding sites to recognize polyubiquitinated proteins
and unfold them using their ATPase activity. The unfolded proteins are transferred to the
catalytic core and proteolytically cleaved.29 Sarcomeric proteins have an average turnover
rate of 5-10 days.30,31 Therefore, they rely on a proper functioning UPS to regulate their
clearance. Once dissociated from the myofibrils, ubiquitin-conjugating enzymes mark the
proteins for proteasomal degradation by adding K48-linked polyubiquitin chains.31,32 In
cardiomyocytes, this step is mediated by the MuRF family of E3 ligases.33,34
AUTOPHAGY
Autophagy cleans up aggregates or proteins via lysosomal breakdown that cannot be
refolded by chaperones or processed by the UPS.35 During macroautophagy, herein referred
to as autophagy, membrane enclosed vesicles are formed containing the targeted cellular
components. First, an isolation membrane is formed engulfing the cytoplasmic material.
The membrane expands until the edges fuse to form the autophagosome.36 Fusion of
the autophagosome with a lysosome leads to an autolysosome which breaks down the
cargo.37 During selective autophagy, proteins carrying a K63-linked polyubiquitin chain are
degraded. In the case the proteasome is overwhelmed with proteins carrying a K48-linked
ubiquitin chain, such as aggregated proteins, they can also be cleared via autophagy.
Their polyubiquitin chain docks to the adaptor protein p62/SQSTM1 which enables the
translocation into the autophagosome.38 Acidic lysosomal hydrolases degrade the captured
material together with the inner membrane and the resulting macromolecules are recycled
into ATP, amino acids and fatty acids.
Autophagy is found to be upregulated in response to starvation, growth factor withdrawal or
high bioenergetic demands.39-42 The ability to sequester and break down entire organelles,
such as mitochondria, peroxisomes, endoplasmic reticulum and intact intracellular
microorganisms, makes autophagy a unique and essential process in the cell. Especially
in post-mitotic cells like cardiomyocytes, basal activation of autophagy is important to
maintain a balanced proteostasis by degradation of long-lived proteins, lipid droplets and
dysfunctional organelles.24 Cardiomyocytes have a low basal autophagic activity under
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normal conditions. Upon stress, the formation of protein aggregates is facilitated and
triggers activation of autophagy.43 Furthermore, cardiac autophagy is initiated in response
to energy stress during periods of nutrient deprivation or high metabolic demand.44
PROTEOSTASIS DERAILMENT IN INHERITED
CARDIOMYOPATHIES
The PQC is of great importance in many cardiac diseases caused by ‘wear and tear’,
including cardiac amyloidosis, myocardial infarction and atrial fibrillation.45-48 The
activation of PQC in a variety of cardiac stress conditions can be considered as a positive
compensatory response to maintain proteostasis. This might be especially true in the
case of inherited CMs, where mutant protein expression is the disease-causing mechanism.
Recent studies provide evidence for a causative role of the PQC in CM. On one hand,
mutations in components of the PQC itself can cause CM. This has been described
for the R120G mutation in CRYAB encoding for the chaperone αB-crystallin, causing
desmin-related CM, and the P209L mutation in the chaperone cofactor BAG3, leading to
juvenile DCM.49,50 Mutations in PQC components as causes of inherited CM are rare, but
PQC impairment can also occur as a result of CM-causing sarcomeric mutations. In this
case, mutant sarcomeric proteins may impair the function of the PQC through overload of
its components including HSPs, UPS and autophagy. This could lead to increased levels of
mutant protein, exacerbating CM disease progression.
So far, the role of PQC has been investigated only in a limited number of studies on
CM caused by sarcomeric gene mutations. In vitro information is available for HCM-
and DCM-causing mutations in ACTC1. Furthermore, it has been studied in vivo with
HCM-causing mutations in MYBPC3, MYH7 and MYOZ2, DCM-causing NEBL mutations
and RCM-causing TNNI3 mutations (Table 3.1). In the following sections, the interaction
between CM and derailments of the different parts of the PQC are described in detail.
Table 3.1: Overview of structural changes and adaptations in the protein quality
control system related to cardiomyopathies.
Gene Pheno- Morphological Chaperones UPS Autophagy
type abnormalities
ACTC1
HCM not reported + (in vitro)51 not reported not reported
DCM not reported + (in vitro)51 not reported not reported







not reported not reported not reported






↓ (mice)55 ↑ (human)56 ↓
(mice)55
DCM not reported not reported not reported not reported




Gene Pheno- Morphological Chaperones UPS Autophagy
type abnormalities
DCM not reported not reported not reported not reported
MYH7
HCM not reported not reported not reported ↑ (human)56
DCM not reported not reported not reported not reported
RCM not reported not reported not reported not reported
MYL2 HCM not reported not reported not reported not reported
MYL3
HCM not reported not reported not reported not reported
RCM ultrastructural
defects (mice)57
not reported not reported not reported















HCM not reported not reported not reported not reported
DCM no evidence of
vacuolization
(human)61




not reported not reported not reported
TNNI3
HCM not reported not reported not reported not reported











not reported ↓(mice)66 not reported




not reported not reported not reported
TPM1
HCM nuclear gigantism68 not reported not reported not reported
DCM accumulation of
TPM1 (mice)69
not reported not reported not reported
RCM not reported not reported not reported not reported
Mixed genotypes are indicated with *. A "+" indicates a positive finding, whereas a "-" indicates
that it has been studied with a negative outcome.
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DIVERSE ABNORMALITIES IN HEAT SHOCK PROTEIN FUNCTION
HSP impairment or activation contribute to disease pathology in CMs. Desmin-related CM
displays HSP impairment and is either caused by mutant desmin itself or mutant chaperone
αB-crystallin. In a normal state, αB-crystallin binds to desmin and thereby prevents
its aggregation.13 Mutant desmin, however, impairs the interaction with αB-crystallin
leading to desmin accumulation and cardiomyocyte dysfunction.70 This suggests aberrant
protein aggregation can cause CM. Correspondingly, the R120G mutation in CRYAB
results in desmin-related-CM as well and also presents with aggregates containing desmin
and mutant αB-crystallin.49 Sanbe et al. showed that upregulation of HSPB8 due to
geranylgeranylacetone treatment reduces the amount of mutant αB-crystallin-containing
aggregates.71 This implies that other HSPs can compensate for the loss of function
to remove aggregates. Furthermore, in vitro experiments have shown that HCM- or
DCM-causing mutations in ACTC1, encoding cardiac actin, can interfere with its folding
by the TRiC chaperonin complex resulting in inefficient incorporation of actin into the
myofilament and its subsequent aggregation.51 Mutations in one specific subdomain of
actin affect protein stability or polymerization, making actin more prone for degradation.
Whereas mutations in other subdomains of actin cause alterations in protein-protein
interactions.72 A gene co-expression analysis of human controls and HCM samples
identified the TRiC chaperonin complex as the most differential pathway thereby further
highlighting its importance in HCM.73
By contrast, various studies on the role of PQC in CMs report on increased levels
of HSPs due to PQC activation. However, it still remains unresolved whether the increased
levels of HSPs are a direct effect of the mutant protein or a compensatory secondary effect
due to increased cellular stress. Therefore, the direct interaction of mutant protein and
HSPs needs to be studied. In mice with a truncating MYBPC3 mutation and an HCM
phenotype, increased levels of αB-crystallin have been found.54 In other CM mouse models,
independent of a sarcomeric mutation, increased levels of HSP70 have been observed.74
A study in patients with chronic heart failure due to DCM revealed a correlation of
serum HSP60 levels with disease severity.75 Since increased levels of HSP27 and HSP70
are associated with a protective effect in models for atrial fibrillation, by maintaining
cardiomyocyte function, one can speculate that increased expression of these HSPs might
be part of a compensatory protective mechanism in CM.74,76
In general, research findings indicate that HSP impairment is detrimental for cardiomyocyte
function due to a higher risk of impaired protein folding and aggregate formation. By
contrast, HSP activation in CM is considered as a beneficial effect and is most likely a
compensatory mechanism of the cell.
DERAILMENT OF THE UBIQUITIN-PROTEASOME SYSTEM
Derailed UPS function in CM affects the degradation of terminally misfolded proteins.
MYBPC3 mutations often lead to expression of truncated protein, which is not
incorporated into the sarcomere because the most C-terminal domain needed for
incorporation is missing.77 Truncated MyBP-C has not been detected in cardiac samples of
HCM patients.78 In addition, very low levels (<4%) of truncated MyBP-C, which were not
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incorporated into the sarcomeres, were found in engineered heart tissue made of MYBPC3
knock-out mouse cardiomyocytes transfected with a truncating MYBPC3 mutation.79
Therefore, it is likely that either the mutant mRNA is degraded via nonsense-mediated
mRNA decay and/or the truncated MyBP-C forms a substrate for immediate degradation
by the UPS or autophagy. Since MyBP-C is highly expressed in cardiomyocytes, high levels
of truncated protein may lead to an increased UPS burden and competitive inhibition of the
proteasome.55,80 In this case, the UPS is overwhelmed by the amount of truncated protein
that needs to be degraded. In line with this hypothesis are analyses of myectomy samples
from HCM patients with sarcomeric mutations which show a decrease in proteolytic
activity (Table 3.1).55,81 Decreased processing through the UPS system is also indicated
by the increase in overall levels of protein ubiquitination in HCM patients and animal
models which is already detectable at an early postnatal phase prior to any other symptom
development.55,66,81,82 Consistent with the studies in MYBPC3 -mutant samples, UPS
perturbations have also been found in mouse heart tissue with TNNT2 mutations.66
Patient samples with a sarcomeric mutation showed higher levels of polyubiquitination and
decreased proteolytic activity compared to healthy controls.81
In addition to overload of the UPS by mutant protein, increased oxidative stress
can also impair the function of the proteasome. In this case, the proteasomal dysfunction
would not be a direct effect of the mutant protein but a consequence of secondary
cellular changes. In CM samples, an increase in oxidation of cytosolic protein content
as well as the 19S proteasome, thereby decreasing the overall proteolytic function of
the 26S proteasome subunit, has been identified.66,81,83 In addition to the proteasome
itself, the expression of ubiquitin ligases can be altered. In an HCM mouse model
with mutant Mybpc3, the muscle specific E3 ligase Asb2β showed decreased mRNA
levels compared to wild-type mice.84 Since one of its targets is desmin, accumulation
of desmin could contribute to the HCM phenotype, as observed for desmin-related
CMs. A large HCM patient cohort and matched healthy controls were screened for
genetic variants in all three members of the MuRF family, since mutations in the gene
encoding MuRF1 were reported to cause HCM.85 In this study, a higher prevalence
of rare variants of the cardiac-specific E3 ligases MuRF1 and MuRF2 was found in
HCM patients.86 These were associated with earlier disease onset and higher penetrance
implying that disturbances of the UPS might act as a disease modifier contributing to HCM.
In contrast to HCM, in DCM the reported UPS derailments could not yet be linked
to sarcomeric mutations. A likely reason for this is that the DCM patient samples did not
carry a sarcomeric mutation and/or the underlying disease cause was not known. Tissue
analysis from explanted DCM hearts revealed increased expression of both E1 and/or E2
enzymes.87,88 Further evidence of increased ubiquitin-conjugating enzyme activity was
detected in end-stage DCM. Here, increased levels of MuRF1 and MAFbx were associated
with increased UPS degradation activity, which might be the cause of ventricle wall thinning
as observed in end-stage DCM patients.89 In line with the increased ubiquitin-conjugating
enzyme levels, increased levels of polyubiquitinated proteins have been detected in DCM
samples.87,88,90,91 This finding is further supported by a 2.3-fold reduced expression of
the deubiquitinating enzyme isopeptidase-T in DCM patients.88 Furthermore, increased
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proteolytic activity of the 26S proteasome as well as the 20S subunit peptidase activity have
been found.89-91 In contrast to HSPs, the answer to the question whether UPS activation
or inhibition would be beneficial in HCM and DCM, is not as straight forward. In an
HCM phenotype, proteasome activation might improve the hypertrophic phenotype due to
increased mutant protein degradation. However, in DCM, increased proteasome function
might augment wall thinning and therefore DCM might benefit from proteasome inhibition.
UNRESOLVED ROLE OF THE AUTOPHAGIC RESPONSE IN
CARDIOMYOPATHIES
Autophagy is a crucial mechanism in CMs that only fulfills its cytoprotective mechanisms
when it is in balance.42 Moderate activation of autophagy has beneficial effects in CM
patients by removing aggregates and supplying the cell with energy.
However, protein degradation due to excessive autophagy has been associated with different
types of CM, including HCM, DCM, ischemic CM and chemotherapy-induced CM.92-97 This
could lead to loss of myofibrils, as observed in end-stage HCM and DCM patients.98,99
In a recent study, the expression of vacuolar protein sorting 34 (Vps34), an important
autophagy regulator, was shown to be decreased in the myocardium of HCM patients and
deletion of Vsp34 resulted in an HCM-like phenotype in mice. Furthermore, decreased
expression of Vsp34 impaired the HSP-autophagy axis, as indicated by αB-crystallin-positive
aggregates.97 HCM patients with mutations in MYBPC3 or MYH7 revealed an upregulation
of autophagic vacuoles and markers, indicating increased autophagic activity.56 In a
homozygous Mybpc3 -mutant HCM mouse model, levels of autophagy markers were
increased on protein level implying autophagic activation. However, mRNA levels of these
markers were not increased. This rather suggests an accumulation of autophagic proteins
due to defective autophagic-lysosomal degradation instead of activation on transcriptional
level.55 In explanted hearts from DCM patients, the imbalance of high uibiquitination
rate and insufficient degradation may contribute to autophagic cell death.88 Vacuolization
in CMs has been reported with mutations in ACTN2, MYBPC3 and NEBL.52,53,59 This
observation suggests that the accumulation of autophagic vacuoles implies cardiomyocyte
stress. However, the interpretation of vacuole accumulation remains unclear since it could
reflect an increase in autophagic activity or an impairment of autophagosome-lysome fusion.
For a correct interpretation of the role of autophagy in CM, autophagic flux in combination
with gene and protein expression data have to be studied in the future.
ENVIRONMENTAL STRESSORS INFLUENCING THE PROTEOSTASIS
NETWORK
Besides the upper mentioned effects of the sarcomeric gene mutations on the PQC, other
environmental stressors, including physiological stress, genetic and epigenetic pathways
and inflammation, can also impair its function.100,101 In CM patients with a sarcomeric
mutation, these stressors can act as second hit and thereby determine disease severity.
Since most of CM patients become symptomatic only in a later stage of their life, the
influence of drugs directed at the PQC system as treatment modality for co-morbidities
and the age-related decline of the PQC are discussed below.
62 CHAPTER 3
3
Several anti-cancer agents block the PQC to cause a lethal proteotoxicity in cancer
cells. Anthracyclines, for example, directly impair its function by enhancing proteasomal
degradation due to increased expression of E3 ligases and increased proteasome activity as
well as inhibition of autophagy in cardiomyocytes.102-105 Furthermore, they disturb Ca2+
homeostasis, leading to endoplasmic reticulum stress, which derails protein folding.102 In
CM patients, dealing already with a sarcomeric mutation, treatment of another non-cardiac
disease can trigger the onset of CM or worsen the clinical outcome. Cardiotoxic side effects
of anthracyclines can lead to anthracycline-associated cardiomyopathy (AACM) which
presents as LV dysfunction and DCM in adults and RCM in children.106,107 Even a low
dose treatment caused anti-cancer agents-induced CM in cancer patients without a history
of cardiac disease. Genetic screening of these patients revealed truncating titin variants
which are known as a genetic cause of DCM. These variants may increase the susceptibility
for anti-cancer agents-induced CM.108 In general, patients having a genetic predisposition
for DCM are more prone to develop AACM after anthracycline treatment.109,110 It can
be speculated that the impairment of the PQC due to the anti-cancer treatment is an
additional burden to the cardiomyocyte. The clinical cardiac phenotype is caused by
insufficient clearance of the mutant protein via UPS and/or autophagy. Therefore, these
findings suggest that PQC impairment by anthracyclines can act as catalysts in the
development of CM in patients with underlying sarcomeric gene mutation.
Ageing represents another cellular stressor leading to toxic mutation effects because
of the late disease onset and development of symptoms in inherited CMs. Clinical
characteristics, such as wall thickness and diastolic function, worsen with increasing
age.111 This could be related to an age-associated decline in proteostatic function,
which is supported by the presence of damaged macromolecules and mitochondria in
aged cardiomyocytes.112 Dysfunctional mitochondria generate high levels of reactive
oxygen species, which promote proteotoxic stress and accelerate detrimental effects on the
cardiomyocyte.113 Also, the activity of the 26S proteasome is decreased during ageing which
is possibly caused by oxidation of its components.66,83,114,115 The age-dependent decline in
proteasome function increases the burden for the autophagic pathway. However, not only
the proteasome, but also the autophagy-lysosomal system declines during ageing.116 As an
example, mTOR, a negative regulator of autophagy, was upregulated during ageing in a
mouse study which indicates decreased autophagic activity.117 As a result, the activity of
the autophagic response might not be sufficient. However, similar to findings related to
the UPS, autophagy was enhanced during ageing in some animal models, suggesting an
increased need for autophagy in aged cells.118 Further research is warranted to investigate
whether the age-related decline of the PQC is causative for CM onset and/or progression.
FUTURE THERAPEUTIC IMPLICATIONS
To improve the clinical outcome of CM patients, modulation of PQC components might
serve as a novel therapeutic strategy. Figure 3.3 summarizes the three different ways and
illustrates how a sarcomeric gene mutation can lead to PQC derailment. In case of a
direct mutation effect on the PQC as well as in combination with secondary hits, targeting
of the PQC would be most beneficial and the most direct way to prevent cardiomyocyte
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dysfunction. In case where the PQC derailment is a consequence of mutation-induced
cellular disturbances, it is important to also target the cellular dysfunction to prevent
further worsening of the PQC.
Figure 3.3: Effects of sarcomeric gene mutations on the protein quality control (PQC) system.
Sarcomeric gene mutations can directly derail PQC function leading to cardiomyocyte dysfunction.
PQC derailments in cardiomyopathies (CMs) can also be a compensatory mechanism to counteract
cardiomyocyte dysfunction caused by the sarcomeric gene mutation. The secondary hit hypothesis
suggests that the PQC of cardiomyocytes carrying a sarcomeric gene mutation is more prone to
derail in response to additional cellular stressors, thereby resulting in cardiomyocyte dysfunction.
As extensively discussed in this review, PQC alterations in CMs are disease- and
mutation-specific leading to either increased or reduced function in one or several of
its components. Therefore, personalized treatment strategies are required to restore a
balanced proteostasis. Potentially, all three PQC components can be therapeutically
targeted with the appropriate compounds.
HSP expression can be induced by the drug geranylgeranylacetone. In animal models of
desmin-related CM, the induction of HSP expression by geranylgeranylacetone resulted in
a beneficial effect on heart function because desmin-aggregate formation was reduced.71
This example suggests that activation of HSPs might also be beneficial in other types of
inherited CMs since HSPs play a crucial role in coping with the mutant protein.
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The derailment of the UPS is context dependent: proteasomal function is decreased
in HCM, RCM and desmin-related CM and increased in DCM.89 Decreased proteasomal
function suggest that the misfolded proteins hamper the UPS by overwhelming it due to
permanent degradation of misfolded proteins. As a consequence, the activity of the UPS
is throttled. Therefore, UPS activation might be a beneficial therapeutic strategy in HCM
and desmin-related CM.89 In line with this, in HCM patients with a TNNT2 mutation
increased proteasomal activity was correlated with a better clinical outcome.66 In contrast,
over-activation of the UPS indicates a direct response of the UPS to the misfolded proteins
to ensure optimal clearance. However, excessive activation of the UPS transforms the
initially beneficial effects into a detrimental maladaptation that possibly contribute to
loss of myofibrils.89 Nevertheless, complete proteasome inhibition itself triggered cardiac
dysfunction and a CM-like phenotype in healthy pigs.119 Therefore, it is important to
achieve a moderate UPS response in DCM to prevent the detrimental effects of complete
proteasome inhibition.
The altered autophagic flux in CMs can be caused on the one hand directly by the
misfolded protein itself or on the other hand indirectly by compensating for the impaired
functionality of the UPS. To optimize the degradation response, the autophagic activity
needs to be pharmacologically titrated into its proteostasis promoting range.120
CONCLUSION
The PQC is crucial for cardiac health and requires the collaboration of all its components
to be functional. Key modulators of the PQC are disease- and mutation-specifically altered
and derailed in CM. Pharmacological targeting of PQC components represents a novel
therapeutic strategy to treat CMs. Since most of the described findings are retrieved from
single CM patients or experimental animal models, systematic studies in larger CM patient
populations are warranted to untie the knot of disease- and mutation-specific derailments
of the PQC.
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Dilated cardiomyopathy (DCM) is defined by the presence of left ventricular dilation and
contractile dysfunction. R120G and D109H mutations in the small heat shock protein
HSPB5 (αB-crystallin) are associated with formation of HSPB5 aggregates and dominantly
inherited DCM. HSP5 has the ability to form dynamic oligomeric complexes for which a key
role in substrate recognition and chaperoning functions is suggested. Interaction between
HSPB5 C-terminal isoleucine-proline-isoleucine (IPI) domain and a hydrophobic groove
including the amino acid serine 135 of the α-crystallin domain enables this oligomerization.
Our aim is to study the underlying mechanism of aggregate formation by HSPB5 mutations
and its effect on chaperone activity and cardiomyocyte function in experimental model
systems.
METHODS
Purified proteins and overexpression of wild-type and mutant forms of HSPB5 in HL-1
cardiomyocytes, HEK293 and S2 cells were used to study the formation of aggregates
including insolubilization, oligomer size, exchange rate, chaperone activity and the effect on
calcium transients (CaT).
RESULTS
HSPB5R120G and HSPB5D109H overexpression resulted in the formation of aggregates with
increased oligomer size and reduced exchange rate, insolubilization, loss of chaperone activity
and CaT amplitudes. Substitution of HSPB5 IPI domain to AAA and the S135Q mutation in
the HSPB5R120G and HSPB5D109H background decreased oligomer size, regained solubility,
partially prevented aggregate formation and partially restored chaperone activity. Elevated
expression of HSPB5D109H; S135Q completely protected against CaT loss. Pharmaceutical
targeting of the IPI domain with a small peptide resolubilized HSPB5R120G and HSPB5D109H.
CONCLUSION
This study shows that substitution of IPI domain to AAA or the S135Q mutation in
the HSPB5R120G and HSPB5D109H background, partially prevent aggregate formation
and restores chaperone activity suggesting a role for altered oligomerization dynamics in
cardiomyocytes remodelling and disease progression. Targeting the altered oligomerization




Dilated cardiomyopathy (DCM) is a condition with left ventricular enlargement and reduced
systolic output.1 Features often observed in DCM patients include an irregular heartbeat
(arrhythmia), shortness of breath (dyspnoea), extreme tiredness (fatigue), fainting episodes
(syncope), and swelling of the legs and feet. Familial (inherited) DCM accounts for about
35 percent of affected individuals.1 DCM-causing mutations affect genes encoding proteins
regulating structure and function of the cardiomyocytes.2 Interestingly, a restricted set
of DCM-causing mutations are found to reside in genes encoding for chaperones, the
caretakers of the cellular proteome.1 Mutations in chaperone genes include gene variants
in BAG33,4, DNAJB65, and HSPB5 (αB-crystallin)6,7. This indicates that in a significant
number of DCM cases, a collapse of protein homeostasis may be key to the disease
pathology either caused by increased substrate fragility or by impaired protein quality
control.8
In this paper, we focus on DCM-causing mutations in the small heat shock protein
HSPB5 (also referred to as αB-crystallin). The frequency of HSPB5 mutations has
not been systematically studied, but occurs less frequent than gene variants in desmin.9
The small heat shock proteins are characterized by a conserved α-crystallin domain and
variable N- and C-termini. There are 10 different human HSPBs (HSPB1-10) of which
HSPB1 and HSPB5 are amongst the most highly and widely expressed members.10,11
Together with HSPB8, these HSPBs increase their cellular expression levels upon a variety
of intrinsic and extrinsic forms of stress.12 HSPB5 binds unfolded proteins and prevents
these from aggregating irreversibly.13,14 Unlike the ATP-driven chaperones (HSPA, HSPC,
chaperonins) all HSPBs, including HSPB5, lack ATPase activity, therefore bound substrates
are generally not released spontaneously. Rather, substrates are released by the ATP-fuelled
HSPA machines to either help them refold or target them towards degradation.15-17
HSPB5 forms homo-oligomeric and hetero-oligomeric complexes with HSPB1, HSPB4,
HSPB6 and HSPB8.18-20 Although the precise role of HSPB5 oligomerization for its function
is not known, oligomeric dynamics seem to determine the state at which HSPB5 binds to
the destabilized client protein and are considered to be crucial for HSPB5 function.21-24
Several interactions contribute to HSPB5 oligomerization. The best characterized
interaction is between the IPI sequence in the C-terminus and a hydrophobic β4-β8 groove
in the α-crystallin domain (ACD). Mutation of the IPI sequence to three alanines results
in a weakening of the interactions within the oligomers and a faster exchange of the
subunits.18,19 Such an increase in oligomer dynamics has been suggested to increase the
chaperone function of HSPB5.25 Inversely, compared to wild-type HSPB5, mutations in
HSPB5 which are associated with diseases, including myofibrillar myopathy, cataract and
DCM, have been shown to result in an increase in oligomeric size,26 which could possibly
underlie decreased oligomeric dynamics and substrate handling/chaperone function. This
in particular has been suggested for the HSPB5R120G and HSPB5D109H mutations that
cause dominantly inherited DCM and cataract and result in early fatality.6,7,27 The R120
and D109 are located at opposite positions in the ACD at the dimer interface and interact
through hydrogen bonds.28,29 The R120G mutation causes a change in conformation of
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the α-crystallin domain and results in a decreased chaperone function.27,28 In patients,
the HSPB5R120G mutation is associated with insolubilization of the protein itself in
muscle tissue.6 HSPB5R120G insolubilization is accompanied by aggregation of desmin, an
intermediate filament protein, resulting in desmin-related cardiomyopathy.6 In cell models,
ectopic expression of HSPB5R120G and HSPB5D109H also leads the insolubilization of the
mutant proteins whereas ectopic expression of HSPB5WT remains detergent soluble.30-32
The underlying mechanism for this aggregation phenotype and how this phenotype
contributes to cellular dysfunction and disease onset is unknown.
In the current study, we demonstrate that expression of HSPB5R120G and HSPB5D109H in
HL-1 cardiomyocytes results in loss of function of HSPB complexes and is associated with
insolubilization of HSPB5 and contractile dysfunction. Introducing a secondary mutation
in the IPI sequence or the hydrophobic groove where the IPI sequence interacts, partially
alleviates protein aggregation and also leads to a partial regain of chaperone function and
coincident improvement of contractile function. Also, addition of IPV peptides, which bind
to the β4-β8 groove in the α-crystallin domain, to lysates of HSPB5R120G and HSPB5D109H
expressing cells results in partial resolubilization of the mutant HSPB5 proteins. These
results demonstrate that interfering with the binding of the IPI domain into the hydrophobic
groove of the ACD results in improved chaperone and contractile function. Therapies
directed at the IPI domain and/or hydrophobic groove may represent a viable strategy for
the treatment of DCM associated with HSPB5 mutations.
METHODS
PLASMIDS
pCMV-Myc-HSPB5, pCMV-Myc-HSPB5R120G and pCMV-Myc-HSPB5D109H were provided
kindly by Katie Mitzelfelt and Ivor Benjamin. The GFP-Luciferase construct was used
from.33 The V5-HSPA1A and V5-DNAJB1, V5-HSPB1 and V5-HSPB7 constructs were
created in our lab.34,35 Mutations were created by using the Quickchange kit (Qiagen) using
the primers provided in Table S1. For cloning HSPB constructs into a Drosophila pUAST
vector, restriction with Bgl2 and Xho1 was used.
CELL CULTURE AND TRANSFECTION
HL-1 cardiomyocytes were cultured in Claycomb medium containing 100 µM Norepinephrine,
0.3 mM L-ascorbic acid, 4 mM L-glutamine, 10% (v/v) FBS and 100 units/mL penicillin and
100 mg/mL streptomycin (Invitrogen) in gelatin (0.02%) coated flasks. 2*105 cells were
plated in gelatin (0.02%) coated wells and transfected after three days with Lipofectamine
2000 (Invitrogen) using a standard protocol. The experiments were performed two days
after transfection.
HEK293 cells were cultured in Dulbecco’s modified eagles medium (DMEM, Gibco)
supplemented with 10% (v/v) fetal calf serum (Greiner Bio-one, Long wood, FL, USA)
plus 100 units/mL penicillin and 100 mg/mL streptomycin (Invitrogen). One day before
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transfection 3,5*105 cells were plated in Poly-L lysin (0.001%, Sigma) coated wells.
Transfection of HEK cells was performed using polyethylenimine (PEI) according to the
manufacturer’s protocol.
S2 cells were cultured in Schneiders medium (Gibco) containing 10% (v/v) FBS and
100 units/mL penicillin and 100 mg/mL streptomycin (Invitrogen). The cells were
transfected using Effectene (Qiagen) according to standard protocol. The cells were
harvested for Western blot two days after transfection.
NP40 FRACTIONATION AND WESTERN BLOTTING
Cells were washed with PBS, lysed in 200 µL NP40 lysis buffer (60 mM KCl, 2 mM MgCl,
10% (v/v) glycerol, 0.4% (v/v) NP40, 50 mM HEPES, pH 7.5) containing fresh protease
inhibitors (EDTA free Complete, Sigma), sonicated and a 40 µL whole cell extract was
taken. Subsequently the samples were spun at 20.000g at 4°C for 20 min and a 40 µL
supernatant fraction (NP40 soluble) was taken. The pellet was washed with lysis buffer
and resuspended in 40 µL 1x Laemmli sample buffer (2% (w/v) SDS, 10% (v/v) glycerol,
0.004% (w/v) bromophenol blue, 0.125 M Tris HCl pH 6,8) and sonicated. 2x Laemmli
sample buffer was added to the whole cell extract and the supernatant fractions.
5% (v/v) β-Mercapthoethanol was added to all samples and they were boiled for 5 min.
Samples were run on 12% (w/v) polyacrylamide gels and transferred onto nitrocellulose
using a semi-dry transfer system (BioRad). The membranes were blocked for at least 1 h in
5% (w/v) milk and incubated in 3% BSA in PBST (PBS 0.1% (v/v) Tween-20) containing
the primary antibody at 4°C overnight. Subsequently the membranes were washed with
PBST and incubated with the secondary antibody (1:4000 in PBST) for 1.5 h. After
washing with PBST the membranes were detected using ECL (ThermoFischer) in the dark
room or on a BioRad Chemidoc Touch.
The antibodies used for Western blot: Myc-tag (1:1000, PL14, Enzo Life Sciences),
β-Actin (1:1000, 8H10D10, Cell Signaling), HSPB5 (1:1000, 1A7.D5, StresMarq) and GFP
(1:1000, JL8, Clontech), HSPB1 (1:1000, ADI-SPA-800, Enzo Life Sciences) and HSPA6
(1:1000, ADI-SPA-754).
SUCROSE GRADIENT FRACTIONATION
HL-1 cardiomyocytes were transfected and samples in NP40 lysis buffer were made as
previously described. Sucrose gradients of 20% to 60% (w/v) sucrose in 10 mM Tris–HCl,
pH 8, 5 mM EDTA, 50 mM NaCl were made using a Biocomp gradient master 108. The
samples were loaded on top and the gradient was spun overnight at 100.000g for 20 h at
4°C in a Sorvall discovery 90SE with an SW41 rotor. Samples of 700 µL were taken from
the top and the protein was precipitated by adding an equal volume of 25% TCA. After
an incubation of 30 min on ice the samples were spun for 15 min at 14.000 rpm 4°C. The
supernatant was removed and the pellet was washed with 500 µL 80% aceton. The samples
were spun for 15 min at 14.000 rpm 4°C, supernatant was removed and the pellets were air
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dried. The pellets were solubilized in 40 µL 1% SDS, 0.1 M NaOH. 40 µL 2x Laemmli buffer
and 5% β-Mercapthoethanol were added and the samples were boiled for 5 min.
LUCIFERASE REFOLDING ASSAY
The luciferase assay was performed in HEK293 cells 1 day after transfection using a protocol
described previously.36
IMMUNOFLUORESCENCE STAINING AND MICROSCOPY
HL-1 cells were plated on gelatine (0.02% gelatine, Sigma) coated cover slips three days
before transfection. Transfection was done as described previously. Two days after
transfection the cells were washed twice with PBS and fixed in 3,7% formaldehyde in PBS
for 20 min. The cover slips were washed twice with 0.1% triton x-100 in PBS (PBT 0.1%)
and permeabilized for 20 min in 0.2% PBT . Blocking was done for 1 h using 5% BSA in
0.1% PBT . Staining with primary antibody was done overnight at 4°C. After a wash with
0.1% PBT the cover slips were incubated with secondary antibody in 0.1% PBT for 2 h
(including DAPI or Rhodamine Phalloidin) and mounted using citifluor (Agar Scientific).
The slides were imaged with a Leica CLSM microscope. The quantifications were done by
a person blinded to the experimental conditions. Antibodies used for immunofluorescence:
Myc-tag (1:250, PL14, Enzo Life Sciences) and ubiquitylated proteins (1:250, FK2, Enzo
Life Sciences).
RECOMBINANT PROTEIN PURIFICATION
Constructs for full length and ACD HSPB5, R120G HSPB5 and HSPB1 were a gift from
the Klevit laboratory (University of Washington), and proteins were expressed and purified
as described.37,38 Briefly, all constructs were transformed in E. coli BL21 (DE3) cells, grown
to an OD600 of 0.6 in Terrific Broth (TB), and induced with 0.5 mM IPTG overnight at
18°C. For full length constructs, cells were pelleted and re-suspended in 50 mM Tris-HCl
pH 8.0, 10 mM imidazole, 500 mM NaCl and lysed by sonication. The cleared lysate was
loaded onto the Ni-NTA spin column (Qiagen) and eluted with buffer containing 300 mM
imidazole. Proteins were concentrated and further purified by size exclusion on a Superdex
200 16/600 column (GE Healthcare) equilibrated with SEC Buffer (50 mM sodium phosphate
pH 7.5, 100 mM NaCl). For ACD constructs, ammonium sulphate was added to a final
concentration of 16.9% (w/v), centrifuged, pellet discarded, and then an additional 16.9%
(w/v) ammonium sulfate was added to the supernatant to precipitate the protein from
solution. Precipitated protein was brought up and dialyzed into MonoQ Buffer A (20 mM
Tris, pH 8.0) overnight, followed by a MonoQ column (0–1 M NaCl gradient), and finally
an SEC on a Superdex S75 (GE Healthcare) equilibrated in SEC Buffer.
ISOTHERMAL TITRATION CALORIMETRY
Small HSPs were dialyzed overnight against SEC Buffer, and peptides were dissolved in
dialysis buffer. Concentration of proteins was determined using BCA assays (Thermo
Scientific), and ITC experiments were performed with a MicroCal ITC200 (GE Healthcare)
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at 25°C. For experiments, 1 mM peptide solution was titrated into a cell containing specified
small HSP at 100 µM. Calorimetric parameters were calculated using Origin® 7.0 software
and fit with a one-site binding model.
LIGHT SCATTERING ASSAYS
Solutions of R120G HSPB5 (30 µM) in SEC Buffer with listed binding partners or buffer
controls were placed in triplicate wells of a clear bottom 384-well plate. The aggregation
reaction was carried out at 37°C with continuous shaking and the OD350 was measured in
a Spectramax M5 microplate reader (Molecular Devices). Readings were taken every 2 min
for 3 h. Baseline curves of non-induced controls (3 replicates) were subtracted from induced
samples (3 replicates).
CALCIUM TRANSIENT MEASUREMENTS
For calcium transient (CaT) measurements, HL-1 cardiomyocytes were co-transfected with
0.75 µg/mL HSPB5 plasmid (wild-type or mutant) and 0.25 µg/mL RFP plasmid. 48 h
post-transfection, HL-1 cardiomyocytes were loaded and incubated at room temperature for
30 min with 1 µM of calcium indicator Fluo-4 AM (Invitrogen, Carlsbad) in Hanks Balanced
Salt Solution (HBSS) buffer (Lonza, Basel) supplemented with 1.7 µM CaCl2·H2O and
0.8 mM MgSO4·7H2O 48 h after lipofectamine transfection. HL-1 cardiomyocytes were
washed 3 times with supplemented HBSS buffer before adding Claycomb medium without
supplements. The Fluo-4 loaded HL-1 cardiomyocytes, stimulated at 1 Hz and 40 V by
a C-Pace system (IonOptix, Westwood), were excited at 488 nm and the light emitted
at 500-550 nm was live recorded with a 40 x 1.3 NA oil-objective of a high-speed Nikon
A1R confocal microscope (Nikon, Minato). Temperature (37°C) and CO2 (5%) were kept
constant in the microscope incubator. Absolute fluorescent signals were recorded and single
cell CaTs of RFP-positive transfected cells were analysed with ImageJ software (National
Institute of Health, Bethesda). To compare fluorescent signals between experiments, the
fluorescent signal at any given time (F) was divided by the fluorescent signal at rest (F0)
(Fcal = F/F0)39 CaTs were at least measured three times. Per experimental day, each CaT
value was normalized to the mean value of overexpressed wild-type HSPB5. Exponential
curve fitting was applied to obtain tau and time to 70% baseline.
QUANTIFICATION AND STATISTICAL ANALYSIS
The Western blots were quantified using ImageJ (NIH). Statistical analysis was done and
graphs were made using Graphpad Prism 5. Plotted values show the average of at least 3
independent experiments and error bars show the standard error of the mean. The Student’s
t-test was used to calculate significance. Statistical significance in CaT measurements was
estimated with Kruskal-Wallis test and Dunn’s multiple comparisons post-hoc test. P-values
below 0.05 were considered significant. In the figures p<0.05 is indicated by a *, p<0.01
by **, and p<0.001 by ***.
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RESULTS
HSPB5R120G AND HSPB5D109H FORM AGGREGATES WHEN EXPRESSED IN
HL-1 CARDIOMYOCYTES
The DCM-associated, dominant HSPB5R120G or HSPB5D109H mutants (Figure 4.1A)
can accumulate protein aggregates in cardiac tissue.6 To model this effect in vitro, we
expressed wild-type HSPB5, HSPB5R120G or HSPB5D109H in HL-1 cardiomyocytes.40 While
wild-type HSPB5 was homogeneously distributed in the cytosol of HL-1 cardiomyocytes,
both the HSPB5R120G and HSPB5D109H formed puncta throughout the cardiomyoyctes
(Figure 4.1B), suggesting formation of aggregates. To confirm aggregation, we fractionated
cardiomyocytes expressing HSPB5 wild-type or mutants using a mild detergent and found
that both mutants, but not wild-type HSPB5 were mainly present in the NP40 insoluble
fraction (Figures 4.1C-D). Immunofluorescence staining showed that ubiquitin partially
co-localized with the HSPB5R120G and HSPB5D109H puncta in the cardiomyoycytes
(Figure 4.1E).
Figure 4.1: HSPB5R120G and HSPB5D109H form aggregates when expressed in HL-1
cardiomyocytes. (A) Schematic representation of the HSPB5 protein. The amino acid sequences
of Myc-HSPB5, Myc-HSPB5R120G and Myc-HSPB5D109H are indicated. (B) Immunofluorescence
staining of HL-1 cardiomyocytes expressing Myc-HSPB5, Myc-HSPB5R120G and Myc-HSPB5D109H
stained for the Myc-tag (green), polymerized Actin (Rhodamine Phalloidin, red) and DNA (DAPI,
blue). (C) Myc-HSPB5, Myc-HSPB5R120G and Myc-HSPB5D109H were transiently expressed
in HL-1. The samples were separated in a NP40 soluble and NP40 insoluble fraction and
analysed by Western blot (D). (E) Immunofluorescence staining of HL-1 cardiomyocytes expressing
Myc-HSPB5R120G and Myc-HSPB5D109H stained for the Myc-tag (red), ubiquitylated proteins
(green) and DNA (DAPI, blue).
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We previously demonstrated that the insolubilization of HSPB5R120G is preventable by
co-expression of proteins of the HSPB family due to formation of hetero-oligomeric
complexes with HSPB5.30 To confirm this result in HL-1 cardiomyocytes and to test whether
the same is true for the HSPB5D109H mutant, we co-expressed either HSPB1 or HSPB7
with the HSPB5R120G and HSPB5D109H mutants. While overexpression of HSPB1, which
forms hetero-oligomers with HSPB5, increased the soluble fraction of both HSPB5R120G
and HSPB5D109H, HSPB7, which does not form hetero-oligomers with HSPB5, did not
(Figure S1). Similarly, co-expression of HSPA1A or DNAJB1 did not prevent or rescue
insolubilization of the two HSPB5 mutants (Figure S1). This suggests that intrinsic
misfolding can be excluded because HSPA1A and/or DNAJB1 should have rescued the
intrinsic misfolding. Moreover, the insolubilization is likely related to the formation of
oligomeric complexes as HSPB1 can compete it away.
MUTATION OF THE IPI DOMAIN REDUCES HSPB5R120G AND HSPB5D109H
INSOLUBILIZATION
To follow up the suggestion that the oligomerization of mutant HSPB5 is crucial for
its presence in protein aggregates, we interfered with the stability of HSPB5 oligomers.
The IPI domain in the C-terminus of HSPB5 is key to oligomer stability. When the IPI
sequence is mutated, it no longer binds to the hydrophobic groove on the ACD. This
weakens interactions within the oligomers and results in formation of smaller oligomers
in vitro.18,19,21-23,29 Consistently, sucrose gradient centrifugation revealed that mutating
the IPI motif into triple alanines (HSPB5IPI > AAA) resulted in smaller complexes than
HSPB5WT (Figure 4.2A).
Just as observed in vitro for HSPB5R120G,27 the HSPB5R120G and HSPB5D109H mutants
formed complexes of increased size (Figure 4.2A). Introduction of the IPI>AAA mutation
in HSPB5R120G and HSPB5D109H to HSPB5R120G; IPI > AAA and HSPB5D109H; IPI > AAA,
respectively also reduced the formation of the very large complexes present in fraction
17 (Figures 4.2A and S2A). In line with these results and consistent with our prediction,
HSPB5R120G; IP > AAA and HSPB5D109H; IPI > AAA had regained solubility (Figures 4.2B and
S2B) and puncta formation was drastically reduced (Figures 4.2C-D).
MUTATION OF THE HYDROPHOBIC GROOVE DECREASES HSPB5R120G AND
HSPB5D109H INSOLUBILIZATION
The IPI domain binds in a hydrophobic groove formed by the β4 and β8 strands of HSPB5.
Serine 135 is part of the β8 strand and is located in between two pockets in which the
isoleucines of the IPI domain bind. Mutating this serine to a glutamine has been shown to
significantly reduce the affinity of the IPI domain for the hydrophobic groove.21-23 As found
for the IPI>AAA mutants, the insolubilization of the double mutants HSPB5R120G; S135Q
and HSPB5D109H; S135Q was significantly reduced when compared to HSPB5R120G and
HSPB5D109H (Figure 4.3A).
However, the S135Q mutation also resulted in lower expression levels of HSPB5
protein (Figure 4.3B). By increasing plasmid concentrations during transfection, we
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Figure 4.2: Mutation of the IPI domain decreases Myc-HSPB5R120G and Myc-HSPB5D109H
aggregation. (A) Samples from HL-1 cardiomyocytes transiently expressing the indicated
Myc-HSPB5 proteins were run on a 20% to 60% sucrose gradient and the fractions were analysed
by Western blot. The quantifications indicate the distribution of the Myc-HSPB5 protein over
the sucrose gradient. (B) The indicated Myc-HSPB5 constructs were transiently expressed in
HL-1 cardiomyocytes and separated in a NP40 soluble and insoluble fraction. The quantification
shows the relative amount of the Myc-HSPB5 protein. (C) Immunofluorescence staining of HL-1
cardiomyocytes expressing the indicated Myc-tagged HSPB5 variants (green) and DNA (DAPI,
blue). The quantification shows the percentage of cells with puncta (D).
expressed different S135Q mutants to levels comparable to those without this mutation and
still found that this reduced the insolubilization compared to HSPB5R120G and HSPB5D109H
proteins (Figures S3A-B).
In order to investigate whether the Myc-tag influences the solubility of the HSPB5
mutants, we expressed untagged HSPB5R120G in Drosophila S2 cells (Figure S3C). These
experiments showed that also the IPI>AAA and S135Q mutations restored the solubility
of untagged HSPB5R120G (Figure S3D). We next generated triple mutants (IPI>AAA and
S135Q in the HSPB5R120G and HSPB5D109H). These also increased the NP40 solubility
compared to the single mutants (HSPB5R120G and HSPB5D109H), but these were not
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Figure 4.3: The S135Q mutation decreases Myc-HSPB5R120G and Myc-HSPB5D109H
aggregation. (A) The indicated Myc-HSPB5 constructs were transiently expressed in HL-1
cardiomyocytes. The quantification shows the relative amount of the Myc-HSPB5 proteins. The
samples were separated in a NP40 soluble and insoluble fraction (B). (C) Immunofluorescence
staining of HL-1 cardiomyocytes expressing the indicated Myc-tagged HSPB5 variants (green) and
DNA (DAPI, blue). The quantification shows the percentage of cells with puncta (D).
more soluble than the HSPB5R120G; S135Q and HSPB5D109H; S135Q or HSPB5R120G; IPI > AAA
and HSPB5D109H; IPI > AAA (Figures 4.3A-B). This is consistent with the notion of direct
contact between the IPI motif and S135 and that abrogation of either one of them suffices
to lower oligomeric stability. The data on solubility were also fully recapitulated when the
formation of puncta in cells was analysed (Figures 4.3C-D). Together, these data show
that insolubilization of HSPB5R120G and HSPB5D109H is mediated via a dominant negative
effect, i.e. the abnormal stabilization of HSPB5 complexes.
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MUTATION OF THE IPI DOMAIN AND S135Q IMPROVE HSPB5R120G AND
HSPB5D109H FUNCTION
In vitro, it has been shown that HSPB5 is a chaperone maintaining heat-unfolded or
chemically unfolded proteins in a state competent for refolding by the ATP-dependent
HSPA-chaperone machinery.17 In contrast, HSPB5R120G lost almost completely such
chaperone activity.27 Besides the diminished formation of HSPB5 aggregates when the
contact between the IPI motif and ACD of HSPB5R120G and HSPB5D109H is disrupted, we
wondered whether this also affects chaperone function. In human HEK293 cells, elevated
expression of HSPB5WT enhances the cellular ability to refold the ectopically expressed
model protein firefly luciferase after heat shock (Figures 4.4A-B).36 Consistent with the
in vitro data,27 HSPB5R120G and HSPB5D109H have almost completely lost this chaperone
activity (Figure 4.4B). Like in HL-1 cardiomyocytes, both the IPI to AAA substitution and
the S135Q mutation reduced the insolubilization of the HSPB5R120G and HSPB5D109H in
HEK293 cells (Figures 4.4A and S4A).
Figure 4.4: The IPI to AAA and the S135Q mutation improve chaperone activity of the
HSPB5R120G and HSPB5D109H mutants. (A) HEK293 cells were transiently transfected with
the indicated Myc-HSPB5 constructs and the expression was analysed by Western blot. (B) The
indicated Myc-HSPB5 variants were co-expressed with GFP-Luciferase. The cells were heat shocked
for 30 min at 43°C and re-incubated for 2 h after 37°C. The graph indicates the Luciferase activity
2 h after heat shock, relative to the Luciferase activity before the heat shock.
Excitingly, the HSPB5R120G; IPI > AAA and HSPB5D109H; IPI > AAA double mutants as well
as the HSPB5R120G; S135Q and HSPB5D109H; S135Q double mutants had regained significant
chaperone function (Figure 4.4B). This effect was not due to a promiscuous activation of
HSF-1 as evidenced by the lack of induction of the expression of typical HSF-1 regulated
chaperones like HSPB1 and HSPA6 (Figure S4B).
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MUTATION OF THE HYDROPHOBIC GROOVE RESTORES CALCIUM
TRANSIENT LOSS IN HL-1 CARDIOMYOCYTE OVEREXPRESSING
HSPB5D109H
Since mutation-related alterations in CaT may contribute to contractile dysfunction,41-43
the effect of the different HSPB5 mutants on intracellular calcium handling were
assessed in HL-1 transfected cardiomyocytes. Elevated expression of HSPB5R120G and
HSPB5D109H resulted in a reduction of peak CaT by approximately 30% compared
to CaT in cardiomyocytes overexpressing wild-type HSPB5 (Figures 4.5A-B and S5).
Modifying the IPI domain (HSPB5eIPI mut) or the hydrophobic groove (HSPB5S135Q) had
no effect on CaT. Introduction of the IPI>AAA mutation and S135Q in HSPB5R120G to
HSPB5R120G; IPI mut and HSPB5R120G; S135Q, respectively, did not restore CaT loss.
These findings show that the presence of both R120G and D109H mutation results
in CaT loss independent of the second mutation. Interestingly, elevated expression of
HSPB5D109H; S135Q completely protected against CaT loss in contrast to HSPB5D109H
and HSPB5D109H; IPI mut. In addition, the effect of wild-type HSPB5, HSPB5D109H and
HSPB5D109H; S135Q on CaT morphology, including time to 70% decay and mean time
constant of CaT decay (tau) were calculated, to determine an effect on relaxation of HL-1
cardiomyocytes. Compared to wild-type HSPB5, HSPB5D109H overexpression resulted in
slightly accelerated, but not significant different, Ca2+ decay indicated by reduction in time
to 70% decay and mean time constant of CaT decay (tau) (Figures 4.5C-D). Elevated levels
of HSPB5D109H; S135Q increased the rate of relaxation and thereby attenuated defective
Ca2+ handling.
Thus, the findings indicate that aggregated HSPB5R120G and HSPB5D109H cause
CaT loss and that the S135Q mutation in the hydrophobic groove protects against CaT
loss in case of HSPB5D109H mutation.
OLIGOMERIC DYNAMICS AND SIZE OF THE HSPB5 VARIANTS DO NOT
CORRELATE WITH FUNCTIONALITY IN VITRO
Based on the cellular data, we decided to purify a subset of the HSPB5 variants to assess
their biochemical behaviour and functionality in vitro. As expected, the oligomeric size of
the two disease-associated mutants HSPB5R120G and HSPB5D109H was higher than that of
wild-type HSPB5 (Figure 4.6A).
Figure 4.5: Effect of HSPB5 variants on calcium transient amplitudes in HL-1
cardiomyocytes. (A) Representative CaT traces and (B) quantified CaT amplitude data of single
HL-1 cardiomyocytes overexpressing wild-type and mutant HSPB5 48 h post-transfection, indicating
HSPB5D109H; S135Q double mutant to rescue CaT function . Exponential curve fitting was applied to
obtain (C) the time to 70% decay and (D) the mean time constant of CaT decay (tau). N = number
of transfections; n = number of measured HL-1 cardiomyocytes that were RFP-positive transfected;
*p<0.05, **p<0.01 and ***p<0.001 versus HSPB5 and ###p<0.001 versus HSPB5D109H.
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Figure 4.6: In vitro characteristics of HSPB5 variants.
(A) Oligomeric size of the complexes of the indicated HSPB5 variants relative to HSPB5 wild-type
(= 1.0) (B) Inverse of the exchange rates of complexes of the indicated variants relative to HSPB5
wild-type (= 1.0) (C) Inverse of the anti-aggregation effects of the indicated variants relative to
HSPB5 wild-type (= 1.0); substrate = α-lactalbumin.
Intriguingly, however, the HSPB5S135Q as well as the IPI mutant HSPB5IPI > GxG that
decrease the IPI-ACD interaction between HSPB5 monomers formed larger oligomers than
the wild-type HSPB5 (Figure 4.6A).21-23
In addition, we were unable to purify the IPI and S135Q variants in the background of the
disease-associated mutants (data not shown), suggesting they are only stable in the context
of mammalian cells expressing HSPB5 or/and other HSPB family members. We next used
fluorescent exchange experiments to test whether oligomeric exchange rates were different
between the HSPB5 variants in a manner that would explain their cellular functionality.
The exchange rates in vitro were higher for wild-type HSPB5 than for both HSPB5R120G
and HSPB5D109H. Furthermore, the exchange rates for HSPB5R120G were higher than for
HSPB5S135Q as well as the IPI mutant HSPB5IPI > GxG (Figure 4.6B). In general, among the
HSPB5 variants tested, there was no correlation between oligomeric size (Figure 4.6A) and
exchange rates (Figure 4.6B). Moreover, when assaying HSPB5 chaperone activity in vitro,
using α-lactalbumin as substrate, both disease-variants were largely inactive (Figure 4.6C),
as expected.21 There was no correlation with oligomeric size (Figure 4.6A), nor with subunit
exchange rates (Figure 4.6B), nor with the cellular data. Together these data imply that the
functionality and aggregation phenotypes of the HSPB5 variants in cells cannot be attributed
to intrinsic properties of the homo-oligomeric proteins only, but must be a combined effect
of these intrinsic properties and interactions with other (wild-type) HSPB partners and
chaperone substrates.
IPV PEPTIDES RESOLUBILIZE HSPB5R120G AND HSPB5D109H
Despite the absence of a correlation between intrinsic oligomeric behaviour of the HSPB5
variants and their chaperone function or the cellular findings, the data using the various
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genetic single and double mutant HSPB5 variants in cells suggested that targeting the
IPI-ACD interaction rescues the adverse phenotypes of the disease-associated variants and
may thus have therapeutic potential. We therefore investigated whether the functionality
of the mutants is restorable in a pharmaceutical manner using a small peptide EITIPVTHE
(IPV peptide). In vitro, the IPV peptide, but not a control EITAPVTHE peptide (APV)
binds to the β4-β8 groove of the crystallin dimer of both wild-type HSPB5 and HSPB5R120G
with equal affinity (Figures 4.7A-B).
Figure 4.7: IPV peptides resolubilize Myc-HSPB5R120G aggregates. (A, B) IPV peptide binds
to HSPB5, HSPB5R120G and HSPB1c. Representative ITC results for binding of IPV and control
peptide, APV, are shown. The average of two independent replicates is shown in the table. Error
is standard error of the mean (SEM). (C) Light scattering of purified, human HSPB5 (30 µM)
treated with IPV peptide (30 µM), APV peptide control (30 µM) or DMSO. Results are the average
of triplicate wells. The error bars represent standard deviation (SD), but are often too small to
be seen. Additionally, the results are representative of three independent experiments. (D, E)
Myc-HSPB5R120G was expressed in HEK293 cells and lysed in NP40 lysis buffer. The cell lysates
were incubated overnight at 4°C with DMSO, IPV peptides or APV peptides and separated in a
NP40 soluble and insoluble fraction.
Using light scattering analyses, the IPV, but not APV peptide reduced the size of the
HSPB5R120G oligomers significantly (Figure 4.7C). Unfortunately, the hydrophobic IPV
peptides are not effectively taken up by cells. Yet, as a proof of concept to test whether the
peptides are also effective within the context of the cell, we generated lysates of HEK293
cells expressing HSPB5R120G, added the peptides and subsequently compared the fraction
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of HSPB5R120G in the NP40 insoluble with and without addition of the IPV peptides. Like
for the purified proteins, also in cell lysates addition of the IPV peptides, but not the APV
peptides resulted in partial resolubilization of the HSPB5R120G mutant (Figures 4.7D-E).
Together, our data imply that targeting the IPI-ACD interaction has therapeutic potential
in HSPB5-related cardiomyopathies.
DISCUSSION
The HSPB5R120G and HSPB5D109H mutations lead to dilated cardiomyopathy, myopathy
and cataract. Misfolding and aggregation of HSPB5 has been proposed as part of the
pathomechanisms. Here, we show that aggregation of both HSPB5R120G and HSPB5D109H
can be reduced by interference with the IPI-ACD interactions between HSPB5 molecules.
This decrease in aggregation is accompanied by a partial restoration of its chaperone and
contractile function.
HSPB5 forms oligomers of heterogeneous size. The dynamics of this oligomerization, i.e.
the constant and rapid disassembly and reassembly of mono- and/or dimers of HSPB5 from
and to the oligomers, has been proposed to be important for its chaperone function.21-24
One of the best characterized interactions in the HSPB5 oligomers is between the IPI motif
in the N-terminus of one HSPB5 monomer with the ACD of an adjacent HSPB molecule.
Our cellular data, using both genetic and pharmacological approaches, reveal that targeting
this IPI-ACD interaction not only decreases the steady state oligomeric sizes of the mutant
HSPB5 complexes, but also counteracts their aggregation-proneness and partially restores
their chaperone and contractile function. This would suggest that the HSPB5R120G and
HSPB5D109H mutants may not be intrinsically dysfunctional chaperones, but that they
have lost their dynamics within the cellular context with either wild-type HSPB5 or other
HSPB members. Therefore, these complexes become trapped with their substrates and no
longer serve as entities from which the ATP-dependent chaperones can extract the client
proteins.
Unexpectedly, whereas our in vitro data confirmed the larger steady state oligomeric
sizes and defective chaperone activities of the HSPB5R120G and HSPB5D109H mutants
(Figure 4.6),27,28 they did not reveal a correlation between oligomeric size and function
(in vitro nor in cells). These experiments also did not reveal a correlation of oligomeric
size with the in vitro subunit exchange rates of the HSPB5 variants when assayed in
isolation. This implies that the functionality of HSPB proteins may not only be related to
intrinsic properties of the monomers and their oligomeric behaviours. Rather, they seem
to also, and maybe even to a large extent, be determined by interactions that they have
within the context of living cells. One such interaction is, obviously, the interaction with
wild-type HSPB5 and other HSPB family members with whom they may from homo-
or hetero-oligomers. In this context, it is intriguing to note that co-expression of those
members of the small heat shock protein family that form hetero-oligomeric complexes
with HSPB5 can block the insolubilization of HSPB5R120G (Figure S1).30 In fact, also in
vitro mixing of wild-type HSPB5, that by itself shows no light scattering (not shown),
completely blocks the light scattering of the large HSPB5R120G oligomers (Figure S6). This
FUNCTIONAL RESCUE OF DISEASE-CAUSING HSPB5 MUTANTS 89
would imply that besides HSPB5-HSPB interactions, also interactions with the cellular
client proteins play a role in the eventual complex stability and dynamics which do or do
not allow efficient substrate recovery by ATP-dependent chaperones.
Irrespective of the lack of understanding of the main determinants of HSPB5 chaperone
function, our data show that preformed aggregates of HSPB5R120G and HSPB5D109H
with their client proteins are not unresolvable aggregated material, but can be reversed
by a pharmaceutical intervention. Therefore, our data provide a proof-of-concept that
interference with IPI-ACD interactions between HSPB5 molecules alters oligomerization
dynamics. This has putative therapeutic value as shown before using chemical chaperones
for HSPB5R120G related cataract treatment.44 Since the peptide used in our experiments is
very hydrophobic and has a very poor membrane permeability, its clinical applicability is
limited and further research is warranted to investigate whether it can be developed into a
therapeutic option.
Calcium handing in cardiac muscle cells is central in cell signalling, contractility and
regulation of rhythm. Here we used HL-1 cardiomyocytes to also define the impact
of HSPB5 mutants on intracellular calcium handling. HL-1 cardiomyocytes share
characteristics with human adult cardiomyocytes and have therefore been successfully
utilized to study pathomechanisms of human atrial fibrillation41-43 and for drug screening
studies.45 Previous studies showed that changes in the expression level of HSPs coincide
with alterations in intracellular calcium handling and cardiac disease progression. Depletion
of HSPB1 decreased CaT amplitudes and changed expression of calsequestrin, a
calcium-binding protein which interacts directly with the ryanodine receptor.46 Comparative
proteomics of HSPB1-null mice revealed that absence of HSPB1 mainly impacted
proteins involved in Ca2+ homeostasis, contraction, energy metabolism and HSPA9.47
HSP20 directly interacts with protein phosphatase 1 and overexpression of HSP20
resulted in phosphorylation of phospholamban at both Ser16 and Thr17 and thereby
enhanced sarcoplasmic reticulum Ca2+ cycling.48 HSPB5 and HSPB2 deficiency in
myocardial ischemia in aging mice caused a reduction of Ca2+ -dependent metabolism
and respiration.49 Currently, knowledge about the effects of mutant HSP caused by point
mutations on calcium handling is limited. Our study shows that the presence of R120G or
D109H mutation have an effect on CaT amplitudes (Figure 4.5). Loss of CaT coincides
with loss of chaperone activity as demonstrated by overexpression of HSPB5R120G and
HSPB5D109H (Figure 4.6). In contrast, overexpression of HSPB5WT and HSPB5S135Q does
not affect CaT amplitude and chaperone activity.
Our finding of R120G mutation disturbing/altering calcium handling is in line with
literature.50 HspB5 R120G transgenic mice showed endoplasmic reticulum (ER) stress
and impaired Ca2+ regulation, including alterations in the expression of Ca2+ -handling
proteins, leading to ageing-related cardiac dysfunction and arrhythmias. Especially for
the R120G, it seems that the sole presence of the mutation will have an effect on Ca2+
handling. Introduction of a second mutation in the hydrophobic groove or IPI domain did
not correct perturbed CaT.
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So far, nothing is published on how the D109H mutation affects Ca2+ handling. Our
findings suggest (1) that aggregated HSPB5D109H causes CaT loss and (2) that the location
of the secondary mutation in HSPB5D109H determines the protection against CaT loss.
While the second mutation in the hydrophobic groove restores the CaT loss, modifying
the IPI domain has no rescuing effect on CaT loss. Moreover, 48 h overexpression of
HSPB5D109H results in mild alterations of CaT decay which may affect relaxation of
cardiomyocytes. Further experiments are required to explain the underlying mechanism for
the difference in CaT amplitudes for HSPB5D109H; IPI mutand HSPB5D109H; S135Q.
Except for HSPB5D109H; S135Q, overexpression of mutant HSPB5 results in a reduction of
peak CaT. These altered CaTs may impair cardiac function. For instance, reduction of
peak CaT in HL-1 cardiomyocytes were accompanied by reduced cell shortening41 and this
diminished cardiac contractility is a characteristic feature of DCM.51 Mutant HSPB5 may
alter cardiomyocyte function via perturbations in Ca2+ kinetics, and thereby contribute to
depressed contractility and to the development of DCM.52
CONCLUSION
This study shows that aggregation of both HSPB5R120G and HSPB5D109H can be reduced
by interference with the IPI-ACD interactions between HSPB5 molecules. This decrease
in aggregation is accompanied by increased solubilisation, a partial restoration of its
chaperone function and in the case HSPB5D109H; S135Q a complete protection against CaT
loss. Targeting the altered oligomerization dynamics may represent a novel strategy to treat
cellular dysfunction in DCM patients carrying HSPB5R120G and HSPB5D109H mutations.
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ABSTRACT
BACKGROUND
Heat shock proteins (HSPs) are important chaperones which regulate the maintenance
of a healthy protein quality control in the cell. Impairment of HSPs is associated with
ageing-related neurodegenerative and cardiac diseases. A well-known compound to increase
HSPs, through the activation of heat shock factor-1 (HSF1), is geranylgeranylacetone
(GGA). GGA increases HSPs in various tissues, but so far, it is unknown whether GGA
can increase HSP expression in human heart tissue.
OBJECTIVE
Test whether oral GGA treatment increases HSP expression in atrial appendages of patients
undergoing cardiac surgery.
METHODS
HSPB1, HSPA1, HSPD1, HSPA5, HSF1 and phosphorylated HSF1 levels were measured
by Western blot analysis in right and left atrial appendages (RAAs and LAAs, respectively)
collected from patients undergoing coronary artery bypass grafting (CABG) who were treated
with placebo (n=13) or GGA 400 mg/day (n=13) 3 days before surgery. Myofilament
fractions were isolated from LAAs to determine the level of HSPB1 and HSPA1 present in
these fractions.
RESULTS
GGA treatment significantly increased HSPB1 and HSPA1 expression levels in RAA and LAA
compared to the placebo group, while HSF1, phosphorylated HSF1, HSPD1 and HSPA5
were unchanged. In addition, GGA treatment significantly enhanced HSPB1 levels at the
myofilaments compared to placebo.
CONCLUSION
Three days of GGA treatment is associated with higher HSPB1 and HSPA1 expression
levels in RAA and LAA of patients undergoing CABG surgery and higher HSPB1 levels at
the myofilaments. These findings pave the way to study the role of GGA as a protective
compound against other cardiac diseases, including postoperative AF.
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INTRODUCTION
Proteostasis, the balance in protein synthesis, folding, assembly, trafficking and clearance
by protein degradation systems, is controlled by the protein quality control (PQC) system.1
The PQC is an exquisitely regulated network in which the most important chaperones,
heat shock proteins (HSPs), play a crucial role. In response to changes in the intra- and
extracellular environment cells upregulate HSPs to maintain proteostasis. HSPs guide
protein folding of nascent proteins, stabilize misfolded proteins, prevent protein aggregation,
guide protein refolding and facilitate degradation of unwanted and damaged proteins.1
HSPs consist of five HSP families: HSPA (HSP70), HSPB (small HSPs), HSPC (HSP90),
HSPD (HSP60), and DnaJB (HSP40), each with several family members and (specific)
co-factors in various cellular localizations, with distinct and overlapping functions.1
Previous studies reveal that especially HSPBs are abundant in cardiomyocytes and
that they safeguard a balanced proteostasis in cardiomyocytes.2 HSPBs interact with
contractile and microtubule proteins, thereby stabilizing the cardiomyocyte structure, and
conserving the contractile and electrophysiological function of the cardiomyocytes.3-5 Upon
cellular stress, such as heat shock, hypoxia, oxidative stress, inflammation and ischemia,
the heat shock response (HSR) is stimulated by activation of heat shock transcription
factors (HSF). HSF1 is the major regulator of HSP transcription in eukaryotes.6 Upon
phosphorylation, the activated HSF1 translocates to the nucleus, and binds to the heat
shock elements in hsp genes, thereby resulting in the transcription and expression of HSPs7
to maintain proteostasis. However, HSP levels decline with age and long term stress
leading to a derailment in proteostasis by altered stability of proteins and accumulation of
protein damage, unfolding and breakdown.1,8 Therefore, impairment of tissue HSP levels is
associated with ageing-related misfolded protein diseases such as Parkinson’s, Huntington’s,
and Alzheimer’s disease, as well as cardiac diseases, including AF and myocardial infarction.1
It is because of the central role of HSPs in PQC that pharmacological modulation of HSP
levels represents an interesting target to treat ageing-related diseases.
A well-known compound to induce HSPs levels, via activation of the heat shock
transcription factor-1 (HSF1), is geranylgeranylacetone (GGA).9 This nontoxic acyclic
isoprenoid compound is since 1984 clinically applied as an anti-ulcer drug in Asian
countries.10,11 Since then, GGA has been examined in numerous disease models in
animals, where it was found to induce HSPs in various tissues, including gastric mucosa,
intestine, liver, peritoneum, kidney, retina, central nervous system, skeletal muscle and
the myocardium.9,12-14 Moreover, pharmacologically induction of HSPs with GGA revealed
pleiotropic protective effects by attenuating electrical as well as structural changes in
experimental models for heart failure, myocardial infarction, desmin-related cardiomyopathy
and AF.4,8,15-19 Therefore, GGA may also represent a protective agent in human heart
diseases, but so far it is unknown whether GGA can increase HSP expression in human
heart tissue. In the current study, we tested whether oral GGA treatment can increase
HSF1-mediated HSP expression in atrial appendages of patients undergoing cardiac surgery.
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METHODS
STUDY POPULATION
Patients scheduled for coronary artery bypass grafting (CABG) surgery received GGA
(Selbex®, Teprenone Eisai Japan) (GGA) (n=13) or placebo (n=13) for 3 days before
and 3 days after on-pump CABG in a dosage of 400 mg per day. Patients selected for this
study did not have a history of AF, confirmed by Holter monitoring and high-resolution ECG
to measure signal-averaged P-wave duration (cut off point of >150 ms for AF indication).
Both patients and physicians were blinded for the treatment. Patients were recruited at
the A.N. Bakulev National Medical Research Center of Cardiovascular Surgery in Moscow,
Russia. The study was approved by the Institutional Committee on Human Research (MEC
Bakulev 12-029/12323). Prior to study enrolment, each patient is provided an oral and
written explanation of the study procedure and written informed consent is obtained from
all patients. The study was carried out according to the principals of the Declaration of
Helsinki. Clinical data from the patients were obtained from electronic patient files.
SAMPLING
Tissue samples of RAA and LAA were collected just before aortic cross-clamping, snap
frozen in liquid nitrogen and stored at -80°C.
WHOLE PROTEIN ISOLATION
Part of the frozen tissue was homogenized on ice with SDS sample buffer (10% (w/v) SDS,
50% (v/v) glycerol, 0.33 M Tris–HCl pH 6.8, 10% (v/v) β-mercaptoethanol,
0.05% (w/v) bromophenol blue and protease and phosphatase inhibitors) using an
Ultra-Turrax. The lysates were centrifuged, supernatant was collected, passed through an
insulin syringe and boiled for 6 min.
MYOFILAMENT FRACTIONATION
Part of the frozen tissue was dissected in F60 buffer (0.447% (w/v) KCl,
0.204% (w/v) Imidazole and 0.041% (w/v) MgCl2·6H2O) containing protease and
phosphatase inhibitors. Supernatant containing cell debris was discarded. A precooled
metal homogenizer bead was placed in the sample tubes and 2 cycles of (a) adding cold
F60 buffer including 1% triton, (b) homogenization in the Qiagen Tissuelyser II for 3 min
at maximum speed, (c) centrifugation at 14,000×g (10 min at 4°C) and (d) removal of the
supernatant (soluble fraction) were performed. Subsequently the pellet was homogenized
in RIPA buffer (R0278, Merck, USA). Supernatant was collected obtaining the myofilament
fraction, which was mixed with 4x NuPage Buffer (6.68% (w/v) Tris-HCl, 6.84% (w/v) Tris
base, 8% (w/v) lithium dodecyl sulphate, 40% (v/v) glycerol, 0.060% (w/v) EDTA,




Equal amounts of protein were analysed by Western blot analysis as described in detail in
the Supplementary Information and Supplementary Information Table S1.
STATISTICAL ANALYSIS




The study population consisted of 26 CABG patients, of whom 13 were treated with placebo
and 13 with GGA. All of them received beta-blockers before surgery. All patients had
normal resting heart rate between 65-70 beats per min, normal cardiac output, with normal
left ventricular ejection fraction between 59-60%. Baseline characteristics of the study
population are summarized in Table 5.1.
Table 5.1: Clinical characteristics.
Treat- Patient Age Gender Multi- LVEF Anterior- NYHA Number poAF
ment number (years) focal (%) posterior or of
athero- LA size CCS CABG
sclerosis (cm) class conduits
Placebo
1 58 Male Yes 60 4,3 II 3 No
2 46 Male No 58 4,3 II 3 No
3 54 Male Yes 59 5,5 II 2 Yes(*)
4 62 Male Yes 65 3,9 II 1 No
5 53 Female Yes 60 4,1 II 2 No
6 46 Male No 58 4,0 II 3 No
7 48 Male No 59 3,7 II 2 No
8 59 Male Yes 56 4,2 II 2 No
9 57 Male No 60 4,9 II 3 No
10 48 Male Yes 60 4,4 II 3 No
11 41 Female No 63 4,7 II 2 No
12 59 Male Yes 60 4,7 II 1 No
13 50 Male No 58 4,5 II 2 No
GGA
1 61 Male Yes 56 4,5 II 3 No
2 60 Male Yes 60 5,3 III 2 Yes(*)
3 50 Male No 59 4,2 II 3 No
4 45 Male Yes 56 4,0 III 2 No
5 50 Male Yes 60 4,2 II 3 No
6 56 Male No 60 4,0 II 3 No
7 53 Male Yes 62 4,0 II 2 No
8 42 Male Yes 56 4,4 III 2 No
9 55 Male Yes 57 4,3 III 3 No
10 51 Male No 58 4,4 III 3 No
11 63 Male Yes 60 4,9 II 3 No
12 50 Male Yes 60 4,2 II 3 No
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Table 5.1: Continued
Treat- Patient Age Gender Multi- LVEF Anterior- NYHA Number poAF
ment number (years) focal (%) posterior or of
athero- LA size CCS CABG
sclerosis (cm) class conduits
13 50 Male Yes 55 4,5 III 2 No
NYHA - New York Heart Association; CCS - The Canadian Cardiovascular Society grading scale for
angina; LVEF - left ventricular ejection fraction. (*) Tachy-form of AF developed at second day after
surgery with heart rate 180-190 per min, which lasted for 8-12 h and was eliminated after amiodarone
infusion.
There was no difference in age (placebo 53 [47 – 59] vs GGA 51 [50 – 58] years,
p=0.797), gender (placebo 11 (84.6%) male vs GGA 13 (100%) male, p=0.480), multifocal
atherosclerosis (placebo 7 (53.8%) vs GGA 10 (76.9%), p=0.411), left ventricular ejection
fraction (LVEF) (placebo 59.7 ± 2.29 vs GGA 58.4 ± 2.18, p=0.149) and left atrial size
(placebo: 4.40 ± 0.474, GGA: 4.38 ± 0.375, p=0.892), yet left atrial enlargement is
correlated with increased risk of poAF (cut-off value >5.0 cm) (p<0.001). All patients in
the placebo group have a NYHA class II, while for the GGA group there are 7 (53.8%)
patients with NYHA class II and 6 (46.2%) with class III (p=0.015). In total, two patients,
one in the placebo and one in the GGA group developed poAF. Both patients revealed
enlarged LA (cut-off value >5.0 cm), which significantly correlates with poAF (p<0.001).
GGA INDUCES HSPB1 AND HSPA1 EXPRESSION IN ATRIAL TISSUE
To study whether GGA increases the expression of HSF1 related HSPs, HSPA1, HSPB1,
HSPD1, HSF1 and phosphorylated HSF1 levels were measured in the atrial appendages.
Expression of HSPA5, which is not HSF1 related, was determined as a negative control.
GGA significantly induced HSPB1 and HSPA1 levels compared to the placebo (p=0.019 and
p=0.021, respectively) (Figures 5.1A-B). Similar levels for HSPD1, a mitochondrial HSP,
and HSPA5, were observed in both the placebo and GGA treated group (Figures 5.1C-D).
HSF1 and phosphorylated HSF1 levels were measured to test whether the HSP-inducing
effect is via HSF1 activation. GGA did not increase protein expression levels of HSF1 and
pHSF1 (Figures 5.1E-F). Lower HSPD1 levels correlated with larger LA size (p<0.01), higher
HSF1 levels correlated with larger LA size (p<0.05) and higher HSPA1 levels correlated with
lower LVEF (p<0.05) (Supplementary Information Table S2).
GGA ENHANCES HSPB1 LEVELS AT THE MYOFILAMENTS
While HSPA1 reveals its protective actions mainly in the cytosol,8 HSPB1 (co)-localizes with
myofilament proteins, including α-actinin, actin and myosin, to stabilize the myofilaments
and/or shielding the contractile proteins from cleavage by cysteine proteases, such as
calpain.8,19-20 Both HSPB1 and HSPA1 levels were higher in RAA and LAA of patients
treated with GGA in the RAA and LAA with the effect more clearly observed in LAA for
HSPB1 (p<0.05) (Figure 5.2).
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Figure 5.1: GGA increases HSF1-mediated HSP expression in atrial appendages of patients
undergoing CABG surgery. Representative Western blots (left 3 lanes placebo, right 3 lanes GGA
treated) and quantified Western blot results for HSPB1 (A), HSPA1 (B), HSPD1 (C), HSPA5 (D),
HSF1 (E) and phosphorylated HSF1 (F) relative to GAPDH in LAA and RAA of patients treated
with placebo or GGA. * is p<0.05 compared to placebo.
To investigate whether the GGA-induced increase in HSPB1 and HSPA1 results in enhanced
co-localization at the myofilaments in human heart tissue, myofilament fractions were
isolated from LAAs and utilized for Western blot analysis. Interestingly, GGA significantly
enhanced HSPB1 levels (p=0.042), but not HSPA1 levels (p=0.851), at the myofilaments
compared to placebo (Figure 5.3).
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Figure 5.2: GGA enhances HSPB1 more in LAA than RAA.
Quantified Western blot results for HSPB1 in RAA and LAA of patients treated with placebo and
GGA. * is p<0.05 compared to placebo.
Figure 5.3: GGA enhances HSPB1 and not HSPA1 levels at the myofilaments compared to
placebo. Quantified Western blot results for (A) HSPB1 and (B) HSPA1 relative to α-actinin in
LAA of patients treated with placebo (P) and GGA (G). * is p<0.05 compared to placebo.
DISCUSSION
Preclinical studies showed HSF1-mediated HSP induction by GGA treatment and subsequent
protection against various cardiac diseases.4,8,15-19 With this study we aimed to obtain proof
of concept for oral GGA treatment to increase HSP levels in human heart tissue. HSPB1,
HSPA1, HSPD1, HSPA5, HSF1 and phosphorylated HSF1 levels were measured by Western
blot analysis in RAAs and LAAs collected from patients undergoing CABG surgery who
were treated with placebo or GGA (400 mg/day for 3 days). GGA treatment associated
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with higher HSPB1 and HSPA1 levels, which are both HSF1 regulated, while it did not
have an effect on mitochondrial HSPD1 and endoplasmic reticulum HSPA5, latest is not
HSF1 regulated. HSF1 and, the activated form of HSF1, phosphorylated HSF1, were
both unchanged. Previous studies showed HSPB1 to protect against cardiac diseases by
(co)-localization to the myofilaments, thereby safeguarding cardiomyocytes from protein
damage and derailment of proteostasis by stabilizing the contractile apparatus.8,19-20 By
utilizing isolated myofilaments, we were able to show that HSPB1, but not HSPA1 levels,
were enhanced at the myofilaments by GGA treatment, in contrast to the placebo treated
atrial tissue samples. Taken together, these data indicate for the first time, that three days
of GGA treatment (400 mg/day) associated with higher HSPB1 and HSPA1 expression levels
in atrial tissue samples of patients undergoing CABG surgery and increased localization of
HSPB1 levels specifically at the myofilaments. These findings pave the way to study the
role of GGA as a protective compound in cardiac diseases, including (po)AF.
INCREASED HSPA1 AND HSPB1 LEVELS IN HEART TISSUE BY GGA
The observed increase in HSPB1 and HSPA1 expression levels in human atrial tissue is
in line with the effect of GGA in preclinical studies. In rabbits, oral GGA treatment
increased HSPA1 expression in the heart (LA), which was associated with protection
against HF-induced electrical and structural remodelling.15 Rats showed enhanced recovery
after ischemia reperfusion injury when treated with GGA (oral 200 mg/kg). In the GGA
treated rats, HSPA1 expression was increased and thereby preserved the structure of the
cardiomyocytes, compared to controls.16 In a myocardial infarction model in rats, oral GGA
treatment increased HSPB1 and HSPB8 levels, resulting in preserved mitochondrial and
cardiac pump function.17 Also, oral GGA treatment in HSPB5 R120G transgenic mice, a
model for desmin-related cardiomyopathy, improved cardiac function and increased survival
via HSPB1 and HSPB8 upregulation.18 Furthermore, GGA’s protective effects have been
extensively studied in various experimental models for AF, including tachypaced HL-1
cardiomyocytes, Drosophila melanogaster and dogs, where GGA treatment increased HSPB1
levels and protected against structural and electrical remodelling and conserved contractile
function upon tachypacing.4,8,19,21 The observed increase in HSPB1 and HSPA1 expression
levels in human atrial tissue, revealed a more pronounced effect in LAA versus RAA. This
is in line with previous studies showing enhanced structural remodelling in LAA compared
to RAA and suggests an increased stress response in LAA.22
Although no dose response and pharmacokinetic studies were conducted in the dog model
for AF, an oral dosage of 4 gr/day was used to reveal a protective effect against AF
progression.4,21 The registered clinical dose for treating gastic ulcers in Japan is 150 mg
GGA per day, revealing a maximal concentration of 2.1 µg/mL GGA in serum at 5 h after
administration. In the current study, three days of oral treatment with 400 mg GGA was
sufficient to increase HSPB1 and HSPA1 levels in human atria. So far, it is unknown whether
this clinical dose will suffice protection of the heart from developing poAF. In both the
placebo and GGA treated groups, one patient developed poAF, and these patients revealed
LA size of >5 cm and average HSPA1 and HSPB1 levels, suggesting the atrial dilation was
the cause of poAF onset. Future studies in larger patient groups should elucidate whether
three days treatment with 400 mg GGA suffices protection against development of poAF.
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ENHANCED HSPB1 LEVELS AT THE MYOFILAMENTS UPON GGA
TREATMENT
Previously, preclinical studies showed that the protective action of GGA against contractile
dysfunction is critically dependent on the induction of HSPB1, as knockdown of HSPB1
abrogated the protective effect.4,9 The current study revealed that GGA treatment associated
with higher HSPB1 levels at the myofilaments in human atrial tissue. This suggests that
HSPB1, (re-)localizes to the myofilaments, thereby shielding the contractile machinery
during stress.8,19-20 This is in line with experimental studies in rats where HSPB1 binds
to cytoskeletal, structural and contractile proteins to conserve proteostasis and thereby
contractile function.23-25 We recently observed that GGA-induced HSPB1 expression also
restores contractile function an experimental model for AF recovery,9 indicating that, next
to prevention of damage, HSPB1 also aids in the recovery from contractile protein damage.
With this proof of concept for GGA to increase HSPs in human atrial tissue, the next logical
step is to investigate in larger study populations, whether GGA protects against cardiac
diseases, including AF, heart failure, myocardial infarction and cardiomyopathy. Monitoring
HSP levels before and, periodically, after GGA treatment in serum/plasma could facilitate
in predicting treatment outcome and possible (progression of) the disease.
POSSIBLE MECHANISMS OF GGA TO INCREASE HSP EXPRESSION
The exact mode of action of HSP induction by GGA in unknown. GGA is thought
to act via HSF1-activation. Although we did not observe an increase in (p)HSF1 by
GGA treatment in the current study, this can be attributed to (p)HSF1’s early and
temporary activation upon stress.9 Recently, we observed that a GGA-derivative enhances
hyperphosphorylation of HSF1, resulting in prolonged binding of HSF1 to the heat
shock element (HSE) in the promotor regions of hsp genes, thereby prolonging hsp gene
transcription and HSP protein expression.9 GGA is expected to work on a similar mechanism.
Next to enhanced phosphorylation of HSF1 by GGA, GGA is described to bind the
C-terminus of HSPA1 in vitro, thereby dissociating HSPA1 from HSF1, which are bound in
non-stressed situations in the cytosol. Free HSF1 can become phosphorylated, resulting in
translocalization to the nucleus and binding to the HSE within the promotor regions of hsp
genes.26 As an alternative mechanism, we previously observed that active RhoA abrogates
HSF1 transcriptional activity by suppressing HSF1 binding to the HSE of hsp genes.27
Activation of RhoA is regulated by natural occurring prenylation. Prenylation, the addition
of C15 (farnesyl) or C20 (geranylgeranyl) isoprenoids to proteins, acts as posttranslational
modifiers of proteins and thereby regulate protein function.28 GGA may compete with
endogenous geranyl groups, thereby resulting in the inhibition of RhoA activation, and
consequently enhancing binding of HSF1 to the HSE region.29 As such, GGA may enhance
HSF1-mediated HSP induction via inhibition of RhoA activation. However, this mode of
action of GGA should be further explored by genetic ablation, competition and enhanced
binding experiments to elucidate the mechanism of action.
104 CHAPTER 5
5
POTENTIAL PROTECTIVE ROLE FOR HSP INDUCTION IN AF
Various studies in human atrial tissue revealed that induction of HSPA1 and HSPB1
expression may have cardioprotective effects against AF. Higher HSPA1 expression levels in
atrial tissue related to a lower incidence of poAF.30-31 In the current study we showed that
GGA treatment associated with higher expression levels of HSPA1 and HSPB1 in human
atria and therefore it is of interest to further explore the effect of GGA in the prevention of
poAF.
A possible protective role for HSPB1 in patients was previously indicated by two
independent studies that report on elevated HSPB1 expression levels in atrial tissue from
patients with short duration of AF and low level of atrial structural changes, including
degradation of sarcomeres.8,32 In addition, elevated HSPB1 levels were found in patients
with paroxysmal AF, while patients with persistent AF revealed lower levels of HSPB1,
suggesting that the HSP response gets activated upon short duration of AF, while it
becomes exhausted with longer duration of AF. Possibly, lower levels of HSPB1 may
indicate derailment of proteostasis, in turn leading to progression of structural changes and
persistence of AF. Thus, securing HSP(B) levels at an adequate level with GGA treatment
may thus limit the induction and progression of AF.
GGA IN CLINICAL PERSPECTIVE
Several experimental studies already indicate a potential beneficial role for HSP induction
via GGA in the prevention cardiac diseases, including AF, heart failure, ischemia reperfusion
injury, myocardial infarction and desmin-related cardiomyopathy.4,8,15-19 As GGA is
marketed in various Asian countries for decades, well tolerated and with a solid safety
profile,33 GGA is a viable approach to treat various cardiac diseases. Future studies
including larger study populations may reveal possible associations between HSP(B1)
levels and demographic and clinical parameters, including NYHA class, atrial pressure,
cardiac output and atrial interstitial fibrosis levels. In the current study, lower HSPD1
levels correlated with larger LA size, higher HSF1 levels correlated with larger LA size and
higher HSPA1 levels correlated with lower LVEF, which can be explained by a larger stress
response and thus increased HSF1 and HSPA1 levels in these patients. Since the size of
the current patient groups was small, further studies are warranted to study the relation
between HSPs and LA size and LVEF.
Particularly, it would be of interest to study the effect of GGA in reducing the incidence
of poAF, since poAF affects 20-40% of the patients undergoing CABG surgery,34 with an
even higher prevalence for patients undergoing valve surgery, either alone or in combination
with CABG.35 Also, GGA may enhance successful recovery of heart function after elective
electrical cardioversion of patients with paroxysmal and/or persistent AF. If successful, this
approach may ultimately result in reduced hospital time, increased quality of life for the
patient and lower costs for the society.
Since most patients with cardiac disease reveal cardiomyocyte remodelling at the
moment of diagnosis, compounds that reverse cardiomyocyte remodelling are clinically
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highly relevant. In a recent study, GGA and GGA-derivatives were shown both to prevent
and also reverse contractile dysfunction in experimental models for AF.9 As such, this study
substantiates previous findings that GGA treatment has high potential as a novel approach
to prevent and reverse cardiac diseases, including AF.
CONCLUSION
Three days of GGA treatment associated with higher HSPB1 and HSPA1 expression levels
in RAA and LAA of patients undergoing CABG surgery and enhances HSPB1 levels at the
myofilaments. These findings pave the way to further study GGA for its protective effects
against cardiac diseases in larger study populations.
Source of funding: The current study has been supported by the LSH-Impulse
grant (40-43100-98-008), the Dutch Heart Foundation (2013T144 and 2013T096) and
CVON-STW2016-14728 AFFIP.
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ABSTRACT
BACKGROUND
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. While
50% of HCM patients carry a sarcomere gene mutation (HCMSMP), the genetic background
is unknown in the other half of the patients (sarcomere mutation-negative, HCMSMN).
Genotype-specific differences have been reported in cardiac function. Moreover, HCMSMN
patients have later disease onset and better prognosis than HCMSMP patients. To define
if genotype-specific derailments at the protein level may explain the heterogeneity in
disease development, we performed a proteomic analysis in cardiac tissue from a clinically
well-phenotyped HCM patient group.
METHODS
A proteomics screen was performed in cardiac tissue from 39 HCMSMP, 11 HCMSMN
patients and 8 non-failing controls. HCM patients had obstructive cardiomyopathy with left
ventricular outflow tract obstruction and diastolic dysfunction. A novel MYBPC32373insG
mouse model was used to confirm functional relevance of our proteomic findings.
RESULTS
In all HCM patient samples we found lower levels of metabolic pathway proteins and higher
levels of extracellular matrix proteins. Levels of total and detyrosinated α-tubulin were
markedly higher in HCMSMP than in HCMSMN and controls. Higher tubulin detyrosination
was also found in two unrelated MYBPC3 mouse models and its inhibition with parthenolide
normalized contraction and relaxation time of isolated cardiomyocytes.
CONCLUSION
Our findings indicate that microtubules and especially its detyrosination contribute to the
pathomechanism of HCMSMP patients. This is of clinical importance since it represents
a potential treatment target to improve cardiac function in HCMSMP patients, whereas a




This study shows that the most prominent derailment at the protein level in cardiac tissue
obtained during myectomy of HCM patients in an advanced disease stage is reduced levels
of proteins involved in metabolic pathways. This is common for all genotypes.
The study further demonstrates that increased levels of detyrosinated tubulin are specific
for sarcomere mutation-positive HCM patients.
The increase in tubulin detyrosination is resembled in a mouse model with the Dutch founder
mutation MYBPC32373insG. Pharmacological inhibition of tubulin detyrosination normalizes
contractile function in isolated cardiomyocytes.
WHAT ARE THE CLINICAL IMPLICATIONS?
Recent and ongoing clinical trials investigate the therapeutic effect of targeting the energy
metabolism in HCM patients which is supported by our proteomic data showing metabolic
derailment.
Lowering tubulin detyrosination presents a potential novel treatment strategy that may
improve contractile function in sarcomere mutation-positive HCM patients. Since HCM
is characterized by diastolic dysfunction, enhancing cardiomyocyte relaxation by lowering
detyrosination of microtubules is considered to be beneficial for HCM patients.
This study provides evidence that there is a need for genotype-specific treatment in HCM.
Due to differences in pathomechanism, not every therapeutic strategy may be beneficial in
all patient groups.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is characterized by diastolic dysfunction and
asymmetric left ventricular (LV) hypertrophy, which lead to LV outflow tract obstruction
(LVOTO) in the majority of cases.1 Mutations in genes encoding sarcomere proteins cause
HCM and are identified in more than half of the patients (sarcomere mutation-positive,
HCMSMP). The heterogeneity in genetic background of HCM is large with more than 1500
identified HCM-causing mutations.2 Approximately 80% of mutations are located in MYH7
and MYBPC3. Less frequent are mutations in TNNT2 and TNNI3.3,4
Previous research in HCM mouse models and humans showed genotype-specific differences
in cellular characteristics and cardiac remodelling and function. Gene-specific differences
in cellular redox and mitochondrial function were reported in mice harbouring a MYH7 or
TNNT2 mutation.5 In accordance with studies in HCM mouse models, studies on patient
myectomy samples reported gene-specific differences in the response to calcium, ADP,
protein kinase A, and length-dependent activation of myofilaments compared to non-failing
cardiomyocytes.6,7 Also, a comparison of two different patient-specific induced pluripotent
stem cell-derived cardiomyocyte cell lines, carrying either a mutation in MYBPC3 or TPM1,
showed differences in calcium handling and electrophysiological properties.8 These in vitro
studies are strengthened by clinical patient studies which revealed a more severe decline
in myocardial efficiency in MYH7 than in MYBPC3 mutation carriers,9 accompanied by a
different response to therapy.10 Notably, there is also a large patient population in which a
disease-causing mutation cannot be identified, the so-called sarcomere mutation-negative
patients (HCMSMN). While the cause of the disease in these patients is unknown, they
present with the same clinical phenotype as HCMSMP patients albeit at older age.3
Moreover, recent data from the SHaRe registry indicate that HCMSMP have a 2-fold greater
risk of adverse outcomes than HCMSMN.11 Whereas LVOTO can be invasively corrected by
surgical myectomy, other symptoms can only be managed by pharmacological therapies,
which do not halt or reverse cardiac disease.1 Knowledge about the cellular changes that
cause cardiac dysfunction and hypertrophy in HCM patients is needed to design new
therapies.
The main goal of this study was to define HCM- and genotype-specific derailments
at the protein level, which may explain the heterogeneity in cardiac characteristics and
disease initiation and progression. Therefore, we used an unbiased proteomics approach in a
large number of myectomy samples from a clinically well-characterized HCM patient group
with (HCMSMP) and without (HCMSMN) sarcomere mutations. We show that lower levels
of metabolic pathway proteins and higher levels of extracellular matrix (ECM) proteins are
the most prominent genotype-independent HCM-specific disease characteristics at the time
of myectomy. However, abundance and detyrosination of α-tubulin was significantly higher
in HCMSMP than in non-failing (NF) controls, with intermediate levels in HCMSMN. Recent
studies in human heart failure identified a central role for detyrosinated microtubules in
regulating cardiomyocyte function and demonstrated the functional benefit upon reversal
of this modification.12,13 Our study in a European HCM patient cohort and genetic HCM
mouse models strengthens the concept that targeting the microtubule network represents
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a therapeutic strategy to correct impaired function, and extends it to HCM caused by
sarcomere mutations.
METHODS
The proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the dataset identifier PXD012467 and are publicly available.
HUMAN CARDIAC SAMPLES
Tissue of the IVS of 50 HCM patients was obtained during myectomy surgery to relieve
LVOTO or after heart transplantation (1 sample, HCM 164). Samples of IVS from 8
healthy NF donors (5 males, 3 females; mean age 45.9 ± 9.7 years) with no history of cardiac
abnormalities was obtained from the Sydney Heart Bank (HREC Univ Sydney 2012/030) and
served as controls. The parameters of all HCM and NF individuals are summarized in Table
S1. In this table we organized HCM patients based on their genotype into 5 sub-groups:
Patients with the Dutch MYBPC3 founder mutation (2373insG), where the truncating
mutation resulted in MYBPC3 haploinsufficiency;14 Patients with MYBPC3 mutations other
than the 2373insG mutation of which 81.8% were truncating mutations as well; Patients
with MYH7 mutations; Patients with mutations in less frequently affected sarcomere genes
(TNNT2, TNNI3 and MYL2); and HCMSMN patients. In line with studies in other cohorts,15
almost all mutations in MYBPC3 were truncating mutations, whereas mutations in other
sarcomeric proteins were missense except the truncating mutation c.814C>T in TNNT2.
PROTEOMICS ANALYSIS
TISSUE HOMOGENIZATION
Pulverized frozen tissue was homogenized in 40 µL/mg tissue 1x reducing sample
buffer (106 mM Tris-HCl, 141 mM Tris-base, 2% (w/v) lithium dodecyl sulphate (LDS),
10% (v/v) glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.18 mM Phenol Red,
100 mM DTT) using a glass tissue grinder. Proteins were denatured by heating to 99°C
for 5 min, after which samples were sonicated and heated again. Debris was removed by
centrifugation at maximum speed for 10 min in a microcentrifuge (Sigma, 1-15K).
PROTEIN FRACTIONATION
Proteins were separated using 1D SDS-PAGE. Samples from each group were loaded
alternating on the gels to avoid bias. Equal volumes of sample (30 µL protein homogenate
per sample, containing approximately 20-30 µg of protein) were loaded on a precast 4-12%
NuPAGE Novex Bis-Tris 1.5 mm mini gel (Invitrogen). Electrophoresis was performed at
200 V in NuPAGE MES SDS running buffer until the dye front reached the bottom of the
gel. Gels were fixed in a solution of 50% ethanol and 3% phosphoric acid, and stained with
0.1% Coomassie brilliant blue G-250 solution (containing 34% methanol, 3% phosphoric
acid and 15% ammonium sulphate). Images of all gels are provided in Figure S1.
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IN-GEL DIGESTION AND NANO-LC-MS/MS
Each gel lane was cut into 5 pieces and in-gel digestion was performed as described
previously.16 Samples were measured by LC-MS per gel band starting at the high molecular
weight (MW) fraction for all samples, before continuing with the next gel band until the
last (low MW fraction) band. Injections alternated between all different group samples to
minimize experimental bias between groups. Analysis of the experiment was performed
as described in Piersma et al.17 Peptides were separated using an Ultimate 3000 Nano
LC-MS/MS system (Dionex LC-Packings, Amsterdam, The Netherlands) equipped with
a 40 cm x 75 µm ID fused silica column custom packed with 1.9 µm, 120 Å ReproSil Pur
C18 aqua (Dr Maisch GMBH, Ammerbuch-Entringen, Germany). Eluting peptides were
ionized at a potential of + 2 kV into a Q Exactive mass spectrometer (Thermo Fisher,
Bremen, Germany). MS/MS spectra were acquired at resolution 17,500 (at m/z 200) in
the orbitrap using an AGC target value of 1x106 charges, a maxIT of 60 ms and an underfill
ratio of 0.1%. Dynamic exclusion was applied with a repeat count of 1 and an exclusion
time of 30 s (additional details to in-gel-digestion and nano-LC-MS/MS are provided in the
Supplemental Methods).
DATA ANALYSIS
MS/MS spectra were searched against a Uniprot human reference proteome FASTA
file (Swissprot_2017_03_human_canonical_and_isoform.fasta, 42161 entries) using
MaxQuant version 1.5.4.1 (details to search settings are provided in the Supplemental
Methods). The mass spectrometry proteomics data are provided in Table S5 and the raw
data have been deposited to the ProteomeXchange Consortium via the PRIDE18 partner
repository with the dataset identifier PXD012467. Beta-binominal statistics were used to
assess differential protein expression between groups, after normalization on the sum of the
counts for each sample.19 Proteins with a p-value below 0.05 were considered significantly
differentially expressed. Proteins which were present in less than 25% of the samples or had
an average normalized count of less than 1.4 were excluded from further functional analysis.
Principal component analysis was performed in R. Therefore quantile normalization and log2
transformation was performed on the normalized counts. The 95th Percentile was taken,
the data median centered and the principal components calculated. Hierarchical clustering
was performed after a statistical multi-group comparison. Proteins with a raw p-value
<0.05 were selected for the pathway analysis. Protein networks were generated utilizing
the STRING database (Search Tool for the Retrieval of Interacting Genes/Proteins) and
visualized with Cytoscape software.20 Protein interaction networks were generated with
ClusterONE and gene ontology (GO) analysis was performed using the BiNGO application
in cytoscape.21,22 Heatmaps for a specific GOs were created with ToppGene Suite23 and
Graphpad Prism v7 software. Venn diagrams were created with InteractiVenn tool24 and
the layout modified if needed.
ANIMAL EXPERIMENTS
The MYBPC32373insG mouse model was engineered using CRISPR/Cas9 (details are
provided in the Supplemental Methods). Echocardiographic phenotyping (Vevo 2100,
Visualsonics) was performed on 7 homozygous MYBPC32373insG mice (3 females, 4 males)
and 8 WT littermates (3 females, 5 males). The age of the mice ranged from 20-28
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weeks. Group size of 7 was determined by a power calculation to achieve a power of
0.8 and an alpha of 0.05 and to detect an effect size of 20% in echocardiography. The
MYBPC3772G>A mice were developed previously25 and maintained on a blackswiss genetic
background. Western blot analysis was performed of the cytosolic fraction of LV tissue in 6
homozygous MYBPC3772G>A mice (2 females, 4 males) and 6 WT littermates (2 females,
4 males). The age of these mice was 55-59 weeks.
INTACT CARDIOMYOCYTE ISOLATION AND MEASUREMENTS
Intact adult cardiomyocytes were isolated from 4 WT and 6 homozygous MYBPC32373insG
mice as described previously.26 Cells were suspended in plating medium composed of
Medium 199 (Lonza), 1% penicillin/streptomycin and 5% bovine serum and plated on a
laminin coated dish (10 µg/ml, Sigma-Aldrich). The cells were incubated for 1 h at 37°C in
humidified air with 5% CO2 to let them attach to the coated dish. Afterwards, non-attached
cells were removed by washing cells with pre-heated culture medium (Medium 199 (Lonza),
1% penicillin/streptomycin, 1x ITS supplement (Sigma-Aldrich) and 0.5 µM cytochalasin D
(Life technologies)). Cells were incubated with DMSO (0.1% v/v) or 10 µM parthenolide
(Sigma) for 2 h. Contractility measurements were performed in tyrode solution (HEPES
10 mM, NaCl 133.5 mM, KCl 5 mM, NaH2PO4 1.2 mM, MgSO4 1.2 mM, glucose 11.1 mM,
sodium pyruvate 5 mM; pH 7.4 at 37°C) at 37°C using the MultiCell system (CytoCypher,
the Netherlands). The dish was field-stimulated at 2 Hz, 25 V and a 4 ms pulse duration.
Changes in sarcomere length were recorded with a high-speed camera and Ionoptix software
(Ionoptix, Westwood MA, USA). The contractility profiles were analysed with the automated
batch analysis software CytoSolver (CytoCypher, Amsterdam, NL). An R2 for peak and
recovery fit >0.95 was selected as inclusion criteria for contraction data.
For protein analysis, cells were incubated with DMSO (0.1% v/v) or 10 µM parthenolide
(Sigma) for 2 h, washed with PBS and directly lysed in loading buffer.
STUDY APPROVAL
The study protocol for the human tissue samples was approved by the local medical ethics
review committees and written informed consent was obtained from each patient prior
to surgery. Animal experiments were performed in accordance with the Guide for the
Animal Care and Use Committee of the VU University Medical Center (VUmc) and with
approval of the Animal Care Committee of the VUmc (CCD-number AVD114002016700)
and conform the guidelines from Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientific purposes.
Extended methods section in the supplementary materials.
RESULTS
NO MAJOR GENOTYPE-SPECIFIC PROTEIN CHANGES
We performed an unbiased proteomics approach to compare the protein expression profile
of 50 interventricular septum (IVS) samples from HCM patients at the time of myectomy
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with 8 NFIVS samples (Table 6.1, Table S1; patient characteristics). Patient characteristics
are shown in Table 6.1.,
Table 6.1: Clinical characteristics of the HCMSMP and HCMSMN patient group.
HCMSMP HCMSMN p-value
(n=38) (n=11)
Sex, male 65.8% (25) 63.6% (7) >0.9999
Age at myectomy (years) 46.2 ± 17.4 53.6 ± 13.9 0.2084
Dimensions
IVS (mm) 21.0 [18.8-23.3] 16.0 [15.0-18.0] <0.0001
LAD (mm) 46.0 ± 6.5 48.1 ± 5.4 0.3861
EDD (mm) 42.5 ± 5.2 44.3 ± 6.4 0.4466
ESD (mm) 21.7 ± 5.0 26.0 ± 2.8 0.2595
Diastolic parameters
E/A ratio 1.16 [0.81-1.54] 0.92 [0.67-1.15] 0.1795
E/e’ ratio 16.2 [13.1-20.1] 21.7 [16.0-33.4] 0.0226
TR velocity (cm/s) 2.3 ± 0.5 NA
Stadium of diastolic
dysfunction
1 46.9% (15) 40.0% (4) >0.9999
2 31.3% (10) 40.0% (4) 0.7071
3 21.9% (7) 20.0% (2) >0.9999
Systolic parameter
FS (%) 47.4 ± 11.7 47.5 ± 0.7 0.9942
LVOTg (mmHg) 54.9 ± 31.9 91.7 ± 40.9 0.0034
Medication
beta blocker 79.5% (31) 63.6% (7) 0.4240
calcium channel blocker 33.3% (13) 45.5% (5) 0.4945
Statins 12.8% (5) 18.2% (2) 0.6407
Displayed are the mean±SD or the median with interquartile range when appropriate. EDD indicates
end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening; HCM, hypertrophic
cardiomyopathy; IVS, interventricular septum; LAD, left atrial diameter; LVOTg, left ventricular
outflow tract gradient; SMN, sarcomere mutation-negative; SMP, sarcomere mutation-positive; and
TR, tricuspid regurgitation.*p<0.05.
Echocardiographic parameters were assessed as described previously.27 All HCM patients
had obstructive HCM and showed impaired diastolic function evident from increased LV
filling pressure indicated by an E/e’ ratio >15 and atrial dilation indicated by increased
left atrial diameter (LAD) compared to reference values.28,29 IVS thickness was higher in
HCMSMP compared to HCMSMN. We identified 3,811 proteins of which we included 2,127
into our analysis after applying our inclusion criteria of an average normalized count of >1.4
and the protein being detected in >25% of samples. This filtered out low-level proteins
that could not be reliably quantified. Samples were grouped based on their genotype and
protein expression changes were analysed in different group-wise comparisons. Table S2
lists all group-wise comparisons and the corresponding number of significantly deregulated
proteins that contributed to the subsequent cluster and gene ontology (GO) analysis.
An unbiased principal component analysis (PCA) of the protein expression data revealed
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separate clustering of the NFIVS and HCM samples, indicating different protein expression
profiles between controls and patients (Figure 6.1A).
Supervised hierarchical clustering of a multi-group comparison revealed separate clusters
for NFIVS and HCM samples (Figure 6.1B). However, in both analysis the HCM samples
did not cluster according to their genotypes, indicating that the protein profile at the time
of myectomy surgery is relatively homogeneous with differences between genotypes that
are not sufficiently large to distinguish them with cluster analysis. Sample HCM 83 did
not cluster with any of the other HCM or NFIVS samples and turned out to have a very
high serum albumin content. This implicated contamination with blood and therefore we
excluded this sample from all further analyses. Sample HCM 164 also showed a unique
protein expression pattern. It may reflect the infant proteome due to the young age (2
months), or the very severe disease stage since this is the only sample obtained from a
heart transplantation. Since the variation in this sample is due to a biological reason, we
did not exclude it.
To validate our experimental approach, we checked the expression of proteins involved
in pathways that are known to be altered in HCM (Figure S2, Table S3). Fibrosis,
characterized by an increase in ECM components, is a well-established feature of HCM
as shown by data from myectomy biopsies and cardiac magnetic resonance imaging of
patients.27,30 In line with the presence of fibrosis in patients, we found increased levels
of fibronectin, thrombospondin 4 and periostin (Figures S2A-C). Since hypertrophy is a
morphological hallmark of HCM, we checked FHL2 expression as a negative regulator of
hypertrophy.31 In line with pro-hypertrophic signalling, reduced FHL2 protein expression
was observed (Figure S2D). The hypertrophic phenotype was also evident from reduced
α-MHC encoded by MYH6, and increased CSRP3 expression in HCM samples (Figures
S2E-F).32,33 Finally, MYBPC3 haploinsufficiency was confirmed in samples with a mutation
in MYBPC3 irrespective of whether the mutation is a truncation or missense mutation
(Figures S2G-H, Table S4).14,34
Additionally, we performed RNA sequencing in a subset of samples. Similar to the
proteomics data, the PCA plot of the RNA data did not show clustering based on genotype
(Figure S3A). The MA-plot depicts all genes with the differentially expressed genes in
red (Figure S3B). Gene set enrichment analysis of the proteomics and transcriptomics
data revealed a significant correlation of upregulated proteins with genes that showed
higher expression levels in HCM compared to NFIVS (FDR<0.001), while less expressed
proteins are positively correlated with genes that showed lower expression levels in HCM
(FDR=0.008). This observation suggested that protein expression changes were well
correlated with the mRNA expression changes between HCM and NFIVS (Figures S3C-D).
HCM-SPECIFIC PROTEIN CHANGES
To identify HCM disease-specific protein expression patterns at the time of myectomy we
grouped all HCM samples (HCMall) and compared them to NFIVS. We identified clusters
of interacting proteins for higher and lower expressed proteins separately.
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Figure 6.1: Clustering of proteome of controls and patient samples.
(A) Principal component (PC) analysis of the filtered protein expression data reveals separate
clustering of the NFIVS samples (n=8) and the HCM samples (n=50) showing that the overall
protein expression profile between NFIVS and HCM samples differs. HCM samples did not form
separate clusters based on genotypes, indicating that genotype does not lead to major changes in
protein expression profile. (B) Hierarchical clustering of a multi-group comparison of all proteins
that are differently expressed at p<0.05 when comparing HCMall with NFIVS. Hierarchical clustering
of all significantly different proteins between HCMall and NFIVS shows that the NFIVS samples cluster
together and are most different from the HCM samples. Also among this selection of proteins, the
HCM samples do not cluster based on genotype.
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Analysis of all significantly lower expressed proteins of HCMall compared to NFIVS
uncovered the highest enrichment in oxidative phosphorylation, generation of precursor
metabolites and energy, NAD metabolic process, translation, fatty acid catabolic process,
regulated exocytosis and neutrophil degranulation (Figure 6.2A, more extensive list in
Figure S4). This shows that the major changes in tissue of HCM patients are in metabolic
pathways related to energy metabolism including both glucose and fatty acid metabolism.
We selected all significantly lower expressed proteins annotated to the pathways and
created a heatmap displaying the log2-fold change for a detailed visualization of protein
changes in the pathway. We included RNA expression data of the corresponding genes to
check if the protein changes coincide with changes at the RNA level. Strikingly, most of
these proteins are not changed on RNA level (Figure S5).
The top clusters of the higher expressed proteins are associated with the GO terms
ECM organization, actin filament-based process, myofibril assembly, muscle contraction,
post-translational protein modification, protein folding and microtubule cytoskeleton
organization (Figure 6.2B, more extensive list in Figure S6). The biggest cluster of more
abundant proteins is ECM organization representing different collagens that are components
of fibrotic tissue. Interestingly, many of these genes showed unaltered RNA levels compared
to NFIVS. The same was observed for the other top clusters of higher expressed proteins,
namely actin filament-based process, myofibril assembly and muscle contraction, where
RNA levels were unaltered or even lower than in NFIVS (Figure S7).
Since HCM at the time of myectomy is characterized by pronounced hypertrophy of
the myocardium, we expected a protein cluster related to hypertrophy among the
significantly increased proteins. Surprisingly, we did not find this. This could be because
the myocardium is not in a state of active hypertrophic growth at the time of sample
collection, or because we did not detect low abundant hypertrophy promoting signalling
proteins. It is also known that several signalling proteins are regulated by post-translational
modifications rather than by abundance on which our proteomics screen was based.
Western blot analysis of the expression and phosphorylation of AKT and ERK, two
well-known inducers of hypertrophy,35,36 showed higher AKT and ERK phosphorylation in
HCMall samples, indicating activation of hypertrophic signalling (Figure S8).
Subsequently, we repeated the cluster and GO analysis restricted to proteins that
are higher and lower expressed if all 5 genotype HCM groups are compared individually to
NFIVS to extract the most consistent and robust changes. Venn diagrams (Figures S9 and
S10) were made to identify overlapping protein changes (76 higher and 92 lower expressed),
which were subsequently used as analysis input.
The results confirmed the findings from the initial analysis showing that the major
HCM-specific protein changes include reduced metabolism, increased ECM remodelling,
and pathways including muscle related processes.
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Figure 6.2: HCM-specific changes in biological processes.
Protein interaction cluster of significantly different proteins between HCMall and NFIVS were
identified and are displayed with the most significant corresponding gene ontology (GO) term. (A)
Top 10 downregulated protein interaction cluster based on cluster size with the most significant
biological process related to this cluster. (B) Top 10 upregulated protein interaction cluster based
on cluster size with the most significant biological process related to this cluster. The colour
gradient from light to dark indicates an increase in fold change.
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SPECIFIC CHANGES FOR HCMSMP AND HCMSMN
To study the pathways that are characteristic for HCMSMP or HCMSMN and might explain
sarcomere mutation-specific changes in cardiac function, we created a Venn diagram of
significantly different proteins in HCMSMP and HCMSMN compared to NFIVS. The Venn
diagrams (Figures 6.3 and S11) illustrate that the majority of significantly different proteins
are similar in HCMSMP and HCMSMN (191 lower and 121 higher expressed proteins).
However, a substantial number of proteins is only changed in either HCMSMP or HCMSMN,
when compared to NFIVS.
The 130 proteins that are specifically less abundant in HCMSMP overlap to a large
degree with the biological processes of the 194 proteins that are significantly less abundant
in both HCMSMP and HCMSMN when compared to NFIVS (Figure S12). Analysis of the 62
proteins that are specifically less expressed in HCMSMN results in clusters related to stress
granule assembly, translational initiation and protein folding (Figure S11).
The majority of the shared higher expressed proteins involve ECM organization (Figure
S13). GO analysis of the 68 proteins that are specifically more abundant in HCMSMP
identified amongst others a protein clusters related to microtubule cytoskeleton organization
(Figure 6.3).
This cluster representing tubulin subunits is solely more abundant in HCMSMP when
compared to NFIVS, and is also among the functional protein cluster of proteins that
are significantly upregulated in HCMSMP when directly compared to HCMSMN (Figure
S14). Since the tubulin network is highly regulated by post-translational modifications, we
determined the levels of total α-tubulin, tyrosinated and detyrosinated tubulin by Western
blot (Figures 6.4 and S15A).
In line with the proteomics data we found an increase in total α-tubulin which is more
prominent in HCMSMP than in HCMSMN (Figure 6.4A). We validated this with another
primary antibody and obtained very comparable results (Figure S15A). A post-translational
modification of tubulin that leads to increased stiffness of cardiomyocytes is detyrosination
of α-tubulin.12 We found markedly elevated detyrosinated tubulin only in HCMSMP samples
(Figure 6.4C), while levels of tyrosinated tubulin were slightly increased in both HCMSMP
and HCMSMN (Figure 6.4B). Within the HCMSMP group, levels of α-tubulin tend to be
highest in the MYBPC3other group and lowest in the MYH7 group, whereas desmin levels
tend to be highest in MYH7.
Levels of tyrosinated and detyrosinated tubulin do not show any genotype-specific
differences. Levels of tyrosinated and detyrosinated tubulin normalized to total α-tubulin
are depicted in Figures S15B-C. Our data show that high levels of tubulin in HCMSMP
represent mostly the detyrosinated form. We also determined desmin protein levels
by Western blot since this protein is associated with microtubules in cardiomyocytes.
Accordingly, desmin levels were elevated in HCM with the largest increase in HCMSMP
(Figure 6.4D).
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Figure 6.3: Differences in upregulated proteins between HCMSMP and HCMSMN.
Protein interaction cluster of proteins that are only significantly upregulated for the HCMSMP
vs NFIVS or the HCMSMN vs NFIVS comparison were identified and are displayed with the most
significant corresponding gene ontology (GO) term. The top 5 protein interaction clusters of
upregulated proteins are displayed The colour gradient from light to dark indicates an increase in
fold change.
INHIBITION OF TUBULIN DETYROSINATION CORRECTS CARDIOMYOCYTE
DYSFUNCTION IN MYBPC3 2373insG MICE
Based on previous studies in human heart failure,13 our data in human myectomy samples
indicate that microtubules may represent a treatment target to correct cardiac dysfunction
in HCM. To provide proof for a role of tubulin in modulating cardiomyocyte function in
HCM caused by a sarcomere gene mutation, we generated a HCM knock-in (KI) mouse
model of the Dutch founder mutation c.2373insG in MYBPC3 (Figures S16A-B). This
mutation introduces a new splice donor site in exon 25 leading to a frameshift and premature
stop codon resulting in an expected truncated protein of 95 kDa.37 As no truncated protein
is found in HCM patients carrying this mutation at the heterozygous state,14 degradation
of mutant mRNA and/or protein is likely. Accordingly, Western blot analysis did not
reveal any truncated MYBPC3 protein in homozygous MYBPC32373insG mice (Figure S16C).
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Figure 6.4: Tubulin expression and posttranslational modifications in HCM patients.
Protein levels of α-tubulin (A), its tyrosinated (B) and detyrosinated forms (C) and desmin
(D), all normalized to GAPDH, in tissue of HCM patients. Kruskal-Wallis test with Dunn’s
multiple comparisons test, ****p<0.0001, ***p=0.0003 in (B), ***p=0.0009 in (D), **p=0.0074,
*p=0.0437 in (A), *p=0.0499 in (B) and *p=0.0357 in (D). Average of the control group is set
to 1. n(NFIVS/HCMSMP/HCMSMN)=6/38/11 for (A), 8/36/11 for (B-C), 8/37/11 for (D).
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Figure 6.5: Tubulin composition in MYBPC3 2373insG and MYBPC3 772G>A mouse models.
Quantification and representative Western blot images of (A) α-tubulin, (B) tyrosinated
tubulin, (C) detyrosinated tubulin and (D) desmin in MYBPC3 2373insG mice and (E) α-tubulin,
(F) tyrosinated tubulin and (G) detyrosinated tubulin in MYBPC3 772G>A mice, respectively.
(A) is normalized to total protein stain (TPS, image provided in Figure S15D), (B-G) are
normalized to GAPDH. Lanes in (A) were run on the same gel but were non-contiguous.
n(WT/MYBPC3 2373insG/772G>A)=6/6 (4 females, 2 males/3 females, 3 males of 20-27 weeks
for MYBPC3 2373insG and the corresponding WT; 2 females, 4 males for of 55-59 weeks for
MYBPC3 772G>A and the corresponding WT) for (A, C, E-G), 6/5 (4 females, 2 males/3 females,
2 males; 20-27 weeks) for (B) and 5/5 (3 females, 2 males/2 females, 3 males; 20-27 weeks) for
(D), unpaired two-tailed t-test, ***p=0.0001 in (C) and p=0.009 in (D), **p=0.0014.
Levels of total and tyrosinated α-tubulin did not differ between the groups, whereas
the detyrosinated tubulin and desmin levels were markedly higher in MYBPC32373insG than
in wild-type (WT) mice (Figures 6.5A-D, loading control to panel A shown in Figure S15D).
To evaluate whether these findings were specific to this model, we assessed the levels
of total and detyrosinated tubulin in a second HCM mouse model carrying a different
MYBPC3 mutation.25 Homozygous MYBPC3772G>A mice showed a strong accumulation
of α-tubulin and no difference in tyrosinated tubulin compared to their WT littermates. In
addition, a trend to higher levels of detyrosinated tubulin was observed (Figures 6.5E-G).
Overall, these mouse models consistently show tubulin changes in cardiomyopathy caused
by MYBPC3 gene mutations.
MYBPC32373insG mice had a severe cardiac phenotype characterized by higher ventricular
weight to body weight ratio, increased LV anterior wall diameter and interventricular
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septum thickness, lower ejection fraction, increased left ventricular internal diameter and
longer isovolumetric relaxation time than WT mice (Figures 6.6A-F). Single cardiomyocytes
from MYBPC32373insG hearts showed contractile deficits compared to WT as shown by
an increase in time to peak of contraction and an impaired relaxation shown by an
increase in time to baseline (Figures 6.6G-H). Inhibition of detyrosination by treatment
with parthenolide (PTL) reduced levels of detyrosinated tubulin by 36% (Figure 6.6J) and
normalized the contraction and relaxation times in MYBPC32373insG mice to baseline WT
levels (Figures 6.6G-H), whereas it had no effect on calcium release and reuptake time in
MYBPC32373insG mice (Figure S17A-B), indicating a direct effect on myofilament function.
Figure 6.6: Morphometric and phenotypic analysis of MYBPC3 2373insG mice and contractile
function of isolated MYBPC3 2373insG cardiomyocytes upon inhibition of tubulin detyrosination.
Quantification of the hypertrophy parameters (A) ventricle weight (VW)/body weight (BW) ratio
and (B) anterior wall thickness in diastole (LWADd) and (C) interventricular septum thickness
in diastole (IVSd) measured by echocardiography. (D) and (E) show parameters of systolic
function measured by ejection fraction and left ventricular internal diameter (LVID) and (F) displays
diastolic function assessed by isovolumetric relaxation time (IVRT). n(WT/MYBPC3 2373insG)=9/9
(4 females, 5 males; 20-27 weeks) for (A) and 8/7 (3 females, 5 resp. 4 males; 25-27
weeks) for (B-F), unpaired two-tailed t-test, ****p<0.0001, ***p=0.0001, *p=0.0215. (G)
displays the effect of tubulin detyrosination inhibition by PTL on the contractile parameter
time to peak 70% and (H) on the diastolic parameter time to baseline 70%. The dotted
line visualizes the WT baseline level. (I) shows example force transients for each condition
of the single cell measurements. For (G-H) N(WT mice)=4 (2 females and 2 males, 13-33
weeks) with total n(cells DMSO/PTL)=191/99 and N(MYBPC3 2373insG mice)=6 (2 females and
4 males, 13-35 weeks) with total n(cells DMSO/PTL)=169/123. (G) and (H) were analysed
by 2way-ANOVA, **p<0.01, ****p<0.0001. (J) Levels of detyrosinated tubulin normalized to
GAPDH in isolated MYBPC3 2373insG cardiomyocytes upon inhibition of tubulin detyrosination by
PTL. Every PTL treated sample was normalized to the DMSO control condition from the same
animal. N(MYBPC3 2373insG mice)=6 (2 females, 4 males, 13-19 weeks); (J) was analysed with an
unpaired two-tailed t-test, ***p=0.0004.




In this study we compared the protein profile of cardiac tissue from HCM patients with
different disease-causing gene mutations to identify common HCM disease changes as well
as genotype-specific protein changes at the time of myectomy. The majority of detected
protein changes were common for all HCM samples and independent of the underlying gene
mutation. Our approach revealed different protein profiles in the presence or absence of
a sarcomere gene mutation. While hypertrophic remodelling in HCMSMP is characterized
by an increase in the levels of proteins involved in microtubule cytoskeleton organization,
HCMSMN samples show reduced levels of proteins involved in protein translation.
DEREGULATED ENERGY METABOLISM PROTEOME
Our analysis revealed that the majority of deregulated proteins are related to energy
metabolism and show a consistent lower expression of proteins involved in oxidative
phosphorylation, glycolysis and fatty acid oxidation. Especially subunits of mitochondrial
respiratory chain complex I, that are part of cluster 1 in Figure 6.2A, are consistently lower
expressed. This is in line with another recent proteomics study of HCM tissue samples in
which reduced levels of energy metabolism proteins was one of the main findings.38 It also
matches observations of energy deficiency in animal models39 and human studies.40,41 Energy
deficiency has been proposed as the primary mutation-induced pathomechanism leading
to compensatory hypertrophy,42 which is supported by the fact that even asymptomatic
mutation carriers without hypertrophy display reduced cardiac energetic status.9,41 The
reduced cardiac efficiency was larger in MYH7 mutation carriers compared to MYBPC3
mutation carriers pointing towards genotype-specific functional differences.9 Our proteomic
analyses did not show gene-dependent differences in proteins involved in cardiac energy
metabolism. This indicates that the deregulated energy metabolism proteome is a secondary
consequence due to cellular stress that is similar in patients with advanced HCM.
PROTEIN HOMEOSTASIS DIFFERS BETWEEN HCMSMP AND HCMSMN
Interestingly, proteins involved in protein translation are less abundant, particularly in
HCMSMN patient tissue when compared to NFIVS, implying that the protein translation
system is either more impaired or differently regulated in HCMSMN. Among the more
abundant proteins, we observed a protein cluster related to protein folding. Protein folding
proteins (chaperones) are needed for correct folding of de novo synthesized proteins as well as
for refolding of misfolded mutant or damaged proteins. Since our data show downregulation
of protein translation, it is unlikely that protein folding proteins are upregulated for folding
of newly synthesized proteins. Instead, we speculate that their expression is upregulated
to repair or remove misfolded (mutant) proteins.43 This is in line with recent data
describing an upregulation of protein folding proteins specifically in HCMSMP samples.44
Protein folding proteins represent potential treatment targets since boosting their expression
has already shown beneficial effects in animal models of other cardiac diseases and in
cardiomyopathies.45-47
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IMPACT OF INCREASED TUBULIN NETWORK ON CARDIOMYOCYTE
FUNCTION IN HCM
A striking observation was the specific upregulation of microtubule subunits and
post-translational modification detyrosination in HCMSMP compared to HCMSMN, when
comparing both to NFIVS. Previous studies indicated important regulatory roles of
microtubules in cardiomyocyte function.48 Recent reports showed that the translation
of the sarcomere proteins is localized to the myofilaments which points to a role of
microtubules in the transportation of mRNA to the myofilament.49,50 Increased expression
of tubulin subunits strengthens the microtubule network and facilitates the transportation
of mRNAs to the sarcomere and concomitant increasing cardiomyocyte stability. In addition
to tubulins, desmin protein level was significantly higher in HCMSMP than in HCMSMN. In
the healthy heart, desmin is localized at the Z-discs forming a striated pattern and playing a
central role in cardiomyocyte mechanical stability.51 Overall, these protein changes suggest
a compensatory mechanism of the cell to ensure sarcomere stability in the presence of a
sarcomere gene mutation.
Furthermore, microtubules and their post-translational modifications play an important
role in cardiomyocyte mechanics, especially in regulating cardiomyocyte stiffness.52,53
Detyrosinated tubulin stabilizes microtubules by inhibiting disassembly54 and can anchor
microtubules to the Z-discs of the sarcomere, most likely via desmin, and enhance stability
and stiffness of the myofilaments and the microtubular network.52 The TUBA4A transcript
is directly synthesized in it is detyrosinated form and an upregulation could at least partly
explain the increase in detyrosinated tubulin. In our RNA sequencing data, the TUBA4A
transcript is however significantly downregulated when comparing HCM with NFIVS and it
is not differentially expressed in the direct comparison of HCMSMP and HCMSMN.
Tubulin detyrosination is enzymatically regulated by the tubulin tyrosine ligase (TTL) and
tubulin carboxypeptidases (TCPs) that have detyrosinating activity and also the TUBA4A
transcript can undergo these reactions.55 Recently, vasohibins have been identified as the
first tubulin detyrosinating enzymes,56,57 and act in complex with small vasohibin-binding
protein (SVBP). In accordance with findings by Robison et al. in explanted hearts of heart
failure and cardiomyopathy patients,12 we observed a specific upregulation of tubulins and
enhanced detyrosination in our genetically well-characterized HCM myectomy samples.
Notably, we found the increase in tubulin detyrosination specific for HCMSMP samples.
Although levels of detyrosinated tubulin are equal between HCMSMP and HCMSMN when
normalized to total levels of α-tubulin, the absolute levels of α-tubulin and detyrosinated
tubulin are much higher in HCMSMP and thereby have a much greater impact on contractile
function in these patients. Chen et al. have already demonstrated the reversibility of
tubulin detyrosination in isolated cardiomyocytes from explanted HCM hearts associated
with an improvement of contractile function.13,58 Here we performed proof-of-concept
studies in HCM mouse models to define the impact of tubulin detyrosination in the
presence of a sarcomere mutation. Homozygous MYBPC32373insG mice replicated the
tubulin detyrosination without an increase in total α-tubulin levels, whereas homozygous
MYBPC3772G>A mice display an increase in total α-tubulin with a trend to increased
tubulin detyrosination. Considering the age difference of the mice with the MYBPC3772G>A
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mice being much older than the MYBPC32373insG mice at the time of analysis, we speculate
that the increase in tubulin detyrosination is an early disease change together with an
increase in desmin protein levels, which is followed by an increase of total α-tubulin during
disease progression and ageing. In MYBPC32373insG mice we showed that the increase
in tubulin detyrosination is accompanied by reduced contraction and relaxation kinetics
in isolated intact cardiomyocytes. Inhibition of tubulin detyrosination by PTL restored
contraction and relaxation kinetics to WT levels in MYBPC32373insG cardiomyocytes.
The used concentration of PTL has already been proven to be sufficient to reduce
detyrosination of tubulin12,59 and Chen et al. and Robison et al. have demonstrated
that the PTL-induced effects on kinetics of contraction are the same as obtained by
overexpression of TTL,12,13 which specifically lowers tubulin detyrosination. The positive
effect of PTL on cardiomyocyte function of MYBPC32373insG cardiomyocytes is therefore
explained by a decrease in cardiomyocyte stiffness due to lower levels of detyrosinated
tubulin.
Overall, our findings in a European HCM patient cohort strengthens the evidence
that increased detyrosination of microtubules contributes to cardiomyocyte stiffness and
dysfunction in HCM. Importantly, we show that this is especially true in the presence of a
sarcomere mutation.
STUDY LIMITATIONS AND CLINICAL IMPLICATIONS
We sex- and age-matched our experimental groups as good as the availability of human
samples allowed us. As seen in Table 6.1, sex and age, as well as most clinical parameters,
are not statistically different between groups. We cannot exclude that differences in disease
progression, as displayed by the difference in IVS thickness, E/e’ ratio and LVOTg between
HCMSMP and HCMSMN, may influence the results. However, collection of patient heart
tissue is only possible at the time of myectomy. Therefore, all our samples have the same
clinical endpoint, i.e. time of myectomy. This is likely the cause for the low number of
genotype-specific protein changes and we cannot exclude that genotype-specific differences
might have occurred at earlier disease stages. Due to unavailability of myocardial biopsies
from asymptomatic mutation carriers, animal models and human-derived cardiomyocyte
muscle models should provide insight into gene-specific pathomechanisms at early disease
stages.
Most of the patients in this study have been on drug therapy, therefore we cannot
exclude that some of the proteomic changes are caused by medication. However, some
of the main findings, e.g. energy deficiency, have also been observed in animal models,39
and the number of patients on the most commonly used drugs does not differ between
HCMSMP and HCMSMN (Table 6.1). Therefore it is more likely that the observed changes
are driven by disease rather than medication.
Although we detected and quantified a large number of proteins in this study, we
do not reach full coverage of the proteome as this method only reliably quantifies the
more abundant proteins. Therefore, our list of differentially expressed proteins is not
comprehensive. Also, we did not assess post-translational modifications in the proteomics
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study which have important regulatory functions. The changes at the protein level
reflect whole tissue alterations and cannot be solely assigned to the mutation-carrying
cardiomyocytes but might also arise from other cell types. However, cardiomyocytes are
responsible for most of the tissue volume and therefore drive most of the protein changes.
Homozygous MYBPC32373insG mice do not fully resemble human HCM patients,
since patients typically carry heterozygous mutations. Whilst both patients and the
homozygous MYBPC32373insG mouse model show hypertrophy and diastolic dysfunction,
the prominent LV systolic dysfunction as observed in the homozygous MYBPC32373insG
mice is not seen in most HCM patients. But due to the lack of phenotype in heterozygous
mice they provide a suitable genetic model of loss of MYBPC3 protein levels.
In our proteomic screen in a large set of human HCM samples we identified reduced
levels of proteins involved in metabolic pathways as the most prominent derailment. This
finding supports recent and ongoing clinical trials investigating the therapeutic effect of
targeting the metabolism in HCM. Based on the proteomic data and functional studies in a
novel HCM mouse model, we propose that an increase in detyrosinated tubulin contributes
to the clinical and cellular differences that we see between HCMSMP and HCMSMN samples
(Figure 6.7).
Detyrosinated microtubules may represent a target for therapeutic intervention in
genetic heart disease because reducing detyrosination improves contractile function in
isolated cardiomyocytes. Since the increase in detyrosinated tubulin is largest in HCMSMP,
this treatment strategy is proposed to be most beneficial in mutation-positive HCM
patients. A specific inhibitor of detyrosination needs to be developed due to the known
off-target effects of PTL. As sarcomere mutation carriers are identified before disease onset,
targeting the microtubules may represent a preventive treatment option.
Figure 6.7: Schematic representation of genotype-independent changes in HCM and
genotype-specific differences in the microtubular system. Our analysis shows that all
HCM patients display downregulation of metabolic pathways (electron transport chain (ETC),
tricarboxylic acid (TCA) cycle, β-oxidation (β-oxid)) and ribosomal proteins (Translation), as
well as an upregulation of protein folding proteins (heat shock proteins, HSPs) and extracellular
matrix (ECM) proteins. HCMSMP patients have a large increase in microtubules and levels of its
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Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder. It
is mainly caused by mutations in genes encoding sarcomere proteins. Mutant forms of
these highly abundant proteins likely stress the protein quality control (PQC) system of
cardiomyocytes. The PQC system together with a functional microtubule network maintains
proteostasis.
METHODS
We compared left ventricular (LV) tissue of 9 donors (controls) with 38 sarcomere
mutation-positive (HCMSMP) and 14 sarcomere mutation-negative (HCMSMN) patients to
define HCM and mutation-specific changes in PQC. Mutations in HCMSMP result in poison
polypeptides or reduced protein levels (haploinsufficiency, HI).
RESULTS
The main findings are: 1) Several key PQC players were more abundant in HCM compared
to controls; 2) After correction for sex and age, stabilizing heat shock protein (HSP)B1, and
refolding HSPD1 and HSPA2 were increased in HCMSMP compared to controls; 3) α-tubulin
and acetylated α-tubulin levels were higher in HCM compared to controls, especially
in HCMHI; 4) Myosin-binding protein-C (cMyBP-C) levels were inversely correlated with
α-tubulin; 5) α-tubulin levels correlated with acetylated α-tubulin and HSPs.
CONCLUSION
Overall, carrying a mutation affects PQC and α-tubulin acetylation. Haploinsufficiency
of cMyBP-C may trigger HSPs and α-tubulin acetylation. Our study indicates that




Hypertrophic cardiomyopathy (HCM) is a common familial cardiac disease with an
estimated prevalence of 1:200.1 It is characterized by an asymmetrically hypertrophied,
non-dilated left ventricle and impaired diastolic function.2 More than 1500 pathogenic
mutations have been identified which most frequently encode proteins in the sarcomere.
Previous studies have shown that sarcomere mutations alter myofilament function (reviewed
recently in 3) However, while the same sarcomere mutation is present in members of one
family, age of onset and disease severity vary greatly between patients spanning from
asymptomatic mutation carriers to symptomatic patients with severe cardiac remodelling.4
This large clinical heterogeneity implies that HCM pathophysiology is more complex than
the functional defects triggered by the gene mutation. Furthermore, pathogenic mutations
were only found in ˜50% of all HCM patients.
4 Moreover, a recent large international
clinical HCM study showed that patients with a mutation in a sarcomere gene have a
2-fold higher risk of adverse outcomes (e.g. heart failure and atrial fibrillation) compared
to patients with no known mutations.5 The exact mechanisms underlying the difference in
disease severity between sarcomere mutation-positive (HCMSMP) and mutation-negative
(HCMSMN) patients are currently unknown.
A mechanism implicated in HCM progression is perturbed protein quality control
(PQC).6,7 Cardiomyocytes contain a multi-layered PQC system for maintaining proper
protein conformation, and for reorganizing and removing misfolded or aggregated (mutant)
proteins.8 The PQC system comprises heat shock proteins (HSPs), the ubiquitin-proteasome
system (UPS), and autophagy.9 HSPs are involved at all stages of sustaining protein
homeostasis: during protein biosynthesis and maturation, in chaperoning the folding,
in protection from environmental stress, in rearrangements of cellular macromolecules
during functional cycles of assembly and disassembly, and finally in targeting proteins for
degradation.10 Terminally misfolded and aggregation-prone proteins are cleared by the two
degradation systems, UPS and autophagy.11 Furthermore, pathways of PQC are strongly
linked to cell architecture, such as the microtubules network.12 As sarcomere proteins are
the most abundant proteins in the heart, maintenance of sarcomere structure and functions
depends on functioning PQC mechanisms. Perturbations in PQC mechanisms may be
aggravated by the presence of sarcomere gene mutations that may explain the difference in
disease severity between HCMSMP and HCMSMN patient groups. Moreover, the proteotoxic
burden on PQC may depend on the type of mutation: in HCM, gene mutations either
result in a ‘poison polypeptide’ (an expressed protein containing a mutated sequence) or
haploinsufficiency where up-regulation of the wild-type protein levels failed to compensate
for reduced total protein.13,14
Here, we identified and quantified key PQC players, such as HSPs and degradation markers
(ubiquitinated proteins, p62, LC3BII) and microtubule network markers (for example
acetylation of α-tubulin) in a large set of myectomy samples from HCMSMP and HCMSMN
patients to define if the presence of a sarcomere mutation differentially affects PQC. In
addition, mutation-specific PQC changes were assessed by comparing HCM with missense
mutations and MYBPC3 (cardiac myosin-binding protein-C) mutations, which cause
haploinsufficiency.
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METHODS
SEPTAL MYECTOMY
Cardiac tissue from the interventricular septum was obtained during myectomy surgery to
relieve left ventricular (LV) outflow tract obstruction. Patients are selected for surgery
at our HCM centre on the basis of the following indications: (1) peak left ventricular
outflow tract (LVOT) gradient ≥50 mmHg at rest or on provocation and (2) presence of
unacceptable symptoms despite maximally tolerated medications consisting of β-blocking
agents and/or calcium channel blockers. The decision to perform surgery was made
after consensus of a heart team consisting of a cardiothoracic surgeon, an interventional
cardiologist, and a cardiologist specialized in HCM care.15 Hypertrophic obstructive
cardiomyopathy was evident from the increased septal thickness with a mean (± SD) of 21
(± 6) mm and high LV outflow tract pressure gradient with a mean (± SD) of 66 (± 37)
mmHg. Next-generation-sequencing was used to check 48 different HCM-associated genes
for variants.16
This study included 52 septal myectomy patients and they are summarized in Table 7.1.
38 HCM patients were tested positive for carrying a gene variant in one of the genes
encoding for sarcomeric protein. Ages of all 38 HCMSMP patients ranged between 15 and
72 with a mean (± SD) of 49 (± 16) years and 68% of these were males. Dependent on
the reported pathomechanism, this group was subdivided into haploinsufficiency (HI) and
poison polypeptide (PP) subgroups.
Seven patients of the HCMHI group were identified as carrying the Dutch founder
mutation (c.2373dupG) in MYBPC3, the gene encoding the A band protein, cardiac
myosin-binding protein-C (cMyBP-C) and twelve patients carried other mutations in
MYBPC3 of which three were missense and the remainder were truncations. Patient ages
ranged between 21 and 71 years with a mean (± SD) of 43 (± 15) years. 79% of these
were males. We collected 19 myectomy samples from HCMPP patients carrying a missense
mutation. Nine patients presented with mutations in the gene for cardiac myosin heavy
chain (MYH7), the second most commonly mutated gene in HCM patients. Four patients
carried mutations in the gene for troponin I (TNNI3), three patients carried troponin T
(TNNT2) mutations and two patients carried myosin light chain 2 (MYL2) mutations.
HCMPP patients were aged between 15 and 72 years with a mean (± SD) of 55 (± 15)
years. 58% of these were males.
Our study included 14 patients with no known sarcomere gene mutation. HCMSMN
patient ages ranged between 22 to 74 with a mean (± SD) of age 57 (± 14). 64%
of these were males. Not all myectomy samples were sufficiently large to perform all analyses.
Finally, the 52 HCM samples were compared with nine samples of healthy donor
hearts that were not used for heart transplantation, often because of poor tissue matching
against patients in the heart failure clinic of St Vincent’s Hospital. While these controls
had no history of cardiac disease, their validity as “controls” is based on their extensive
use as such in publications from a wide range of other laboratories. We therefore assume
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these donors are representative of diverse human population. Consistent with the HCM
patients, these donor were 67% male, with a mean age (± SD) of 43 (± 14) years, ranging
from 19 to 65. All donor hearts were perfused with ice-cold cardioplegia, transported on
ice to the Sydney Heart Bank where ˜1 g samples were snap frozen and stored in liquid
nitrogen. The average values of control cardiac samples (n=9) are indicated by the dotted
lines in Figures 7.1 to 7.4 and Figure 7.6. The distribution of the controls are shown in
the Supplementary Materials (Figure S1) as well as uncropped full-width images of the
membranes (Figure S2). The patients study protocol was approved by the local ethics
committees and donor hearts were approved by the University of Sydney (HREC #7326).
All collections were made with written informed consent obtained from each patient prior
to surgery and from the donors’ next of kin.,
Table 7.1: Characteristics of controls and manifest HCM patients.
Num- Code Reported Affected Gene/ Type of Sex Age ST LVOT
ber pathome- gene protein mutation (F/ (mm) (mm-
chanism variant M) Hg)
1 HCM 4217-20 HI MYBPC3 c.2373dupG truncation M 32 23 64
2 HCM 4318-22 HI MYBPC3 c.2373dupG truncation M 60 23 77
3 HCM 10320 HI MYBPC3 c.2373dupG truncation M 26 20 13
4 HCM 10420 HI MYBPC3 c.2373dupG truncation M 33 24 31
5 HCM 12020 HI MYBPC3 c.2373dupG truncation M 27 24 61
6 HCM 12320 HI MYBPC3 c.2373dupG truncation F 59 12 64
7 HCM 16920 HI MYBPC3 c.2373dupG truncation M 52 - -
8 HCM 3418,20,23 HI MYBPC3 c.1790G>A;
p.Arg597Gln
missense F 47 20 38
9 HCM 36
17,18,20-25





truncation M 55 25 96





missense M 35 27 3
13 HCM 6320,23 HI MYBPC3 c.2827C>T truncation M 33 21 25
14 HCM 7120 HI MYBPC3 c.2827C>T truncation M 49 16 9
15 HCM 8220 HI MYBPC3 c.2783C>T;
p.Ser928Leu
missense M 71 20 64
16 HCM 11317,20 HI MYBPC3 c.2827C>T truncation M 21 45 27
17 HCM 11620 HI MYBPC3 c.2827C>T truncation F 53 - -
18 HCM 12420 HI MYBPC3 c.2827C>T truncation M 53 21 41
19 HCM 13320 HI MYBPC3 c.442G>A truncation M 58 - -
1 HCM 2718-20,25 PP MYH7 c.4130C>T;
p.Thr1377Met





missense F 46 20 77






missense M 34 17 85
4 HCM 9220 PP MYH7 c.2685A>C;
p.Glen895His
missense M 66 - -
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Table 7.1: Continued
Num- Code Reported Affected Gene/ Type of Sex Age ST LVOT
ber pathome- gene protein mutation (F/ (mm) (mm-
chanism variant M) Hg)
5 HCM 10620 PP MYH7 c.2783A>T;
p.Asp928Val
missense M 35 16 16
6 HCM 11420 PP MYH7 c.976G>C;
p.Ala326Pro
missense M 69 19 71
7 HCM 11920 PP MYH7 c.3367G>A;
p.Glu1123Gln
missense M 41 20 81
8 HCM 13020 PP MYH7 c.976G>C;
p.Ala326Pro
missense M 72 18 27
9 HCM 131 PP MYH7 c.1987C>T;
p.Arg663Cys
missense F 52 21 41
10 HCM 16620 PP MYH7 c.2080C>T;
p.Arg694Cys
missense F 66 - -
11 HCM 5518,23,25 PP TNNI3 c.433C>T;
p.Arg145Trp
missense M 46 23 100
12 HCM 5918,25 PP TNNI3 c.433C>T;
p.Arg145Trp
missense M 66 16 67
13 HCM 163 PP TNNI3 c.433C>T;
p.Arg145Trp
missense F 64 - -
14 HCM 170 PP TNNI3 c.433C>T;
p.Arg145Trp
missense F 69 - -
15 HCM 132 PP TNNT2 c.814C>T;
p.Arg272Cys
missense F 15 - -
16 HCM 173 PP TNNT2 c.832C>T;
p.Arg278Cys
missense M 58 - -
17 HCM 175 PP TNNT2 c.832C>T;
p.Arg278Cys
missense M 61 - -
18 HCM 135 PP MYL2 c.64G>A;
p.Glu22Lys
missense M 68 - -
19 HCM 88 PP MYL2 c.401A>C;
p.Glu134Ala
missense F 57 - -
1 314527-39 Ctrl - M 39 - -
2 402133-45 Ctrl - F 53 - -
3 404933-42,46-51 Ctrl - M 65 - -
4 512646-49,52 Ctrl - F 55 - -
5 600842,53-55 Ctrl - M 40 - -
6 701227-32,56,57 Ctrl - M 19 - -
7 704033-36,55,58 Ctrl - M 37 - -
8 705455,59 Ctrl - M 33 - -
9 800455 Ctrl - F 50 - -
HI: haploinsufficiency; PP: poison polypeptide; SMN: sarcomere mutation-negative; Ctrl: healthy
donor hearts; F: female; M: male; Age at time of surgery; ST: septal thickness; LVOT: left outflow
tract pressure gradient at rest. Patients without significant obstruction (LVOT gradient <20 mmHg),
but with severe heart failure symptoms, received an extended myectomy in order to increase LV filling.
WHOLE PROTEIN ISOLATION
Frozen tissue was dissected on dry ice and homogenized with RIPA buffer (0.05 M
C4H11NO3·HCl pH 8.0, 0.15 M NaCl, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium
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deoxycholate, 1% (w/v) sodium dodecyl sulphate) using a Tissuelyser II (Qiagen).
The lysates were centrifuged, supernatant was collected and passed through an
insulin syringe (Becton Dickinson Microlance needle, 25 gauge). Whole protein
lysate was mixed with 4x Laemmli sample buffer (8% (w/v) sodium dodecyl sulphate,
40% (v/v) glycerol, 0.04% (w/v) bromophenol blue, 0.240 M C4H11NO3·HCl pH 6.8, 10 mM
β-mercaptoethanol, 0.01 M NaF, 0.001 M Na3VO4, cOmplete mini protease inhibitor
cocktail (Roche)), boiled for 5 min and stored at -80°C.
ELECTROPHORESIS AND WESTERN BLOTS
Equal amounts of protein (10 µg) were separated on pre-cast SDS-PAGE 4-12% criterion
gels (Bio-Rad) and transferred onto nitrocellulose membranes (Bio-Rad). Membranes
were blocked in 5% (w/v) skim milk/1x TBST for 1 h at room temperature and
incubated overnight at 4°C with the following primary antibodies in 3% (w/v) BSA/1x
TBST: mouse anti-acetylated α-tubulin (T7451, Sigma-Aldrich), mouse anti-α-actinin
(A7811, Merck KGaA), mouse anti-HSPA1 (ADI-SPA-810, Enzo Life Sciences), mouse
anti-HSPA2 (66291-1, Proteintech Group), mouse anti-HSPB1 (ADI-SPA-800, Enzo Life
Sciences), rabbit anti-HSPB5 (ADI-SPA-223, Enzo Life Sciences), rabbit anti-HSPB7
(ab150390, Abcam), rabbit anti-HSPD1 (ADI-SPA-805, Enzo Life Sciences), mouse
anti-GAPDH (10R-G109a, Fitzgerald Industries International), mouse anti-LC3B (#2775,
Cell Signaling Technology), rabbit anti-p62 (#5114, Cell Signaling Technology),
mouse anti-α-tubulin (T9026, Sigma-Aldrich), rabbit anti-ubiquitin (#3933, Cell
Signaling Technology). Membranes were incubated for 1 h at room temperature with
horseradish peroxidase-conjugated secondary antibody (DakoCytomation), raised in goat, in
3% (w/v) BSA/1x TBST. Signals were detected by Amersham Imager 600 (GE Healthcare)
and quantified by densitometry (ImageQuant TL, GE Healthcare). To correct for loading
differences, protein amounts were expressed relative to GAPDH.
STATISTICAL ANALYSES
Data were analysed with SPSS Statistics version 22.0 for Windows (IBM Corporation,
US) and GraphPad Prism version 7.0 (GraphPad Software Inc., US). Data in figures are
presented as means ± standard errors of the mean (SEM) per group and in text, data
are presented as means ± standard deviations (SD). Distribution of each data set was
determined by Q-Q plots and then double checked by Kolmogorov-Smirnov and Shapiro
Wilk tests after data collection was completed. Normally distributed data was analysed with
unpaired t-test (comparing 2 groups) and ordinary one-way ANOVA (comparing > 2 groups)
with Tukey’s multiple comparisons post-hoc test (comparing ≤ 3 groups) and Dunnett’s
multiple comparisons post-hoc test (comparing > 3 groups). To analyse non-parametric
data, Mann-Whitney U test (comparing 2 groups) and Kruskal-Wallis test with Dunn’s
multiple comparisons post-hoc test (comparing > 2 groups) were used. A two-sided p<0.05
was considered to indicate statistical significance. Multivariate generalized linear model
testing (detailed description in the Supplementary Materials) was performed to study the
main effects of different mutation groupings, sex, and age at operation on PQC proteins
which were used as dependent variables.
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RESULTS
CHANGES OF PROTEIN QUALITY CONTROL IN HCMSMP AND HCMSMN
We investigated the expression levels of key PQC proteins to determine if they are altered
in patients with HCM at the time of myectomy compared with the levels in LV samples
from healthy controls. As the mutant sarcomere proteins may directly affect PQC, we used
Western blots to compare myectomy samples from 38 HCMSMP and 14 HCMSMN patients
with LV tissue from nine healthy controls that were age- and sex-matched to the HCM
samples (Table 7.1).
HSPs THAT STABILIZE TARGET PROTEINS
Dependent on their function, HSPs are classified in two categories: stabilizing HSPs
and HSPs with refolding capacity. Stabilizing HSPs (HSPB1 (also known as HSP27),
HSPB5 (αB-crystallin), HSPB7 (cardiovascular HSP)) have relatively low molecular weights
(15-30 kDa). They stabilize misfolded proteins using an ATP-independent holdase activity,
thereby preventing their aggregation (Figure 7.1A). Compared to controls, the HCMSMP
samples expressed significantly higher levels of HSPB1 and HSPB7, while HSPB5 appeared
to be unaltered (Figure 7.1C; Table 7.2).,
Table 7.2: Overview of results on statistical testing for differences between controls, HCMSMP
and HCMSMN.
Adjusted p-value post-hoc testing









HSPB1 Kruskal-Wallis 0.0019 0.0018 0.2113 0.3302
HSPB5 Ordinary one-way ANOVA 0.1297 0.1090 0.3807 0.8174
HSPB7 Kruskal-Wallis 0.0060 0.0048 0.0341 >0.9999
Refolding
HSPs
HSPD1 Ordinary one-way ANOVA 0.0004 0.0003 0.0530 0.2123
HSPA1 Kruskal-Wallis 0.3636 0.6382 >0.9999 >0.9999
HSPA2 Ordinary one-way ANOVA 0.0101 0.0071 0.1008 0.7334
Protein
degradation
Ubiquitin Kruskal-Wallis 0.2159 0.3094 >0.9999 0.9890
p62 Ordinary one-way ANOVA 0.1087 0.5822 0.7531 0.1046
LC3BII Kruskal-Wallis 0.0451 0.0384 0.2455 >0.9999
Tubulin
network
α-tubulin Ordinary one-way ANOVA <0.0001 <0.0001 0.0119 0.0019
Acetylated
α-tubulin
Kruskal-Wallis <0.0001 <0.0001 0.0451 0.0516
p<0.05 is considered to be significant.
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We then quantified the protein levels of these stabilizing HSPs (HSPB1, HSPB5 and
HSPB7) in HCMSMN samples. Only HSPB7 was significantly higher in HCMSMN compared
to controls (Figure 7.1C; Table 7.2). Despite this, there were no significant differences in
stabilizing HSPs levels between HCMSMP and HCMSMN.
HSPs THAT REFOLD TARGET PROTEINS
Next we investigated the expression levels of HSPD1 (HSP60), HSPA1 (HSP70 and
HSP72) and HSPA2 (HSP70-2) that have an ATP-dependent folding activity. These
HSPs have molecular weights >30 kDa and either refold misfolded proteins or assist in
their degradation. HSPD1 is mainly located in mitochondria while HSPA1 and HSPA2 are
cytosolic, but when they are exposed to heat stress, both translocate to the nucleus.60,61
Compared to controls, significantly higher levels of HSPD1 and HSPA2 were observed in
HCMSMP samples, while HSPA1 levels were not significantly changed. Levels of HSPs
with refolding capacity were not significantly different in HCMSMN compared to controls,
although HSPD1 and HSPA2 showed a trend to higher levels. There were no significant
differences in HSPs with refolding capacity between the two HCM groups (Figure 7.2;
Table 7.2).
DEGRADATION OF PROTEINS
PQC is also involved in the degradation of proteins and therefore levels of ubiquitination,
p62 and LC3BII were assessed. The antibody used for ubiquitin recognizes polyubiquitinated
proteins without distinguishing between K48-linked polyubiquitin chains (predominantly
targeted by proteasomal degradation) and K63-linked polyubiquitin chains (targeted
by autophagic degradation).62 Levels of ubiquitin and the ubiquitin-binding autophagic
adaptor protein p62 were unaltered in both HCM groups compared to controls. Levels
of the autophagosome marker LC3BII were significantly higher in HCMSMP compared to
controls, while only some samples of the HCMSMN group had higher levels of LC3BII
(Figure 7.3; Table 7.2).
To ensure that the significant differences detected by ANOVA testing were not related to
differences in age and/or sex of the myectomy patients, we performed multivariate testing
(Wilks’ Lambda test). This test uses age, sex and the HCM grouping (controls, HCMSMP
and HCMSMN) as the effects and the HSPs, ubiquitination, p62, and LC3BII as dependent
variables. We found an overall significant difference in levels of key PQC players based on
the different mutation groups (Table 7.3), while sex and age at operation had no significant
effect on levels of key PQC players.,
Table 7.3: Multivariate Testsa: HCM grouping (controls, HCMSMP, and HCMSMN), sex and age
at operation.
Effect Value F Hypothesis df Error df Significance Partial eta
squared
Intercept 0.260 14.561b 9.000 46.000 <0.001 0.740
HCM
grouping
0.479 2.278b 18.000 92.000 0.006 0.308
Sex 0.754 1.664b 9.000 46.000 0.126 0.246
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Table 7.3: Continued




0.717 2.016b 9.000 46.000 0.059 0.283
a Design: Intercept and HCM grouping and sex and age at operation; b exact statistic; F: F statistic for
the given effect and test statistic; Hypothesis df: Number of degrees of freedom in the model; Error
df: Number of degrees of freedom associated with the model errors; Partial eta squared: estimate of
effect size; p<0.05 is considered to be significant.
To determine which of the individual key PQC players differ among groups when taking into
account sex and age, we performed tests for between-subjects effects. This test revealed
statistically significant differences among groups for HSPB1 and HSPD1 (Table 7.4).,
Table 7.4: Tests for between-subjects: HCM grouping (controls, HCMSMP, HCMSMN) as an effect











HSPB1 23.286 2 11.643 6.031 0.004 0.182 0.261
HSPB5 1.777 2 0.889 2.495 0.092 0.085 0.088
HSPB7 9.725 2 4.863 3.319 0.044 0.109 0.162
Refolding
HSPs
HSPD1 11.104 2 5.552 10.543 <0.001 0.281 0.323
HSPA1 0.258 2 0.129 0.981 0.381 0.035 0.055
HSPA2 1.724 2 0.862 5.114 0.009 0.159 0.171
Protein
degradation
Ubiquitin 1.433 2 0.716 2.101 0.132 0.072 0.097
p62 0.733 2 0.367 2.498 0.092 0.085 0.122
LC3BII 12.839 2 6.420 2.276 0.112 0.078 0.111
df: Number of degrees of freedom in the model; F: F statistic for the given effect and test statistic;
Partial eta squared: estimate of effect size; R squared: proportion of the variance in the dependent
variable that is predictable from the independent variable; Bonferroni correction: statistical significance
at p<0.0056 (α/9 = 0.05/9 = 0.0056).
Since we found between-subjects main effects, we performed contrast analysis to determine
significant pairwise differences between controls and the two HCM patient groups corrected
for age and sex. A simple main effects analysis revealed significantly higher levels of HSPB1,
HSPD1 and HSPA2 in HCMSMP compared to controls (Table 7.5), while a trend to higher
levels of HSPD1 was observed in HCMSMN. Overall, our analyses showed increased levels
of several HSPs in HCMSMP and HCMSMN compared to controls, while no significant
differences between HCMSMP and HCMSMN were observed.,
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Figure 7.1: Stabilizing HSPs.
(A) Under stress conditions when native proteins are destabilized and begin to unfold, stabilizing
HSPs dissociate from homo- and/or heterogeneous oligomeric complexes into dimers to bind
these partially misfolded proteins. Thereby, stabilizing HSPs prevent the aggregation of misfolded
proteins. Figure reproduced and adapted with permission from Dorsch, L.M. et al., Pflügers Archiv –
European Journal of Physiology; published by Springer Berlin Heidelberg, 2018. (B) Representative
blot images for HSPB1, HSPB5, and HSPB7 expression. (C) Higher levels of HSPB1 and HSPB7
in HCMSMP (n=38) compared to controls. Higher HSPB7 levels in HCMSMN (n=12) compared
to controls (n=9; average is shown as dotted line). HSPB1 and HSPB5 protein levels were not
different in HCMSMP (n=14) compared to controls. There were no significant differences between
HCMSMP and HCMSMN. Each dot in the scatter plots represents an individual sample. *p<0.05
and **p<0.01 versus controls.
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Figure 7.2: HSPs with refolding capacity.
(A) HSPs with ATPase activity and stabilizing HSPs bind to the misfolded protein to stabilize and
further process it. HSPs with refolding capacity either refold the misfolded protein to its native
structure or, if refolding is impossible, the HSPs assist in the degradation pathways to degrade
the misfolded protein. Figure reproduced and adapted with permission from Dorsch, L.M. et al.,
Pflügers Archiv – European Journal of Physiology; published by Springer Berlin Heidelberg, 2018.
(B) Representative blot images for HSPD1, HSPA1, and HSPA2 expression. (C) Higher levels of
HSPD1 and HSPA2 in HCMSMP (n=38) compared to controls. HSPs with refolding capacity were
unaltered in HCMSMN (HSPD1, HSPA1: n=14; HSPA2: n=12) compared to controls. There were
no significant differences between HCMSMP and HCMSMN. Each dot in the scatter plots represents
an individual sample. **p<0.01 and ***p<0.001 versus controls.
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Figure 7.3: Degradation pathways.
(A) Misfolded proteins with polyubiquitin chains linked via lysine 48 (K48) are mainly degraded
by the proteasome. Misfolded proteins carrying K63-linked polyubiquitin chains and aggregated
proteins enter the autophagic pathway. Figure reproduced and adapted with permission from
Dorsch, L.M. et al., Pflügers Archiv – European Journal of Physiology; published by Springer
Berlin Heidelberg, 2018. (B) Representative blot images for ubiquitin, p62, and LC3BII expression.
(C) Protein levels of ubiquitin and p62 did not differ between HCM and controls samples. Higher
levels of LC3BII in HCMSMP (n=38) compared to controls. There were no significant differences
between HCMSMP and HCMSMN (ubiquitin, p62: n=12; LC3BII: n=13). Each dot in the scatter
plots represents an individual sample. *p<0.05 versus controls.
Table 7.5: Simple Contrast Results (K Matrix) for HCM grouping (controls, HCMSMP, HCMSMN)
as an effect and correction for differences in age at operation and sex.
Dependent Variable
Stabilizing HSPs Refolding HSPs Protein degradation




Contrast Estimate 1.804 0.447 1.164 1.242 0.177 0.491 0.441 0.128 1.319
Standard error 0.520 0.223 0.453 0.271 0.136 0.154 0.218 0.143 0.628
Significance 0.001 0.050 0.013 <0.001 0.198 0.002 0.049 0.375 0.040
95%
CI
Lower Bound 0.761 -<0.001 0.257 0.698 -0.095 0.183 0.003 -0.159 0.060




Contrast Estimate 1.522 0.178 0.929 0.961 0.086 0.452 0.301 -0.160 1.335
Standard error 0.650 0.279 0.565 0.339 0.169 0.192 0.273 0.179 0.784
Significance 0.023 0.524 0.106 0.006 0.613 0.031 0.274 0.374 0.094
95%
CI
Lower Bound 0.220 -0.380 -0.204 0.282 -0.253 0.041 -0.245 -0.519 -0.236
Upper Bound 2.825 0.737 2.062 1.641 0.426 0.810 0.848 0.198 2.907
CI: Confidence Interval; Bonferroni correction: statistical significance at p<0.0028 (α/18 = 0.05/18 = 0.0028).
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CHANGES OF PROTEIN QUALITY CONTROL: HCM DISEASE MECHANISM
All studied HCMSMP patients are heterozygous for the mutation implying the potential
to produce either/or both the mutant and wild-type protein.14 Either the expression of
mutant protein, which above a threshold (the ‘poison polypeptide’ mechanism) level might
become toxic or an inability to upregulate the haplotype protein levels to meet the needs
of the heart (the ‘haploinsufficiency’ mechanism) might underlie HCM.14 Truncation and
missense MYBPC3 mutations usually involve haploinsufficiency as the disease mechanism
since total cMyBP-C protein level is lower and the mutant protein has not been detected
in human myectomy samples.13,63
We determined whether key PQC players are differently changed in samples with
haploinsufficiency (HI) and poison polypeptide (PP) by comparing 19 MYBPC3 mutation
samples (HCMHI) with 19 HCMSMP samples carrying a missense mutation (HCMPP).
Proteomics analysis using mass spectrometry revealed significantly lower cMyBP-C protein
levels in the HCMHI samples compared to the HCMPP patients, consistent with a protein
haploinsufficiency mechanism (Figure 7.4).64
Figure 7.4: cMyBP-C haploinsufficiency.
Mass spectrometry-based proteomics analysis revealed lower levels of cMyBP-C in HCMHI (n=19)
compared to controls (n=5) and HCMPP (n=18). Each dot in the scatter plot represents an
individual sample. ***p<0.001 versus controls and ###p<0.001 versus HCMPP.
No significant differences in PQC components were observed between HCMHI and HCMPP
(Figure 7.5; Table 7.6).,
Table 7.6: Overview of results on statistical testing for differences between HCMHI and HCMPP.
Statistical test p-value
Stabilizing HSPs
HSPB1 Unpaired t-test 0.4040
HSPB5 Unpaired t-test 0.6236
HSPB7 Mann-Whitney U test 0.4181
Refolding HSPs





HSPA1 Unpaired t-test 0.8044
HSPA2 Unpaired t-test 0.2096
Protein degradation
Ubiquitin Unpaired t-test 0.6099
p62 Unpaired t-test 0.5868
LC3BII Unpaired t-test 0.4297
Tubulin network
α-tubulin Unpaired t-test 0.0074
Acetylated α-tubulin Unpaired t-test 0.0079
Acetylated α-tubulin/α-tubulin Mann-Whitney U test 0.1629
p<0.05 is considered to be significant.
MICROTUBLE NETWORK
Microtubule-based transport of proteins is required for autophagy and is thus an essential
part of PQC. Acetylation of α-tubulin is associated with stable microtubules and is used
as a marker of their stability.65,66 Mouse models of familial HCM showed higher levels of
acetylated α-tubulin.67 Compared to controls, α-tubulin expression levels were significantly
higher in both HCMSMP and HCMSMN (Figures 7.6A-B; Table 7.2).
In addition, acetylation of α-tubulin was significantly higher in both HCM patient groups
compared to controls (Figures 7.6A-B). The increases in levels of α-tubulin and acetylated
α-tubulin were significantly higher in HCMSMP compared to HCMSMN.
When comparing mutation type, significantly higher levels of α-tubulin and acetylated
α-tubulin were observed in HCMHI compared to HCMPP (Figure 7.6C, Table 7.6).
The levels of acetylated α-tubulin significantly correlated with α-tubulin (Figure 7.6D),
which is in line with the observation that acetylation of α-tubulin compartmentalizes on
the stable microtubules. Moreover, a significant inverse linear correlation was present
between cMyBP-C protein level and α-tubulin in HCM with a sarcomere gene mutation
(Figure 7.6E). Overall, these data show that the presence of a sarcomere mutation coincides
with a more extensive and stabilized microtubule network in HCM.
STRONG CORRELATION OF HSPs WITH α -TUBULIN
Since the PQC is strongly linked to the microtubules network, we performed multivariate
testing (Wilks’ Lambda test) using levels of α-tubulin, sex and age at operation as effects
and the HSPs, ubiquitination, p62, and LC3BII as dependent variables. There was an
overall statistically significant difference in levels of key PQC players based on α-tubulin
levels (Table 7.7).
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Figure 7.5: Pathomechanism of HCM and key PQC players.
(A) Stabilizing HSPs (HSPB1, HSPB5, HSPB7), (B) HSPs with refolding capacity (HSPD1,
HSPA1 HSPA2) and (C) degradation markers (ubiquitin, p62, LC3BII) were not significantly
different between HCMHI (n=19) and HCMPP (n=19). Each dot in the scatter plots represents
an individual sample. Figure reproduced and adapted with permission from Dorsch, L.M. et al.,
Pflügers Archiv – European Journal of Physiology; published by Springer Berlin Heidelberg, 2018.
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Figure 7.6: Pathomechanism of HCM and acetylation of α-tubulin.
(A) Representative blot images for α-tubulin and acetylated α-tubulin. (B) Higher levels of
α-tubulin and acetylated α-tubulin in HCMSMP (n=38) and HCMSMN (α-tubulin: n=14; acetylated
α-tubulin: n=12) compared to controls. Significant difference of α-tubulin levels between HCMSMP
and HCMSMN (##p<0.01). (C) Higher levels of α-tubulin and acetylated α-tubulin in HCMHI
(n=19) than HCMPP (n=19). (D) The levels of α-tubulin correlated well with acetylated α-tubulin
(E) Significant inverse linear correlation of α-tubulin with cMyBP-C. Controls = open squares,
HCMSMP = filled circles, HCMSMN = open circles, HCMHI = filled triangles, HCMPP = filled
rhomboids. Each dot in the scatter plots and the correlation analyses represents an individual
sample. *p<0.05 and ***p<0.001 versus controls and ##p<0.01 and ###p<0.001 versus HCMPP.
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Table 7.7: Multivariate Testsa: α-tubulin (all samples), sex, and age at operation.
Effect Value F Hypothesis df Error df Significance Partial eta squared
Intercept 0.389 8.186b 9.000 47.000 <0.001 0.611
α-tubulin 0.427 7.009b 9.000 47.000 <0.001 0.573
Sex 0.774 1.523b 9.000 47.000 0.168 0.226
Age at
operation
0.791 1.384b 9.000 47.000 0.223 0.209
a Design: Intercept and α-tubulin and sex and age at operation; b exact statistic; F: F statistic for the
given effect and test statistic; Hypothesis df: Number of degrees of freedom in the model; Error df:
Number of degrees of freedom associated with the model errors; Partial eta squared: estimate of effect
size; p<0.05 is considered to be significant.
To determine which of the key PQC players differ when α-tubulin levels are changing, we
performed tests for between-subjects effects. This testing revealed that α-tubulin had a
significant effect on all measured HSPs, but not on the degradation markers (Table 7.8).
The correlation of HSPs and α-tubulin levels is visualized in Figure S3.,
Table 7.8: Tests for between-subjects: α-tubulin as an effect and correction for differences in











HSPB1 38.460 1 38.460 23.663 >0.001 0.301 0.368
HSPB5 3.630 1 3.630 11.485 0.001 0.173 0.176
HSPB7 14.246 1 14.246 10.504 0.002 0.160 0.209
Refolding
HSPs
HSPD1 10.273 1 10.273 19.305 >0.001 0.260 0.303
HSPA1 1.370 1 1.370 12.580 0.001 0.186 0.203
HSPA2 1.723 1 1.723 10.410 0.002 0.159 0.171
Protein
degradation
Ubiquitin 0.419 1 0.419 1.187 0.281 0.021 0.047
p62 0.418 1 0.418 2.793 0.100 0.048 0.087
LC3BII 3.849 1 3.849 1.312 0.257 0.023 0.058
df: Number of degrees of freedom in the model; F: F statistic for the given effect and test statistic;
Partial eta squared: estimate of effect size; R squared: proportion of the variance in the dependent
variable that is predictable from the independent variable; Bonferroni correction: statistical significance




The incomplete penetrance, age-related onset and the large clinical variability in disease
severity imply a complex HCM pathophysiology mechanism. Especially, patients with a
sarcomere mutation have a higher risk for adverse outcomes. The underlying causes for
difference in disease between HCMSMP and HCMSMN remain unclear.
Here we determined protein levels of key PQC players, including HSPs and degradation
markers, and acetylation of α-tubulin by Western blot analysis in a large set of cardiac
samples from HCMSMP and HCMSMN patients to define PQC changes in HCM at the time
of myectomy, and identified if the presence of a sarcomere mutation mediates changes in
PQC mechanisms and tubulin network. One of the limitations of the current study is that
patients had a severe phenotype with LVOT obstruction. Therefore, this group may not be
representative for all patients with HCM.
Main findings of our PQC assessment are that: 1) Several HSPs and autophagy
markers are higher in HCM compared to controls, but there are no major differences
between HCMSMP and HCMSMN or mutation type (haploinsufficiency versus poison
polypeptide) at the time of myectomy; 2) After correction for sex and age at operation,
the major increases in HCMSMP compared to controls were observed in the stabilizing
HSPB1 and the refolding HSPD1 and HSPA2; 3) The most significant increase compared
to control samples was observed in the levels of α-tubulin and acetylated α-tubulin with
significant differences between mutation group: HCMHI > HCMPP > HCMSMN; and 4)
Levels of α-tubulin significantly correlated with levels of acetylated α-tubulin and all HSPs
(Figure 7.7).
Overall, our analyses indicate that carrying a HCM-causing mutation affects PQC and
α-tubulin acetylation. We propose that reduced levels of cMyBP-C caused by MYBPC3
mutations trigger HSPs and α-tubulin acetylation, and may present a pathomechanism
in cMyBP-C haloinsufficiency-mediated HCM. The possible impact of the observed PQC
changes is discussed below.
ELEVATED LEVELS OF HSPs IN HUMAN HCM
We identified higher levels of HSPB1, HSPD1, and HSPA2 in HCMSMP compared to
controls which could not be explained by differences in sex and age at operation (Table 7.5).
Our findings are in line with studies in human end-stage heart failure studies samples,
which showed increases in HSPD1 and HSPB1 compared to controls.68
HSPB1 is implicated in different cardio-protective processes involving interception of
misfolded proteins, cytoskeletal organization, anti-apoptotic and anti-oxidant properties.69
Therefore, its expression may improve the resistance of tissue exposed to stress and injuries.70
While moderate cardiac expression of HSPB1 protects against doxorubicin-induced cardiac
dysfunction through anti-oxidative stress, reports on effects of HSPB1 overexpression
are inconsistent.71 Overexpression of HSPB1 conferred protection against myocardial
ischemia-reperfusion injury72 whereas overexpression of HSPB1 caused reductive stress
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Figure 7.7: Schematic representation of PQC and microtubular system assessment in HCM.
Our analyses show that HSPB1, HSPD1 HSPA2, α-tubulin and acetylated α-tubulin are increased
in HCM, especially when a sarcomere mutation is present, while HSPB5, HSPB7, HSPA1 and
degradation markers are not changed in HCM compared to controls. Levels of α-tubulin (orange
balls) and acetylated α-tubulin (small yellow balls attached to α-tubulin in the lumen of polymerized
microtubules (blue and orange balls)) are more increased when haploinsufficiency (HI), characterized
by lower levels of cardiac myosin-binding protein-C (green lines), is the underlying pathomechanism
instead of poison polypeptides (PP). =: similar to controls; ↑: significantly increased compared to
controls; ↓: significantly decreased compared to controls.
and cardiomyopathy in another study.73 Further experiments are needed to clarify if the
observed increase in HSPB1 is actually beneficial and may be a response to stress exposure.
HSPD1 fulfils multiple tasks in a cell by refolding key proteins after their import
into the mitochondria, transporting of proteins between the mitochondrial matrix and
the cytoplasm of the cell, and binding to cytosolic pro-apoptotic proteins to sequester
them.74 Upregulation of HSPD1 due to mitochondrial impairment is suggested to be an
indicator of mitochondrial stress.75 15-20% of HSPD1 is located at extra-mitochondrial
sites suggesting important physiological roles at other locations.61 In human end-stage
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heart failure, HSPD1 localizes to the plasma membrane thereby losing anti-apoptotic and
protective effects and becoming detrimental to the cell.76 Impairment of HSPD1-mediated
anti-stress response has been reported in dilated cardiomyopathy (DCM) which progressed
to end stage heart failure.77 Here, we identified higher levels of HSPD1 which may indicate
mitochondrial stress, which has been reported in HCM.78
Western blot analysis, showed higher levels of HSPA2 in HCMSMP compared to
controls. In our mass-spectrometry based proteomics study, HSPA2 was highly upregulated
in cardiac disease (Figure 7.8A).64
Figure 7.8: Upregulated HSPA2 in HCM in proteomics screen.
(A) In a mass-spectrometry based proteomics study, HSPA2 levels were higher in HCMHI (n=20)
and HCMothers (n=30) samples, including HCMPP and HCMSMN, compared to controls (n=8). (B)
Significant inverse correlation of HSPA2 levels determined by Western blot analysis with cMyBP-C.
Controls = open squares, HCMHI = filled triangles, HCMPP = filled rhomboids, HCMSMN = open
circles, HCMothers = hexagons. Each dot in the scatter plots and correlation analysis represents an
individual sample. ***p<0.001 versus controls.
HSPA2 has been reported in heart tissue and low expression was identified in fibroblasts.60,79
Recently, HSPA-family chaperones have been suggested to interact with cMyBP-C to
regulate its turnover.80 Moreover, a significant inverse linear correlation was present
between cMyBP-C protein levels and HSPA2 (Figure 7.8B). Therefore, HSPA2 may be an
additional regulator of cMyBP-C. Further experiments are warranted to explain the role of
HSPA2 in haploinsufficiency for cMyBP-C.
In contrast, levels of HSPB5 and HSPA1 in HCM samples were not different compared to
controls after adjusting for sex and age differences. Several studies have shown that HSPB5
and HSPA1 are both increased early in response to acute hypertrophic signalling, but with
opposite functions. While HSPB5 is involved in counteracting acute cardiac remodelling
by suppressing hypertrophic signalling pathways, HSPA1 supports pro-hypertrophic
signalling pathways81,82 The increase of HSPA1 was transient and attenuated 14 days after
isoproterenol-infusion in a mouse model for cardiac hypertrophy.82 Consistent with our
findings in myectomy samples from patient with advanced disease, HSPA1 levels were not
changed in septal myectomy samples of HCM patients and end-stage heart failure patients
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compared to controls.68,80 Increased HSPA1 in the heart protects against acute cardiac
stress, but not against chronic cardiac stress.83
Based on these studies, we propose that HSPB5 and HSPA1 levels are not changed
in HCM myectomy samples because of persistent chronic hypertrophic stimuli leading to
their blunted response. Further research is warranted to investigate if the failure to increase
HSPB5 implies a loss of responsiveness at advanced disease stage because HSPB5 seems
to play a beneficial role in hypertrophic signalling.
PROTEIN DEGRADATION IN HCM
Defects in the turnover of key sarcomere proteins may account for both hypertrophic and
functional defects.9 UPS dysfunction is characterized by accumulation of ubiquitinated
proteins, altered proteasome activity, and changes in expression of UPS proteins or E2
and E3 enzymes.84 Upon correction for sex and age, no significant changes were observed
in levels of degradation-associated markers in HCM, such as HSPB7, ubiquitin, p62 and
LC3BII. Compared to the protein folding-supportive HSPB1 and HSPB5, HSPB7 plays
a critical role in preventing protein aggregation.85 Genetic variants in HSPB7 have been
associated with advanced heart failure and systolic dysfunction.86 In a zebrafish model,
HSPB7 is involved in early post-damage processing of large cytoskeletal proteins and
the loss of HSPB7 function is accompanied by increased damaged protein load, protein
aggregation and risk for cardiomyopathy.87
Due to the use of an antibody recognizing both K48- and K63-linked polyubiquitinated
chains, we do not know if the ratio between K48- and K63-linked polyubiquitinated proteins
is altered in HCM. Therefore, we cannot draw any conclusion about the functionality of
the proteasome which would be indicated by an increase in K48-linked polyubiquitinated
proteins. LC3BII and p62 are both markers for autophagosomes because in selective
autophagy, the cargo adapter protein p62 links polyubiquitinated proteins to the autophagic
machinery via LC3.88 We did not find a change in autophagosome markers, but this finding
does not exclude the prospect that the autophagic flux might be impaired. Autophagy
has been implicated in the pathogenesis of a wide range of cardiac pathologies.62,88
Pre-clinical models of pressure overload-induced cardiac hypertrophy show that the increase
of autophagic flux correlates with the degree of hypertrophy and therapeutic inhibition of
autophagy is accompanied by reduced amount of fibrosis.89
Our analysis of protein degradation markers, indicate that there is no enhancement
of protein degradation pathways at the time of myectomy. This may indicate that




INCREASED MUTATION-DEPENDENT PROLIFERATION AND ACETYLATION
OF α -TUBULIN
Our protein analyses revealed significantly increased levels of α-tubulin in both HCM
groups (Figure 7.6A), which correlated with an increase in α-tubulin acetylation and levels
of all HSPs. Changes of microtubules distribution occur at the onset of hypertrophy.90
In chronically hypertrophied hearts, the increase of microtubules has been shown to be a
major cause of contractile defects.91 Two different hypotheses may explain microtubule
densification: (1) Microtubules may be involved in myofibrillogenesis and an increase
in microtubules would be required when new myofibrils are formed in hypertrophied
cardiomyocytes, and (2) Microtubules may be intracellular compression-bearing elements
needed to cope with increased contractile stress on cardiomyocytes.92,93 In failing human
hearts, accumulation of microtubules impedes sarcomere motion and contributes to
decreased ventricular compliance.94 Our results are in line with literature, showing an
increase in α-tubulin in the HCM myocardial tissue.95
The underlying pathomechanism seems to have an effect on extent of increase in
α-tubulin and acetylated α-tubulin, since we observed the largest increase in samples with
haploinsufficiency for cMyBP-C. An intact microtubule-based cytoskeleton contributes
to the stabilization of myofibril structure in the cardiomyocytes and HSPs may preserve
this relationship.96 Post-chaperonin tubulin-folding cofactors, such as HSPs and other
tubulin-associated proteins, regulate the synthesis, transport, and storage of α- and
β-tubulin.97 For instance, HSPA1 binds to native tubulin dimers and microtubules to assist
in proper tubulin folding.98 In addition, HSPB5 prevents aggregation of tubulin and the
chaperone activity is accompanied by the formation of large complexes between HSPB5
and tubulin.99 We identified that α-tubulin level significantly correlates with all investigated
HSPs.
In addition to HSPs, acetylation of α-tubulin was higher in both HCM groups
(Figure 7.6B). Acetylation of α-tubulin directly tunes the compliance and resilience from
mechanical breakage to ensure the persistence of long-lived microtubules.100 Moreover,
acetylation of α-tubulin most often compartmentalizes on the stable microtubules and
is suggested to increase assembly of autophagic cargo along microtubules, thereby
initiating augmented autophagic degradation in the heart.101,102 Interestingly, there is
a strong linear relation between acetylated and total α-tubulin levels (Figure 7.6D).
This may suggest hyperacetylation of α-tubulin which is a common response to several
cellular stresses. For example, acetyltransferase induction is triggered by the release of
mitochondrial reactive oxygen species (ROS) and by AMP kinase.103,104 Noteworthy, the
underlying pathomechanism (HI versus PP) seems to have an effect on extent of increase
in α-tubulin and acetylation of α-tubulin, since we observed the largest increase in samples
with haploinsufficiency for cMyBP-C. As such, our analyses suggest that proliferation
of the microtubular network represents a pathomechanism in HI-mediated HCM. Based
on previous studies,100-104 we propose that the increased tubulin network may function
to maintain cellular stability and enhance autophagic flux of damaged proteins, while
it may impair contractile function.95,105 Future studies are warranted to establish the
link (cause-consequence) between reduced cMyBP-C protein levels, increased α-tubulin
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acetylation and cardiomyocyte contractile function and hypertrophy that may underlie
initiation and progression of cardiac disease in MYBPC3 mutation carriers.
INTER-INDIVIDUAL DIFFERENCES
We observed large inter-individual differences in various key PQC players and tubulin
network, especially in the presence of a sarcomere mutation. This variability may be explained
by the large variability among HCM-causing mutations, which may all have a distinct effect
on cellular PQC. Most of the mutation sites of proteins affect stability and aggregation but
rarely its function.106 This concept is supported by the fact that HCMHI mutations cause
a rather heterogeneous cMyBP-C haploinsufficiency, with some samples having relatively
low cMyBP-C, and others having still relatively high protein level. Loss of cMyBP-C levels
correlates very well with α-tubulin, thereby supporting the diverse response to a change in
sarcomere protein composition in the case of HCMHI. The microtubule response correlates
significantly with the expression level of cMyBP-C, and may represent a direct compensation
for the loss of cMyBP-C as cMyBP-C is known to have a central regulatory role in myofibril
development and stability.107 In line with this, reduced myofibril density was detected in
septal myectomy samples from HCMSMP patients compared to HCMSMN patients.18 While
the excessive microtubular response to cMyBP-C haploinsufficiency may be an attempt to
maintain myofibril stability, it may aggravate cardiac dysfunction by altering cytoskeletal
mechanical properties.95,105
CONCLUSION
In summary, our data show that the hypertrophied muscle of HCM patients is characterized
by an increased and stabilized tubular network which may be an adaptive response to
cardiomyocyte growth. While this compensatory response may aid to stabilize cardiomyocyte
architecture, this structural adaption may contribute to reduced function of the HCM
myocardium.
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ABSTRACT
BACKGROUND
Sex-differences in clinical presentation contribute to the phenotypic heterogeneity of
hypertrophic cardiomyopathy (HCM) patients. While disease prevalence is higher in men,
women present with more severe diastolic dysfunction and worse survival. Until today, little
is known about the cellular differences underlying sex-differences in clinical presentation.
METHODS
To define sex-differences at the protein level, we performed a proteomic analysis in cardiac
tissue obtained during myectomy surgery to relieve left ventricular outflow tract obstruction
of age-matched female and male HCM patients harbouring a sarcomere mutation (n=13 in
both groups). Furthermore, these samples were compared to 8 non-failing controls. Women
presented with more severe diastolic dysfunction.
RESULTS
Out of 2099 quantified proteins, direct comparison of male and female HCM samples
revealed only 46 significantly differentially expressed proteins. Increased levels of tubulin
and heat shock proteins were observed in female compared to male HCM patients. Western
blot analyses confirmed higher levels of tubulin in female HCM samples. In addition, proteins
involved in carbohydrate metabolism were significantly lower in female compared to male
samples. Furthermore, we found lower levels of translational proteins specifically in male
HCM samples. The disease-specificity of these changes were confirmed by a second analysis
in which we compared female and male samples separately to non-failing control samples.
Transcription factor analysis showed that sex hormone-dependent transcription factors may
contribute to differential protein expression, but do not explain the majority of protein
changes observed between male and female HCM samples.
CONCLUSION
In conclusion, based on our proteomics analyses we propose that increased levels of tubulin
partly underlie more severe diastolic dysfunction in women compared to men. Since heat
shock proteins have cardioprotective effects, elevated levels of heat shock proteins in females
may contribute to later disease onset in woman, while reduced protein turnover in men may
lead to the accumulation of damaged proteins which in turn affects proper cellular function.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease with
a prevalence of 1:200-500.1,2 Clinically, it is characterized by unexplained asymmetric left
ventricular hypertrophy and diastolic dysfunction.3,4 A pathogenic mutation is identified in
about 50-60% of all patients.5 Both genetic and clinical heterogeneity is large, with more
than 1500 identified gene mutations, and mutation carriers who are asymptomatic, die of
acute cardiac arrest or show end-stage heart failure.6
Sex-differences in clinical presentation contribute to the phenotypic heterogeneity of
HCM. Several large cohort studies observed a higher disease prevalence in men representing
55-65% of the total HCM population.7-11 At HCM diagnosis, women are on average 9 years
older than men,7,12 and at the time of myectomy surgery women are on average 7 years
older than men.13 While women display less ventricular remodelling,14,15 several studies
have demonstrated more severe diastolic dysfunction13,16-18 and worse survival compared to
men.19 Based on recent studies, our group put forward the hypothesis that disease severity
in female patients with HCM is underestimated because females have smaller hearts than
men, and the diagnostic criterion of ≥15 mm wall thickness does not take into account
a correction by body surface area (BSA).20 Consequently, women may be diagnosed at a
later disease stage, since it takes more time for them to reach the diagnostic threshold
of 15 mm wall thickness. This is supported by the observation that differences in wall
thickness between genotype-positive men and women, that presented for cardiac screening,
are mitigated after correction for BSA.21
Recently, efforts have been made to understand the sex-specific phenotypical differences
on a cellular level. Single cardiomyocyte studies did not observe sex-specific changes
in passive stiffness compared to non-failing controls, and the HCM-related increase in
myofilament Ca2+-sensitivity was similar in male and female HCM patients, implying that
the sex-difference in diastolic dysfunction is not explained by sarcomere function itself.13
However, women had more fibrosis compared to men, expressed more compliant titin and
showed reduced levels of calcium-handling proteins.13 These findings are first indications of
differences between males and females on a cellular level. To further investigate cellular
alterations that may underlie the sex-differences in HCM, we analysed protein expression
data of males and females in a proteomics data set of septal myocardial tissue that was
collected during myectomy surgery.
By direct comparison of male and female samples we found higher levels of tubulin
subunits and heat shock proteins in females. The levels of α-tubulin, determined by
Western blot analysis, correlate with diastolic function displayed as E/e’ and may therefore
at least partly underlie the sex-difference in diastolic dysfunction. The increased levels of
heat shock proteins in females are proposed to be cardioprotective22,23 and may contribute
to later disease onset in women.
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METHODS
PROTEOMICS ANALYSIS
The proteomics data in this study is a new analysis of a subset of the samples that were
included of the study from Schuldt et al. 2021, where we identified HCM-specific protein
changes compared to non-failing controls. We here focus on sex-specific protein changes in
HCM by comparing cardiac samples from age-matched female and male genotype-positive
HCM patients. In addition, a comparison was made between the proteomics data from the
female and the male group, and the proteomic data from the non-failing control group.
HCM patient tissue from the interventricular septum (IVS) of HCM patients was obtained
during myectomy surgery to relieve left ventricular outflow tract obstruction (LVOTO).
The study protocol for the human tissue samples was approved by the local medical ethics
review committees and written informed consent was obtained from each patient prior to
surgery.
For the analysis of sex-differences age-matched sarcomere mutation-positive (SMP)
female (n=13) and male (n=13) samples were compared in a group-wise comparison using
the beta binomial test as described previously.24,25 Furthermore, the male and female SMP
samples were compared to 8 non-failing healthy controls (NFIVS; 5 females and 3 males)
obtained from the Sydney Heart Bank (HREC Univ Sydney 2012/030). The non-failing
controls have no history of cardiac disease and do not take any medication. The clinical
characteristics of the groups are summarized in Table 8.1, individual patient characteristics
are displayed in Table S1.,
Table 8.1: Clinical characteristics.
HCMfemale HCMmale p
(n=13) (n=13)
Age at myectomy (years) 48.5 ± 17.7 49.8 ± 15.5 0.85
LVOTg (mmHg) 60.4 ± 31.8 55.6 ± 32.2 0.72
LV parameters
LAD (mm) 45.5 ± 4.3 48.4 ± 7.3 0.25
IVS (mm) 21.0 [20.0-23.0] 21.0 [18.3-23.0] 0.80
IVSi 12.5 [10.0-13.8] 10.0 [8.3-10.8] 0.07
EDD (mm) 41.5 [39.3-42.8] 43.5 [40.0-46.5] 0.39
ESD (mm) 16.7 ± 1.2 24.9 ± 4.7 *0.02
Systolic parameter
FS (%) 56.7 ± 2.5 44.4 ± 12.3 0.13
Diastolic parameters
E/A ratio 1.20 [0.79-2.17] 0.87 [0.74-1.40] 0.34
E/e’ ratio 20.3 [17.9-32.7] 13.9 [12.6-16.0] ***0.0003
TR velocity (cm/s) 2.6 [2.1-2.9] 2.3 [2.2-2.4] 0.20
Grade of diastolic dysfunction
1 11.1% (1) 75.0% (9) **0.008
2 55.6% (5) 8.3% (1) *0.046
3 33.3% (3) 16.7% (2) 0.61
Medication
beta blocker 84.6% (11) 84.6% (11) >0.9999






statins 15.4% (2) 23.1% (3) >0.9999
Table displays clinical characteristics of female and male HCM patient group with testing for statistical
differences. Abbreviations: LVOTg, left ventricular outflow tract gradient; LAD, left atrial diameter;
IVS, interventricular septum; IVSi, indexed interventricular septum thickness corrected for body surface
area (BSA); EDD, end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening.
TISSUE HOMOGENIZATION
Pulverized frozen tissue was homogenized in 40 µL/mg tissue 1x reducing sample
buffer (106 mM Tris-HCl, 141 mM Tris-base, 2% (w/v) lithium dodecyl sulphate (LDS),
10% (v/v) glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.18 mM Phenol Red,
100 mM DTT) using a glass tissue grinder. Proteins were denatured by heating to 99°C
for 5 min, after which samples were sonicated and heated again. Debris was removed by
centrifugation at maximum speed for 10 min in a microcentrifuge (Sigma, 1-15K).
PROTEIN FRACTIONATION
Proteins were separated using 1D SDS-PAGE. Samples from each group were loaded
alternating on the gels to avoid bias. Equal volumes of sample (30 µL protein homogenate
per sample, containing approximately 20-30 µg of protein) were loaded on a precast 4-12%
NuPAGE Novex Bis-Tris 1.5 mm mini gel (Invitrogen). Electrophoresis was performed at
200V in NuPAGE MES SDS running buffer until the dye front reached the bottom of the
gel. Gels were fixed in a solution of 50% ethanol and 3% phosphoric acid, and stained with
0.1% (w/v) Coomassie brilliant blue G-250 solution (containing 34% (v/v) methanol, 3%
(v/v) phosphoric acid and 15% (w/v) ammonium sulphate).
IN-GEL-DIGESTION
In-gel digestion was performed as described previously.26 The proteins were in-gel reduced
with 10 mM DTT and alkylated with 54 mM iodoacetamide. Each gel lane was cut into 5
pieces which were subsequently sliced into 1 mm3 cubes. Proteins were digested in-gel with
6.3 ng/ml trypsin. Peptides were extracted from gel slices with 1% formic acid and 5% formic
acid/50% acetonitrile and concentrated in a vacuum centrifuge prior to nano-LC-MS/MS
measurement. Samples were measured by LC-MS per gel band starting at the high molecular
weight (MW) fraction for all samples, before continuing with the next gel band until the last
(low MW fraction) band was measured. Injections alternated between all different group
samples to minimize experimental bias between groups.
NANO-LC-MS/MS
Analysis of the experiment was performed as described in Piersma et al.27 Peptides
were separated using an Ultimate 3000 Nano LC-MS/MS system (Dionex LC-Packings,
Amsterdam, The Netherlands) equipped with a 40 cm x 75 µm ID fused silica
PROTEOMIC SEX DIFFERENCES IN HCM 173
column custom packed with 1.9 µm,120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH,
Ammerbuch-Entringen, Germany). After injection, peptides were trapped at 6 µL/min on
a 10 mm × 100 µm ID trap column packed with 5 µm, 120 Å ReproSil Pur C18aqua at 2%
buffer B (buffer A: 0.5% acetic acid (Fischer Scientific), buffer B: 80% acetonitrile, 0.5%
acetic acid) and separated at 300 nl/min in a 10–40% buffer B gradient in 60 min (90 min
inject-to-inject). Eluting peptides were ionized at a potential of + 2 kV into a Q Exactive
mass spectrometer (Thermo Fisher, Bremen, Germany). Intact masses were measured at
resolution 70,000 (at m/z 200) in the orbitrap using an automatic gain control (AGC)
target value of 3x106 charges. The top 10 peptide signals (charge-states 2+ and higher)
were submitted to MS/MS in the HCD (higher-energy collision) cell using 1.6 amu isolation
width and 25% normalized collision energy. MS/MS spectra were acquired at resolution
17,500 (at m/z 200) in the orbitrap using an AGC target value of 1x106 charges, a maxIT
of 60 ms and an underfill ratio of 0.1%. Dynamic exclusion was applied with a repeat count
of 1 and an exclusion time of 30 s.
DATA ANALYSIS
MS/MS spectra were searched against a Uniprot human reference proteome FASTA
file (Swissprot_2017_03_human_canonical_and_isoform.fasta, 42161 entries) using
MaxQuant version 1.5.4.1. Enzyme specificity was set to trypsin and up to two missed
cleavages were allowed. Cysteine carboxamidomethylation was treated as fixed modification,
and methionine oxidation and N-terminal acetylation as variable modifications. Peptide
precursor ions were searched with a maximum mass deviation of 4.5 parts per million
(ppm) and fragment ions with a maximum mass deviation of 20 ppm. Peptide and protein
identifications were filtered at a false discovery rate (FDR) of 1% using the decoy database
strategy. The minimal peptide length was 7 amino acids, the minimum Andromeda score
for modified peptides was 40, and the minimum delta score was 6. Proteins that could
not be differentiated based on MS/MS spectra alone were grouped to protein groups
(default MaxQuant settings). Searches were performed with the label-free quantification
option selected. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE28 partner repository with the dataset
identifier PXD012467. Beta-binominal statistics were used to assess differential protein
expression between groups, after normalization on the sum of the counts for each sample.24
Proteins with a p-value below 0.05 were considered significantly differentially expressed.
Proteins which were present in less than 25% of the samples or had an average normalized
count of less than 1.4 were excluded from further functional analysis. Principal component
analysis was performed in R. Therefore quantile normalization and log2 transformation
was performed on the normalized counts. The 95th Percentile was taken, the data median
centred and the principal components calculated. Hierarchical clustering was performed
after a statistical multi-group comparison. Protein networks were generated utilizing
the STRING database (Search Tool for the Retrieval of Interacting Genes/Proteins) and
visualized with Cytoscape software.29 Protein interaction networks were generated with
ClusterONE and gene ontology (GO) analysis was performed using the BiNGO application





The ToppFun tool from the ToppGene Suite was used to identify transcription factors of
significantly different proteins between HCMfemale and HCMmale .33 All significantly different
proteins between HCMfemale and HCMmale were used as input.
WESTERN BLOT
For analysis of protein levels by Western blot, whole tissue lysates were used from either
the proteomic analysis or were prepared as described previously.34 Proteins were separated
on precast SDS-PAGE 4-12% criterion gels (Bio-Rad) and transferred to polyvinylidene
difluoride or nitrocellulose membranes. Site-specific antibodies directed to acetylated
α-tubulin (Sigma, T7451), HSPA1 (Enzo Life Sciences, ADI-SPA-810), HSPA2 (Proteintech
group, 66291-1), HSPB1 (Enzo Life Sciences, ADI-SPA-800), HSPB5 (Enzo Life Sciences,
ADI-SPA-223), HSPB7 (abcam, ab150390), HSPD1 (Enzo Life Sciences, ADI-SPA-805),
HSPA4 (Cell Signaling, 3303S), HSP90 (Cell Signaling, 4874S), α-tubulin (Sigma, T9026),
tyrosinated tubulin (Sigma, T9028), detyrosinated tubulin (abcam, ab48389), and GAPDH
(Cell Signaling, 2118S; Fitzgerald, 10R-G109a) were used to detect the proteins which were
visualized with an enhanced chemiluminescence detection kit (Amersham) and scanned
with Amersham Imager 600. Protein levels were determined by densitometric analysis and
normalized to GAPDH.
STATISTICS
Graphpad Prism v8 software was used for statistical analysis. Normally distributed
data (except proteomics data) were statistically analysed with the Student’s t-test when
comparing 2 groups and with one-way ANOVA when comparing more than 2 groups.
Non-normally distributed data were analysed with Mann-Whitney test. Linear regression
was statistically tested with Pearson correlation. Data are presented as means ± standard
errors of the mean, clinical characteristics are presented as mean ± standard deviation or
median with interquartile range when appropriate. Categorical data was statistically analysed
using Fisher’s exact test and presented as frequencies. A p-value ≤0.05 was considered as
significantly different.
RESULTS
To define sex-specific protein changes in HCM, we compared the protein expression profile
of male and female HCM samples. We performed a new analysis on a subset of patients
from our proteomics data set.25 We compared age-matched samples from 13 male and 13
female sarcomere mutation-positive (SMP) HCM patients. The genotype distribution of
both groups is depicted in Figure 8.1 and shows that the majority of mutations in both
groups are located in the thick filament genes MYBPC3 and MYH7.
Clinical characteristics of the groups are summarized in Table 8.1. Both male and female
patients had obstructive HCM. While male patients presented with a larger LV end-systolic
diameter (ESD), females displayed more severe diastolic dysfunction, indicated by a
higher E/e’ ratio compared to male patients, and more females with diastolic dysfunction
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Figure 8.1: Genotypes in female and male HCM patient groups.
The pie charts indicate the number of patients with a mutation in MYBPC3, MYH7, TNNT2,
TNNI3 and MYL2 for the female and male group, respectively.
stage 2.35,36 Although there is no difference between women and men in absolute IVS
thickness, the women included in this study showed a higher IVS thickness when corrected
for BSA compared to males (25% increase, p=0.07; Table 8.1). This is in line with a
previous study showing significant differences in IVS thickness between women and men
when corrected for BSA.13
FEMALES EXPRESS MORE TUBULIN AND HEAT SHOCK PROTEINS
Out of 2099 quantified proteins, only 46 proteins were significantly differentially expressed
in the direct comparison of the female and male group. Two functional protein interaction
clusters were identified for both the 14 downregulated and the 32 upregulated proteins
in females compared to males. The functional protein clusters that were less expressed
in females compared to males were related to muscle filament sliding and carbohydrate
catabolic process (Figure 8.2A).
The functional protein clusters of proteins that are more expressed in females compared to
males are chaperone-mediated protein complex assembly and action potential (Figure 8.2B).
Chaperone-mediated complex assembly is, based on the number of proteins in this
cluster (18, 39% of the differentially expressed proteins), the dominating protein cluster
in the comparison of female and male SMP HCM samples. Interestingly, this cluster
contains mainly heat shock proteins (HSPs) and tubulin subunits. HSPs and tubulin
have already been investigated before by our group in the context of SMP and sarcomere
mutation-negative HCM samples.25,34 Therefore, we now further determined if there are any
sex-differences at the protein levels of tubulin and a selection of HSPs that were assessed by
Western blot. While we did not observe significant sex-differences in the levels of HSPA1,
HSPA2, HSPB5, HSPB7, HSPA4 and HSP90, we found a trend to higher levels of HSPD1
(p=0.0957) and HSPB1 (p=0.0850) in female compared to male samples (Figure 8.3,
re-analysed from the dataset from Dorsch et al.34).
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Figure 8.2: Functional protein cluster of the direct comparison of HCMfemale and HCMmale.
(A) illustrates the functional protein cluster of the proteins that are significantly lower expressed
in females compared to males. (B) shows the functional protein cluster of the proteins that are
significantly higher expressed in females compared to males. For each protein cluster the most
significant biological process is given. Proteins with a p-value <0.05 were used for the analysis.
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Figure 8.3: Protein levels of heat shock proteins determined by Western blot.
Panel (A), (B) and (C) show representative Western blot images. Panel (D-K) display quantified
protein levels for HSPA1, HSPA2, HSPD1, HSPB1, HSPB5, HSPB7, HSPA4 and HSP90,
respectively. Data were statistically analysed by unpaired two-tailed t-test. Dashed line indicates
protein levels in the NFIVS. Western blot dataset is partly derived from Dorsch et al. and re-analysed
for the age-matched samples included in the current study.34
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Although the HSPs assessed by Western blot do not show significant differences between
females and males, the data are in line with the small fold changes found in the proteomics
data and point towards higher levels of HSPs in female compared to male HCM tissue.
Likewise, we analysed the sex-differences in our tubulin data set (Figure 8.4, re-analysed
from the datasets from Dorsch et al. 2019 and Schuldt et al. 2021.25,34
In line with the proteomics data, levels of α-tubulin were significantly higher in females
compared to males, whereas we did not find any sex-differences in the posttranslational
modifications acetylation, tyrosination and detyrosination. To determine if elevated
levels of tubulin may correlate with diastolic dysfunction, we plotted levels of α-tubulin
with the clinical parameter E/e’ for male and female patients separately (Figure 8.4E).
Female patients have higher levels of α-tubulin in combination with more severe diastolic
dysfunction, as indicated by increased E/e’, compared to male patients who show lower
levels of α-tubulin with less severe diastolic dysfunction.
PROTEINS INVOLVED IN TRANSLATION ARE SPECIFICALLY
DOWNREGULATED IN MALE HCM PATIENTS COMPARED TO NON-FAILING
CONTROL MYOCARDIUM
As an additional approach, we compared the protein expression of both the male and the
female group to NFIVS to look at specific sex-related protein changes compared to non-failing
myocardium, thereby identifying proteins that are not only sex- but also disease-specific. We
have identified 236 proteins that are less expressed and 214 proteins that are more expressed
in the female HCM patients versus NFIVS. In the male HCM patients we identified 251
lower expressed proteins and 156 more abundant proteins compared to NFIVS. The top
10 functional protein interaction clusters of the females compared to NFIVS are listed in
Table 8.2 and the top 10 protein clusters of the male samples compared to NFIVS are
displayed in Table 8.3.,
Table 8.2: Top 10 differentially regulated pathways in HCMfemale vs NFIVS.
Downregulated proteins Upregulated proteins
Pathway (GO ID) nodes p Pathway (GO ID) nodes p
Cellular respiration
(45333)





28 1.7205E-22 Muscle contraction (6936) 19 1.9361E-16
Monocarboxylic acid
metabolic process (32787)





20 1.0701E-24 Organelle localization
(51640)
13 1.6284E-8






12 3.4079E-11 Striated muscle cell
development (55002)
12 6.9444E-9





11 5.0201E-14 Regulation of cell
migration (30334)
9 1.3513E-8
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Table 8.2: Continued
Downregulated proteins Upregulated proteins
Pathway (GO ID) nodes p Pathway (GO ID) nodes p
Cellular detoxification
(1990748)





8 9.5592E-12 Membrane organization
(61024)
8 4.7889E-6
Table lists the top 10 functional protein cluster (based on size) of the down- and upregulated proteins
for the comparison of HCMfemale with NFIVS. Displayed are the most significant biological process
(gene ontology), the number of nodes in the cluster and the p-value.
,
Table 8.3: Top 10 differentially regulated pathways in HCMmale vs NFIVS.
Downregulated proteins Upregulated proteins
Pathway (GO ID) nodes p Pathway (GO ID) nodes p
Cellular respiration
(45333)












































12 3.2195E-12 Regulation of podosome
assembly (71801)
6 9.2900E-6
Table lists the top 10 functional protein cluster (based on size) of the down- and upregulated proteins
for the comparison of HCMmale with NFIVS. Displayed are the most significant biological process (gene
ontology), the number of nodes in the cluster and the p-value.
The complete set of protein interaction clusters resulting from this analysis is shown in
Figures S1-S4. To identify differences between female and male HCM using this analysis
approach, we created Venn diagrams of the significantly different proteins from the female
vs NFIVS and the male vs NFIVS comparison to look at overlapping proteins that are shared
by both comparisons, and proteins that are unique for either males or females compared to
NFIVS (Figures 8.5 and 8.6, Venn diagrams).
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Figure 8.4: Protein levels of α-tubulin and its posttranslational modifications determined
by Western blot. Panels (A-D) show protein levels of α-tubulin (A), acetylated tubulin (B),
tyrosinated tubulin (C) and detyrosinated tubulin (D) with representative images. Data were
statistically analysed by unpaired two-tailed t-test, #p=0.0407. Dashed line indicates protein levels
in the NFIVS. Western blot dataset is new analysis of a subset of samples from Dorsch et al. and
Schuldt et al.25,34 (E) shows correlation of α-tubulin levels with E/e’ ratio.
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Figure 8.5: Functional protein cluster of the downregulated proteins that are unique for either
HCMfemale and HCMmale when compared separately to NFIVS. A Venn diagram was created with
the significantly lower expressed proteins between HCMfemale and NFIVS and HCMmale and NFIVS, to
identify the downregulated proteins that are unique for either males or females, or shared by both
groups. Panel (A) illustrates the functional protein cluster of the proteins that are only significantly
lower expressed in females when compared to NFIVS, whereas (B) shows the functional protein
cluster of the proteins that are significantly lower expressed in males when compared to NFIVS. For
each protein cluster the most significant biological process is given. Proteins with a p-value <0.05
were used for the analysis.
182 CHAPTER 8
8
Figure 8.6: Functional protein cluster of the upregulated proteins that are unique for either
HCMfemale and HCMmale when compared separately to NFIVS. A Venn diagram was created with
the significantly higher expressed proteins between HCMfemale and NFIVS and HCMmale and NFIVS,
to identify the upregulated proteins that are unique for either males or females or shared by both
groups. Panel (A) illustrates the functional protein cluster of the proteins that are only significantly
higher expressed in females when compared to NFIVS. The proteins only significant for HCMmale
did not give any functional protein cluster. For each protein cluster the most significant biological
process is given. Proteins with a p-value <0.05 were used for the analysis.
Of the proteins that are downregulated compared to NFIVS we identified 181 proteins that
are overlapping between males and females. These proteins belong mainly to metabolic
pathways (Figure S5), and can be considered as general HCM-specific protein changes. 55
of the downregulated proteins are only significantly different for the females. The functional
protein clusters of these proteins are related to respiratory electron transport chain, cellular
lipid catabolic process, response to activity, small molecule catabolic process, neutrophil
degranulation, energy deprivation by oxidation of organic compounds and response to
aldosterone (Figure 8.5A). 70 downregulated proteins are only significantly different in the
male group and cluster analysis revealed that the biggest protein cluster is related to the
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biological process translation. It contains many ribosomal proteins that have a consistently
high fold-change compared no NFIVS. Other clusters are related to amide biosynthetic
process and several processes related to energy metabolism like ketone body biosynthetic
process, electron transport chain and tricarboxylic acid metabolic process. Furthermore,
we obtained protein clusters related to pyridoxal phosphate biosynthetic process, cellular
water homeostasis, glutathione metabolic process and extracellular matrix disassembly
(Figure 8.5B).
MICROTUBULAR AND HEAT SHOCK PROTEINS ARE SPECIFICALLY
UPREGULATED IN FEMALE HCM PATIENTS WHEN COMPARED TO
CONTROLS
For the upregulated proteins, 140 proteins are significantly more expressed in both females
vs NFIVS and males vs NFIVS. The functional protein interaction clusters are illustrated
in Figure S6. The 74 proteins that are significantly higher in females compared to
controls result in clusters related to response to unfolded protein, chylomicron assembly,
membrane organization, regulation of cell migration, negative regulation of microtubule
polymerization or depolymerization, positive regulation of cellular component organization,
sarcomere organization, glycophagy, muscle organ development and carboxylic acid
biosynthetic process (Figure 8.6A). With the cluster response to unfolded protein and
negative regulation of microtubule polymerization or depolymerization the results of this
approach are in line with the direct comparison of female and male HCM samples in
which these proteins were represented by the cluster chaperone-mediated protein complex
assembly. 8 of the 74 proteins that are significantly higher expressed only in females (CRK,
HSPA4, TUBB6, ALDH1B1, DMD, LMOD2, HNRNPA3 and TFRC) overlap with the 46
proteins significantly different in the direct male and female comparison and may represent
important candidates to define the female group (Figure 8.7).
The 16 proteins that are only significantly higher in HCM males compared to NFIVS did not
form any functional protein cluster. Of these proteins, only the protein SLC27A6 (solute
carrier family 27 member 6/long chain fatty acid transport protein 6) overlaps with the
46 proteins that are significantly different in the direct comparison of females and males.
As being significantly higher expressed compared to both NFIVS and females, SLC27A6,
involved in long chain fatty acid uptake, may be an important candidate defining the male
HCM patients.
TRANSCRIPTIONAL REGULATION OF SIGNIFICANTLY DIFFERENT
PROTEINS BETWEEN HCMfemale AND HCMmale IS NOT DOMINATED
BY SEX HORMONES
Since sex hormones also act as transcription factors, we analysed if sex-hormone-related
transcription factors can be responsible for the 46 significantly differentially expressed
proteins of the direct comparison between female and male HCM samples (Figure 8.2).
Possible transcription factor bindings sites were analysed with the ToppFun database.
372 transcription factors were identified that have binding-sites in the 46 proteins that
are significantly different between female and male HCM patient samples. The 10 most
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Figure 8.7: Normalized counts of proteins that are significantly upregulated in HCMfemale
compared to HCMmale and are uniquely upregulated in females when compared to NFIVS. (A)
CRK, (B) HSPA4), (C) TUBB6, (D) ALDH1B1, (E) DMD, (F) LMOD2, (G) HNRNPA3 and (H)
TFRC. #p<0.05, ##p<0.01, unpaired two-tailed t-test.
significant transcription factors are shown in Table S2. Of these we found 7 to be
sex-hormone related (Table S3). These 7 transcription factors are involved in the regulation
of 5 significantly different proteins between male and female HCM myocardium: HSPD1,
PYGM, DMD, ENO3 and TFRC. Of these, DMD, ENO3 and TFRC are also significantly
different when comparing females with NFIVS (Figures 8.5 and 8.6). With PYGM and ENO3
involved in carbohydrate metabolism, DMD involved in muscle organization and HSPD1 as
a member of the PQC, we thereby identified candidate proteins that may be regulated by
sex hormone-related transcription factors. However, the bioinformatical analysis revealed
that the 5 proteins also have binding sites for another 258 of the 372 identified transcription
factors. Based on this we can conclude that the differences found between female and male
samples may be partly due to transcriptional regulation by sex hormones but that this is
not the dominant mechanism driving sex-dependent differential protein expression.
DISCUSSION
In this study we analysed sex-differences at the protein level in proteomics data of HCM
patient tissue to define sex-specific protein expression which may explain the difference in
clinical presentation. The direct comparison of the male and female patient groups resulted
in only a small number of significantly different proteins. Compared to males, female HCM
patients display lower levels of myofilament proteins related to the biological process muscle
filament sliding and have elevated levels of tubulin and HSPs. Consistently, by subtracting
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the baseline differences using an additional non-failing control group, we observed a more
profound elevation of HSPs and the microtubule processes in female HCM patients.
SET OF 8 PROTEINS CONSISTENTLY DEFINES THE FEMALE HCM PATIENTS
A study investigating sex-differences in gene expression at the mRNA level in idiopathic
cardiomyopathy patients found 1837 differently expressed genes between male and female
patients, of which the large majority of 1377 genes had a fold change <1.2.37 Considering
these low fold changes on a gene expression level, little changes at the protein level are to
be expected. We found expression levels of 8 proteins significantly higher in females when
directly compared to males, and also uniquely significant for females when compared to
NFIVS (Figure 8.7). Thereby, these proteins are disease-specific and may play an important
role in defining the female patient group. One of these proteins is CRK, which is an
adaptor protein with SH2 and SH3 domains but no catalytic region. It functions in signal
transduction processes and has been shown to be involved in cardiac development.38 HSPA4
is a heat shock protein that acts as nucleotide exchange factor for HSP70 chaperones. Its
expression is upregulated in response to pressure overload and in human heart failure, which
is thought to be a beneficial response as it helps degrading misfolded proteins.39 TUBB6
is a β-tubulin subtype that forms microtubules together with α-tubulin. Elevated levels of
tubulin have been observed in heart failure.40 ALDH1B1 is an aldehyde dehydrogenase that
is involved in alcohol metabolism and has been shown to function in glucose metabolism.41
DMD encodes for dystrophin and connects the actin cytoskeleton with the extracellular
matrix. As actin cross-linker, it plays an important role for the mechanical properties of
the cardiomyocyte. Elevated levels in females may be explained by its gene location on
the X-chromosome. Mutations in DMD have been associated with muscular dystrophies
and X-linked dilated cardiomyopathy.42 LMOD2 is the cardiac isoform of leiomodin, an
actin-binding protein involved in thin filament assembly. Studies in adult mice have shown
that LMOD2 has an essential role in maintaining proper cardiac thin filament length and
coinciding force generation.43 HNRNPA3 is a heterogeneous nuclear ribonucleoprotein that
binds to single-stranded telomeric repeats to stabilize them,44 and TFRC encodes for the
transferrin receptor that promotes iron uptake.45
ELEVATED LEVELS OF HSPs AND TUBULIN ARE IN LINE WITH A MORE
SEVERE PHENOTYPE
The most prominent difference in our study were higher levels of tubulin and HSPs
in female compared to male HCM patient samples taken at the time of myectomy.
Interestingly, sex-differences in the expression of HSPs have been observed before. Higher
levels of HSPA1A have been measured in healthy female rat hearts compared to male,
and these increased levels were oestrogen dependent.46 We also found by bioinformatical
analysis that HSPD1, which is elevated in female compared to male HCM myocardium,
can be regulated by the oestrogen-related receptor α. It may be speculated that the
oestrogen-dependent HSP induction, that is known to be cardioprotective,47 has also
beneficial effects in HCM, leading to lower disease penetrance and later disease onset in
women. Indeed, HSP activation has been shown to have beneficial effects on heart function
in a mouse model of desmin-related cardiomyopathy in which HSP expression was induced
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by geranylgeranylacetone.48 In our study we observed increased protein expression of HSPs
in tissue samples from symptomatic stage II HCM patients, which raises the question if the
optimal therapeutic window for HSP induction might already be at an earlier preclinical
stage of the disease. This warrants further studies in iPSC-derived human heart models
and other cardiomyopathy animal models.
Cytoskeletal proteins like tubulin and desmin are known to be elevated in heart failure.40
Our group has previously shown that tubulin protein levels are increased in HCM myectomy
tissue compared to NFIVS.25,34 Interestingly, tubulin and desmin protein content has been
shown to correlate well with left ventricular end-diastolic pressure (LVEDP) in heart
failure.40 As increased LVEDP indicates diastolic dysfunction, cytoskeletal protein levels
correlate directly with diastolic dysfunction. Furthermore, tubulin has in combination with
its posttranslational modifications a direct effect on contractile function, as detyrosinated
tubulin binds to desmin and causes a stiffening of the myofilament.49-51 As increased levels
of tubulin in females compared to males correlate with more severe diastolic dysfunction,13
proof-of-concept studies in model systems have to show whether this is a causal relationship
during HCM development.
MALE SAMPLES DISPLAY LOWER LEVELS OF TRANSLATIONAL PROTEINS
Ribosomal and protein synthesis-related proteins, which form the cluster “translation”, were
significantly downregulated in male HCM patients compared to NFIVS. Interestingly, it
was recently shown that cMyBP-C protein synthesis and degradation rates were slowed
down in induced pluripotent stem cell-derived cardiomyocytes harbouring a heterozygous
MYBPC3 mutation.52 The authors proposed that cells harbouring a MYBPC3 truncating
mutation may have the capacity to attain normal levels of cMyBP-C protein and thereby
preserve cardiomyocyte function. On the other hand, protein turnover is needed to
replace aged/damaged proteins. Thus, while reduced protein turnover may preserve protein
stoichiometry and thereby cardiomyocyte function, it may lead to accumulation of damaged
proteins in the sarcomere. Our data are in line with the study of Helms and colleagues,
and imply reduced protein turnover in particular in male HCM hearts at the time of
myectomy. Increasing protein translation rate to maintain proper protein turnover represents
an attractive avenue to further explore.
SEX-SPECIFIC DIFFERENCE IN CARBOHYDRATE METABOLISM
Downregulation of metabolic pathways is a general HCM disease hall mark25,53 and
accordingly we did not find major differences in these pathways between males and females.
However, females showed lower levels of proteins related to carbohydrate catabolic process
(Figure 8.2A), including muscle associated glycogen phosphorylase (PYGM) and β-enolase
(ENO3). Mutations in both of these genes have been associated with glycogen metabolism
disorders.54 Consequently, reduced levels of PYGM and ENO3 impair glycogen metabolism
in women. Our transcription factor analysis showed that both PYGM and ENO3 can be
regulated by sex hormone transcription factors. The findings indicate that women may be
less metabolically flexible to adapt to altered metabolic demand, at least during disease
development. Imaging studies have shown that reduced cardiac efficiency occurs already
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at the early disease stage in asymptomatic male and female mutation carriers55,56 and may
indicate that metabolic changes may be present in the very early stages before the onset of
cardiac remodelling.
MORE FIBROSIS IN FEMALE PATIENTS IS NOT REFLECTED AT PROTEIN
LEVEL
It has been observed that female HCM patient samples show more fibrosis compared to
male samples.13 Interestingly, this difference is not reflected at protein level. Neither in
the direct comparison of female and male HCM samples, nor in the analysis compared
to NFIVS, we observed a specific increase in extracellular matrix proteins for females. In
the current proteomics analysis, increased expression of extracellular matrix proteins was a
general disease hallmark, and common for both female and male group. The methodological
difference between quantifying proteins involved in extracellular matrix organization in this
proteomics analysis and measuring the actual fibrotic area in tissue sections as performed
by Nijenkamp et al. may underlie the divergent findings.
STUDY LIMITATIONS
The findings in this study are observational and provide a starting point for further validation
in an independent cohort and proof-of-concept studies in disease models. Due to the limited
availability of non-failing heart tissues, the male control samples used in this study are not
age-matched with the male HCM samples, which may contribute to observed differences in
protein expression. Furthermore, the group size of only female or male non-failing samples
is too small to perform comparisons of HCM and controls of the same sex. Therefore,
follow-up studies would benefit from age-matched and increased numbers of non-failing
controls to differentiate between sex- and disease-specific differences in protein expression.
As our findings point towards a possible role of sex hormone regulation, information about
the hormonal state of the female subjects should be collected for future studies.
CONCLUSION
This proteomic analysis of female and male SMP HCM tissue highlights that elevated
protein levels of tubulin correlate with more severe diastolic dysfunction in females. Another
aspect which warrants further research is reduced protein turnover, in particular in male
HCM, which may represent an adaptive mechanism to maintain protein stoichiometry,
though may also have a negative impact and result in ‘aged’ sarcomeres. Further research
in experimental model systems is needed to determine if targeting tubulin and protein
quality control at an early disease stage prevent the progression of cardiac dysfunction.
Conflict of Interest: The authors declare that the research was conducted in the absence
of any commercial or financial relationships that could be construed as a potential conflict
of interest.
Sources of funding: We acknowledge the support from the Netherlands Cardiovascular
188 CHAPTER 8
8
Research Initiative: An initiative with support of the Dutch Heart Foundation,
CVON2014-40 DOSIS and NWO (NWO-ZonMW; 91818602 VICI grant to Jolanda van
der Velden).
SUPPLEMENTARY FILES - ONLINE
https://www.frontiersin.org/articles/10.3389/fcvm.2021.612215/full#
supplementary-material
PROTEOMIC SEX DIFFERENCES IN HCM 189
REFERENCES
1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in
a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary
Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785-9.
2. Semsarian C, Ingles J, Maron MS, Maron BJ. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy.
Journal of the American College of Cardiology. 2015;65(12):1249-54.
3. Authors/Task Force, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on
diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of
Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79.
4. Michels M, Olivotto I, Asselbergs FW, van der Velden J. Life-long tailoring of management for patients
with hypertrophic cardiomyopathy : Awareness and decision-making in changing scenarios. Neth Heart J.
2017;25(3):186-99.
5. Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric
cardiomyopathies: state of the art. Cardiovasc Res. 2015;105(4):397-408.
6. Ingles J, Burns C, Barratt A, Semsarian C. Application of Genetic Testing in Hypertrophic Cardiomyopathy for
Preclinical Disease Detection. Circ Cardiovasc Genet. 2015;8(6):852-9.
7. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical
presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):480-7.
8. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Gender-specific differences in the clinical
features of hypertrophic cardiomyopathy in a community-based Japanese population: results from Kochi RYOMA
study. J Cardiol. 2010;56(3):314-9.
9. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy
in a regional United States cohort. JAMA. 1999;281(7):650-5.
10. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic
cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation.
2000;102(8):858-64.
11. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, et al. Hypertrophic Cardiomyopathy With Left
Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020;141(17):1371-83.
12. Bos JM, Theis JL, Tajik AJ, Gersh BJ, Ommen SR, Ackerman MJ. Relationship between sex, shape, and substrate in
hypertrophic cardiomyopathy. Am Heart J. 2008;155(6):1128-34.
13. Nijenkamp L, Bollen IAE, van Velzen HG, Regan JA, van Slegtenhorst M, Niessen HWM, et al. Sex Differences at
the Time of Myectomy in Hypertrophic Cardiomyopathy. Circ Heart Fail. 2018;11(6):e004133.
14. Schulz-Menger J, Abdel-Aty H, Rudolph A, Elgeti T, Messroghli D, Utz W, et al. Gender-specific differences in left
ventricular remodelling and fibrosis in hypertrophic cardiomyopathy: insights from cardiovascular magnetic resonance.
Eur J Heart Fail. 2008;10(9):850-4.
15. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. 2003;112(3):302-7.
16. Chen YZ, Qiao SB, Hu FH, Yuan JS, Yang WX, Cui JG, et al. Left ventricular remodeling and fibrosis: Sex differences
and relationship with diastolic function in hypertrophic cardiomyopathy. Eur J Radiol. 2015;84(8):1487-92.
17. Borlaug BA, Redfield MM, Melenovsky V, Kane GC, Karon BL, Jacobsen SJ, et al. Longitudinal changes in left
ventricular stiffness: a community-based study. Circ Heart Fail. 2013;6(5):944-52.
18. van Velzen HG, Schinkel AFL, Baart SJ, Huurman R, van Slegtenhorst MA, Kardys I, et al. Effect of Gender and
Genetic Mutations on Outcomes in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(11):1947-54.
19. Geske JB, Ong KC, Siontis KC, Hebl VB, Ackerman MJ, Hodge DO, et al. Women with hypertrophic cardiomyopathy
have worse survival. Eur Heart J. 2017.
20. van Driel B, Nijenkamp L, Huurman R, Michels M, van der Velden J. Sex differences in hypertrophic cardiomyopathy:
new insights. Curr Opin Cardiol. 2019;34(3):254-9.
21. Huurman R, Schinkel AFL, van der Velde N, Bowen DJ, Menting ME, van den Bosch AE, et al. Effect of body surface
area and gender on wall thickness thresholds in hypertrophic cardiomyopathy. Neth Heart J. 2020;28(1):37-43.
22. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res. 2001;51(4):637-46.
23. Golenhofen N, Perng MD, Quinlan RA, Drenckhahn D. Comparison of the small heat shock proteins alphaB-crystallin,
MKBP, HSP25, HSP20, and cvHSP in heart and skeletal muscle. Histochem Cell Biol. 2004;122(5):415-25.
24. Pham TV, Piersma SR, Warmoes M, Jimenez CR. On the beta-binomial model for analysis of spectral count data in
label-free tandem mass spectrometry-based proteomics. Bioinformatics. 2010;26(3):363-9.
25. Schuldt M, Pei J, Harakalova M, Dorsch LM, Schlossarek S, Mokry M, et al. Proteomic and Functional Studies Reveal
Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy. Circ Heart
Fail. 2021:CIRCHEARTFAILURE120007022.
26. Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, et al. Proteomics of mouse
BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value
in human breast cancer. Mol Cell Proteomics. 2012;11(7):M111 013334.
27. Piersma SR, Broxterman HJ, Kapci M, de Haas RR, Hoekman K, Verheul HM, et al. Proteomics of the TRAP-induced
platelet releasate. J Proteomics. 2009;72(1):91-109.
190 CHAPTER 8
8
28. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE
database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res.
2019;47(D1):D442-D50.
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.
30. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories
in biological networks. Bioinformatics. 2005;21(16):3448-9.
31. Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat
Methods. 2012;9(5):471-2.
32. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-based tool for the analysis of sets
through Venn diagrams. BMC Bioinformatics. 2015;16:169.
33. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene
prioritization. Nucleic Acids Res. 2009;37(Web Server issue):W305-11.
34. Dorsch LM, Schuldt M, dos Remedios CG, Schinkel AFL, de Jong PL, Michels M, et al. Protein Quality Control
Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy. Cells. 2019;8(7).
35. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber
quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography,
a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.
36. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation
of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107-33.
37. Fermin DR, Barac A, Lee S, Polster SP, Hannenhalli S, Bergemann TL, et al. Sex and age dimorphism of myocardial
gene expression in nonischemic human heart failure. Circ Cardiovasc Genet. 2008;1(2):117-25.
38. Park TJ, Boyd K, Curran T. Cardiovascular and craniofacial defects in Crk-null mice. Mol Cell Biol.
2006;26(16):6272-82.
39. Mohamed BA, Barakat AZ, Zimmermann WH, Bittner RE, Muhlfeld C, Hunlich M, et al. Targeted disruption of
Hspa4 gene leads to cardiac hypertrophy and fibrosis. J Mol Cell Cardiol. 2012;53(4):459-68.
40. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, et al. Increased expression of cytoskeletal, linkage,
and extracellular proteins in failing human myocardium. Circ Res. 2000;86(8):846-53.
41. Singh S, Chen Y, Matsumoto A, Orlicky DJ, Dong H, Thompson DC, et al. ALDH1B1 links alcohol consumption and
diabetes. Biochem Biophys Res Commun. 2015;463(4):768-73.
42. Pecorari I, Mestroni L, Sbaizero O. Current Understanding of the Role of Cytoskeletal Cross-Linkers in the Onset and
Development of Cardiomyopathies. Int J Mol Sci. 2020;21(16).
43. Pappas CT, Farman GP, Mayfield RM, Konhilas JP, Gregorio CC. Cardiac-specific knockout of Lmod2 results in a
severe reduction in myofilament force production and rapid cardiac failure. J Mol Cell Cardiol. 2018;122:88-97.
44. Tanaka E, Fukuda H, Nakashima K, Tsuchiya N, Seimiya H, Nakagama H. HnRNP A3 binds to and protects mammalian
telomeric repeats in vitro. Biochem Biophys Res Commun. 2007;358(2):608-14.
45. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell.
2004;117(3):285-97.
46. Voss MR, Stallone JN, Li M, Cornelussen RN, Knuefermann P, Knowlton AA. Gender differences in the expression of
heat shock proteins: the effect of estrogen. Am J Physiol Heart Circ Physiol. 2003;285(2):H687-92.
47. Knowlton AA, Korzick DH. Estrogen and the female heart. Mol Cell Endocrinol. 2014;389(1-2):31-9.
48. Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, Yamauchi J, et al. Protective effect of geranylgeranylacetone
via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One. 2009;4(4):e5351.
49. Robison P, Caporizzo MA, Ahmadzadeh H, Bogush AI, Chen CY, Margulies KB, et al. Detyrosinated microtubules
buckle and bear load in contracting cardiomyocytes. Science. 2016;352(6284):aaf0659.
50. Chen CY, Caporizzo MA, Bedi K, Vite A, Bogush AI, Robison P, et al. Suppression of detyrosinated microtubules
improves cardiomyocyte function in human heart failure. Nat Med. 2018;24(8):1225-33.
51. Caporizzo MA, Chen CY, Bedi K, Margulies KB, Prosser BL. Microtubules Increase Diastolic Stiffness in Failing
Human Cardiomyocytes and Myocardium. Circulation. 2020;141(11):902-15.
52. Helms AS, Tang VT, O’Leary TS, Friedline S, Wauchope M, Arora A, et al. Effects of MYBPC3 loss-of-function
mutations preceding hypertrophic cardiomyopathy. JCI Insight. 2020;5(2).
53. Coats CJ, Heywood WE, Virasami A, Ashrafi N, Syrris P, Dos Remedios C, et al. Proteomic Analysis of the Myocardium
in Hypertrophic Obstructive Cardiomyopathy. Circ Genom Precis Med. 2018;11(12):e001974.
54. Tarnopolsky MA. Myopathies Related to Glycogen Metabolism Disorders. Neurotherapeutics. 2018;15(4):915-27.
55. Guclu A, Knaapen P, Harms HJ, Parbhudayal RY, Michels M, Lammertsma AA, et al. Disease Stage-Dependent
Changes in Cardiac Contractile Performance and Oxygen Utilization Underlie Reduced Myocardial Efficiency in Human
Inherited Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(5).
56. Timmer SA, Germans T, Brouwer WP, Lubberink M, van der Velden J, Wilde AA, et al. Carriers of the hypertrophic
cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy
and microvascular dysfunction. Eur J Heart Fail. 2011;13(12):1283-9.




Tubulin signature and desmin
levels in pig and mouse models
for cardiomyopathies and human
heart failure samples
8
Larissa M. Dorsch, Oana Sorop, Aryan Vink, Michelle Michels, Cristobal G. dos Remedios,





Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are characterized by concentric
and eccentric remodelling of the heart, respectively. HCM is associated with impaired
diastolic function, while DCM patients show reduced systolic function, and both HCM and
DCM can develop into end-stage heart failure (HF). The microtubular network and its
post-translational modifications (tubulin signature) play a central role in cardiac structure
and function. Animal models with concentric and eccentric cardiac remodelling may be
used to study tubulin-mediated functional changes during disease progression. To study if
animal models show changes in the tubulin signature that are observed in patients with
HCM and DCM, we here defined the tubulin signature in myocardium of animal models
with concentric and eccentric cardiac remodelling caused by pressure overload, myocardial
infarction or a gene defect.
METHODS
We defined the levels of total, acetylated and detyrosinated α-tubulin and desmin in
a pressure-overload concentric hypertrophic pig model, aged pigs with a heavy body
weight and a disproportionately low stroke volume, mice carrying the HCM-associated
MYBPC3772G>A mutation exposed to a voluntary wheel-running protocol and cardiac tissue
from HCM and DCM patients, including paediatric DCM patients, ranging from NYHA class
II-III to end-stage (NYHA class IV) heart failure with an idiopathic, ischemic and genetic
origin.
RESULTS
The 18 months old pigs were characterized by an altered tubulin signature, including
decreased levels of total, acetylated and detyrosinated α-tubulin. NYHA class II-III
HCM patients had the strongest increase in tubulin signature. Within the HF cohorts,
detyrosinated α-tubulin was increased in end-stage HCM and paediatric DCM patients and
acetylated α-tubulin was increased in ischemic heart disease patients. Pressure overload or a
genetic trigger initiating the development of hypertrophy resulted in increased desmin levels
in biopsies from NYHA class II-III HCM patients, pressure-overload concentric hypertrophic
pig model and homozygous MYBPC3772G>A mice.
CONCLUSION
Our data suggest increased desmin levels as an early event in compensated hypertrophy.
Animal models only partially recapitulated the proliferated and modified tubulin signature
and changes in desmin levels seen in patients. The most proliferated and modified
microtubule network was observed in NYHA class II-III HCM patients indicating a target
group for tubulin modifying therapies to re-write the tubulin signature.
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INTRODUCTION
Cardiac disease has diverse etiologies ranging from valvular defects, hypertension, or an
ischemic or genetic insult. Aortic stenosis and hypertension cause concentric remodelling
of the heart which is characterized by increase of left ventricular (LV) wall thickness to
a greater extent than the volume of the LV cavity, while an ischemic insult (myocardial
infarction) causes eccentric remodelling in which the heart dilates and the wall becomes
thin.1 Gene defects may cause concentric or eccentric cardiac remodelling and are known
as hypertrophic and dilated cardiomyopathy (HCM and DCM, respectively).
Cardiac function and structure is governed by the cytoskeleton which consists of
sarcomeres and non-sarcomeric structures. The non-sarcomeric cytoskeleton is formed
by microtubules and intermediate filaments. Little is known about the changes in
non-sarcomeric structures during onset and progression of cardiac disease, while the
microtubular network undergoes multiple post-translational modifications. Acetylation
(ac) of α-tubulin at Lys40 decreases flexural rigidity of microtubules and thereby protects
microtubules to mechanical bending-induced breakage and diassembly.2,3 Previously in
chapter 7, we reported increased levels of acetylated α-tubulin in septal myectomy samples
of HCM patients, especially when a sarcomere gene mutation was present.4 In samples
with truncation or missense MYBPC3 mutations causing haploinsufficieny of cMyBP-C we
observed the biggest increase in α-tubulin and acetylation of α-tubulin.4
The Prosser’s group reported proliferation of microtubules and intermediate filaments, and
the posttranslational detyrosination of microtubules in hearts from transplant recipients.5-7
Detyrosination (detyr) is the removal of tyrosine from the C-terminus of α-tubulin and
significantly affects stability and density of the cardiomyocyte cytoskeleton and cell
biomechanics.8 The microtubule changes were causally linked to increased stiffness and
viscoelasticity that reduce contractility and slow both contraction and relaxation.5-7,9 Our
group observed in chapter 6 increased levels of detyrosinated α-tubulin at the time of
septal myectomy of HCM patients.10 In addition, increased levels of detyrosinated α-tubulin
were found in a MYBPC32373insG mouse model and its inhibition normalized contraction
and relaxation kinetics of isolated cardiomyocytes.10
It has been shown before that intermediate filaments cross-link with microtubules in
a detyrosination-dependent manner.11,12 Recently, desmin, which forms structural bundles
along the Z-disc,13 was identified as a sarcomeric microtubule anchor.7 Studies with
desmin knock-out mice revealed that desmin cross-links with detyrosinated α-tubulin to
structurally reinforce the microtubule network.7 In addition, removal of desmin decreased
cytoskeletal stiffness, disorganized the microtubule network and pharmacological inhibition
of detyrosination did no longer modulate viscoelasticity.7 In line with the increase in
detyrosinated α-tubulin, increased desmin levels have been reported in heart failure (HF)
patients and at the time of septal myectomy of HCM patients (chapter 6).6,10
We studied the microtubule network in cardiac tissue from HCM and DCM patients
with different disease stages ranging from NYHA class II-III to end-stage HF (NYHA class
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IV) with an idiopathic, ischemic and genetic origin. To define changes in microtubules and
it post-translational modifications in cardiac remodelling at early disease development, we
here studied the mircotubule network in different pig and mouse models. We compared
sham-operated pigs to aortic banding (AoB)-treated pigs of the same age. AoB has been
used to model pressure-overload concentric hypertrophy.14-17 In addition, sham-operated,
4 months old pigs were compared to 18 months old pigs. These aged pigs had a heavy body
weight (BW) and a disproportionately low stroke volume due to diastolic perturbations.18
In a further data set, we used exercised wild-type (WT) mice and mice carrying MYBPC3
point mutation on one or both alleles, which is associated with human HCM.
METHODS
HUMAN CARDIAC SAMPLES
Cardiac samples were collected from adult patients with obstructive HCM (HCMSt II; n=38;
26 males, 12 females; mean age 48±16 years), end-stage HCM (HCMSt IV; n=7; 3 males,
4 females; mean age 44±13 years), ischemic heart disease (ISHD; n=7; 6 males, 1 female;
mean age 56±6 years), idiopathic DCM (IDCM; n=7; 4 males, 1 females; mean age 51±4
years), end-stage DCM with identified DCM-causing mutation (DCMend; n=7; 5 males, 2
females; mean age 56±8 years) and 7 paediatric patients with DCM (DCMped; 2 males,
3 females; mean age 10±3 years). Samples from 8 healthy non-failing donors (5 males,
3 females; mean age 47±11 years) served as controls. Parameters of all HCM and DCM
individuals and donors are summarized in Table 9.1. All samples were obtained after written
informed consent from each patient prior to surgery and from the patients’ or donors’ next
of kin.,
Table 9.1: Characteristics of HCM, DCM and non-failing individuals.
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Nr.: Number; F: female; M: male; Age: age at septal myectomy/heart transplantation; FS: fractional
shortening; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic dimension;
LVESD: left ventricular end-systolic dimension; Ctrl: healthy donor hearts; HCMSt II: early HCM;
HCMSt IV: end-stage HCM; ISHD: ischemic heart disease; IDCM: idiopathic DCM; DCMend: adult
end-stage DCM; DCMped: paediatric DCM; ACM: arrhythmogenic cardiomyopathy; #: LVEDD and
LVESD expressed as Z-score for body surface are in paediatric samples.
Interventricular septum tissue of HCM patients was collected during myectomy surgery
to relieve (LV) outflow tract obstruction. Cardiac tissue from end-stage HCM patients
was obtained during heart transplantation surgery. HCM samples were approved by the
local ethics board of the Erasmus Medical Center Rotterdam, the Netherlands (protocol
number MEC-2010-40). LV tissue from ISHD and IDCM samples were acquired during
transplantation from the University of Sydney, Australia, with the ethical approval of the
Human Research Ethics Committee #2012/2814. Genetic DCM samples were acquired
during transplantation from the Biobank of the University Medical Center Utrecht, the
Netherlands and approved by the Biobank Research Ethics Committee, Utrecht, the
Netherlands (protocol number WARB 12/387). Paediatric DCM samples were approved by
the local ethics board of the Erasmus Medical Center Rotterdam, the Netherlands (protocol
number MEC-2015-233). Five of these samples were obtained during transplantation and
two samples were post-mortem.
Donor samples were obtained from the Sydney Heart Bank, Australia with the ethical
approval of the Human Research Ethics Committee (HREC Univ Sydney 2012/030).
Mostly because of poor tissue matching against patients in the heart failure clinic of St
Vincent’s Hospital, these hearts were not used for heart transplantation. Their validity
as “controls” was based on their extensive use as such in publications from a wide range
of other laboratories. We therefore assumed that these donors are representative of the
diverse human population.
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We acknowledge the uneven distribution between patient numbers and mutations and tissue
locations (IVS and LV). However, our tissue characterization was dependent on available
cardiac tissue and clinical parameters. Due to limited tissue availability, not all analyses
could be performed in all patient/control samples.
PIGS: STUDY POPULATION
All studies were performed in accordance with the Council of Europe Convention
(ETS123) and the Directive (2010/63/EU) for the protection of vertebrate animals used for
experimental and other scientific purposes, and with approval of the Animal Care Committee
of Erasmus University Medical Center Rotterdam, the Netherlands. Experiments were
performed in Yorkshire x Landrace pigs and we included 3 study conditions (n=6): aortic
banding (AoB)-treated and sham-operated pigs for 3 weeks of either sex and 4 months old
when sacrificed weighing 18-29kg and 18 months old sows with a heavy BW (170–216kg).
One week prior to surgery, pigs arrived for acclimatization at the central animal housing
facility of Erasmus University Medical Center in Rotterdam, the Netherlands. Twice a day,
pigs were fed compound feed in accordance with their BW and had free access to drinking
water. Starting twelve hours before surgery, pigs were denied access to food.
SURGICAL INSTRUMENTATION AND MEASUREMENTS OF 18 MONTHS OLD PIGS
The surgical instrumentation and measurements have been described previously.19,20 Briefly
as outlined in,18 pigs were sedated with a cocktail of Tiletamine/Zolazepam (5mg·kg-1),
Xylazine (2.25mg·kg-1) and atropine (0.03mg·kg-1 i.m.), anaesthetized with sodium
pentobarbital (6mg·kg-1 i.v.) and intubated for ventilation with O2 and N2 (1:3 v/v). A
catheter was inserted into the right jugular vein and advanced into the superior vena cava
for infusion of sodium pentobarbital (10-12mg/kg·h-1 i.v.) to maintain anaesthesia. A
fluid-filled catheter was inserted into the right carotid artery for the measurement of mean
arterial pressure.
A Swan-Ganz catheter (5 corodyn TD F7, Braun, Melsungen, Germany) was inserted into
the left jugular vein, via a sheath introducer, and advanced into the pulmonary artery
for the measurement of mean pulmonary artery pressure and pulmonary capillary wedge
pressure, and for thermodilution-based measurement of CO (Abbott Laboratories, North
Chicago, IL, USA). A 7F conductance catheter (CD Leycom, Hengelo, The Netherlands)
was inserted into the left carotid artery, via a sheath introducer, and advanced into the left
ventricle (LV) for measurement of LV volume. The conductance catheter was calibrated
using the thermodilution CO measurements and hypertonic saline before LV volume
measurements were obtained. Subsequently, the conductance catheter was replaced by
a micro-manometer-tipped catheter (SPC-370s, Millar Instruments, Houston, TX, USA)
for measurement of LV pressure (LVP) and its first derivative (LVdP/dt). LVdP/dt at
a pressure of 40 mmHg (LVdP/dtP=40) was used as an afterload-independent index of
systolic cardiac function. Heparin (10,000 I.U., i.v.) was administered before arterial blood
gasses and haemodynamics were measured.
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Subsequently, the chest was opened via sternotomy and the pericardial space was opened.
After stabilization, ultrasound echocardiography recordings were made by placing the
ultrasound probe directly onto the epicardium and obtaining short-axis recordings (Aloka
SSD 4000; Aloka Company, Tokyo, Japan).
Just before sacrifice left ventricular biopsies were obtained, snap frozen and stored
in liquid nitrogen until further analysis. Finally, animals were sacrificed, heart was excised
and weighed. After removal of the large vessels, total heart weight (HW) was determined.
Then, the atria and right ventricle were dissected and left ventricular weight (LVW) was
determined.
AORTIC BANDING TREATMENT AND SHAM-OPERATION IN 4 MONTHS OLD PIGS
As previously described in Duncker’s group, Swine were sedated with ketamine (20 mg/kg,
i.m.) and midazolam (1 mg/kg, i.m.). Under isoflurane anaesthesia, a left thoracotomy
was performed and the proximal ascending aorta was dissected free, and, in AoB-animals a
band was placed, resulting in a systolic pressure gradient of 68±3 mmHg. Subsequently,
the chest was closed and the animals were allowed to recover.
Three weeks later, swine were re-anaesthetised with sodium pentobarbital (15 mg/kg, i.v.),
intubated, and placed on a positive-pressure ventilator (O2:N2=1:3 v/v). Catheters were
inserted into the right external jugular vein for infusion of physiological saline and sodium
pentobarbital (10-15 mg/kg/h) to maintain anaesthesia. Following sternotomy, fluid-filled
catheters were surgically inserted into the aorta for measurement of aortic blood pressure.
Subsequently, arterial and coronary venous blood samples were simultaneously obtained,
Following arresting and excision of the heart, myocardial tissue samples from the left
ventricular anterior wall were harvested.
MICE: EXERCISE PROTOCOL AND ECHOCARDIOGRAPHY
Experiments were performed in accordance with the Guide for the Animal Care and Use
Committee of the VU University Medical Center (VUmc) and with approval of the Animal
Care Committee of the VUmc (DEC-number FYS12-03) Amsterdam, the Netherlands. In
total, 37 5-week-old mice were included in the study. Exercise wild-type (WTEX; n=10)
and heterozygous (HETEX; n=9) and homozygous (HOMEX; n=10) MYBPC3 -targeted
KI mice with a G>A transition on the last nucleotide of exon 6 (c.772G>A), in Black
Swiss genetic background of either sex were exposed to an 8-week voluntary wheel-running
protocol, and the running distances were monitored in individual animals.21
Wild-type sedentary mice (WTsed; n=7) and exercised mice (after the 8-week exercise
protocol) of ˜13 weeks of age were sedated with 4% isoflurane and ventilated with
0.25 l/min O2 and 0.45 l/min air. To maintain the anaesthetized condition, mice were
ventilated with ˜2% isoflurane and identical O2 and air flow rates. Subsequently,
2D-echocardiographic recording (Siemens Acuson Sequoia, Siemens Healthineers, Erlangen,
GER) was performed on the LV short axis at mid-papillary level. LV end-diastolic as well as
end-systolic lumen was determined from the M-mode images. Fractional shortening (FS)
was calculated from the short axis M-mode images as 100% x (LV end-diastolic lumen-LV
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end-systolic lumen)/LV end-diastolic lumen. After the echocardiogram, the LV (including
the interventricular septum) and right ventricle (RV) were weighed and subsequently
stored in liquid nitrogen (N2). Due to limited tissue availability, not all analyses could be
performed in all mice samples.
TISSUE HOMOGENIZATION
Pulverized frozen tissue was homogenized in 40 µL/mg tissue 1× reducing sample buffer
(106 mM Tris-HCl, 141 mM Tris-base, 2% (w/v) lithium dodecyl sulfate, 10% (v/v) glycerol,
0.51 mM ethylenediaminetetraacetic acid, 0.22 mM SERVA Blue G250, 0.18 mM Phenol
Red, and 100 mM dithiothreitol) using a glass tissue grinder. Proteins were denatured by
heating to 99°C for 5 min, after which debris was removed by centrifugation at maximum
speed for 10 min in a microcentrifuge (Sigma, 1-15K).
ELECTROPHORESIS AND WESTERN BLOTS
Equal amounts of protein (10 µg (pigs and human samples) and 5 µg (mice samples))
were separated on pre-cast SDS-PAGE 4–12% criterion gels (Bio-Rad, Hercules, CA,
USA) and transferred onto PVDF membranes (GE Healthcare, Chicago, IL, USA).
The membranes were blocked in 5% (w/v) skim milk/1× TBST (20 mM Tris, 150 mM
NaCl, 0.1% (v/v) Tween-20) for 1 h at room temperature and incubated overnight at 4°C
with the following primary antibodies in 3% (w/v) BSA/1× TBST: mouse anti-acetylated
α-tubulin (T7451, Sigma-Aldrich, Saint Louis, MO, USA), rabbit anti-desmin (#5332,
Cell Signaling Technology, Danvers, MA, USA), rabbit anti-detyrosinated α-tubulin
(ab48389, Abcam, Cambridge, UK), mouse anti-GAPDH (10R-G109b, Fitzgerald Industries
International, Acton, MA, USA), rabbit anti-GAPDH (#2118, Cell Signaling), mouse
anti-MYBPC3 (sc-137180, Santa Cruz, Dallas, TX, USA), and mouse anti-α-tubulin
(T9026, Sigma-Aldrich). Membranes were incubated for 1 h at room temperature with
horseradish peroxidase-conjugated secondary antibody (DakoCytomation, Santa Clara, CA,
USA), raised in goat, in 3% (w/v) BSA/1x TBST. Western blots were developed with
Amersham ECL prime Western blotting detection reagent and images were acquired using
Amersham Imager 600 and quantified by densitometry by ImageQuant TL software (all GE
Healthcare). To correct for loading differences, protein amounts were expressed relative to
GAPDH.
STATISTICAL ANALYSES
Data were analysed with SPSS Statistics version 26.0 for Windows (IBM Corporation,
Armonk, NY, USA) and GraphPad Prism version 8.2.1 (GraphPad Software Inc., San Diego,
CA, USA). Results are expressed as means ± standard errors of the mean (SEM) in graphs
and as means ± standard deviation in text. After data collection, the distribution of each
data set was determined by Q-Q plots and then double checked by Kolmogorov-Smirnov
and Shapiro Wilk tests. Normally distributed data were analysed with unpaired t-test
(comparing 2 groups) and ordinary one-way ANOVA (comparing > 2 groups) with Tukey’s
multiple comparisons post-hoc test (comparing ≤ 3 groups). To analyse non-parametric
data, the Mann-Whitney U test (comparing 2 groups) and the Kruskal-Wallis test with
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Dunn’s multiple comparisons post-hoc test (comparing > 2 groups) were used. A two-sided
p<0.05 was considered statistically significant.
RESULTS
DEFINING THE TUBULIN SIGNATURE IN EARLY HCM AND END-STAGE HCM
AND DCM
We defined the tubulin signature and desmin levels in cardiac tissue from HCM and DCM
patients with different disease stages ranging from NYHA class II-III to end-stage HF
(NYHA class IV) with an idiopathic, ischemic and genetic origin (Figure 9.1). We observed
highly increased levels of α-tubulin, acetylated α-tubulin and desmin in HCMSt II compared
to Ctrl and HCMSt IV (Figures 9.1B-C,E). Expression of detyrosinated α-tubulin was
increased in both HCMSt II and HCMSt IV compared to Ctrl (Figure 9.1D). Normalization to
α-tubulin revealed a trend to increased levels of acetylated α-tubulin in HCMSt II compared
to control and detyrosinated α-tubulin was increased in HCMSt IV compared to Ctrl and
HCMSt II (Figures 9.1F-G).
When comparing different end-stage eccentric HF samples, we observed no changes in levels
of α-tubulin, desmin and acetylated α-tubulin normalized to α-tubulin (Figures 9.1H,K-L).
Compared to control, acetylated α-tubulin was increased in ISHD patients and detyrosinated
α-tubulin (normalized to α-tubulin) in DCMped (Figures 9.1I,J,M).
Figure 9.1: Microtubule remodelling and increased desmin levels are most prominent in
early HCM. (A) Representative blot images with uncropped membranes in Figure S1. In (B-G),
early (HCMSt II) and end-stage (HCMSt IV) HCM samples were compared to controls (Ctrl) and in
(H-M), end-stage DCM samples including ISHD, IDCM, adult (DCMend) and paediatric (DCMped)
were compared to Ctrl. Quantified levels of (B, H) α-tubulin, (C, I) acetylated α-tubulin, (D, J)
detyrosinated α-tubulin, (E, K) desmin, (F, L) acetylated α-tubulin normalized α-tubulin and (G,
M) detyrosinated α-tubulin . The average value of the Ctrl are indicated by the dotted line in the
respective scatter plots. HCM samples = filled squares, HCMSt II = brighter red bar, HCMSt IV =
darker red bar, DCM samples = filled triangles, ISHD = brown bar, IDCM = purple bar, DCMend
= darker blue bar, DCMped = brighter blue bar. Each dot in the scatter plots represents an
individual sample. *p<0.05 **p<0.01 and ***p<0.001 versus Ctrl, ##p<0.01 and ###p<0.001
versus HCMSt IV. Measurements are mean ± SEM.
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DEFINING THE TUBULIN SIGNATURE IN AGED AND AORTIC BANDING
TREATED PIGS
We compared sham-operated, 4 months old pigs to untreated, 18 months old pigs. Due
to the age difference, the BW of both groups was different, therefore we used the formula
LV weight = 0.6 x BW∧0.78 to scale the LV weight to BW.22,23 The 4 months old pigs
showed a 22% reduced (p=0.0003) LV weight to BW ratio compared to expected value of
1.0. (Figure 9.2A).
Figure 9.2: Cardiac characteristics in (A-D) 4 months (n=6) or 18 months old pigs (n=5
(A) or 6 (B-D)) and (E-H) sham-operated (same as 4 months old pigs in upper panel) or
AoB-treated pigs (n=6). (A, E) Normalized left ventricular weight/body weight (LVW/BW)
ratios. (B, F) Echo LV ejection fractions (LVEF). (C, G) Normalized LV end-diastolic lumen
area (LV-EDA) and (D, H) normalized LV end-systolic lumen area (LV-ESA). Normalization was
performed to take into account that cardiac geometry and function fail to scale proportionally with
increasing BW.18,22-23 4 months, sham-operated = open circles, 18 months = bold open circles,
AoB-treated = filled circles. Each dot in the scatter plots represents an individual sample. *p<0.05,
**p<0.01 and ***p<0.001 versus 4 months, sham-operated pigs. Measurements are mean ± SEM.
This was accompanied by a 21% lower (p=0.01) LV ejection fraction (LVEF) in the aged
pigs (Figure 9.2B). Since LV end-diastolic and end-systolic lumen area (LV-EDA and
LV-ESA) fail to scale proportinally with increasing BW, we normalized EDA and ESA
according to the formula EDV = 41 x BW∧0.37 (Figures 9.2C-D).18,24 Aged pigs were
characterized by a 31% increase (p=0.03) in LV-EDA and a 65% increase (p=0.008) in
LV-ESA.
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We compared the same control cohort to AoB-treated animals. After three weeks
of intervention, normalized LV weight to BW ratio was double (p<0.001) in AoB-treated
pigs compared to sham-treated pigs (Figure 9.2E). In contrast to the difference in cardiac
geometry, cardiac function, including LVEF, normalized LV-EDA and normalized LV-ESA,
was comparable between AoB-treated and sham-operated pigs (Figures 9.2F-H).
As a next step, we studied the microtubule network and the respective post-translational
modifications of LV biopsies in the ageing and aortic banding pig models (Figure 9.3).
Compared to 4 months old pigs, we observed reduced levels of α-tubulin (46%; p=0.04),
acetylated α-tubulin (51%, p=0.005) and detyrosinated α-tubulin (68%, p=0.01) in
18 months old pigs (Figures 9.3B-D). Levels of desmin and acetylated α-tubulin when
normalized to α-tubulin were not different between both age groups (Figures 9.3E-F). In
18 months old pigs, levels of detyrosinated α-tubulin were 50% reduced (p=0.02) when
normalized to α-tubulin (Figure 9.3G).
Levels of total, acetylated and detyrosinated α-tubulin were not different between
AoB-treated and sham-operated pigs (Figures 9.3H-J). In AoB-treated pigs, levels of desmin
were 83% increased (p=0.04) (Figure 9.3K).
NO DIFFERENT TUBULIN SIGNATURE IN EXERCISED MICE CARRYING A
MYBPC3 point mutation
In a further data set, we used exercised wild-type (WTEX) mice and mice carrying
MYBPC3772G>A point mutation on one (HETEX) or both (HOMEX) alleles. We observed
no differences in cardiac characteristics, including LVW to tibia length ratio, fractional
shortening, LV end-diastolic diameter (LV-EDD) and LV end-systolic diameter (LV-ESD)
between sedentary (WTsed) and WTEX mice (Figure 9.4).
HOMEX mice were characterized by an 88% increase (p<0.0001) in LVW to tibia length, a
49% decrease (p=0.01) in fractional shortening, a 22% increase (p<0.0001) in LV-EDD and
a 26% increase (p=0.007) compared to WTsed mice and the two other exercise mice groups.
When studying the effect on tubulin signature, we observed no changes in levels of
total, acetylated and detyrosinated α-tubulin among sedentary WTsed, WTEX and mutant
exercised mice (Figure 9.5). We observed a 168% increase (p=0.005) of desmin in HOMEX
mice compared to WTsed mice (Figure 9.5E). Homozygous MYBPC3 mice had 90%
reduced levels (p=0.002) of cMyBP-C compared to WTsed (Figure 9.5F). Also compared
to the other exercise mice, the cMyBP-C were significantly reduced in HOMEX mice.
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Figure 9.3: Reduced levels of microtubules and posttranslational modifications in aged pigs;
increased desmin levels after AoB intervention. (A) Representative blot images; dashed lines
indicate lanes which were run on the same membrane but were non-contiguous. Uncropped
membranes are presented in Figure S2. In (B-G), 4 months old pigs were compared to 18 months
old pigs and in (H-K), this 4 months, sham-operated pigs were compared to AoB-treated pigs (n=6
per group). Quantified levels of (B, H) α-tubulin, (C, I) acetylated α-tubulin, (D, J) detyrosinated
α-tubulin, (E, K) desmin. Due to significant differences in α-tubulin levels, (F) acetylated α-tubulin
and (G) detyrosinated α-tubulin were normalized to α-tubulin . 4 months, sham-operated = open
circles, 18 months = bold open circles, AoB-treated = filled circles. Each dot in the scatter plots
represents an individual sample. *p<0.05 and **p<0.01 versus 4 months, sham-operated pigs.
Measurements are mean ± SEM.
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Figure 9.4: Cardiac characteristics in 13 weeks old MYBPC3 772G>A mice.
(A) Normalized left ventricular weight (LVW)/tibia length ratios, (B) fractional Shortening, (C)
LV end-diastolic diameter (LV-EDD) and (D) LV end-systolic diameter in sedentary wild-type
(WTsed, n=7), exercise wild-type (WTEX, n=10), exercise heterozygous (HETEX, n=9) and exercise
homozygous (HOMEX, n=10) mice. The average value of the WTsed mice are indicated by the
dotted line in the respective scatter plots. WTEX = white bar, HETEX = bar with diagonal lines,
HOMEX = grey bar, exercise mice = filled rhomboids. Each dot in the scatter plots represents an
individual sample. *p<0.05, **p<0.01 and ***p<0.001 versus WTsed, ##p<0.01 and ###p<0.001
versus HOMEX mice. Measurements are mean ± SEM.
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Figure 9.5: Increased levels of desmin and reduced levels of cardiac myosin binding protein
C (cMyBP-C) in exercise mice which are homozygous for MYBPC3 point mutation. (A)
Representative blot images; dashed lines indicate lanes which were run on the same membrane but
were noncontiguous. Uncropped membranes are presented in Figure S3. In (B-F), sedentary
wild-type (WTsed), exercise wild-type (WTEX), exercise heterozygous (HETEX) and exercise
homozygous (HOMEX) mice were used to determine levels of (B) α-tubulin, (C) acetylated
α-tubulin, (D) detyrosinated α-tubulin, (E) desmin and (F) cMyBP-C. The average value of the
WTsed mice are indicated by the dotted line in the respective scatter plots. WTEX = white bar,
HETEX = bar with diagonal lines, HOMEX = grey bar, exercise mice = filled rhomboids. Each
dot in the scatter plots represents an individual sample. **p<0.01 versus WTsed, #p<0.05 and
##p<0.01 versus HOMEX mice. Measurements are mean ± SEM.
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DISCUSSION
In this study, we determined the tubulin signature and desmin expression in cardiac tissue
from various pig and mouse models as well as HCM and DCM patients with different
disease stages ranging from NYHA class II-III to end-stage HF (NYHA class IV) with an
idiopathic, ischemic and genetic origin. Figure 9.6 visualizes and summarizes our findings
of the different models and patient samples indicating the most proliferated and modified
tubulin signature and desmin expression in early HCM patients compared to the respective
controls.
Figure 9.6: Heat map displaying the mean values of the Western blot analyses for the human
(Figure 9.1), pig (Figure 9.3) and mouse samples (Figure 9.5). Blue colour indicates lower
protein expression and red indicates higher protein expression compared to the respective control.
Mean values above 5 are presented in dark red. Fields containing a statistically significant value
are surrounded by boxes.
TUBULIN SIGNATURE IN EARLY HCM AND END-STAGE HCM AND DCM
We observed the strongest increase in tubulin signature in HCMSt II patients. Interestingly,
in end-stage HCM the levels of the tubulin signature were similar to control, except for
detyrosinated α-tubulin which was strongly increased when normalized to α-tubulin. When
comparing different end-stage eccentric HF samples, we mostly observed no changes
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in tubulin signature. Compared to control, acetylated α-tubulin was increased in ISHD
patients and detyrosinated α-tubulin in DCMped.
Whilst detyrosinated α-tubulin has been reported as a cardiomyocyte motion modifier,5,7
the effect (compensation or consequence) of changes in acetylation of α-tubulin has not
been studied. Available information suggests that acetylated α-tubulin compartmentalizes
on stable microtubules and promotes autophagy due to increased assembly of autophagic
cargo along microtubules.25-26 Interestingly, stable, long-lived microtubules provide a
substrate for luminal acetylation, but acetylation itself has been proposed to mechanically
stabilize microtubules thereby prolonging the lifetime of microtubules and protecting them
from mechanical ageing.2 Moreover, an increase of tubulin acetylation has also been
described in response to oxidative stress, for example inhibition of histone deacetylates has
been suggested to protect the myocardium against oxidative stress induced injury.27 Further
research is needed to understand whether the observed increase in acetylated α-tubulin
in HCMSt II and ISHD samples is sufficient to promote autophagy and to buffer oxidative
stress. In addition, it may also be interesting to investigate the functional effect of tubulin
acetylation.
Partially in contrast to our findings, microtubule network was found to be highly
proliferated and detyrosinated in failing myocytes of human LV explanted tissues collected
from a myocardial rich, minimally fibrotic region of the mid LV wall.6-7 Information whether
the HCM and DCM patients had a genetic origin was not further investigated in both
studies. The characteristics of the respective patient groups and tubulin modifications are
listed in Table 9.2.,












49.9 ± 3.6 59.3 ± 1.5 55.5 ± 2.0 - 53.8 ± 1.5
LVEF ± SD
[%]
42.9 ± 2.4 17.8 ± 2.2 14.1 ± 1.0 - 57.4 ± 1.8
Tubulin ↑↑ ↑ ↑↑↑ - =




50.9 ± 3.0 58.9 ± 1.6 57.8 ± 2.0 47 ± 4.9 50.8 ± 2.6
LVEF ± SD
[%]
42.0 ± 4.3 13.3 ± 1.1 13.2 ± 0.8 31.1 ± 2.8 57.2 ± 2.7
Tubulin ↑↑↑ ↑ ↑↑↑ ↑ =
Detyrosination ↑↑↑ ↑ ↑↑↑ ↑ =
Post-Vad DCM: DCM following ventricular assist device support; SD: deviation; LVEF: left ventricular
ejection fraction; ↑: increase, -: not measured; =: unchanged.
Natural co-founders such as differences in age ranges, sex, genotype and selection of cardiac
regions from which the biopsies were taken may explain the partially different findings in
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tubulin signature of HF patients in the various studies. For example, the HF patients with
end-stage HCM included in our study were obviously younger than the ones in the studies of
Prosser’s group warranting the need to investigate how the tubulin signature changes with
ageing. Moreover, in a proteomics analysis of septal myectomy samples from HCM patients
(chapter 8), our group revealed an increased microtubule network in female compared to
male HCM patients.28 In another study, we observed the clear pattern that the levels of total
and acetylated α-tubulin were changed dependent on the genotype in septal myectomies
in the following order: HCM with haploinsufficiency > HCM with a poison polypeptide >
genotype-negative HCM (chapter 7).4 A description of the tubulin signature in the different
regions of the heart is still lacking, but of utmost importance to understand how the selection
of a specific region is introducing a bias when comparing different studies.
EFFECT OF AORTIC BANDING TO MODEL ACUTE PRESSURE-OVERLOAD
CONCENTRIC HYPERTROPHY
We compared sham-operated to AoB-treated pigs of the same age. Since pressure-overload
was initiated 3 weeks before sacrifice, we were able to study the consequences of acute
concentric hypertrophy in the absence of any co-founding pathomechanisms such as a
gene mutation. As expected, AoB-treated pigs were characterized by a double as high
normalized LVW/BW ratio compared to sham-operated pigs. Interestingly, we did not
observe any changes in tubulin signature which is in line with the fact that the cardiac
function, including LVEF, LV-EDA and LV-ESA was comparable between AoB-treated and
sham-operated pigs.
Previously, the effect on microtubule network of LV pressure overload has been studied in
various animal models with contradictory results. In line with our findings, no microtubule
proliferation was observed in guinea pigs29-30 and cats31 with pressure overload hypertrophy.
In contrast to that, microtubule proliferation was shown in dogs32 and mice33 with LV
pressure overload-induced cardiomyopathy. Potential reasons for these conflicting outcomes
could be either underlying species differences in response to LV pressure overload or the
differences in severity of the disease models. For example, compensated hypertrophy
due to LV pressure overload in dogs did not affect tubulin expression, while microtubule
proliferation was observed when hypertrophy transitioned from a compensated into a
decompensated state.32 Therefore, the normal cardiac function in our AoB-treated pigs
may be reflected by an unchanged tubulin signature which may possibly be altered in
decompensated hypertrophy. In the above mentioned animal models only total microtubule
levels were studied and information about the fine-tuning of the tubulin code are lacking.
EFFECT OF AGEING AND BODY GROWTH IN PARALLEL
In our study, we used 18 months old pigs with a high BW. Previously, it has been
reported that LV dimensions and function do not scale with BW in modern pigs according
to allometric scaling laws.18,22-23 In addition, high BW pigs were characterized by a
high LV systolic pressure.18 This chronic LV pressure overload was suggested to be
responsible for the increase in interstitial collagen levels and the impaired LV relaxation
contributing to diastolic perturbations as observed in our 18 months old pigs.18,34 Since
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we observed a weaker tubulin signature, including decreased levels of total, acetylated
and detyrosinated α-tubulin in the 18 months old pigs, detyrosinated α-tubulin can be
excluded as a potential contributor to the diastolic perturbations seen in this model. More
research is needed to understand the causes and consequences for the weaker tubulin
signature and whether modulation of the tubulin signature would have an effect on the
disproportionately low stroke volume. Hereby, it is important to include healthy ageing
pigs with a normal cardiac function as a control group to reduce the complexity of the model.
One limitation of our study is the comparison of the 18 months old pigs to sham-operated,
4 months old pigs. Part of the 18 months old pigs was obtained from another breeder.
Moreover, the sham-operated pigs were studied several years before the 18 months old
pigs, hence these animals likely have a slightly different genetic background. In addition,
the 18 months old pigs were only females, while in the AoB study both males and females
were used. Male pigs were selected for their rapid gain of skeletal muscle weight.35 So
this may have resulted in relatively lower normalized LVW/BW ratio’s in sham-operated,
4 months old pigs as compared to the 18 months old female pigs. Furthermore, our
proteomics study in chapter 8 revealed sex differences in microtubule remodelling indicated
by a proliferated microtubule network in female HCM patients.28 In future, it would be
interesting to determine the tubulin signature in female pigs of the lowest weight category
of the van Essen study,18 which is comparable to the weights of the sham-operated pigs.
TUBULIN SIGNATURE IN MYBPC3 MICE
In a further data set, we used exercised WT mice and mice carrying the MYBPC3
c.772G>A mutation on one or both alleles, which is associated with human HCM, to study
the effect of this mutation under exercise. Exposure to an 8-week voluntary wheel-running
protocol did not change the tubulin signature and levels of desmin as observed from our
comparison of sedentary and exercised WT mice.
Interestingly, a similar tubulin signature as in WT mice was observed in hetero- and
homozygous exercised mice and desmin levels were increased in HOMEX. This unchanged
tubulin signature differs from our previous study with older homozygous MYBPC3 mice.
We observed normal α-tubulin levels and increased levels of detyrosinated α-tubulin and
desmin in homozygous, 20 to 28 weeks old MYBPC32373insG mice and in homozygous, 55
to 59 weeks old MYBPC3772G>A, we observed an increase in α-tubulin and a tendency to
increased detyrosination of α-tubulin.10 Desmin levels were not investigated in the latter
group.
These findings suggest that the tubulin signature and desmin expression may be
changed in a time-dependent sequence in response to a genetic trigger such as the strongly
reduced cMyBP-C levels in HOMEX mice which were accompanied by cardiac dysfunction
and hypertrophy. Hereby, an intermediate stage may be represented by an increase in
desmin levels, followed by more detyrosination of α-tubulin and lastly an increase in the
microtubule network with a tendency to increased detyrosination of α-tubulin. Further
research is needed to understand the age-dependent differences in tubulin signature and
desmin expression and their functional ramifications in MYBPC3 mice.
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ASSESSMENT OF DESMIN EXPRESSION IN ANIMAL MODELS AND HEART
FAILURE PATIENTS
Next to defining the tubulin signature, we assessed the desmin expression in our sample
collection to better understand whether we could observe a pattern between the tubulin
signature and desmin expression. This was especially relevant in the context that desmin
has been identified as a sarcomeric microtubule anchor7 and that intermediate filaments
cross-link with microtubules in a detyrosination-dependent manner.11-12 Compared to the
respective control, we detected either normal or increased levels of desmin. The latter
was the case in HCMSt II, HOMEX mice and AoB-treated pigs. In line with our data, it
has been suggested that increased desmin levels are observed during the development
of hypertrophy in response to maintain organization of sarcomeres independent of the
underlying pathology.36-37 Moreover, one of the functions of desmin is to counteract
external stresses.38-39 In 4-week and 8-week thoracic aorta banded guinea-pigs to model
compensated left ventricular pressure overload hypertrophy and decompensated congestive
HF, an increase of desmin expression on the level of mRNA transcripts and proteins has
been detected.30 In contrast to our findings, investigating the cytoskeleton remodelling
of explanted failing human myocardium revealed an increase of desmin filaments.37 In
comparison to non-failing and compensated hypertrophic hearts, upregulation of full-length
desmin and some low molecular weight bands previously identified as post-translationally
modified desmin products, that are prone to misfolding, aggregation and cleavage,40 were
detected in biopsies of HCM, DCM and ISHD patients with HF.6 In our Western Blots
analyses, we only detected full-length desmin due to usage of an anti-desmin antibody
targeting a carboxy-terminal epitope. Besides the increase of desmin levels, disorganization
of desmin filaments has been described coinciding with contractile dysfunction.6,37 Higher
levels of intact desmin are likely caused by either an increased desmin expression or
a decreased capability of the cardiomyocytes to efficiently degrade desmin.41 Since
increased desmin levels in HF regardless of the underlying cause are often accompanied
by posttranslational modification-driven formation of intracellular protein aggregates,40-41
further research is warranted to improve our understandings about the extent of these
changes and their functional ramifications.
Our data suggest that desmin levels are increased in early concentric hypertrophy,
while our HF patient cohort was characterized by desmin levels comparable to controls.
Furthermore, we observed that desmin expression was independent of the levels of
detyrosinated α-tubulin. Along with reporting expression levels, it is also important to
study the levels of low molecular weight post-translationally modified desmin products,





Cardiomyopathies underlie complex pathomechanisms and animal models only partially
recapitulate the proliferated and modified tubulin signature and changes in desmin levels.
Age, sex, genotype and selection of heart region are likely to introduce a bias in the
tubulin signature. Our findings emphasize the necessity to establish better model systems to
precisely elucidate the effect (compensation or consequence) on contractility, microtubule
dynamics and stability of the observed tubulin signature in HCM and DCM patients and to
test potential drugs re-writing the tubulin signature.
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ABSTRACT
Variants in genes encoding contractile proteins can lead to diverse cardiomyopathy
phenotypes and one of these genes is TNNI3 which encodes cardiac Troponin I
(TnI). We aimed to generate clustered, regularly interspaced, short palindromic repeats
(CRISPR) / CRISPR-associated (Cas)9-edited Drosophila melanogaster as a model system
to understand the pathomechanisms of two distinct gene variants E97X and K144W in
TNNI3 (wupA in Drosophila melanogaster). Both variants represent orthologues of the
clinically relevant TNNI3 variants R98X and R145W in humans. Our attempt using
scarless CRISPR/Cas9-mediated genome editing to make these strains was not successful.
This result was caused either by employing an experimental strategy which can lead to
low or no activity of the Cas9/single-guide RNA (sgRNA) complexes or by targeting
the haplolethal region 16F of Drosophila melanogaster. In the latter case, to introduce
the nucleotide changes, the eye-specific 3xP3-DsRed selection marker was inserted during
homology-directed repair which may affect one or several breakpoints in close proximity
to the insertion site and thereby interrupt TnI protein expression. As a consequence,
this may result in a lethal phenotype of both CRISPR edited strains. By sharing our
unsuccessful attempt, we intend to create awareness about potential pitfalls of using our
scarless CRISPR/Cas9 editing approach while targeting a haplolethal region.
10
INTRODUCTION
Cardiomyopathies are a heterogeneous group of diseases of the myocardium that are
associated with mechanical and/or electrical dysfunction and are a major cause of
morbidity and mortality.1 Pathogenic variants in the sarcomere gene TNNI3 which encodes
cardiac Troponin I (TnI) can lead to diverse cardiomyopathy phenotypes.2,3 Reported
TNNI3 variants account for 2.2% of all likely pathogenic and pathogenic gene variants
in hypertrophic cardiomyopathy (HCM) and 0.6% in dilated cardiomyopathy (DCM).4
Moreover, TNNI3 gene variants are the most prevalent cause of restrictive cardiomyopathy
(RCM).5 In the literature, the gene encoding troponin I in Drosophila melanogaster has
been referred to as wings up A (wupA), held-up (hdp), and TnI. Here, we use the FlyBase
standard wupA (CG7178) name when referring to this gene. We aimed to introduce
cardiomyopathy-specific wupA variants in Drosophila melanogaster to define underlying
pathomechanisms.
Drosophila melanogaster is a relatively inexpensive model system, easy to keep and
causes minimal ethical and safety issues. The relatively short life cycle of Drosophila
melanogaster reduces enormously the time to wait until research material is available
compared to vertebrate models. Material of adults can be studied 10 days after fertilization
of the egg when maintained at 25°C.6 The high reproduction rate makes it easy to generate
and include large numbers of flies for experimental approaches.6 Compared to transgenic
mouse models, transgenic Drosophila melanogaster models are readily amenable to large
scale genetic or pharmacologic screens.7,8 Drosophila melanogaster, the simplest genetic
model system with a heart, exhibits strong gene conservation with human genes, including
75% of disease-related genes.9,10 Furthermore, it has been used as an efficient model for
functional studies in cardiomyopathies.9,10
We performed sequence alignments of Drosophila melanogaster and
cardiomyopathy-causing gene variants listed in our human tissue biobank. Here, we
selected two TNNI3 gene variants, the R98X and R145W. In addition, the R145W gene
variant fulfilled our requirement for non-truncating mutations because the orthologous
amino acid in Drosophila melanogaster belongs to the same physicochemical group. After
evaluating the robustness of Drosophila melanogaster as a model system to study inherited
cardiomyopathies, we intended to upscale the number of gene variants.
The R98X has been associated with different clinical phenotypes, i.e. DCM or HCM.4,11
At a nucleotide level, R98X is caused by a 292 C→T mutation that is predicted to result
in a premature stop codon at amino acid 98. The resulting truncated cardiac TnI protein
lacks troponin C and actin binding domains.5,11 Analysis of left ventricular cardiac tissue
of patients with the truncating R98X gene variant showed reduced full length cTnI protein
levels, i.e. while no truncated form of cTnI was observed indicating that the outcome of
the R98X variant is haploinsufficiency instead of a dominant-negative effect and altered
stoichiometry.11
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The R145W mutation was initially detected in patients with idiopathic RCM.12 Subsequent
studies reported the R145W as an RCM- and HCM-causing variant in individuals with
variable clinical characteristics leading to its classification as a pathogenic variant.12-15 This
variant is a Dutch founder mutation and represents 27% of all TNNI3 gene variants.15
Previously, wupA mutant strains were set up by mutagenic chemicals, especially
ethyl methane sulfonate mutagenesis.16,17 Here, we applied, for the first time, scarless
clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated
(Cas)9-mediated genome editing to specifically generate two Drosophila melanogaster
strains with the wupA variants E97X and K144W, which are the orthologues changes for
the two human TNNI3 variants R98X and R145W, respectively. CRISPR/Cas9 system
is a preferred tool to generate targeted mutations in Drosophila melanogaster because
of the following benefits in comparison to other site-specific nuclease techniques such as
zinc-finger nuclease (ZFN) and transcription activator-like effector nuclease (TALEN).18
First, CRISPR/Cas9 is more feasible for upscaling gene editing project because only
changing the 20-basepair guide RNA is sufficient for Cas9 to distinguish genes. Cas9
cutting sites are spread abundantly in the Drosophila melanogaster genome. To target
another gene with ZFN or TALEN, the engineering of another protein is required.18 Second,
there are several established routes how Cas9 can be delivered into the model system which
increased the likelihood of success and provides more flexibility.19-21 Third, co-injection of
a donor vector carrying a selection marker, such as 3xP3-DsRed, with Cas9 facilities and
speeds up the screening process.19
Our scarless CRISPR/Cas9 approach is based on using Cas9 endonuclease complexes
with a single-guide RNA (sgRNA), which is designed to match a ˜20bp target sequence,
and to cause double strand cleavage of the target sequence. The sgRNA is characterized
by a protospacer-adjacent motif (PAM) (the trinucleotide 5’-NGG-3’) immediately 3’ of
the 20bp target sequence.22,23 Supplying a donor plasmid in excess was intended to be
used as the desired homologous template and to introduce the defined changes in the
target DNA.24 Next to the defined changes to be introduced, our donor plasmid design
also contains the promotor 3xP3 and the selection marker DsRed. This selection marker
cassette is flanked by PBac transposon ends. The TTAA site, the PBac transposase
recognition motif, is duplicated upon knock-in of the selection marker and restored to a
single TTAA site upon excision of the selection marker by PBac transposase.19,23 The
workflow of the our seamless CRISPR/Cas9 approach is shown in Figure 10.1.
The wupA gene results in 13 transcripts and 13 protein isoforms. The transcripts RC and
RF, the two most abundant transcripts in which both target sites are present, were used as
reference transcripts to introduce the gene variants. Since hereditary cardiomyopathies are
most commonly inherited by dominant transmission,25 we aimed to generate strains that
are heterozygous for the wupA variants.
It has been shown before that wupA variants can cause cardiomyopathies. For
example, an alanine to valine change within all TnI isoforms (A116V in wupA-PG/PH;
A31V in wupA-PK-PM; A55V in remaining isoforms) causes impaired systolic function
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Figure 10.1: Workflow of seamless CRISPR/Cas9-based genome editing to introduce wupA
variants. Double-stranded DNA donor plasmid contains the nucleotide changes (AAG to TGG) to
introduce the K144W variant and the marker cassette PBacDsRed with the two PBac terminals,
3xP3-DsRed and two homology arms. Homology-directed repair of the CRISPR/Cas9-mediated
double strand break in the genome results in insertion the of knock-in cassette PBacDsRed. This
is an intermediate step for visible marker screening. Following DsRed-mediated identification of
engineered strains, the marker cassette can be easily and scarlessly removed through a single cross
to PBac transposase.
in heterozygote and homozygote wupAhdp2 strains. Homozygote wupAhdp2 Drosophila
melanogaster also showed cardiac enlargement recapitulating the clinical phenotype of
human DCM.16 While Drosophila melanogaster thus represents an experimental tool to
study cardiomyopathies, our usage of CRISPR/Cas9 editing to introduce wupA mutations
in combination with knock-in of an eye-specific selection marker failed.
Instead of being able to provide any insight in these cardiomyopathy wupA variants
and their impact, we share here our attempt and data on failure to generate these
CRISPR-edited Drosophila melanogaster strains with the hope to prevent loss of time and
research money by other groups who may want to use a similar method to target genes
within haplolethal regions in Drosophila melanogaster and can inform future attempts to
improve methodology.
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METHODS
SEAMLESS CRISPR/CAS9-BASED GENOME EDITING WAS USED TO
INTRODUCE THE E97X AND K144W VARIANTS
CRISPR/Cas9-mediated mutagenesis was performed by WellGenetics Inc. (Taipei City,
Taiwan) using modified methods of Kondo and Ueda.21 While Kondo and Ueda used
transgenic CRISPR components, we used injected plasmids. In brief, genomic DNA was
obtained from injection strain w1118. PCR was performed using KOD FX DNA polymerase
(TOYOBO, KFX-101) on BioRad S1000 Thermal Cycler. Sequencing results were BLAT
against Drosophila melanogaster genome (August 2014 Assembly, BDGP Release 6) using
UCSC Genome Bioinformatics and the genomic codons option was selected for codon
colouring.26,27 The respective guide RNA (Table 10.1) was cloned into U6:96Ab (U6-2)
promoter plasmid.21
Table 10.1: Design of CRISPR target site, guide RNAs and homology arms.
E97X K144W
guide RNA1 guide RNA2 guide RNA1 guide RNA2
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For both gene variants, guide RNA1 was used for the first round of injections and guide
RNA2 was used for the second round of injections (Table 10.1). The donor plasmid
containing a red fluorescent marker cassette with 3xP3 promoter driving DsRed expression
in the eyes which was flanked by piggyBac (PBac) transposon ends and two homology arms
with the gene variants was cloned into the pUC57-Kan vector (Figure 10.1; Supplementary
Material: E97X and K144W Donor Designs).
WupA-targeting guide RNAs (100ng) and heat shock-inducible Cas9 (100ng) were
supplied in DNA plasmids, together with donor plasmid (500ng) for microinjection into
embryos of control strain w1118. The first two rounds of microinjection of K144W were
done on [LWG208] w1118, which was newly obtained from Bloomington Stock Number
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6326 (SNP mapping stock, isogenic 2nd and 3rd chromosomes).28 Since this is the
isogenic background for Exelixis P and PBac insertions, SNP variation for CRISPR editing
would be reduced. However, it neither survived well nor gave any positive strains. All
further microinjections of E97X and K144W were therefore done on [LWG012] w1118
strain, obtained from Bloomington Stock Center. Identification of engineered strains was
performed via the 3xP3-DsRed marker by screening for DsRed expression in the eye.19,29
F1 flies carrying the 3xP3-DsRed selection marker were further validated by genomic
PCR and sequencing. CRISPR generated a break in wupA and was replaced by cassette
PBacDsRed. The TM6B balancer was used for selection of heterozygous offspring at larval
stage. Following DsRed-mediated identification of engineered strains, the marker cassette
can be easily and scarlessly removed through a single cross to PBac transposase,19,23 but
was not applied in this study.
ANALYSIS OF CRISPR INTEGRATION OF THE SELECTION MARKER OF
K144W VARIANT
Genomic DNA was obtained from a single fly of each stock following single-fly DNA
preparation using Gloor’s protocol.30 Injection strain w1118 was used as a negative control
and donor plasmid as a positive control for integration examination. PCR was performed
using KOD FX DNA polymerase (TOYOBO, KFX-101) on BioRad S1000 Thermal Cycler
(Table 10.2).,
Table 10.2: Steps and conditions of thermo cycling for Integration and Validation PCR.
Steps Temperature Time Cycles
Initial denaturation 94°C 2 min 1
Denaturation 98°C 10 sec
30Annealing 55°C 30 sec
Extension 68°C 2 min
Final extension 68°C 5 min 1
End/Hold 15°C Forever
CRISPR/homology-directed repair may go through different repairing routes. Integration
of donor plasmid in CRISPR editing alleles is a common phenomenon. “No integration”
contains only one copy of selection marker. “Single integration of donor plasmid” contains
the vector backbone, two copies of homology arms and selection marker.
Integration test is to exclude alleles with donor vector integration and only
keep the strains with simple editing to avoid the genomic complications. For
integration PCR 1, forward primer (5’–CAACTGTTGGGAAGGGCGAT) was designed
outside the upstream homology arm in the backbone plasmid and reverse primer
(5’–CGAGGGTTCGAAATCGATAA) was designed at 3xP3 promoter. For integration
PCR 2, forward primer (5’-TTTGACTCACGCGGTCGTTA) was designed at 3’ PBac
terminal and reverse primer (5’–CATTAGGCACCCCAGGCTTT) was designed outside the
downstream homology arm in the backbone plasmid. While single integration of donor
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plasmid will have the amplicon, the corrected editing will not have the amplicon. 1kb Plus
DNA RTU Ladder from Biomate (BR343-500) was used as reference on a 1.2% agarose
gel and 0.5x TAE buffer.
CRISPR VALIDATION OF KNOCK-IN CASSETTE PBacDsRed FOR K144W
VARIANT
Genomic DNA was obtained from a single fly of each stock following single-fly
DNA preparation. Injection strain w1118 was used as a negative control. PCR
was performed using KOD FX DNA polymerase (TOYOBO, KFX-101) on BioRad
S1000 Thermal Cycler (Table 10.2). Using genomic PCR and sequencing
methods to verify CRISPR alleles of wupA by testing if the knock-in cassette
PBacDsRed was correctly used as template for homology-directed repair and was
incorporated into guide RNA1 cutting site. For upstream PCR, forward primer
(5’-TCTCTCTGTCACTTTTCTCTGTG) was designed at 5’ outside the homology arm and
reverse primer (5’-CGAGGGTTCGAAATCGATAA) was designed at 3xP3 promoter. For
downstream PCR, forward primer (5’-TTTGACTCACGCGGTCGTTA) was designed at 3’
PBac terminal repeat and reverse primer (5’-GGCATGGCAAGGTAGAAAGA) was designed
at 3’ outside the downstream homology arm. Only cassette PBacDsRed, which was inserted
into the gene locus will have the amplicon. 1kb Plus DNA RTU Ladder from Biomate
(BR343-500) was used as reference on a 1.2% agarose gel and 0.5x TAE buffer.
RESULTS
TARGET SEQUENCES OF GUIDE RNAs PRESENT IN INJECTION STRAIN
We designed the guide RNAs according to the following four criteria: distance from
knock-in site to cutting site of Cas9, predicted off targets on other chromosomes, GC
content of target sequence and thymine numbers at 17th to 20th nucleotide of the guide
RNA target site. Quality of the guide RNA was considered as strong when the distance
was shorter than 50 base pairs, without any off targets, 45%-70% GC content of the target
sequence and 0 or 1 thymine. Quality of the guide RNA was classified as weak when the
distance was between 50 to 100 base pairs, presence of potential off targets on untargeted
chromosomes, 40% or 75% GC content of the target sequence and 2 thymines. All four
designed guide RNAs showed at least three strong quality characteristics (Table 10.1).
Furthermore, we performed genomic sequencing of the injection strain to verify that all
guide RNA loci for the E97X and K144W variants were as indicated. No SNPs were found
on the guide RNAs in 3 independent reads in the injection strain. The target sequence of
each guide RNA was present in the genome of the injection strain (Figures 10.2A-B and
Supplementary Material). With this information, guide RNAs and donor plasmids were
prepared. As illustrated in Figures 10.2C-D, for both gene variants the selection marker
knock-in will be positioned within an exon.
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Figure 10.2: BLAT results to show alignment of the guide RNAs and independent reads of
the injection strain with the wupA transcripts. The target sequence of both guide RNAs (gRNA1
and gRNA2; Table 10.1) for the (A) E97X variant and the (B) K144W variant were present in three
independent reads (A) (w1118_1, w1118_2, w1118_3) and (B) (w1118_4, w1118_5, w1118_6)
of the injection strain. The independent read sequences of the injection strain are available in the
Supplementary Material. The 13 wupA transcripts were indicated below with codon boundaries
depicted by alternating lighter and darker blue shades. Bright green codon indicates methionine
and cyan text indicates spliced codon. Continuous black bars of the target sequence of guide RNAs
and the independent reads of the injection strains indicate completely matched sequence overlap
with the wupA transcripts. In (A) the targeted exon is present in 4 wupA transcripts and in (B)
sequence is present in all 13 wupA transcripts. Schematic illustration of successful integration of
selection marker cassette with (C) E97X and (D) K144W variant in the wupA locus. Red bar with
asterisk on top indicates position of gene variant. Numbers below illustration indicate the exons.
NO POSITIVE STRAINS AFTER MICROINJECTION OF E97X DONOR
PLASMID
We performed two rounds of microinjection in more than 400 embryos to introduce the
E97X variant, but failed to get any 3xP3-DsRed-positive strain. In the first round after
microinjection of guide RNA1, survival rate was low with 41 adults out of 207 injected
embryos. In the second round after microinjection of guide RNA2, survival rate and fertile
rate were all within normal range with 81 adults and 24 fertile crosses out of 222 injected
embryos, but without any positive strain. Since we excluded failure to introduce the E97X
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variant due to missing target sequence in the genome (Figure 10.2 and Supplementary
Material), we also performed sequencing of the donor plasmid. Both upstream and
downstream homology arms in the donor plasmid were sequenced to check if both are
specific to wupA (Figure 10.3A and Supplementary Material). No mismatches were found
in the coding sequence of wupA. Since the donor plasmid was correctly composed as
designed, failure due to inaccurate design of donor plasmid was also excluded.
Figure 10.3: BLAT results of the homology arms.
Both upstream and downstream homology arms in the (A) E97X and (B) K144W donor
plasmids were sequenced ((A) 1_E97X_homology_arm – 4_E97X_homology_arm; (B)
1_K144W_homology_arm – 3_K144W_homology_arm). The sequence reads were aligned to
wupA transcripts and the donor plasmid designs. No mismatches were found in the coding sequence
of wupA. The 13 wupA transcripts were indicated in blue below. Differences in nucleotides are
highlighted as follows: red – genome and query sequence have different bases at this position;
orange – the query sequence has an insertion (or genome has a deletion/alignment gap) at this
point; purple – the query sequence extends beyond the end of the alignment. Double horizontal
lines are drawn to indicate when the alignment has gaps in both the genome and query sequence.
ONE 3xP3-DsRed-POSITIVE STRAIN AFTER MICROINJECTION K144W
DONOR PLASMID
We injected more than 400 embryos from two rounds of microinjection to introduce the
K144W variant and got only one 3xP3-DsRed-positive strain, when guide RNA1 was used.
This strain was further investigated. To exclude general mistakes in our genome editing
approach leading to no K144W positive strains, we performed genomic sequencing of
the injection strain (Figure 10.2 and Supplementary Material) and the donor plasmid.
Sequencing of both upstream and downstream homology arms in the donor plasmid
revealed that the donor plasmid sequence was as designed (Figure 10.3B and Supplementary
Material). We, therefore, excluded inaccurate design of the donor plasmid as a possibility
UNSUCCESSFUL SCARLESS CRISPR/Cas9 EDITING APPROACH 229
for failure next to the presence of the target sequence in the genome (Figure 10.2 and
Supplementary Material).
DONOR PLASMID INTEGRATION AND INCORRECT INCORPORATION OF
KNOCK-IN CASSETTE PBacDsRed INTO GUIDE RNA CUTTING SITE
We checked the 3xP3-DsRed-positive strain to exclude strains with vector backbone
integration, which is a common phenomenon in CRISPR edited alleles, and to only keep
the strains with integration of selection marker at the correct guide RNA1 cutting site
to avoid genomic complications and off-target strains. PCR bands at expected sizes for
both integration PCR 1 (1508bp) and integration PCR 2 (1356bp) were observed from the
donor plasmid which was used as positive control for the vector backbone (Figures 10.4A-B
and S1). No bands at expected sizes were observed from negative control sample w1118.
Positive and negative control samples indicated that the primer pairs for integration test
were highly specific. PCR bands at expected sizes for both integration PCR 1 and 2 were
observed from the 3xP3-DsRed-positive strain suggesting that integration of the vector
backbone has occurred.
In parallel, we tested if the knock-in cassette PBacDsRed was correctly used as template for
homology-directed repair. No bands at expected sizes (upstream PCR: 1588bp; downstream
PCR: 1480bp) were observed from negative control sample w1118, indicating high specificity
of the PCR reactions (Figures 10.4C-D and S1). In the lane loaded with the downstream
PCR product of the 3xP3-DsRed-positive strain we observed a weak signal at approximately
1600bp. The intensity was weaker than normal and occurred at a wrong size. We observed
no PCR product for upstream PCR. This suggests that the insertion of cassette PBacDsRed
into wupA gene locus did not occur as designed.
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Figure 10.4: Donor plasmid integration and incorrect incorporation of knock-in cassette
PBacDsRed into guide RNA cutting site. (A) Schematic of primer design (integration PCR 1
(Int PCR 1) and integration PCR 2 (Int PCR 2)) to check for integration of vector backbone
in 3xP3-DsRed-positive strain. Correct editing will have no amplicon (scenario 1) and single
integration of donor plasmid will have the amplicon (scenario 2). (B) Donor plasmid was
used as a positive control and w1118 as a negative control. The 3xP3-DsRed-positive strain
(3xP3-DsRed+) showed integration of vector backbone. (C) Schematic of the primer design to
check for incorporation of knock-in cassette PBacDsRed into guide RNA cutting site to introduce
K144W variant. (D) No bands were detected in upstream PCR (Up PCR) and downstream PCR
(Down PCR) for negative control sample w1118. The 3xP3-DsRed-positive strain (3xP3-DsRed+)
showed a weak signal in the downstream PCR indicating that the knock-in cassette PBacDsRed
was not located in the right locus due to missing amplicon in the upstream PCR. Primer sequences
for both Int PCR and Up/Down PCR are provided in the Materials and Methods section. In both
cases, (B) and (D), lanes were run on the same gel but were noncontiguous. Full-length gels are
presented in Figure S1.
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DISCUSSION
In the current study, we aimed to generate two Drosophila melanogaster strains
heterozygous for the wupA variants E97X and K144W by the application of scarless
CRISPR/Cas9-mediated genome editing to define cardiac pathomechanisms induced by
wupA variants. We injected more than 800 embryos with in total 4 different guide
RNAs to set up the two distinctive wupA mutant strains, but struggled to reach the step
allowing screening for DsRed expression in the eyes for both variants (Figure 10.1). DsRed
expression in the eyes suggests the introduction of the precise gene variant due to the
simultaneous knock-in of the PBac-flanked 3xP3-DsRed selection marker. We observed
that guide RNA1 to introduce E97X variant strongly affected survival rate.
Validation of our only 3xP3-DsRed-positive strain after CRISPR/Cas9-mediated genome
editing to introduce the K144W variant in wupA revealed, that first, part of the backbone
of the donor plasmid was inserted instead of only the selection marker. Second, the
knock-in cassette PBacDsRed was not correctly incorporated into the guide RNA1 cutting
site. We obtained a weak band at the wrong size in downstream PCR suggesting either a
false-positive signal of an off-target strain or ends-in integration at the target locus. We did
not further investigate the downstream PCR product by sequencing, even though it would
have provided valuable information whether there was sufficient CRISPR/Cas9 activity to
cause a double strand break. In addition, we know that vector backbone integration has
occurred, therefore it would have been better to use a long PCR protocol. In line with that,
complicated homology repair events may have occurred causing that the distance between
the two primers became too long.
Due to genomic sequencing of the injection strain and the donor plasmids we were
confident to exclude that a general mistake was made in the design of our genome editing
approach which may be the explanation for having no positive stains with both distinctive
wupA variants. Previously, this CRISPR/Cas9-mediated genome editing approach has
been successfully used to generate variants in other Drosophila melanogaster genes such
as SH3PX1, tan and white.19,21,23 Therefore, we at least were confident that this genome
editing approach is feasible for our model system. Nevertheless, CRISPR/Cas9 activity
is highly dependent on guide RNA folding, thermodynamic stability of the sgRNA-DNA
duplex as well as target accessibility within the context of chromatin.31 These variabilities
make it hard to predict activity at an untargeted locus such as the wupA gene. To maximise
the chances of successful cleavage, it is advised to design multiple sgRNAs for each desired
target31 as we did (see Table 10.1). Since we injected more than 800 flies with 4 different
guide RNAs, but only generated one 3xP3-DsRed-positive strain, this may suggest a low
efficient design of the guide RNA plasmid. We selected the 20 nucleotide sequence of the
guide RNA fulfilling many strong criteria (Table 10.1). Therefore the choice of U6:96Ab
(U6-2) promotor may be causative for the low efficiency. Hence it would be interesting to
test a more potent promoter, such as U6:3.32
In addition, generating one 3xP3-DsRed-positive strain out of 800 injected embryos
also indicates a very low or no CRISPR/Cas9 activity. Furthermore our gel electrophoresis
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was inconclusive whether the incorporation of the selection marker has happened at the
target site or off-target. Our experimental strategy, injection of plasmids into wild-type
seems to reveal low or no activity of CRISPR/Cas9-mediated double strand breaks at the
target sites and therefore selecting a more optimized CRISPR tool such as a fully transgenic
strategy may boost cleavage activity.33 One disadvantage of this strategy is that first the
fully transgenic flies need to be set up, so the overall time needed for the completion of the
CRISPR/Cas9 approach will be longer.
The following explanations are based on the assumption that CRISPR/Cas9 activity
was sufficient to cause double strand breaks. The inclusion of the large PBacDsRed
cassette from the donor plasmid into the wupA gene may interrupt TnI expression and
as a consequence affects viability of the CRISPR edited strains. Large indels such as the
PBacDsRed cassette in the repair process of double strand breaks targeted to constitutively
spliced coding exons may be sufficient to produce a non-functional protein.34 We were then
wondering if our intended changes affected constitutively spliced coding exons. According
to Flybase, the wupA gene consists of 10 exons and differential splicing produces 13
transcripts leading to 13 protein isoforms (Figure 10.5A). There are four different variants
of exon 6 (6a1/6a, 6a2/6b, 6b1/6c and 6b2/6d) and isoforms differing at this exon are
mutually exclusive.35 The E97X variant is located in exon 6b2 and since this exon is only
spliced into the transcripts wupA-RC, wupA-RF, wupA-RG and wupA-RH, hence the E97X
variant will affect four of the 13 transcripts. The K144W variant is located in exon 8 which
is a mandatory exon of all transcripts. Therefore, by trying to introduce the E97X and
K144W variants, a different number of transcripts was affected. In the case of K144W,
this led to complete non-functional TnI proteins of one allele, while in the case of E97X
only four TnI isoforms of one allele were affected.
Using the same technique to target constitutive exons of Mhc, another gene encoding the
sarcomeric protein myosin heavy chain, resulted in the successful generation of mutant
lines. In the Supplementary Material we provide the design and the validation of our Mhc
mutant strain heterozygous for the R402Q gene variant (Figure S2 and Table S1).
Genome editing by CRISPR causing reduced numbers of TnI isoforms or complete
depletion of TnI on one allele seems to be detrimental in Drosophila melanogaster. One
reason may be that TnI plays an important role during early development in Drosophila
melanogaster.37 TnI-depleted cells lose apico-basal polarity and reduce proliferation.38
Furthermore, TnI is expressed before muscle progenitors begin to fuse in Drosophila
melanogaster, and sarcomere morphogenesis is affected by TnI depletion as Z discs fail to
form.39
Another reason for having no positive strains may be the localization of the wupA itself. TnI
is encoded in the haplolethal region 16F.36 Haplolethality is caused by the one dose presence
of a gene locus instead of the double dose.40 Easy applicable genetic manipulation made
Drosophila melanogaster to the preferred model system to study systematically this unusual
phenomenon.41,42 A comprehensive inventory of haploinsufficient genes revealed that six
haplolethal genes are present Drosophila melanogaster.43 The effect and consequence of
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Figure 10.5: Transcripts of the wupA gene and molecular map of wupA gene variants.
(A) Representation of the TnI-coding (black) and non-coding (white) exons of the 13 transcripts
for wupA. Arrow head indicates the direction of transcription for this gene. Dashed red lines
indicate the affected exons by introduction of the wupA gene variants E97X and K144W. (B)
Different wupA gene variants lead to different phenotypes ranging from viable, semi-dominant
lethal (SDL) to dominant lethal (DL). Rearrangements affecting at least one breakpoint in the
wupA gene lead to a (semi)-dominant lethal phenotype. Single letter code indicates the restriction
sites of the relevant restriction enzymes: B, BamHI; G, BglII; H, HindIII; P, PstI, R; EcoRI; L, SalI.
Horizontal lines between restriction sites indicate the range of uncertainty in the location of each
breakpoint. So far four dominant lethal and two semi-dominant lethal gene variants were mapped:
22622DL (deletion of the chromosomal segment 16F-18D), 9916DL (inversion), 18242DL (insertion
of 540bp), 32322DL (insertion of ˜3kb), 8384SDL (insertion of ˜8kb) and 24597SDL (deletion of
˜0.4kb). Changes in the point mutation category are viable: wupA
hdp2 Drosophilae melanogaster
carry a point mutation on all transcript isoforms resulting in an alanine to valine change (A116V
in wupA-RG/RH; A31V in wupA-PK-PM; A55V in remaining isoforms) and wupAhdp3 Drosophilae
melanogaster fail to produce all exon 6b1-containing isoforms due to one nucleotide displacement of
the 3’ AG splice site. Red arrows indicate the position of the insertion sites for the large PBacDsRed
cassettes for two variants E97X and K144W. Molecular map was adapted from.36
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CRISPR editing of haplolethal region is rarely studied and only single reports can be found
in the context of reducing the transmission of vector-borne diseases.44 In addition, targeting
with CRISPR/Cas putative haplolethal X-linked genes led to significant lethality at the
embryonic and subsequent stages.45
The 16F region extends along 100 kb and includes at least 14 genes and the normal
haplolethal function depends on the integrity of a critical 4-kb window of mostly
non-coding sequences within the wupA transcription located toward the 3’ end.36
Dominant lethal variants in the haplolethal region, which are even lethal in heterozygotes,
result from chromosomal rearrangements including insertions, inversions and deletions
with at least one breakpoint in the TnI-encoding gene within the critical 4-kb window
(Figure 10.5B).36
Besides this dominant lethal domain, there are two additional domains in the wupA
gene in which rearrangements lead to a semi-dominant lethal phenotype or a recessive
lethal phenotype. The three domains are located in untranslated regions: dominant lethal
and semi-dominant lethal within the wupA gene and recessive lethal immediately upstream
of this gene.36 As indicated in the molecular map (Figure 10.5B), both variants, E97X and
K144W, are within the critical 4-kB window. This suggests that the introduction of the
nucleotide changes in combination with knock-in of the PBacDsRed cassette may affect
one or several breakpoints in close proximity to the insertion site and consequently resulted
in a dominant lethal phenotype of both CRISPR edited strains. While dominant lethality
caused by chromosomal rearrangement of exon 8 has been observed before, such as the
540 bp insertion variant 18242 DL,36 our report may suggest dominant lethality also caused
by an insertion in exon 6b2. In addition, this would indicate that the four transcripts,
wupA-RC, wupA-RF, wupA-RG and wupA-RH, as highly relevant for viability.
LIMITATION OF THIS STUDY
A limitation of our study is the lethality of the study material that made it impossible to
provide direct evidence for the cause of failure to make the wupA mutant strains.
CONCLUSION
As far as we know, this was the first trial to make E97X and K144W wupA strains by the
application of scarless CRISPR/Cas9-mediated genome editing, we did not succeed to get
any positive strains. Our approach to introduce nucleotide changes in combination with
knock-in of the 3xP3-DsRed selection marker in the critical 4-kb window of the haplolethal
region 16F may have failed either due to our experimental strategy, such as injection of
plasmids, usage of a low efficient guide RNA promoter and low CRISPR/Cas9 activity,
or by targeting a haplolethal region. We recommend to pay attention to select a more
successful CRISPR/Cas9 strategy to modify nucleotides of haplolethal genes, such as for
example transgenic flies or plasmids with a more potent guide RNA promoter. In addition,
selecting another CRISPR/Cas9 approach, such as for example a Co-CRISPR strategy,46,47
may not result in lethality due to the prevention of large selection marker cassette, but
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still allowing rapid screening for CRISPR/Cas9-induced events. In summary, we showed
that it is difficult to target wupA with our experimental CRISPR/Cas9 strategy and more
systematic research is required regarding genome editing of haplolethal genes.
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Hypertrophic cardiomyopathy (HCM) is the most frequent inherited cardiac disease. In
about one third of HCM patients the causative pathogenic gene variant is in MYH7, that
encodes β-myosin heavy chain (β-MHC). Previously, Drosophila melanogaster has been
demonstrated as a powerful tool to investigate Mhc function. Therefore, we aimed to
assess the potential of Drosophila melanogaster as a model organism for HCM-causing
MYH7 variants.
METHODS
We generated clustered, regularly interspaced short palindromic repeats
(CRISPR) / CRISPR-associated (cas)9-edited Drosophila melanogaster carrying either
the Mhc gene variant R402Q or S1376M. Both variants represent orthologues of the
clinically relevant human MYH7 variants R403Q and T1377M. We determined contractile
properties and the expression levels and phosphorylation of the sarcomeric proteins
in semi-intact heart tube preparations. In addition, lumen and heart muscle areas of
transversal cuts of the heart tube of female, homozygous transgenic flies were quantified
and immunofluorescence of Mhc was performed.
RESULTS
We confirmed the successful set-up of scarless CRISPR/Cas9-edited hetero- and homozygous
Mhc mutant flies. Our molecular analyses revealed no changes in expression of Mhc and
other sarcomeric (phospho-)proteins. Morphological abnormalities were also absent in Mhc
mutant strains illustrated by similar lumen and heart muscle areas, and Mhc localization
and spacing as observed in control flies. However, both Mhc mutant strains revealed
impaired contractility evident from reduced peak height, fractional shortening and time to
peak compared to wild-type flies.
CONCLUSION
Taken together, we observed no molecular or morphological abnormalities in female flies
homozygous for the Mhc variants R402Q and S1376M. Our data suggests that flies with Mhc
R402Q and S1376M variants had a functional phenotype which was not caused by molecular
biological and morphological abnormalities. Since our mutant Drosophila melanogaster
strains show early mutation-mediated impaired contractile function, this model system may
be used to study secondary disease mechanisms that underlie cardiac remodelling in HCM.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most frequent inherited cardiac disease with
a prevalence of 1:200 to 1:500.1 HCM entails hypertrophy, that is often asymmetrical, of
the left ventricle in the absence of other causes for hypertrophy, and histological features
of myocyte hypertrophy, myofibrillar disarray and interstitial fibrosis.2,3 Left ventricular
diastolic dysfunction has been reported as a hallmark of HCM that occurs in the majority of
patients.4,5 Dominant pathogenic variants in genes that encode sarcomeric proteins cause
inherited forms of HCM in 60% of all cases.6 Two distinct genes (MYH6 and MYH7)
encode for two myosin heavy chain (MHC) isoforms, the α- and β-form, with β-MHC
being the predominate in human ventricular myocardium.7 Mutation hotspots are found
at highly conserved residues of MYH7 gene, encoding β-MHC, and in rare cases patients
show a MYH6/MYH7 hybrid gene.7,8 About one third of the HCM cases are caused by
heterozygous mutations in MYH7.6 However, the genotype-phenotype relationship is not
straightforward, as the age of onset and clinical presentation are highly variable even in
people that carry the same mutation, spanning from asymptomatic gene variant carrier to
development of severe hypertrophy at young age.9,10 The first identified pathogenic variant
to cause HCM was Arg403Gln (R403Q) in MYH7.11 Until today, more than 400 different
variants in MYH7 have been identified to cause HCM.12 In a large cohort of unrelated
patients with HCM, MYH7 variant carriers were diagnosed at a younger age and had more
hypertrophy compared to HCM patients without MYH7 variants, but sudden death among
first-degree relatives had not a greater frequency.9 In addition, the Sarcomeric Human
Cardiomyopathy Registry (SHaRe) revealed that patients with mutations in MYH7 had a
higher risk of the overall composite outcome, atrial fibrillation and advanced heart failure
compared to patients with MYBPC3 mutations.13
Drosophila melanogaster is a well-studied genetic model organism for understanding
molecular mechanisms of human disease and investigating disease gene functions. The
Drosophila melanogaster proteome shows a 67% similarity and about 75% of human
disease loci can be mapped to counterparts in Drosophila melanogaster.14,15 In addition,
it is a relatively inexpensive model system, easy to maintain with a short life cycle and
causes minimal ethical and safety issues. Adult material becomes available 10 days post
fertilization when kept at 25°C.16 Previous studies revealed Drosophila melanogaster as
an efficient model for functional studies in cardiomyopathies.14,15 Likewise, Drosophila
melanogaster serves as a powerful tool to investigate Mhc function because there is a
single Mhc gene (CG17927), which encodes 20 unique Mhc isoforms via alternative RNA
splicing.17,18 The benefit of single gene rather than a multigene family is that there are no
isoforms produced by other muscle myosin genes which could complicate the analysis or
interfere with the results.
We aligned HCM-causing MYH7 variants listed in our human tissue biobank with
the Mhc sequence of Drosophila melanogaster to select two MYH7 variants, the R403Q
and Thr1377Met (T1377M). Our minimal requirement was that the orthologous amino acid
to modify in Drosophila melanogaster should at least belong to the same physiochemical
group. The MHC protein has two functional domains: the globular head region is mapped
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from the amino-terminus until exon 22 and the elongated rod region starts at exon 23.11
We studied the effect of the location of the gene variant by selecting one variant leading
to an amino acid change in the head (R403Q) and one in the tail (T1377M) region of the
protein. The selected R403Q variant has been associated with a shorter life expectancy.7
Between different species including Drosophila melanogaster, this amino acid residue is
highly conserved.11 In a large cohort study, gene variants at the amino acid 1377 of β-MHC
were identified as a mutational hot spot.9 This variant is listed as “likely pathogenic”
in ClinVar and in silicon prediction of pathogenicity suggests a deleterious effect on the
mutant protein.19
In our study, we used scarless clustered, regularly interspaced, short palindromic
repeats (CRISPR) / CRISPR-associated (Cas)9-mediated genome editing to specifically
generate two Drosophila melanogaster strains with the Mhc variants R402Q and S1376M,
which are the orthologues changes for the two human MYH7 variants R403Q and T1377M,
respectively. We chose the CRISPR/Cas9 approach because of the feasibility to co-inject
Cas9 with a donor vector carrying the eye-specific selection marker 3xP3-DsRed which
speeds up the screening process for mutant flies.20 As mentioned before, there is one
Mhc gene encoding multiple protein isoforms. Both gene variants are located in the
constitutive exons 8 and 16 (exception Mhc-RT: exons 7 and 15, respectively) and
therefore, will be present in all Mhc isoforms. To reflect the dominant transmission of
inherited cardiomyopathies,21 we aimed to engineer strains being heterozygous for the Mhc
variants. The aim of this study was to assess the potential of Drosophila melanogaster as
a model organism for HCM-causing Mhc variants.
METHODS
SEAMLESS CRISPR/CAS9-BASED GENOME EDITING WAS USED TO
INTRODUCE THE R402Q AND S1376M VARIANTS
Clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated
(Cas)9-mediated mutagenesis was performed by WellGenetics Inc. (Taipei City, Taiwan)
using modified methods of Kondo and Ueda,22 such as injected plasmids instead of using
transgenic CRISPR components. In brief, genomic DNA was obtained from injection strain
w1118. PCR was performed using KOD FX DNA polymerase (TOYOBO) on BioRad S1000
Thermal Cycler. Sequencing results were BLAT against Drosophila melanogaster genome
(August 2014 Assembly, BDGP Release 6) using UCSC Genome Bioinformatics and the
genomic codons option was selected for codon colouring.23,24 The respective guide RNA
(Table 11.1) was cloned into U6 promoter plasmid.
Table 11.1: Design of CRISPR target site, guide RNAs and homology arms.
R402Q S1376M









Cutting Site +5981 nt from ATG of Mhc +16356 nt from ATG of Mhc
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The donor plasmid containing a red fluorescent marker cassette with 3xP3 promoter driving
DsRed expression in the eyes which was flanked by piggyBac (PBac) transposon ends
and two homology arms with the gene variants was cloned into the pUC57-Kan vector
(Supplementary Material: R402Q and S1376M Donor Designs). Mhc-targeting guide
RNAs (100ng) and heat shock-inducible Cas9 (100ng) were supplied in DNA plasmids,
together with donor plasmid (500ng) for microinjection into embryos of control strain
w1118. The first round of microinjection was done on [LWG208] w1118, which was newly
obtained from Bloomington Stock Number 6326 (SNP mapping stock, isogenic 2nd and 3rd
chromosomes).25 Since this is the isogenic background for Exelixis P and PBac insertions,
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SNP variation for CRISPR editing would be reduced. However, it neither survived well nor
gave high number of fertile crosses and positive strains. All further microinjections of R402Q
and S1376M were therefore done on [LWG012] w1118 strain, obtained from Bloomington
Stock Center. Identification of engineered strains was performed via the 3xP3-DsRed marker
by screening for DsRed expression in the eye.20,26 F1 flies carrying the 3xP3-DsRed selection
marker were further validated by genomic PCR and sequencing. CRISPR generated a break
in Mhc and was replaced by cassette PBacDsRed. Either Sp or CyO balancer was used
for selection of heterozygous offspring. After molecular validation, the Mhc variants were
balanced by CyO.
ANALYSIS OF CRISPR INTEGRATION OF THE SELECTION MARKER FOR
R402Q AND S1376M VARIANTS
Genomic DNA was obtained from a single fly of each stock following single-fly DNA
preparation using Gloor’s protocol.27 Injection strain w1118 was used as a negative control and
both donor plasmids as positive controls for integration examination. PCR was performed
using KOD FX DNA polymerase (TOYOBO, KFX-101) on BioRad S1000 Thermal Cycler
(Table 11.2).,
Table 11.2: Steps and conditions of thermo cycling for Integration and Validation PCR.
Steps Temperature Time Cycles
Initial denaturation 94°C 2 min 1
Denaturation 98°C 10 sec
30Annealing 55°C 30 sec
Extension 68°C 2 min
Final extension 68°C 5 min 1
End/Hold 15°C Forever
CRISPR/homology-directed repair may go through different repairing routes. Integration
of donor plasmid in CRISPR editing alleles is a common phenomenon. “No integration”
contains only one copy of selection marker. “Single integration of donor plasmid” contains
the vector backbone, two copies of homology arms and selection marker. Integration test is
to exclude alleles with donor vector integration and only keep the strains with simple editing
to avoid the genomic complications.
For integration PCR 1, forward primer (R402Q: 5’-CAACTGTTGGGAAGGGCGAT;
S1376M: 5’-CAACTGTTGGGAAGGGCGAT) was designed outside the upstream homology
arm in the backbone plasmid and reverse primer (R402Q: 5’-CGAGGGTTCGAAATCGATAA;
S1376M: 5’-CGAGGGTTCGAAATCGATAA) was designed at 3xP3 promoter. For
integration PCR 2, forward primer (R402Q: 5’-TTTGACTCACGCGGTCGTTA; S1376M:
5’-TTTGACTCACGCGGTCGTTA) was designed at 3’ PBac terminal and reverse primer
(R402Q: 5’-CATTAGGCACCCCAGGCTTT; S1376M: 5’-CATTAGGCACCCCAGGCTTT)
was designed outside the downstream homology arm in the backbone plasmid. While single
integration of donor plasmid will have the amplicon, the corrected editing will not have the
amplicon. 1kb Plus DNA RTU Ladder from Biomate (BR343-500) was used as reference
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on a 1.2% (w/v) agarose gel and 0.5x TAE buffer.
CRISPR VALIDATION OF KNOCK-IN CASSETTE PBacDsRed FOR R402Q AND
S1376M VARIANTS
Genomic DNA was obtained from a single fly of each stock following single-fly DNA
preparation. Injection strain w1118 was used as a negative control. PCR was performed
using KOD FX DNA polymerase (TOYOBO, KFX-101) on BioRad S1000 Thermal
Cycler (Table 11.2). Using genomic PCR and sequencing methods to verify CRISPR
alleles of Mhc by testing if the knock-in cassette PBacDsRed was correctly used as
template for homology-directed repair and was incorporated into guide RNA1 cutting
site. For upstream PCR, forward primer (R402Q: 5’-ATGTAAGTGGTCGCCAAACC;
S1376M: 5’-TCTTCTTTCGAAGAGCTTTGGT) was designed at 5’ outside the
homology arm and reverse primer (R402Q: 5’-CGAGGGTTCGAAATCGATAA;
S1376M: 5’-CGAGGGTTCGAAATCGATAA) was designed at 3xP3 promoter. For
downstream PCR, forward primer (R 402Q: 5’-TTTGACTCACGCGGTCGTTA;
S1376M: 5’-TTTGACTCACGCGGTCGTTA) was designed at 3’ PBac terminal
repeat and reverse primer (R402Q: 5’-GAGCGATGGCGGATAATTT; S1376M:
5’-CCTTCTTGCCTCCCTTGAG) was designed at 3’ outside the downstream homology
arm. Only cassette PBacDsRed, which was inserted into the gene locus will have the
amplicon. 1kb Plus DNA RTU Ladder from Biomate (BR343-500) was used as reference
on a 1.2% (v/v) agarose gel and 0.5x TAE buffer.
EXCISION OF 3xP3-DsRed SELECTION MARKER
Following DsRed-mediated identification of engineered strains, the marker cassette
can be easily and scarlessly removed through a single cross to PBac transposase.20,28
Therefore, either w[1118]; Mhc R402Q CRISPR{PBacDsRed}/ CyO or w[1118]; Mhc
S1376M CRISPR{PBacDsRed}/ CyO were mated with Bloomington Stock Number
8285 w[1118]; CyO, P{Tub-PBac\T}2/wg[Sp-1]. To verify successful excision of
selection marker (3xP3-DsRed) in either w[1118]; Mhc R402Q CRISPR/ CyO or
w[1118]; Mhc S1376M CRISPR/ CyO, genomic DNA was obtained from single
fly of each stock following single-fly DNA prep. Injection strain w1118 was used
as a negative control. Forward primer (R402Q: 5’-ATACCAACAGCAAGCCTTCG;
S1376M: 5’-CAGGTGTCTCAGCTGTCCAA) was designed at upstream homology
arm and reverse primer (R402Q: 5’-TAGCAGGTCGACTGGTGATG; S1376M:
5’-GAGCGGGCAACGCCATCCAT) was designed at downstream homology arm. PCR
was performed using KOD FX DNA polymerase (TOYOBO, KFX-101) on BioRad S1000
Thermal Cycler. 1kb Plus DNA RTU Ladder from Biomate (BR343-500) was used as
reference on a 1.2% (w/v) agarose gel and 0.5x TAE buffer. Using the w[1118]; Mhc
R402Q CRISPR/ CyO strain, the PCR product with expected size band (R402Q: 575bp)
were excised and submitted to Mission Biotech for gel extraction and sequencing. Using
the w[1118]; Mhc S1376M CRISPR/ CyO strain, the PCR product of the genomic
PCR with the forward primer (5’-CAGGTGTCTCAGCTGTCCAA) and reverse primer
(5’-GGAACAGCTCGGTGGAGTAG) was sequenced.
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FLY STRAINS AND CULTURE
We used the following transgenic strains: w[1118]; Mhc R402Q CRISPR/ CyO, w[1118];
Mhc R402Q CRISPR/ Mhc R402Q CRISPR, w[1118]; Mhc S1376M CRISPR/ CyO and
w[1118]; Mhc S1376M CRISPR/ Mhc S1376M CRISPR. [LWG012] w1118 injection strain was
used as a wild-type control. Flies were maintained on a 2.6% (w/v) yeast, 1.7% (w/v) agar,
5.4% (w/v) sugar and 0.13% (w/v) nipagin medium in a humidified, temperature-controlled
incubator at 25°C without a defined light-dark cycle.
PRO-Q DIAMOND AND SYPRO RUBY STAINING
Adult flies were anesthetized 21 days after birth with Fly Nap (Carolina Biological).
Semi-intact heart tube preparations were made following Ocorr’s protocol.29 In brief,
after an initial cut to remove the head, ventral nerve cord and legs, the preparation was
submerged in an oxygenated, artificial hemolymph solution (108 mM NaCl, 8 mM MgCl2,
5 mM KCl, 2 mM CaCl2 dehydrate, 1 mM NaH2PO4, 5 mM HEPES, 4 mM NaHCO3, 10 mM
sucrose, 5 mM trehalose, pH 7.1). The posterior tip of the abdomen was cut off and the
ventral abdominal cuticle including the abdominal organs was removed. The semi-intact
heart tube preparations were collected in a microcentrifuge tube and homogenized
in 10 µL/mg tissue 1× reducing sample buffer (106 mM Tris-HCl, 141 mM Tris-base,
2% (w/v) lithium dodecyl sulphate, 10% (v/v) glycerol, 0.51 mM ethylenediaminetetraacetic
acid, 0.22 mM SERVA Blue G250, 0.18 mM Phenol Red, and 100 mM dithiothreitol) using
a plastic tissue grinder. Proteins were denatured by heating to 99°C for 5 min. Debris
was removed by centrifugation at maximum speed for 10 min in a microcentrifuge (Sigma,
1-15k).
Following the protocol of Zaremba,30 10 µg of protein lysates were separated on pre-cast
SDS-PAGE 4-12% criterion gels. Gels were fixed in fixation solution (50% (v/v) methanol,
10% (v/v) acetic acid) for 1 h and according to the manufacturer’s protocols stained for
Pro-Q Diamond and SYPRO Ruby (both Life technologies). A Peppermint Stick molecular
weight marker (Life technologies) and a precision Plus Protein Dual Colour Standards
(Bio-Rad) were used for molecular weight estimation.
MYOSIN HEAVY CHAIN COMPOSITION
A specialized sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was
used to determine the myosin heavy chain isoform composition of semi-intact heart tube
preparations. Female flies, age two weeks, were anesthetized with Fly Nap (Carolina
Biological). Anesthetized flies were prepared so that of the abdomen only the dorsal cuticle
with the heart tube surrounded by fat bodies was left. While dissecting, the preparation
was submerged in F60 buffer (60 mM KCl, 30 mM Imidazole and 2 mM MgCl2, pH 7.4)
containing protease and phosphatase inhibitors. 5 semi-intact heart tube preparations were
collected in a microcentrifuge tube, 100 µL F60 buffer including 1% (v/v) triton X-100 was
added and the tissue was homogenized using a plastic tissue grinder. Supernatant was
discarded after centrifugation at maximum speed for 10 min in a microcentrifuge (Sigma,
1-15k). Pellet was resuspended in 100 µL SDS sample buffer, boiled for 5 min at 95°C
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and centrifuged at maximum speed for 10 min to remove cell debris. The stacking gel
contained a 4% (w/v) acrylamide concentration (pH 6.7), and the separating gel contained
7% (w/v) acrylamide (pH 8.7) with 30% (v/v) glycerol. The gels were run for 24 h at 15°C
and a constant voltage of 275 V. Thereafter, the gels were silver-stained, scanned, and
analysed with ImageQuant TL (GE Healthcare) software.
HISTOLOGICAL ANALYSIS OF HEART MUSCLE AND LUMEN AREAS
Adult female flies were collected 21 days after birth and fixed in Telly’s fixative
(60% (v/v) ethanol, 3.33% (v/v) formalin, 4% (v/v) glacial acetic acid) overnight at 4°C.
According to the protocol of Xu,31 the samples were embedded in paraffin after ethanol
dehydration through sequential gradients and xylene washes. Paraffin blocks were sectioned
serially at 4 µm thickness in transverse orientation. Sections were rehydrated, stained
with hematoxylin and eosin, and imaged using Microscope Zeiss FLM imager M.1 63x
oil objective. The heart wall thickness was measured by QuPath software.
WHOLE MOUNT IMMUNOSTAINING AND MICROSCOPY
Semi-intact heart tube preparations of female flies were prepared 14 days after birth as
described in the section Pro-Q Diamond and SYPRO Ruby staining for whole mount
staining and arrested using 10 mM EGTA in artificial hemolymph for 10 min. The relaxed,
semi-intact heart tubes were fixed in 4% (w/v) paraformaldehyde and bleached 2x 15 min in
1x TBS (20 mM Tris, 150 mM NaCl) including 3% (v/v) H2O2. Samples were permeablized
in 1x phosphate buffered saline (PBS, 154 mM NaCl, 2.4 mM KH2PO4, 7.7 mM Na2HPO4,
pH 7.4) containing 0.1% (v/v) Triton X-100 for 30 min, blocked in 1x PBS containing
1% (w/v) BSA and 10% (v/v) donkey serum for 30 min and then incubated overnight at
4°C with primary antibodies: mouse anti-Mhc (1:250; DSHB Hybridoma Product 3E8-3D3
deposited to DSHB by Saide, J.D.) and rabbit anti-α-tubulin (1:100; abcam ab52866).
Secondary antibody incubation was performed at room temperature for 1h: Alexa Fluor 555-
and Alexa Fluor 647-conjugated secondary antibodies (1:250; Invitrogen), DAPI (1:1.000;
Sigma-Aldrich) and Alexa Fluor 488 Phalloidin (1:100; Thermo Fisher Scientific). The
samples were then placed in slides and mounted with mowiol 4-88. The images were taken
with a 60x 1.4 NA oil-objective on the Nikon A1R confocal microscope (Nikon) and analysed
with ImageJ software (National Institute of Health).
MEASUREMENT OF CARDIAC PARAMETERS
Semi-intact heart tube preparations of female flies were prepared at 14 days after birth as
described in the section Pro-Q Diamond and Sypro Ruby staining and artificial hemolymph
was refreshed. The dish, containing on average 9 fly preparations, was placed in a
high-throughput inverted microscope (Olympus 20x 0.75 aperture objective lens, Olympus,
Shinjuku, Japan) set-up (CytoCypher, Amsterdam, the Netherlands) and the heart tubes
were visualized. We used the camera-based MultiCell microscope system (CytoCypher,
Amsterdam, the Netherlands) and Ionoptix LLC software (Westwood, Massachusetts) to
measure functional cardiac parameters at 25°C. Temporal data were determined by pixel
correlation (Sampling Units: Frequency (Hz)) and spatial data by SoftEdge as an acquisition
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task and the Box mode (Sampling Units: Period (s)). Videos were recorded for 10 sec. The
software CytoSolver (CytoCypher) was used to analyse the transients.
STATISTICAL ANALYSIS
Data were analysed with GraphPad Prism version 8.0 and data in the figures are presented
as means ± standard errors of the mean (SEM) per group. The distribution of each data set
was determined by Q-Q plots and then double checked by Kolmogorov-Smirnov and Shapiro
Wilk tests after data collection was completed. Normally distributed data were analysed
with ordinary one-way ANOVA and non-parametric data with Kruskal-Wallis test. In both
cases, Dunnett’s multiple comparisons was used as a post-hoc test. A two-sided p<0.05 was
considered to indicate statistical significance. Figures were assembled with Adobe Illustrator
CS6.
RESULTS
DESIGN OF GUIDE RNAs AND VALIDATION OF HOMOLOGY ARMS OF
DONOR PLASMIDS
For the design of the guide RNAs the following four criteria were taken into account: distance
from knock-in site to cutting site of Cas9, predicted off targets on other chromosomes, GC
content of target sequence and thymine numbers at 17th to 20th nucleotide of the guide
RNA target site. We considered the quality of the designed guide RNAs as strong because
the distance was shorter than 50 base pairs (bp), no prediction of off-targets on other
chromosomes, 45%-70% GC content of the target sequence and 0 or 1 thymine (Table 11.1).
To verify that all guide RNA loci for the Mhc R402Q and S1376M variants were as
indicated, we performed genomic sequencing of the injection strain. Guide RNAs and the
3 independent reads of the injection strain were free of any SNPs. Per variant, the target
sequence of the guide RNA was present in the genome of the injection strain (Figure 11.1
and Supplementary Material). With this information, guide RNAs and donor plasmids were
prepared.
Both upstream and downstream homology arms in both donor plasmids were sequenced
to confirm the specificity to Mhc/CG17927. BLAT results of the homology arms revealed
two mismatches for the R402Q variant and four mismatches for the S1376M variant in the
coding sequence of Mhc/CG17927 (Figure 11.2 and Supplementary Material).
Five of the six mismatches did not lead to amino acid changes and were considered
synonymous SNPs. One mismatch caused an amino acid change which was also observed
in the injection strain, suggesting this mismatch is a missense mutation.
VALIDATION OF POSITIVE STRAINS AFTER MICROINJECTION OF R402Q
AND S1376M DONOR PLASMIDS
We performed two rounds of microinjection in more than 400 embryos per gene variant.
Microinjection of the injection strain [LWG208] w1118 was not successful as indicated by
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Figure 11.1: BLAT results show alignment of the guide RNAs and independent reads of the
injection strain with the Mhc transcripts. The target sequence of both guide RNAs (Table 11.1)
for the (A) R402Q and the (B) S1376M variant were present in three independent reads (A)
(w1118_1, w1118_2, w1118_3) and (B) (w1118_4, w1118_5, w1118_6) of the injection strain.
The independent read sequences of the injection strain are available in the Supplementary Material.
The 21 Mhc transcripts were indicated below with codon boundaries depicted by alternating lighter
and darker blue shades. Continuous black bars of the target sequence of guide RNAs and the
independent reads of the injection strains indicate completely matched sequence overlap with the
Mhc transcripts.
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Figure 11.2: BLAT results of the homology arms.
Both upstream and downstream homology arms in the (A) R402Q and (B) S1376M donor
plasmids were sequenced ((A) 1_R402Q_homology_arm – 3_R402Q_homology_arm; (B)
1_S1376M_homology_arm – 4_S1376M_homology_arm). The sequence reads were aligned to
the 21 Mhc transcripts (indicated in blue below), the donor plasmid designs and the injection strain
reads (w1118_1 to w1118_6). We found in (A) two mismatches and in (B) four mismatches in
the coding sequence of Mhc/CG17927. Mismatches (boxed in green) that do not lead to amino
acid changes were considered synonymous SNPs. The mismatch (boxed in orange) that leads to
amino acid change was also found in the injection strain (w1118_1 to w1118_3). The disconnected
grey/red mismatches regions (boxed in purple) are aligned to similar coding exons of Mhc. Red
boxes indicate designed point mutations. Differences in nucleotides are highlighted in the black
bars as follows: red – genome and query sequence have different bases at this position; orange –
the query sequence has an insertion (or genome has a deletion/alignment gap) at this point; purple
– the query sequence extends beyond the end of the alignment. Double horizontal lines are drawn
to indicate when the alignment has gaps in both the genome and query sequence.
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8 adults, 3 fertile crosses and no selection marker positive strains (3xP3-DsRed+) for
the Mhc R402Q variant and by 3 adults, 1 fertile cross and 1 3xP3-DsRed+ strain for
the Mhc S1376M variant. We improved efficiency by performing microinjection in the
[LWG012] w1118 strain. In total, 219 embryos were microinjected with the Mhc R402Q
variant which resulted into 122 adults, 37 fertile crosses and 7 3xP3-DsRed+ strains.
Microinjection of 200 embryos with Mhc S1376M variant led to 68 adults, 40 fertile crosses
and 4 3xP3-DsRed+ strains.
The 3xP3-DsRed+ strains with either the Mhc R402Q or S1376M variant were
further screened to exclude strains with vector backbone integration, which is a common
phenomenon in CRISPR edited alleles. Moreover, we checked integration of selection marker
at the correct guide RNA cutting sites to avoid genomic complications and off-target strains.
Both donor plasmids were used as a positive control for vector backbone integration
and we observed the PCR bands at expected sizes for integration PCR 1 (R402Q: 1506bp;
S1376M: 1508bp) and integration PCR 2 (R402Q: 1317bp: S1376M: 1451bp) (Figures 11.3
and S1). As expected, no bands were observed from negative control sample w1118. Positive
and negative control samples indicated that the primer pairs for integration tests were
highly specific. In addition, we detected no PCR products from 3xP3-DsRed+ strains
heterozygous for Mhc R402Q and S1376M variants, suggesting that no vector backbone
integration has occurred at Mhc/CG17927 gene locus.
Moreover, we investigated if the knock-in cassette PBacDsRed was correctly used as
a template for homology-directed repair and as a consequence, has been incorporated
into guide RNA cutting site. We observed no bands from negative control sample w1118,
indicating high specificity of the PCR reactions (Figures 11.4 and S2). PCR products at
expected sizes for upstream PCR (R402Q: 1601bp; S1376M: 1583bp) and downstream
PCR (R402Q: 1433bp; S1376M: 1606bp) were detected in samples from 3xP3-DsRed+
strains heterozygous for Mhc R402Q and S1376M variants, indicating PBacDsRed cassette
insertion into Mhc/CG17927 gene locus at correct orientation.
EXCISION OF SELECTION MARKER (3xP3-DsRed)
We used genomic PCR and sequencing to verify PiggyBac transposition alleles of
w[1118]; Mhc R402Q CRISPR [PBacDsRed]/ CyO and w[1118]; Mhc S1376M CRISPR
[PBacDsRed]/ CyO strains by testing if the selection marker (3xP3-DsRed) was precisely
excised and left one TTAA sequence embedded in the coding region of Mhc/CG17927. We
observed PCR bands at expected sizes for excised strains with Mhc R402Q (575bp) and
S1376M (261bp) mutation suggesting the excision of the selection marker (Figures 11.5
and S3). In our control samples, including injection strain w1118 and unexcised strains with
the selection marker, we detected the expected bands which indicated that the primer pairs
for excision PCR were highly specific. Sequencing of the excision PCR products per strain
confirmed the excision of the selection marker (3xP3-DsRed) and revealed the designed
point mutation in both mutant strains as well as one exogenous TTAA motif embedded in
the coding region of Mhc.
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Figure 11.3: No donor plasmid integration in 3xP3-DsRed+ strains.
(A) Schematic of primer design (integration PCR 1 (Int PCR 1) and integration PCR 2 (Int PCR
2)) for Mhc R402 variant to check for integration of vector backbone in 3xP3-DsRed-positive
strain. Correct editing will have no amplicon (scenario 1) and single integration of donor plasmid
will have the amplicon (scenario 2). Donor plasmid of (B) Mhc R402Q and (C) S1376M variants
were used as a positive control and w1118 as a negative control. The 3xP3-DsRed-positive strains
(3xP3-DsRed+) showed single integration of vector backbone. Primer sequences for both Int PCR
are provided in the Materials and Methods section. In both gels, (B) and (C), lanes were run on
the same gel but were non-contiguous. Full-length gels are presented in Figure S1.
MOLECULAR BIOLOGICAL CHARACTERIZATION
We used semi-intact heart tube preparations to check the expression levels and
phosphorylation levels of a variety of sarcomeric proteins. In our analysis, we included the
following strains: w1118, heterozygous and homozygous for Mhc R402Q (R402Q+/- and




Figure 11.4: Correct incorporation of knock-in cassette 3xP3-DsRed into guide RNA cutting
site. Schematic of the primer designs to check for incorporation of knock-in cassette 3xP3-DsRed
into guide RNA cutting site to introduce (A) R402Q or (B) S1376M variant and the respective
PCR products. No obvious bands were detected in upstream PCR (Up PCR) and downstream PCR
(Down PCR) for negative control sample w1118. The 3xP3-DsRed-positive strain (3xP3-DsRed+)
showed an amplicon in Up/Down PCR. Primer sequences for Up/Down PCR are provided in the
Materials and Methods section. In both cases, (A) and (B), lanes were run on the same gel but
were non-contiguous. Full-length gels are presented in Figure S2.
Figure 11.5: Successful excision of selection marker (3xP3-DsRed) in Mhc R402Q (A-C) and
S1376M (D-F) strains. PCR band at expected size of (A) 575bp or (D) 261bp was observed from
heterozygous sample (excised) of (A) w[1118]; Mhc R402Q CRISPR/ CyO or (D) w[1118]; Mhc
S1376M CRISPR/ CyO strains for excision PCR. (A) A 575bp product or (D) no PCR product was
observed in negative control sample w1118. (A) A 575bp and a 2271bp band or (D) a 1956bp band
were detected in heterozygous un-excised line (3xP3-DsRed+). (B, E) Sequence read (Sbjct) was
aligned with exercised donor sequence (Query) using Blast 2. (C, F) Sequencing chromatogram
showing introduced gene variant and TTAA motif. One exogenous TTAA motif (boxed in purple)
was left and embedded in the coding exon of Mhc after excision. Designed point mutation (C)
R402Q or (F) S1376M of Mhc was boxed in orange. unrel. sample = sample unrelated to this
study. In both cases, (A) and (D), lanes were run on the same gel, but were non-contiguous.
Full-length gels are presented in Figure S3.
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We separated female from male flies. Compared to w1118, we neither observed a difference
in expression levels of Mhc, actin and Troponin I (TnI) nor in phosphorylation levels of Mhc,
Troponin T (TnT) and TnI (Figure 11.6). In all Mhc mutant strains, we observed a signal
around 80 kDa on the ProQ-stained gels, which suggests an additional phosphorylated
protein in the mutant compared to control strains. Further investigation is warranted to
align this signal to the respective protein.
To further investigate the Mhc expression in our Mhc mutant Drosophila melanogaster
strains, we performed a SDS-PAGE analysis to separate Mhc isoforms of semi-intact heart
tube preparations (Figure 11.7). We limited our selection to the extreme genotypes Mhc
R402Q+/+ and S1376M+/+ and female flies due to the bigger body size. We limited
our selection to the extreme genotypes Mhc R402Q+/+ and S1376M+/+ and female flies
due to the bigger body size. All following experiments were therefore only performed in
females. Using Drosophila melanogaster homogenates we detected a strong signal close
to the band height of the skeletal slow MHC/cardiac β-MHC isoform. Quantification of
this overall Mhc signal revealed no differences between the various genotypes. In some
homogenates, the signal consisted of two bands, including a stronger upper band and a
weaker lower band, which was closer to the skeletal slow MHC/cardiac β-MHC isoform.
The composition of the Drosophila melanogaster Mhc signal is displayed in Figure 11.7C.
From the 9 pooled fly samples used in this analysis, 100% of the upper band was
observed in 5 samples. In the pooled samples with both bands, the amount of the upper
band was reduced up to 74%. We did not observe an obvious pattern between the genotype
and the occurrence of two Mhc bands.
MORPHOLOGICAL CHARACTERIZATION
To examine the cardiac structure in more detail, hematoxylin and eosin staining was
performed in transverse sections at three different selected regions of the heart tube on
3 week old female flies (Figure 11.8).
We observed that the Drosophila melanogaster heart is characterized by two single rows
of contractile cells that form an inner lumen (myocardium), with opposite directionality
(from lateral to medial, in the dorsal layer, and longitudinal in the ventral layer), and
non-muscular pericardial cells aligned along the myocardium.15 The first selected transverse
cut was immediately posterior the conical chamber, the second one was located at half
length of the heart tube when the first alary muscle bundle appeared and the last cut was
close to the posterior end of the heart tube. Since hypertrophy of the heart wall would
either increase the heart muscle area or decrease the lumen of heart tube,32 we determined
the lumen and heart muscle areas. We observed that both areas were similar in the mutant
strains to w1118 at the different anatomical regions of the heart tube. We demonstrated
that the heart tube sections closer to the conical chamber are characterized by a bigger
heart muscle area independent of the analysed strains.
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Figure 11.6: No changes in expression of (phospho-)proteins in semi-intact heart tube
preparations. (A) Representative gel stained with Pro-Q Diamond and SYPRO Ruby. Arrows
on the side indicate quantified sarcomere proteins. Arrow head at 80 kDa indicates additional
phospho-band in mutants. Quantification of (B) phospho-Mhc, (C) phospho-TnT, (D)
phospho-TnI, (E) Mhc, (F) actin (used as protein reference band) and (G) TnI. Purple color =
female sample; blue colour = male sample. Each value per graph was normalized to the mean
value of female w1118.
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cardiac β-MHC isoform. (A) SDS-PAGE of semi-intact heart tube preparations in comparison to
a human muscle homogenate expressing fast (2A and 2X) and slow/cardiac β-MHC isoforms. Ref:
reference band used for normalization. (B) Quantification of the overall Mhc signal at the height
of the slow/β-MHC isoform. (C) Quantification of the composition of the signal in (B) with a
predominant upper band in all samples and a weaker lower band in some samples.
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Figure 11.8: Lumen and heart muscle areas comparable to w1118.
(A) Schematic illustration of the three selected transverse slides of the heart tube and the analysis
mask. (B) Representative images with arrow pointing to the heart tubes (Scale bar = 20 µm).
Quantified analysis of the (C) lumen and (D) heart muscle areas. Number of symbols per bar




To investigate the effect of mutant Mhc on sarcomeric organization, we stained semi-intact
heart tube preparations for Mhc, Phalloidin and α-tubulin. Again, we limited our selection
to the extreme genotypes Mhc R402Q+/+ and S1376M+/+ and female flies due to the
bigger body size. Although the sarcomeric structure and components of Drosophila
melanogaster cardiomyocytes is similar to mammalian cardiac cells,33 morphological
differences can be observed. As mentioned before, two different cell layers can be observed.
The heart tube is formed by contractile cells oriented from lateral to medial, and the ventral
cell layer covering the heart tube is described as hybrid, non-myocardial muscle cells.15 Our
immunofluorescence staining revealed similar localization of mutant Mhc in the sarcomeres
compared to controls, and regular arrangement of myofibrils along all z-stacks of the heart
tube. We selected representative images for the ventral longitudinal muscle based on the
straight appearance of myofibrils and determined the distance between consecutive Mhc
bands (Figure 11.9).
Since a difference between the conical chamber, similar to the dorsal cells of the heart tube,
and the remaining heart tube was clearly visible, we performed this analysis at two regions:
at the half length of the heart tube and at the conical chamber near the aorta ring. In the
latter region the cardiomyocytes can be representative from both areas (conical chamber
and dorsal region). We observed in the ventral longitudinal muscle layer that consecutive
Mhc bands were spaced closer to each other in the conical chamber than in the half length
of the heart tube. The various genotypes did not show a difference in spacing of Mhc bands.
FUNCTIONAL CHARACTERIZATION
Female flies of 14 days of age with the extreme genotypes Mhc R402Q+/+ and S1376M+/+
were used for semi-intact heart tube preparations to determine heart function compared to
age-matched controls (Figure 11.10). At baseline, there was no difference in distance of the
two heart walls compared to w1118. Both Mhc mutant strains showed functional impairments
including reduced peak height (R402Q: 80%; S1376M: 91%) and fractional shortening
(R402Q: 79%; S1376M: 90%) and shorter time to peak 50% (R402Q: 78%; S1376M:
76%), peak 90% (R402Q: 86%; S1376M: 86%) and return 50% (R402Q: 86%; S1376M:
87%). Time to return 90% was comparable to w1118. While the contraction strength was
more impaired in strains carrying the Mhc R402Q variant, time to peak parameters were
similarly affected by both Mhc variants.
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Figure 11.9: Normal Mhc localization and spacing in Mhc mutant strains.
(A) Schematic illustration of the two selected areas of the heart tube. (B) Representative images
(merge and Mhc staining; Scale bar = 20 µm) for the ventral longitudinal muscle layer at the conical
chamber near the aorta ring (left side) and at the half length of the heart tube (right side). (C)
Quantification of the distance of consecutive Mhc bands in both regions. Number of symbols per
bar indicate the number of measured distances. (D) Representative two-dimensional graphs of the
pixel intensities (Gray Value) along a distance of 30 µm in a selected area of the conical chamber.
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Figure 11.10: Functional impairment of Mhc mutant strains.
Quantified analysis of (A) the distance between the two heart walls during diastole, (B) peak
height, (C) fractional shortening, (D) time to peak 50%, (E) time to peak 90%, (F) time to return
50% and (G) time to return 90%. Number of symbols per bar indicate the number of measured
Drosophilae melanogaster. * denotes p<0.05, **p<0.01 and ***p<0.001 compared to w1118 and
## denotes p<0.01 compared to S1376M mutation.
CHARACTERIZATION OF DROSOPHILA STRAINS WITH MHC VARIANTS 263
DISCUSSION
In the current study, we used scarless CRISPR/Cas9-mediated genome editing to specifically
generate two Drosophila melanogaster strains with the orthologous HCM-causing Mhc
variants R402Q and S1376M. Via PCR, we ensured that only strains without vector
backbone integration and with correct orientation of the insertion were used for further
analyses (Figure 11.4). We succeeded with our CRISPR/Cas9 approach to set up
heterozygous strains for both variants and confirmed the excision of the selection marker
3xP3-DsRed by PCR and sequencing (Figure 11.5).
Maintaining the strains w[1118]; Mhc R402Q CRISPR/ CyO and w[1118]; Mhc S1376M
CRISPR/ CyO revealed viable homozygous offspring (w[1118]; Mhc R402Q CRISPR/ Mhc
R402Q CRISPR and w[1118]; Mhc S1376M CRISPR/ Mhc S1376M CRISPR, respectively).
This provided us the opportunity to study the effect of 100% mutant protein in comparison
to a mixture of wild-type and mutant protein in a single Mhc gene setting. In contrast to
our Drosophila melanogaster model, which can live up to 50 days, Myh6 R403Q+/+ mice
are viable for only 7 days after birth.37 We performed molecular and histological analysis to
investigate if these Mhc variants cause cardiac remodelling as observed in HCM, but did
not observe any sign of structural abnormalities in the mutant lines compared to w1118.
NO MOLECULAR ABNORMALITIES
We defined the levels of different sarcomeric proteins, especially the levels of Mhc, since
myofilament protein stoichiometry can be altered in cardiac disease.34 Moreover, reduced
phosphorylation of cardiac TnI has been reported in HCM patients.35 Therefore, we
performed a Pro-Q Diamond and SYPRO Ruby staining to systematically assess the
(phospho-)protein levels in semi-intact heart tube preparations including both sexes and all
five different strains (Figure 11.6). Our Pro-Q Diamond staining revealed a strong signal
for phospho-Mhc which was comparable between the different groups. This finding is in
contrast to human and porcine cardiac samples which do not show any phosphorylation of
MHC.34,36 In comparison to w1118, we observed similar expression of Mhc in the various
Mhc mutant strains. This is in line with a Myh6 R403Q+/+ mouse model revealing no
changes in expression levels of Mhc.37 Therefore, our findings indicate that both variants
do not affect overall Mhc expression, and in other assays phenotypical differences based
on changes in protein expression can be excluded. Previously, it has been shown that
TnT is readily phosphorylated,38 and here we provided proof that TnT is endogenously
phosphorylated in semi-intact heart of Drosophila melanogaster with similar levels in the
different genotypes. In contrast to HCM patients,35 we did not observe a reduction in
phospho-TnI levels.
In addition, we analysed the Mhc expression in semi-intact heart tube preparations
of female flies of the strains w1118, Mhc R402Q+/+ and S1376M+/+ on a SDS-PAGE gel
(Figure 11.7). This is a standard technique to investigate the various MHC isoforms in
human cardiac and skeletal muscle.39 We observed a Mhc signal slightly above the skeletal
slow/cardiac β-MHC band. In line with the SYPRO Ruby staining, Mhc expression in the
strains Mhc R402Q+/+ and S1376M+/+ was comparable to w1118. In some lanes, the
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Mhc signal consisted of two bands due to the occurrence of an additional lower band with
a weaker signal which may suggest a mixture of various Mhc isoforms dependent on the
preparations. Our semi-intact heart tube preparations contain various muscles, including
the heart tube. Information about which Mhc isoforms are expressed in semi-intact
heart tube preparations is lacking since there is no entry for the heart in the FlyAtlas2
database which provides data about transcripts expression in various tissues.40 Spatially
and temporally regulated expression of Mhc alternative exons has been studied during
Drosophila melanogaster embryogenesis and revealed the expression of a single transcript
containing the exon combination 3a-7a-9b-11d-15b in cardioblasts at late stage 15.41
Similar to the human situation in which cardiac β-MHC isoform is expressed in both
cardiac muscle and some skeletal muscles, this Mhc exon combination was also detected in
dorsal acute and ventral oblique body wall muscles.41 Unlike vertebrates, isoform changes
within a particular muscle have not been documented during Drosophila melanogaster
development.18 Further research is warranted to investigate which Mhc isoforms are present
in semi-intact heart tube preparations. This may help to understand why we observed
different Mhc isoform compositions in some preparations.
NO MORPHOLOGICAL ABNORMALITIES
Transverse sections at three different regions of the heart tube were analysed and revealed
no changes in the lumen and heart muscle areas in Mhc mutant strains compared to w1118
(Figure 11.8). This indicates that cardiac morphology is not affected by the presence of
homozygous Mhc variants. One limitation of this study is that we only included 3-week
old flies for this analysis meaning that we cannot exclude that hypertrophy might have
occurred at an older age of Mhc mutant strains. In contrast to that, we know from a
large unrelated cohort study that HCM patients harbouring MYH7 variants are diagnosed
at a younger age, have more hypertrophy and a higher risk for adverse cardiac outcomes
than HCM patients without a MYH7 variant.9,13 Especially the MYH7 variant R403Q is
considered as pathogenic leading to a “malignant” course. Our data indicates that this
pathogenicity and malignant disease course is not conserved in Drosophila melanogaster,
even though the amino acid residue R402 and neighbouring residues are highly conserved.11
Staining semi-intact heart tube whole mounts of female flies of the strains w1118,
Mhc R402Q+/+ and S1376M+/+ showed a normal Mhc incorporation and localization,
and myofibrils were arranged regularly (Figure 11.9). In line with previous findings,
pericardial cells were Mhc-negative.41 Moreover, we quantified the spacing of consecutive
Mhc bands at two regions of the ventral longitudinal muscle layer and did not observe
any difference in spacing of Mhc bands between the different genotypes. In contrast to
our findings, morphological abnormalities, such as myofibril disarray and hypertrophy,
have been reported for various model systems including in MYH7 R403Q+/- 3D human
iPSC-derived cardiac microtissue and Myh6 R403Q+/+ mice.37,42 Myofibril disarray has
also been reported in heterozygous transgenic flies expressing the Drosophila melanogaster
equivalent of the human HCM-causing MYH7 K146N variant which developed a
phenotype including hypercontractility, increased tension generation periods and decreased
diastolic/systolic.43 The analysed flies were 1- and 3-week-old. There are no detailed
reports about the morphological changes of HCM patients with MYH7 R403Q and T1377M.
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Overall, our data show no changes in myosin expression, sarcomere alignment or
cardiomyocyte size in flies harbouring a homozygous R402Q and S1376M Mhc mutation
at 14 and 21 days of age.
IMPARIED CONTRACTILITY
In line with our morphological analyses, our functional characterisation revealed that at
baseline all strains showed a comparable distance between the two heart walls. The reduced
peak height, fractional shortening and the shorter time to peak, observed in the Mhc mutant
strains, indicates impaired contraction. Since we detected that time to return 50% was
shorter in the mutant strains, but normalized when time to return 90% was reached, this
may suggests different relaxation kinetics in mutant flies. Further research is necessary
to understand the functional impairments and disease progression in Mhc mutant flies.
Consistent with the pathogenicity of the R403Q variant in humans,7 contraction strength,
including peak height and fractional shortening, was more severely impaired in mutants
carrying the R402Q variant.
CONCLUSION
In summary, our analyses revealed that heterozygous and homozygous strains with the
R402Q and S1376M Mhc gene variants, do not alter expression level or incorporation of Mhc,
and no morphological abnormality such as hypertrophy is induced. Homozygous R402Q
and S1376M strains did show functional abnormalities, indicative for mutation-mediated
effects independent of structural remodelling. In conclusion, our Drosophila melanogaster
strains with R402Q and S1376M show early mutation-mediated impaired cardiac contractile
function, and may be used as model system to study secondary disease mechanisms that
underlie cardiac remodelling in HCM.
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According to the working group on Myocardial and Pericardial Diseases of the European
Society of Cardiology, cardiomyopathies (CMs) are defined by abnormal myocardial structure
and function in the absence of any other diseases sufficient to cause these abnormalities.1
The two most common types are hypertrophic CM (HCM), characterized by increased left
ventricular (LV) wall thickness often occurring asymmetrically and diastolic dysfunction,
and dilated CM (DCM) with the hallmarks of LV dilation and systolic dysfunction.1 Familial
forms are characterized by an autosomal dominant inheritance pattern and many pathogenic
gene variants (mutations) are localized in genes encoding sarcomeric proteins.2 Both HCM
and DCM can develop into advanced heart failure which poses a considerable mortality risk.3
Until today, there are no effective medical options to halt or reverse disease progression, and
cardiac transplantation represents the best effective long-term treatment for all end-stage
heart failure patients.4 The heterogeneous clinical presentation of patients with inherited
CMs further complicates clinical approaches and validation of new treatment strategies. In
chapter 2, we provide a comprehensive clinical evaluation of two large families carrying
gene variants in TPM1. Our data illustrate this clinical heterogeneity, which includes
differences in age-dependent penetrance and disease severity between individuals with
the identical genetic variant. Consequently, this striking heterogeneity and the highly
variable age of onset imply that the pathophysiology of inherited CMs is more complex
than the functional defects triggered by the gene variant. Therefore, it is of utmost
importance to adequately identify additional disease triggers and understand the underlying
pathomechanisms.
By combining cellular, genetic and clinical data from well-phenotyped patient cohorts and
different disease models for CMs, we investigated potential disease triggers. In this thesis,
we focused on assessing the status of the protein quality control (PQC) system and the
microtubule network. Both systems are highly dynamic,5,6 and proper functionality of
the PQC system is dependent on the microtubule network and vice versa.7 Especially,
inter-individual differences in the capacity of the PQC8 and the coincident derailed
adaptations to stress triggers may contribute to the striking heterogeneity in clinical
presentation.
Chapter 1 introduced the national research consortium CVON-DOSIS on cardiomyopathies
that aimed to identify determinants of susceptibility in inherited cardiomyopathy and
received funding by the Netherlands Heart Foundation. Clinically relevant observations of
collaborations between clinical and preclinical researchers are: (1) Diastolic dysfunction
in female is more severe at the time of septal myectomy than in male hypertrophic CM
(HCM) patients; (2) Indexation for body size should be implemented to set the diagnostic
threshold for LV thickening in HCM; (3) Cell-to-cell variability is present in the hearts of
patients with a Dutch MYBPC3 founder mutation; (4) Compelling evidence that altered
metabolism and PQC are central disease modifiers in CMs. Chapter 1 closed with an
outline of this thesis.
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CARDIOMYOPATHY IN A DISH: USING CELL CULTURE SYSTEMS TO MODEL
INHERITED CARDIOMYOPATHIES
In chapter 2, we described a large family with a DCM-causing TPM1 variant and
identified compound heterozygote TPM1 variants in a child with restrictive CM with
family members carrying HCM(-like) phenotypes. Overexpression of TPM1 variants in
HL-1 cardiomyocytes led to time-dependent progressive deterioration of cardiomyocyte
calcium transient (CaT) amplitudes. The dose-dependent effect on CaT was opposite
for DCM- and HCM-associated TPM1 variants and may be determined by the mixture
of variant and wild-type TPM1. The reduced CaT amplitudes and structural changes
occurred irrespective of TPM1 variants and the clinical CM phenotype. Taken together,
reduced CaT amplitudes may contribute to the poor cardiac contraction seen in affected
individuals.
While HL-1 cardiomyocytes are a quick, cheap and easy in vitro model to check the
effect of gene variant overexpression, it may be interesting to follow up our TPM1 study
with human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CM). Patient
derived hiPSC-CM provide a versatile new tool because they often recapitulate the respective
hallmarks of inherited CMs, retain the genetic blueprint and thereby tremendously improve
our understanding of underlying molecular mechanisms.9 The advent of hiPSC-CM offers
insights into the very early pathophysiology, such as contractile alterations that appear first
in the course of the disease, unobscured by compensatory responses.10 Moreover, using
CRISPR/Cas9 technology to modify one allele better recapitulates the human disease
situation than overexpression of mutant protein on top of the wild-type proteins which is
important in a stoichiometry-controlled environment such as the myofilament proteins.
Whether our findings in HL-1 cardiomyocytes are recapitulated in hiPSC-CM, which have
a higher potential to recapitulate the patient phenotype, is difficult to predict. Systematic
functional characterization and comparison of HL-1 cardiomyocytes to stem cell-derived
cardiomyocytes or hiPSC-CM is limited so far to electrophysiological properties.11,12 In line
with our data, Ca2+ handling abnormalities were observed in patient derived hiPSC-CM
carrying the D175N variant in TPM1.13 Especially the usage of a genetically encoded
Ca2+ indicator may improve our understanding due to the direct visualization of changes
in Ca2+ flux at the myofilaments.14 Besides Ca2+ flux measurements in hiPSC-CM, there
are diverse systems and methods for performing mechanical measurements of contractility,
ranging from single cell techniques to multicellular tissue-like constructs.15 Deciphering
the mechanisms to enable the massive hiPSC-CM expansion made it possible to produce
a sufficient number of cardiomyocytes needed for experiments such as large-scale drug
screening and 3-dimensional tissue engineering applications.16 hiPSC-CM represents a
model with the potential to identify novel pathomechanisms and head into the direction of
personalized medicine.
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Besides the cell-culture systems (chapter 2 and 4), we used a variety of animal models
for CMs spanning from Drosophila melanogaster (chapter 10 and 11) via Mus musculus
(chapter 6 and 9) to Sus scrofa domesticus (chapter 9). We used all these models to
recapitulate some hallmarks of CMs with the aim to improve our understanding of the
underlying pathomechanisms and ultimately, to translate it back to the human phenotype.
Each system has its weak points either by not mimicking a respective hallmark or by
the inability to translate the findings to the human phenotype. Therefore, we want to
highlight here the importance to evaluate firstly whether the used system is appropriate
for the asked research question. In chapter 9, we assessed systematically the microtubule
network in various pig and mouse models to define the recapitulating potential of each
model system. In chapter 11, we phenotyped two point mutations in the myosin heavy
chain gene of Drosophila melanogaster, which cause HCM in humans, to determine if these
mutant Drosophila melanogaster strains represent a model for inherited CMs.
THE ROLE AND DERAILMENT ROUTE OF PQC IN INHERITED
CARDIOMYOPATHIES
So far, studies investigating the role of PQC in CMs caused by sarcomeric gene mutations
are limited. In chapter 3, we provided an overview of the reported structural changes and
adaptations in PQC related to inherited CMs. Hereby, we observed that PQC derailment can
be (1) a direct effect of the mutation-induced activation, (2) a compensatory mechanism
due to mutation-induced cellular dysfunction or (3) a consequence of the simultaneous
occurrence of the mutation and a secondary hit. Personalized treatment strategies should
be addressed to the disease- and mutation-specific changes of key modulators in PQC.
Perturbations in PQC mechanisms may be aggravated by the presence of sarcomere gene
mutations and may explain the difference in disease severity between genotype-positive and
genotype-negative patients. Therefore, we defined HCM and mutation-specific changes in
key PQC players and the microtubule network (chapter 7). We observed the following
main findings: (1) Several key PQC players were more abundant in HCM compared to
controls; (2) After correction for sex and age, stabilizing HSPB1 and refolding HSPD1
and HSPA2 were increased in sarcomere mutation-positive HCM compared to controls;
(3) α-tubulin and acetylated α-tubulin levels were higher in HCM compared to controls,
especially in HCM with cMyBP-C haploinsufficiency; (4) cMyBP-C levels were inversely
correlated with α-tubulin; and (5) α-tubulin levels correlated with acetylated α-tubulin and
HSPs.
In addition to measuring increased levels of a distinct set of HSPs in genotype-positive HCM
patients (chapter 6 and 7), a histological characterization to determine the intracellular
localization of these HSPs is similarly paramount due to the spatial organization of
the PQC into compartments.5,17 Localized translation and degradation processes are
important to ensure robust and efficient spatial and stoichiometric control of sarcomere
maintenance.18 For example HSPD1 is a mitochondrial HSP19 and its translocation to
the plasma membrane is detrimental to the cell because of the loss of anti-apoptotic and
protective effects.20 Hence, the specific localization within the cells defines the functional
properties of HSPs. Building a histopathological library to link the spatial expression of
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the distinct HSPs with the mutant protein expression in patient and compare it to control
samples will provide valuable information about how the PQC system may be derailed and
which intervention should be considered at all.
To further assess whether our findings point towards proliferations of the microtubule
network as a novel pathomechanisms in cMyBP-C haploinsufficiency-mediated HCM, a
detailed histological characterization is mandatory. Previously, intercellular variation of
cMyBP-C myofilament protein levels was described in cardiomyocytes of HCM patients with
MYBPC3 gene variants.21,22 Hence, it would be similarly interesting to determine if there
is an intercellular variability in the microtubule network. An enrichment of microtubules
coinciding with cMyBP-C free patches may thereby suggest a direct compensation for the
loss of cMyBP-C on a cellular level. In contrast, an overall increase in the microtubule
network may indicate a secondary response regulated on the level of the myocardium due
to the MYBPC3 -caused impaired contractility. This cell-to-cell variability has also been
described for MYH7 mutations and substantial variability in contractility and mutant
MYH7 -mRNA levels were observed.23,24
HEAT SHOCK PROTEIN-BASED THERAPEUTIC OPTIONS FOR DCM
PATIENTS WITH HSPB5 GENE VARIANTS
DCM-causing mutations in HSPB5 were studied in chapter 4. We observed that
overexpression of mutant HSPB5 in various cell systems resulted in loss-of-function of
HSPB complexes and coincided with insolubilisation of HSPB5 and loss of CaT amplitudes.
Since oligomerization of HSPB5 proteins is enabled by interaction between C-terminal
isoleucine-proline-isoleucine (IPI) domain and the hydrophobic groove in the α-crystallin
domain, we studied the effect of loss-of-function mutations in both domains. Introducing a
secondary mutation in one of these domains in addition to our HSPB5 mutants, decreased
formation of aggregates which was accompanied by increased solubilisation and a partial
restoration of the chaperone function. In a next step, it is necessary to study the potential
therapeutic effect in more complex models and include more functional measurements.
In addition, HSPs play a central role in PQC and for that reason pharmacologic modulation
of HSP levels represents an interesting target in aging-related protein misfolding diseases.
We tested whether oral geranylgeranylacetone (GGA) treatment increased HSP expression
in atrial appendages of patients undergoing cardiac surgery (chapter 5). Three days of
GGA treatment resulted in higher levels of HSPB1 and HSPA1 in the atrial appendages of
patients undergoing surgery and higher HSPB1 levels at the myofilaments.
Here we provided direct proof that oral administration of GGA has an HSP boosting effect
in human cardiac tissue. Previously, the in vivo HSP inducing effect of oral GGA treatment
was studied in mutant HSPB5 mice containing the R120G mutation and controls.25
Interestingly, GGA profoundly enhanced the induction of a discrete subset of small HSPs,
including HSPB8 and HSPB1, in mutant mice compared to the induction of HSPA1
in controls.25 Overall, this suggests that GGA induces the expression of distinct HSPs
dependent on tissue-specific HSP expression profile and underlying stress trigger.
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While we focused on determining various HSP expression levels after GGA treatment in
chapter 5, the in vivo protective effects of HSP induction on disease development was
investigated in studies with rodents. For example, overexpression of HSPB8 or boosting by
GGA treatment had a cardioprotective effect and led to a partial reduction of aggregates
formation.25,26 Therefore, combining the GGA treatment with peptides targeting the altered
oligomerization dynamics, as discussed in chapter 4, may pave a new treatment strategy
in DCM patients carrying HSPB5 variants. In this case, the loss of function of HSPB
complexes would be counteracted by the HSP boosting response of GGA and the peptide
treatment would interfere with the oligomerization dynamics of mutant HSPB5 proteins
and thereby prevent formation of aggregates.
DERAILED METABOLISM AS KEY DRIVER OF DISEASE IN HCM
Puzzled by the striking clinical heterogeneity and the aim to define genotype-specific
changes at the protein levels, we performed an unbiased proteomics approach in cardiac
tissue from a clinically well-phenotyped HCM patient group. Our proteomic analysis
revealed derailment of metabolic pathways related to energy metabolism as the most
prominent derailment in all HCM patients (chapter 6). We observed lower expression
of proteins involved in oxidative phosphorylation, glycolysis, and fatty acid oxidation.
Dysregulation of metabolic proteins was also a main finding of another proteomic study
using HCM tissue samples.27 Strikingly, studies with confirmed gene variant carriers and
normal echocardiographic findings classified abnormality of cardiac energetics as an early
feature in HCM pathogenesis.28,29 Environmental and genetic factors have been suggested
as dysregulators of the bioenergetic-metabolite interactome leading to a decreased capacity
of the metabolic network to adapt and thereby causing progressive loss of cell and tissue
function.30 Therefore, metabolic modulators are currently under investigation to test
whether they have a potential to alleviate HCM symptoms.31,32
Besides the direct contractile consequences, alterations in the energy metabolism may also
affect other high energy dependent processes, such as protein synthesis and removal.33
Recent insights have uncovered a complex interplay between PQC and metabolism,
including bidirectional signalling, transcriptional control, and substrate provision.34 Each
component of the PQC, including HSPs, UPS and autophagy, is intimately linked to
metabolism.34,35 Further studies are mandatory to precisely dissect the impact of derailed
energy metabolism on the functionality and adaptability of the PQC system in HCM
patients.
SEX-DIFFERENCES IN CLINICAL MANIFESTATION AND CELLULAR
PROPERTIES
As aforementioned, sex-differences are observed in the clinical presentation of HCM patients
and contribute to the phenotypic heterogeneity.36-38 In chapter 8, we analysed a proteomic
data set of septal myocardial tissue of sarcomere mutation-positive HCM patients to
investigate if molecular differences underlie sex-differences in clinical presentation. We
found an increase in microtubule network and HSPs in female compared to male HCM
patients. Due to the direct correlation of cytoskeletal proteins with diastolic dysfunction, we
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suggested that elevated tubulin levels partly underlie the more severe diastolic dysfunction
in women. In addition, the elevated HSPs levels in females may offer cardio-protective
effects and could contribute to the later disease onset. In male HCM patients we observed
lower levels of translational proteins which may result in ‘aged’ sarcomeres. In summary,
our data revealed sex-specific differences in levels of tubulin and HSPs.
Our findings and the higher risk of mortality and developing severe heart failure symptoms
of women point to the need to study the sex-effect on long-term myocardial performance
in HCM.38 While rodent models of HCM are an appropriate model to study sex-based
differences in hypertrophy signalling pathways and cardiomyocyte calcium sensitivity,39,40
murine studies failed to show a consistent effect of sex hormones on HCM development.39
In line with our data showing increased levels of HSPs in women, also other components of
the PQC system are affected in a sex-dependent manner. For example, diverse sex-related
regulation of autophagy protein levels has been reported in a cardiac ischemia-reperfusion
rat model.41,42 Interestingly, organism-wide proteasome activity mapping revealed no sexual
dimorphism in mice hearts, but a tremendous age-related decline in both sexes.43 This
highlights again the importance to use sex-specific longitudinal HCM model systems to
study the microtubules dynamics and the age-related decline in PQC, as well as to allow the
exposure to the different female hormone profiles. A longitudinal model system, including
early and advanced disease stages, will help to determine if and when would be the optimal
time frame to intervene with sex-specific treatment strategies targeting the microtubules
and PQC.
TUBULIN SIGNATURE IN CARDIOMYOPATHIES
Pathways of PQC are strongly linked to the microtubule network and properties and
function of this network are fine-tuned by the ‘tubulin code’ determined by alternative
tubulin isotypes and a variety of post-translational modifications.44 To study the changes in
microtubules and its post-translational modifications in cardiac remodelling during disease
development, we determined the tubulin signature at the time of septal myectomy (chapter
6 and 7). While increased levels of α-tubulin and acetylated α-tubulin were observed in all
HCM samples, but more pronounced when a sarcomere mutation was present, increased
levels of detyrosinated α-tubulin were specific for sarcomere mutation-positive patients
with HCM. Moreover, our sex-based analysis (chapter 8) revealed elevated protein levels
of tubulin correlate with more severe diastolic dysfunction in women.
Triggered by these findings, we investigated the microtubule signature and desmin
levels, a sarcomeric microtubule anchor, in patients with advanced heart failure and various
mouse and pig models for cardiac diseases (chapter 9). In contrast to HCM patients
with NYHA class II-III, the levels of desmin, acetylated and total α-tubulin in a more
advanced HCM stage were comparable to controls. Interestingly, detyrosinated α-tubulin
was strongly uncoupled from the normal α-tubulin levels in patients with advanced HCM.
Increased levels of detyrosinated α-tubulin were also observed in paediatric DCM patients.
In contrast to the big changes seen in our human patient myocardium, tubulin changes
in the various animal models of cardiovascular disease were modest. As observed in the
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biopsies from NYHA class II-III HCM patients, the development of hypertrophy initiated by
pressure overload, such as 3 week aortic banding (AoB) in pigs, or a genetic trigger, such
as strongly reduced levels of cMyBP-C in homozygous MYBPC3772G>A mice, coincided
with increased desmin levels. We observed a compensated, concentric hypertrophic
in AoB-treated pigs which was characterized by a normal cardiac function and tubulin
signature. In 18 months old pigs with a high body weight and disproportionately low stroke
volume, we excluded that detyrosinated α-tubulin contributed to the reported diastolic
disturbances because of an overall decreased tubulin signature.
Our comparison of sedentary wild-type mice to mice exposed to an 8-week voluntary
wheel-running protocol revealed that exercise had no effect on the tubulin signature
and desmin levels. The unchanged tubulin signature in 13 weeks old, heterozygous and
homozygous MYBPC3772G>A differs from our previous study with older homozygous
MYBPC3 mice. We observed normal α-tubulin levels and increased levels of detyrosinated
α-tubulin and desmin in 20 to 28 weeks old homozygous MYBPC32373insG mice, and an
increase in α-tubulin and a tendency to increased detyrosination of α-tubulin in 55 to
59 weeks old homozygous MYBPC3772G>A mice (chapter 6). Furthermore, contractile
function was normalized by pharmacological inhibition of detyrosination of α-tubulin in
isolated cardiomyocytes.
Our data indicate that the tubulin signature, including total, acetylated and detyrosinated
α-tubulin, is increased most at the time of myectomy compared to healthy controls and
an altered tubulin signature coincides with diastolic dysfunction. We provide proof that
lowering detyrosination of α-tubulin may be a potential novel treatment strategy in patients
with sarcomere mutation-positive HCM to improve contractile function and emphasize the
need for genotype-specific treatment strategies in HCM. Further experiments are warranted
to determine the effect of this treatment strategy in advanced HCM and paediatric DCM.
HCM underlies a complex pathomechanisms and animal models only partially recapitulate
the tubulin remodelling. We showed that an aged mouse model with the Dutch founder
mutation MYBPC32373insG is mimicking the altered tubulin signature best. This emphasizes
the need to establish better model systems to precisely elucidate the effect (compensation
or consequence) on contractility, microtubule dynamics and stability of the observed tubulin
signature in HCM patients and to test potential drugs re-writing the tubulin signature.
DROSOPHILA MELANOGASTER – A MODEL SYSTEM TO STUDY INHERITED
CARDIOMYOPATHIES
In the third part of this thesis, we investigated whether Drosophila melanogaster is a model
system to study inherited CMs. In chapter 10, we described and provided explanations
for our unsuccessful attempt to make CRISPR/Cas9 edited wupA-mutant strains. WupA
is the orthologue for the human TNNI3 gene encoding Troponin I. TnI has a central
role during early development and the gene locus within the haplolethal region 16F in
Drosophila melanogaster.45-47 Our genome editing approach causing reduced numbers
of TnI isoforms or complete depletion of TnI had probably detrimental consequences for
sarcomere morphogenesis because under TnI depletion Z discs fail to form.48 We advise to
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select a genome editing approach which does not lead to depletion of TnI isoforms.
In chapter 11, we studied two CRISPR/Cas9 edited Mhc-mutant strains to investigate
the effects of HCM-causing variants located in either the head or the tail region of
the protein. We provided a detailed characterization of the morphology of the heart
tube. Initially, we planned to compare HCM- and DCM-causing mutations in Drosophila
melanogaster, but had to deviate from the plan since the wupA mutants were not viable.
Drosophila melanogaster is an interesting model to address histology-based research
question because the heart tube consists of spirally oriented myofibrils covered by a
ventral layer of longitudinal non-myocardial muscle cells running along the heart tube.49
Moreover, the myofibrils display a clear striation pattern and the sarcomeric proteins are
similar to mammalian cardiomyocytes.49,50 In comparison to hiPSC-CMs, the effect of
high fat or high sugar diet on cardiac function of Drosophila melanogaster can easily be
studied.51,52 The short life-time and the high reproduction number provide the opportunity
to analyse intergenerational inheritance pattern, such as the high fat diet-induced cardiac
lipotoxicity.53 Therefore, genome-edited Drosophila melanogaster may be an interesting
and low cost in vivo model to address histology- or diet-based research questions.
FUTURE PERSPECTIVE
In this thesis, we studied the PQC and tubulin signature in inherited CMs. So far, advances
in elucidating PQC in the heart are relatively limited.34 The aspect that both systems, PQC
and microtubule network, are of a highly dynamic nature needs to be implemented in future
model system to further elucidate the pathomechanisms of inherited CMs. Fluorescent
tracking along the disease progression in simple, and complex cell-based systems and
building a strong histopathological library of human tissue biopsies will provide valuable
spatial and temporal data.54 In addition, as observed at different part of this thesis, the
PQC system is not a system which stands alone, but interacts with the microtubule network
and metabolism, and both expression and regulation show sex-dependent differences. An
improved and coordinated understanding of consequences and compensatory mechanisms
when one system is derailed is warranted.
Interestingly, each component of the PQC system, including HSPs, ubiquitin-proteasome
system and autophagy, is inherent dichotomy: each is capable of beneficial changes, and
each is capable of destructive changes.34 The ongoing puzzle is to determine whether
quantitative differences (too much or too little) or qualitative distinctions are causative
for the dichotomy.34 Therefore, it is of utmost importance to determine the range of
physiological concentration in health and disease for key PQC players and find new
analytical tools to measure the individual capabilities.
Using the most adequate model system recapitulating the respective hallmarks of
inherited CMs and taking sex- and genotype-based differences into account will be
paramount to test potential drugs modulating the PQC and tubulin signature to find new
personalized treatment strategies.
DISCUSSION AND FUTURE PERSPECTIVE 281
REFERENCES
1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a
position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur Heart J. 2008;29(2):270-6.
2. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, et al. The MOGE(S) classification for a
phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol.
2013;62(22):2046-72.
3. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: a position
paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76.
4. Levine A, Gupta CA, Gass A. Advanced Heart Failure Management and Transplantation. Cardiol Clin.
2019;37(1):105-11.
5. Chen B, Retzlaff M, Roos T, Frydman J. Cellular strategies of protein quality control. Cold Spring Harb Perspect
Biol. 2011;3(8):a004374.
6. Robison P, Prosser BL. Microtubule mechanics in the working myocyte. J Physiol. 2017;595(12):3931-7.
7. Sontag EM, Vonk WIM, Frydman J. Sorting out the trash: the spatial nature of eukaryotic protein quality control.
Curr Opin Cell Biol. 2014;26:139-46.
8. Humburg P, Maugeri N, Lee W, Mohr B, Knight JC. Characterisation of the global transcriptional response to heat
shock and the impact of individual genetic variation. Genome Med. 2016;8(1):87.
9. Hoes MF, Bomer N, van der Meer P. Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling:
A Focus on Gene Editing and Tissue Engineering. Stem Cells Transl Med. 2019;8(1):66-74.
10. Buikema JW, Wu SM. Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease
Models. Curr Cardiol Rep. 2017;19(4):30.
11. Marcu IC, Illaste A, Heuking P, Jaconi ME, Ullrich ND. Functional Characterization and Comparison of Intercellular
Communication in Stem Cell-Derived Cardiomyocytes. Stem Cells. 2015;33(7):2208-18.
12. Wells SP, Waddell HM, Sim CB, Lim SY, Bernasochi GB, Pavlovic D, et al. Cardiomyocyte functional screening:
interrogating comparative electrophysiology of high-throughput model cell systems. Am J Physiol Cell Physiol.
2019;317(6):C1256-C67.
13. Ojala M, Prajapati C, Polonen RP, Rajala K, Pekkanen-Mattila M, Rasku J, et al. Mutation-Specific Phenotypes
in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or alpha-Tropomyosin Mutation for
Hypertrophic Cardiomyopathy. Stem Cells Int. 2016;2016:1684792.
14. Sparrow AJ, Sievert K, Patel S, Chang YF, Broyles CN, Brook FA, et al. Measurement of Myofilament-Localized
Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations. Circ Res.
2019;124(8):1228-39.
15. Sewanan LR, Campbell SG. Modelling sarcomeric cardiomyopathies with human cardiomyocytes derived from induced
pluripotent stem cells. J Physiol. 2020;598(14):2909-22.
16. Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, et al. Wnt Activation and Reduced Cell-Cell
Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem
Cell. 2020;27(1):50-63 e5.
17. Sontag EM, Samant RS, Frydman J. Mechanisms and Functions of Spatial Protein Quality Control. Annu Rev
Biochem. 2017;86:97-122.
18. Lewis YE, Moskovitz A, Mutlak M, Heineke J, Caspi LH, Kehat I. Localization of transcripts, translation, and
degradation for spatiotemporal sarcomere maintenance. J Mol Cell Cardiol. 2018;116:16-28.
19. Soltys BJ, Gupta RS. Immunoelectron microscopic localization of the 60-kDa heat shock chaperonin protein (Hsp60)
in mammalian cells. Exp Cell Res. 1996;222(1):16-27.
20. Lin L, Kim SC, Wang Y, Gupta S, Davis B, Simon SI, et al. HSP60 in heart failure: abnormal distribution and role
in cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol. 2007;293(4):H2238-47.
21. Parbhudayal RY, Garra AR, Gotte MJW, Michels M, Pei J, Harakalova M, et al. Variable cardiac myosin binding
protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy. J Mol Cell
Cardiol. 2018;123:59-63.
22. Theis JL, Bos JM, Theis JD, Miller DV, Dearani JA, Schaff HV, et al. Expression patterns of cardiac myofilament
proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic
cardiomyopathy. Circ Heart Fail. 2009;2(4):325-33.
23. Kraft T, Montag J. Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy.
Pflugers Arch. 2019;471(5):719-33.
24. Kraft T, Montag J, Radocaj A, Brenner B. Hypertrophic Cardiomyopathy: Cell-to-Cell Imbalance in Gene Expression
and Contraction Force as Trigger for Disease Phenotype Development. Circ Res. 2016;119(9):992-5.
25. Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, Yamauchi J, et al. Protective effect of geranylgeranylacetone
via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One. 2009;4(4):e5351.
26. Sanbe A, Yamauchi J, Miyamoto Y, Fujiwara Y, Murabe M, Tanoue A. Interruption of CryAB-amyloid oligomer
formation by HSP22. J Biol Chem. 2007;282(1):555-63.
27. Coats CJ, Heywood WE, Virasami A, Ashrafi N, Syrris P, Dos Remedios C, et al. Proteomic Analysis of the Myocardium
in Hypertrophic Obstructive Cardiomyopathy. Circ Genom Precis Med. 2018;11(12):e001974.
282 CHAPTER 12
12
28. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, et al. Hypertrophic cardiomyopathy due to
sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.
J Am Coll Cardiol. 2003;41(10):1776-82.
29. Witjas-Paalberends ER, Guclu A, Germans T, Knaapen P, Harms HJ, Vermeer AM, et al. Gene-specific increase in
the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res.
2014;103(2):248-57.
30. Hill BG, Shiva S, Ballinger S, Zhang J, Darley-Usmar VM. Bioenergetics and translational metabolism: implications
for genetics, physiology and precision medicine. Biol Chem. 2019;401(1):3-29.
31. Leviner DB, Hochhauser E, Arad M. Inherited cardiomyopathies–Novel therapies. Pharmacol Ther. 2015;155:36-48.
32. Fumagalli C, De Gregorio MG, Zampieri M, Fedele E, Tomberli A, Chiriatti C, et al. Targeted Medical Therapies for
Hypertrophic Cardiomyopathy. Curr Cardiol Rep. 2020;22(2):10.
33. Catic A. Cellular Metabolism and Aging. Prog Mol Biol Transl Sci. 2018;155:85-107.
34. Wang ZV, Hill JA. Protein quality control and metabolism: bidirectional control in the heart. Cell Metab.
2015;21(2):215-26.
35. Chang J, Knowlton AA, Xu F, Wasser JS. Activation of the heat shock response: relationship to energy metabolites.
A (31)P NMR study in rat hearts. Am J Physiol Heart Circ Physiol. 2001;280(1):H426-33.
36. Nijenkamp L, Bollen IAE, van Velzen HG, Regan JA, van Slegtenhorst M, Niessen HWM, et al. Sex Differences at
the Time of Myectomy in Hypertrophic Cardiomyopathy. Circ Heart Fail. 2018;11(6):e004133.
37. van Driel B, Nijenkamp L, Huurman R, Michels M, van der Velden J. Sex differences in hypertrophic cardiomyopathy:
new insights. Curr Opin Cardiol. 2019;34(3):254-9.
38. Lakdawala NK, Olivotto I, Day SM, Han L, Ashley EA, Michels M, et al. Associations Between Female Sex, Sarcomere
Variants and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020.
39. Blenck CL, Harvey PA, Reckelhoff JF, Leinwand LA. The Importance of Biological Sex and Estrogen in Rodent Models
of Cardiovascular Health and Disease. Circ Res. 2016;118(8):1294-312.
40. Birch CL, Behunin SM, Lopez-Pier MA, Danilo C, Lipovka Y, Saripalli C, et al. Sex dimorphisms of crossbridge cycling
kinetics in transgenic hypertrophic cardiomyopathy mice. Am J Physiol Heart Circ Physiol. 2016;311(1):H125-36.
41. Chen C, Hu LX, Dong T, Wang GQ, Wang LH, Zhou XP, et al. Apoptosis and autophagy contribute to gender
difference in cardiac ischemia-reperfusion induced injury in rats. Life Sci. 2013;93(7):265-70.
42. Le TY, Ashton AW, Mardini M, Stanton PG, Funder JW, Handelsman DJ, et al. Role of androgens in sex differences
in cardiac damage during myocardial infarction. Endocrinology. 2014;155(2):568-75.
43. Jenkins EC, Shah N, Gomez M, Casalena G, Zhao D, Kenny TC, et al. Proteasome mapping reveals sexual dimorphism
in tissue-specific sensitivity to protein aggregations. EMBO Rep. 2020;21(4):e48978.
44. Janke C, Magiera MM. The tubulin code and its role in controlling microtubule properties and functions. Nat Rev
Mol Cell Biol. 2020;21(6):307-26.
45. Sahota VK, Grau BF, Mansilla A, Ferrus A. Troponin I and Tropomyosin regulate chromosomal stability and cell
polarity. J Cell Sci. 2009;122(Pt 15):2623-31.
46. Casas-Tinto S, Ferrus A. Troponin-I mediates the localization of selected apico-basal cell polarity signaling proteins.
J Cell Sci. 2019;132(8).
47. Prado A, Canal I, Ferrus A. The haplolethal region at the 16F gene cluster of Drosophila melanogaster: structure and
function. Genetics. 1999;151(1):163-75.
48. Marin MC, Rodriguez JR, Ferrus A. Transcription of Drosophila troponin I gene is regulated by two conserved,
functionally identical, synergistic elements. Mol Biol Cell. 2004;15(3):1185-96.
49. Taghli-Lamallem O, Plantie E, Jagla K. Drosophila in the Heart of Understanding Cardiac Diseases: Modeling
Channelopathies and Cardiomyopathies in the Fruitfly. J Cardiovasc Dev Dis. 2016;3(1).
50. Choma MA, Suter MJ, Vakoc BJ, Bouma BE, Tearney GJ. Physiological homology between Drosophila melanogaster
and vertebrate cardiovascular systems. Dis Model Mech. 2011;4(3):411-20.
51. Diop SB, Birse RT, Bodmer R. High Fat Diet Feeding and High Throughput Triacylglyceride Assay in Drosophila
Melanogaster. J Vis Exp. 2017(127).
52. Na J, Musselman LP, Pendse J, Baranski TJ, Bodmer R, Ocorr K, et al. A Drosophila model of high sugar diet-induced
cardiomyopathy. PLoS Genet. 2013;9(1):e1003175.
53. Guida MC, Birse RT, Dall’Agnese A, Toto PC, Diop SB, Mai A, et al. Intergenerational inheritance of high fat
diet-induced cardiac lipotoxicity in Drosophila. Nat Commun. 2019;10(1):193.
54. Macario AJ, de Macario EC. Molecular mechanisms in chaperonopathies: clues to understanding the histopathological
abnormalities and developing novel therapies. J Pathol. 2020;250(1):9-18.




In dieser Doktorarbeit geht es um Kardiomyopathien. Das sind Erkrankungen des
Herzmuskels (Myokardium), bei denen sich die Struktur des Muskelgewebes verändert und
die Leistungsfähigkeit verloren geht. Das beeinträchtigte Herz kann nicht mehr genügend
Blut durch den Kreislauf befördern und es entsteht eine Herzschwäche (Herzinsuffizienz).
Man unterscheidet drei Hauptformen: dilatative (DCM), hypertrophe (HCM) und restriktive
(RCM) Kardiomyopathie.
Bei der DCM dilatiert und verdünnt sich die Wand der linken Herzkammer. Dadurch ist
die Kontraktion des Herzmuskels verringert und weniger Blut wird gepumpt.
Bei der HCM kommt es zu einer Verdickung des Herzmuskels in der linken Herzkammer.
Die Verdickung tritt am häufigsten am Septum auf und kann eine Verengung verursachen,
die den Blutfluss vom linken Ventrikel zur Aorta verringern oder blockieren kann. Die
Ventrikel müssen stärker pumpen, um die Verengung oder Blockade zu überwinden. Hinzu
kommt, dass sich der Herzmuskel schlechter entspannen kann, was die Füllung des Herzens
mit Blut einschränkt.
Bei der RCM, die sehr selten ist, wird vermehrt Bindegewebe in den Herzmuskel
eingelagert, dadurch versteift die linke Herzkammer. Die Starrheit des Myokardiums
erschwert die Füllung mit Blut durch großen Widerstand, wodurch sich die Ventrikel nicht
genügend füllen können und zu wenig Blut in den Kreislauf gepumpt wird.
Alle drei Kardiomyopathien können genetisch bedingt sein, was bedeutet, dass das
Krankheitsbild durch eine erbliche Veranlagung (Mutation in der DNA) verursacht werden
kann. In dieser Arbeit haben wir genetisch bedingte Fälle untersucht und uns auf
Mutationen fokussiert, die den Herzmuskelapparat betreffen. Interessanterweise können
Mutationen im gleichen Gen sowohl DCM, HCM als auch RCM verursachen, wie wir
in Kapitel 2 anhand des Gens TPM1 zeigen. Hinzu kommt, dass der Krankheitsverlauf
individuell sehr unterschiedlich ist, auch bei Patienten mit der genetisch identischen
Variante. Unsere Daten in Kapitel 2 veranschaulichen diese klinische Heterogenität und
implizieren, dass die Pathophysiologie von vererbbaren Kardiomyopathien komplexer ist
als das simple Vorhandensein einer Genvariante. Daher ist es von größter Bedeutung,
zusätzliche Krankheitsauslöser, sogenannte Trigger, zu identifizieren, um den zugrunde
liegenden Pathomechanismus besser zu verstehen. Wir haben zelluläre, genetische und
klinische Daten aus gut erforschten Patientenkohorten und verschiedene Modellsystemen
für Kardiomyopathien verwendet, um mögliche Trigger zu untersuchen. In dieser
Arbeit konzentrierten wir uns auf das Proteinqualitätskontrollsystem (PQC) und das
Mikrotubuli-Netzwerk.
Das PQC System ist ein zellulärer Schutzmechanismus, der für die Aufrechterhaltung
eines funktionierenden Proteoms verantwortlich ist. Hierbei werden defekte oder mutierte
Proteine von Hitzeschockproteinen (HSPs) erkannt und falls eine Reparatur nicht möglich
ist, wird dieses abgebaut.
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Mikrotubuli sind kleine, röhrenförmige Proteinkomplexe, die aus α- und β-Tubulin
aufgebaut sind. Sie bilden die Grundlage für das Cytoskelett und geben damit der Zelle
eine gewisse mechanische Stabilität. Es ist bekannt, dass sich das Mikrotubuli-Netzwerk
bei verschiedenen Krankheiten umbaut.
Bisher ist die Anzahl an Studien, die die Rolle der PQC bei genetisch bedingten
Kardiomyopathien untersucht haben, begrenzt. In Kapitel 3 geben wir deshalb einen
Überblick über die strukturellen Veränderungen und wie sich das PQC System anpasst.
Hierbei beobachteten wir, dass die Entgleisung des PQC Systems entweder direkt durch
die Mutation oder sekundär in Folge von zellulären Veränderungen durch die Mutation
verursacht sein kann.
In Kapitel 4 wird der Fokus auf zwei Genvarianten des kleinen Hitzeschockproteins
HSPB5 verlagert, die beide DCM verursachen. In einem ersten Schritt haben wir die beiden
HSPB5-Varianten in verschiedenen Zellsystemen überexprimiert, um den Funktionsverlust,
wie zum Beispiel die Bildung von Aggregaten, zu studieren. In einem zweiten Schritt
demonstrierten wir, dass das Einfügen einer zusätzlichen Mutation die Proteinaggregation
verringert und zur Funktionswiederherstellung führt. Die potenzielle therapeutische
Wirkung dieser zusätzlichen Mutation muss nun in komplexeren Modellen in weiteren
Studien untersucht werden.
Weil die HSPs für das PQC System wichtig sind, stellt die pharmakologische
Modulation der HSP-Spiegeln eine interessante Behandlungsmöglichkeit für altersbedingte
Proteinfehlfaltungserkrankungen dar. Wir haben in Kapitel 5 gezeigt, dass eine orale
Einnahme von Geranlylgeranylaceton (GGA) kurz vor einer Herzoperation die Expression
von bestimmten HSPs im Herzvorhof von Patienten erhöht.
In Kapitel 6 wurde das Proteom von HCM-Patienten mit gesunden Kontrollproben
verglichen. Unsere Analyse ergab, dass in den Patientenproben weniger Proteine exprimiert
werden, die für die zelluläre Energiegewinnung wichtig sind. Des Weiteren wiesen Patienten
mit einer Genmutation im Vergleich zu Patienten ohne Mutation eine stark erhöhte Menge
an α-Tubulin auf, insbesondere von der detyrosinierten Form. Wir zeigten in einem
Mausmodell mit einer häufigen HCM Mutation, dass eine pharmakologische Verringerung
der detyrosinierten Tubulin-Form ein vielversprechender neuer Therapieansatz darstellt, da
sich die Funktion der Herzmuskelzellen verbesserte.
In derselben HCM-Patientengruppe haben wir die Proteinspiegel wichtiger PQC Bausteine,
wie zum Beispiel stabilisierende HSPs, HSPs mit der Kapazität Proteine zu falten und
diverse Proteinabbaumarker, sowie Bestandteile des Mikrotubuli-Netzwerkes bestimmt
(Kapitel 7). Hier war die Überlegung, dass die Genmutationen oft den Muskelapparat
betreffen und diese Proteine einen großen Bestandteil von Herzmuskelzellen ausmachen.
Eine große Anzahl an beschädigten Proteinen könnte zu einer Beeinträchtigung des PQC
Systems führen und möglicherweise erklären, weshalb Patienten mit einer Genmutation
in einem früheren Alter erkranken und an einem schlimmeren Krankheitsverlauf leiden.
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Darüber hinaus beobachteten wir interindividuelle Unterschiede in der Kapazität des PQC
und entgleisten Anpassungen an Stressauslöser, was zur klinischen Heterogenität beitragen
könnte. Übereinstimmend mit Kapitel 6 war α-Tubulin, sowie auch dessen acetylierte
Form, besonders erhöht in Patienten mit einer Genmutation.
Auch geschlechtsspezifische Unterschiede prägen das klinische Erscheinungsbild und tragen
möglicherweise zur phänotypischen Heterogenität von HCM-Patienten bei. In Kapitel 8
analysierten wir Geschlechtsunterschiede auf Proteinebene in HCM-Patientengewebe und
demonstrierten, dass Frauen mehr α-Tubulin sowie auch höhere Mengen an HSPs haben.
In Kapitel 9 befassten wir uns mit dem Mikrotubuli-Netzwerk in verschiedenen Maus-
und Schweinmodellen für Hypertrophie und/oder Herzinsuffizienz. Im Gegensatz zu
den deutlichen Mikrotubuli-Veränderungen, die wir in den Patientenproben detektiert
haben, waren die Veränderungen in den verschiedenen Tiermodellen minimaler. Darüber
hinaus untersuchten wir, ob das Mikrotubuli-Netzwerk auch in anderen vererbbaren oder
erworbenen Herzerkrankungen, wie DCM und ischämische Herzerkrankungen, umgebaut
wird. Unsere Daten zeigten, dass die Tubulin-Signatur, einschließlich gesamtes, acetyliertes
und detyrosiniertes α-Tubulin, im Vergleich zu gesunden Kontrollen und den anderen
Herzerkrankungen zum Zeitpunkt der Septummyektomie von HCM-Patienten am stärksten
erhöht ist.
Im letzten Teil dieser Doktorarbeit wurden Fruchtfliegen (Drosophila melanogaster)
als ein Modellsystem für vererbbare Kardiomyopathien untersucht. Mittels der Genschere
CRISPR-Cas9 wurde versucht, verschiedene klinisch relevante Mutationen in das Erbgut
einzufügen. In Kapitel 10 fokussierten wir uns auf zwei Mutationen in dem Gen TNNI3
(wupA in Drosophila melanogaster), wobei eine Variante DCM und die andere HCM
beim Menschen verursacht. Unser Ansatz war nicht erfolgreich und daher liefern wir an
dieser Stelle verschiedene Erklärungen dafür. In Kapitel 11 wurden zwei verschiedene
Mutationen ins Mhc Gen eingeführt, beide führen zu HCM im Menschen, jedoch befinden
sich die Varianten an ganz unterschiedlichen Stellen des Mhc Proteins. Die Mhc-mutierten
Fruchtfliegen verglichen wir mit der Kontrollgruppe (w1118) und zeigten, dass morphologisch
und molekularbiologisch keine Unterschiede bestehen.
In dieser Doktorarbeit wurden die PQC und Mikrotubuli-Signatur in vererbbaren
Kardiomyopathien untersucht. Potenzielle Anknüpfstellen wurden aufgezeigt und es wird
auf die Implementierung dynamischer Modellsysteme in zukünftigen Studien appelliert,
um den Einfluss des PQC Systems und des Umbaus des Mikrotubuli-Netzwerkes auf den
Pathomechanismus in Kardiomyopathien besser zu verstehen.
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